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Chapter 1: General Introduction
A historical perspective
In the years following the ground-breaking discovery of Mycobacterium 
tuberculosis by Robert Koch in 1882, similar mycobacteria were isolated 
from a wide variety of animal and environmental sources. At the time, these 
were all considered “atypical M. tuberculosis”.1 In the following decades, it 
became evident that the genus Mycobacterium comprises three separate parts: 
I) the Mycobacterium tuberculosis complex, causative agents of tuberculosis 
in humans and animals, II) M. leprae, the causative agent of leprosy, and 
III) the “atypical” mycobacteria. From the 1950’s on, the pathogenicity of 
these “atypical” mycobacteria to humans was increasingly recognized.1 This 
recognition followed a key publication by Buhler and Pollack,2 in which they 
described two cases of pulmonary disease similar to tuberculosis, but caused 
by what they called the “yellow bacillus”. The “yellow bacillus” was named after 
its production of a bright yellow pigment after exposure to light; this species is 
today known as M. kansasii.
In addition to “atypical pulmonary tuberculosis”, specific diseases were 
attributed to the “atypical” mycobacteria, including pediatric cervical 
lymphadenitis and skin disease by M. marinum (swimming pool granuloma) 
and M. ulcerans (Buruli ulcer).1 At the time, it was often suggested that these 
“atypical” mycobacteria had arisen in some way as a result of the introduction 
of chemotherapy for tuberculosis, with streptomycin, isoniazid and para-
aminosalicylic acid.3 Various attempts were even made to create “atypical” 
mycobacteria, by repeated in vitro exposure of M. tuberculosis to various drugs; 
although drug resistance, a hallmark feature of “atypical” mycobacteria, could 
be induced, the resulting strains were still M. tuberculosis.3
Just four years after Buhler and Pollack, the first cases of disease caused 
by “atypical” mycobacteria were recorded in the Netherlands. Manten 
reported three patients who had been admitted to a sanatorium on a 
clinical and radiological suspicion of tuberculosis. All their sputum 
samples grew the “yellow bacillus” on culture, in large quantities.4 
The increasing recognition of their ability to cause human disease led to a 
long discussion on the correct nomenclature of the “atypical” mycobacteria. 
Different authors in different periods have proposed the names anonymous 
mycobacteria, environmental mycobacteria, atypical mycobacteria, 
opportunist mycobacteria, mycobacteria other than tubercle bacilli (MOTT) 
and nontuberculous mycobacteria.1 As these mycobacteria make up the 
majority of species within the genus Mycobacterium, the term “atypical” is 
debatable. Moreover, many of these mycobacteria are no longer anonymous and 
there is no evidence that they are environmental or opportunistic pathogens 
by definition. Hence, we prefer the term nontuberculous mycobacteria (NTM) 
and it will be used throughout this thesis.
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To facilitate structured clinical and taxonomical study, Runyon proposed a 
classification of NTM into four major groups, based on growth rate and colony 
pigmentation, in his seminal 1959 review.3 His bacteriological classification, 
which remained in use until the wide-scale application of molecular techniques, 
is summarized in Table 1.
Much of the early research in the Netherlands also focused on the classification 
of mycobacteria based on bacteriological features. Coster made an important 
contribution with his animal inoculation experiments. These experiments 
revealed that NTM could be distinguished from M. tuberculosis complex 
bacteria by inoculation of the bacteria in the anterior chamber of the eye of 
rabbits.5 In the rabbit eye, NTM caused only local nonspecific inflammation, 
while M. tuberculosis caused destructive granulomatous disease.5 
The bacteriological focus was strongly criticized by Manten in his 1965 
landmark review. He stated that knowledge on clinical NTM disease in the 
Netherlands lagged behind on that of physicians and researchers in other 
countries.6 This review first coined the issue of clinical relevance of NTM 
isolation from non-sterile sites, for which Manten proposed a scale based on 
culture results (Table 2). 
Applying these criteria to 240 patients with NTM isolates in the 1956-1964 
period, he identified 135 cases of definite NTM disease. The majority were 
Group Characteristics Important species
I Slow growth; Pigmentation after 
exposure to light (Photochromogens)
M. kansasii, M. szulgai, 
M. simiae
II Slow growth; Pigmentation without 
light exposure (Scotochromogens)
M. scrofulaceum, M. xenopi, 
M. gordonae
III Slow growth; No pigmentation (Non-
chromogens)
M. avium, M. intracellulare, 
M. malmoense
IV Rapid growers M. fortuitum, M. abscessus, 
M. chelonae
Culture results Interpretation
Repeated positive cultures yielding high numbers of 
bacterial colonies
Definite infection
Low numbers of bacteria isolated on a few occasions, or a 
single positive culture with high numbers of colonies
Probable infection
A single positive culture with a low number of colonies Possible infection
Table 1: Classification of nontuberculous mycobacteria according to Runyon3
Table 2: Manten’s scale of clinical relevance of nontuberculous mycobacteria 
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adult males with pulmonary M. kansasii disease, followed by children with M. 
scrofulaceum cervical lymphadenitis. Both M. avium and the rapidly growing 
mycobacteria were infrequently isolated and rarely caused disease.6
With the limited array of antimycobacterial drugs available at the time and 
extensive in vitro resistance of NTM to those drugs, Manten painted a grim 
picture of the therapeutic options. He stated that “[effective] chemotherapy 
for these infections is an illusion”. Surgical resection was considered the only 
option for NTM disease.6
In the 1960s, a growing number of cases of pulmonary NTM disease were 
reported. The demographics of the patients described were strikingly similar: 
predominantly males, with an average age of 50 to 55 years and pre-existent 
pulmonary diseases including chronic obstructive pulmonary disease and 
prior tuberculosis.7 The predominant species isolated differed by region. Based 
on the publications by Manten and colleagues, Selkon reported that in the 
Netherlands and neighbouring countries, M. kansasii was most frequent; in 
most parts of the USA, isolates of Runyon class III predominated.7
Two interesting clinical reports were published in this period. First, the first 
case of M. marinum skin infection (“swimming pool granuloma”) was recorded 
in the Netherlands in 1968.8 Second, there was the observation that some coal 
miners suffered disease due to photochromogenic mycobacteria, mainly M. 
kansasii, rather than the presumed silico-tuberculosis.9 Wolinsky had already 
recorded that induction of silicosis in guinea pigs, by quartz powder inhalation, 
increased their susceptibility to pulmonary M. kansasii disease.10
Despite the growing recognition of the capacity of NTM to cause disease in 
humans, the focus of research in the Netherlands remained on bacteriology. 
Extending the work on classification and identification initiated by Coster,5 
Schuitemaker introduced phage typing of mycobacteria in the Netherlands 
in 1963.11 Phage typing is a technique based on exposing bacteria to a set of 
previously selected bacteriophages, viruses that can infect and kill bacteria. 
Bacteria will be able to survive some phages and will be killed by others. 
This pattern is generally species-specific and can thus serve as a method of 
identification (Figure 1).11 
Schuitemaker’s phage typing technique enabled the later work on the etiology of 
NTM disease. The first important contribution on this topic in the Netherlands 
was a study performed in the city of Rotterdam, where sampling of tap water 
resulted in almost 50% of the samples growing M. kansasii. Some of the M. 
kansasii phage types encountered in water samples were also noted in clinical 
specimens in the same region, suggesting tap water as a source of human 
infection.12 This interesting finding led to a nationwide study of swimming 
pool, whirlpool and tap water samples. From these samples, the potentially 
pathogenic M. kansasii, M. avium, M. szulgai and M. fortuitum were isolated.13 
Studies on environmental presence of NTM were conducted in many parts of 
the world in this period; NTM were commonly found in soil, natural water 
16
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and on plants. Nontuberculous mycobacteria can be isolated from such a wide 
variety of environmental samples because they can grow at wide ranges of 
temperature, pH, salinity, and oxygen tension. Their common resistance to 
disinfectants and capacity for biofilm formation enables their survival in man-
made environments including water systems.14
Clinical NTM disease again came to attention during the early stages of the 
human immunodeficiency virus (HIV) epidemic. In patients with very low 
CD4 counts, typically below 50 cells/μL, disseminated NTM disease was 
among the most frequent and most severe infections.15 Over 95% of these 
infections are caused by M. avium, although over the course of time many 
species have been recorded as causative agents of HIV-related disseminated 
NTM disease.15 The advent of prophylactic therapy, first with rifabutin, later 
with macrolide antibiotics, and later of highly active antiretroviral therapy 
(HAART) significantly reduced the incidence, morbidity and mortality of 
HIV-associated disseminated NTM disease,16 at least in the USA and Europe 
where prophylaxis and HAART are available. 
Clinical features of disease caused by nontuberculous mycobacteria
Now, 50 years after the seminal review by Runyon and the first diagnoses of 
pulmonary NTM disease in the Netherlands by Manten, it is clear that NTM are 
environmental bacteria capable of causing a wide range of infections in humans, 
all in very specific groups of patients. Pulmonary NTM disease has three distinct 
presentations. Cavitary disease resembles conventional tuberculosis both 
clinically and radiologically. This disease mostly affects the upper lung lobes 
and patients often have a productive cough, weight loss and fatigue. Although 
the symptoms are very much like pulmonary tuberculosis, the clinical course 
is generally more prolonged. This type of disease is most common in patients 
Figure 1: Phagetyping results 
of four different Mycobacterium 
isolates. The plates are enriched 
with series of phages, which 
kill susceptible bacteria. The 
dark spots in the plates are 
zones where the locally present 
phage has killed the bacterium. 
The pattern resulting from the 
susceptibility of the bacterium to 
the different phages can be used 
for identification and typing 
purposes.
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with pre-existing pulmonary disease, including chronic obstructive pulmonary 
disease (COPD) and prior pulmonary tuberculosis. A wide variety of NTM 
species have been recorded as causative agents of cavitary disease. Patients are 
mostly males, their average age is 50-60 years.17 The second type of pulmonary 
NTM disease is nodular-bronchiectatic disease. Radiologically, the disease is 
characterized by bronchiectasis and multiple small nodular lesions commonly 
affecting the right middle lobe and the lingula. This disease type is mostly caused 
by M. avium complex or M. abscessus bacteria and commonly affects an older, 
female population without a significant history of pulmonary disease. These 
patients tend to have a distinct body habitus with scoliosis, pectus excavatum and 
mitral valve prolaps. Pulmonary NTM disease in these women has been labeled 
the “Lady Windermere syndrome”, after the main character of Oscar Wilde’s 
famous 1893 play “Lady Windermere’s Fan”.18 The name was chosen to convey 
the fastidious behavior that Reich and Johnson believed was the reason that this 
disease primarily affected women: habitual voluntary suppression of cough, as 
it is considered socially unacceptable behavior.18 The third type of pulmonary 
disease caused by NTM is a disease very similar to hypersensitivity pneumonitis. 
This rarest form of pulmonary NTM disease has a very distinct etiology. Patients 
are exposed to NTM, mainly M. avium complex bacteria in aerosols produced 
by “hot tubs”; small steam baths for personal use. Hence, this disease is often 
referred to as “hot tub lung”. Clinically, patients present with cough, dyspnea 
and fever. Radiological findings include diffuse infiltrates with nodular lesions 
throughout all lung fields. Ground glass opacities and a mosaic pattern are often 
present on high-resolution computed tomography (HRCT) scans. Although 
the exact pathogenesis remains controversial, it is thought to be a combination 
of infection and inflammation; the latter may be provoked by NTM antigens.19 
The histopathology is that of granulomas, usually non-necrotizing; organizing 
pneumonia or interstitial pneumonia is rare.20 Patients are usually nonsmokers, 
similar to patients with other forms of hypersensitivity pneumonitis.
Extrapulmonary disease due to NTM is generally rare. An important exception 
is pediatric lymphadenitis caused by NTM. This relatively benign disease affects 
immunocompetent children below six years of age, although this age range is 
different in different NTM species. In the Netherlands the annual incidence 
has been estimated at 77 cases per 100.000 children. Children usually present 
with a painless swollen submandibular or cervical lymphnode in the absence 
of generalized symptoms.21 The second most important extrapulmonary 
disease due to NTM is disseminated disease, which generally affects severely 
immunocompromised patients, including those infected by HIV and patients 
using immunosuppressive drugs. In HIV-infected patients, disseminated 
NTM disease is mainly caused by M. avium and presents insidiously with 
fever, weight loss and night sweats.22 Disseminated disease caused by M. 
chelonae, M. abscessus and M. kansasii tends to affect patients with an impaired 
immunity due to factors other than HIV. These diseases present with multiple 
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subcutaneous nodules or abscesses.14,17 Localized skin disease also occurs. 
Mycobacterium marinum is its most common causative agent. These infections 
are contracted from contaminated water sources, such as fish tanks. Infections 
often emerge in wounds acquired during cleaning of the fish tanks. Hence, 
this localized disease due to M. marinum is often referred to as the “fish tank 
granuloma”; it has been called “swimming pool granuloma” as well, after 
another frequent source of infection.1,8,14 
Most ear and eye infections are caused by rapidly growing mycobacteria. 
Mycobacterium chelonae and M. abscessus infections have been noted after eye 
surgery, especially after laser in situ keratomileusis (LASIK).23 Mycobacterium 
abscessus is also the most frequent causative agent of ear infections in children, 
often after tympanostomy tube placement.24 Both are severe and difficult to treat 
infections, which may result in permanent visual disability and hearing loss.
The wide range of infections caused by NTM is reflected by the wide array of 
sources from which NTM are isolated in the Netherlands. Table 3 provides 
an overview of the sources of the isolates submitted to the Dutch National 
Mycobacteria Reference Laboratory (part of the Laboratories for Infectious 
Diseases and Perinatal Screening, National Institute for Public Health and the 
Environment; RIVM) in the 2000-2006 period. Pulmonary isolates make up 83% 
of all NTM isolates referred to the RIVM. It is obvious from Table 3 that all other 
types of extrapulmonary NTM disease are clinical rarities in the Netherlands. 
Nevertheless, their obscurity should not preclude their thorough study. 
The impact of nontuberculous mycobacteria on other disease 
processes
The NTM are not just causative agents of human infections. A role for 
Mycobacterium avium paratuberculosis in the pathogenesis of Crohn’s disease 
(a chronic inflammatory bowel disease) is still debated.25,26 Mycobacterium 
avium paratuberculosis causes Johne’s disease in cattle, which shares some 
clinical features with Crohn’s disease in humans. The bacteria are present in 
milk of infected cows; it has been estimated that 30-70% of Dutch cow herds 
are infected by M. avium paratuberculosis.27
A second aspect of NTM has received a lot of attention is the influence of 
NTM exposure to the efficacy of Bacille Calmette Guérin (BCG) vaccination. 
Previous researchers have suggested that strong environmental exposure to 
NTM reduces the protection of BCG against pulmonary tuberculosis.28 This 
exposure differs by region, due to different environmental niches. Hence the 
protective effect of BCG also differs by region.28 On the other hand, many 
countries have reported rising incidences of pediatric lymphadenitis caused 
by NTM after cessation of mass BCG vaccination.29,30 Apparently, BCG 
vaccination does offer some protective immunity to pediatric NTM disease. 
Prior tuberculosis also has such a protective effect against NTM disease, at 
least in HIV-infected persons.31,32
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Advances in laboratory diagnosis
Until the late 1990’s, the laboratory diagnosis of NTM disease in the 
Netherlands relied on microscopy and culture on solid media; the RIVM 
identified NTM isolates by their colony morphology, growth rate and a delicate 
series of biochemical tests. These tests were notoriously irreproducible and 
identification results could take weeks or months to obtain. For clinicians, the 
long turnaround time severely limited the utility of these results and few NTM 
isolates were submitted. It was only in the late 1990’s that the fast and robust 
molecular tools for NTM identification became widely available to clinical and 
reference laboratories.33 For laboratories without access to DNA sequencers, 
the line-probe assays were developed, which hybridize an amplified DNA 
fragment with a series of short DNA stretches, called oligonucleotides, from 
various NTM species, which are attached to a paper strip. The hybridization 
with a specific oligonucleotide leads to a color reaction at the binding site of 
the oligonucleotide on the paper strip. The localization of the resulting colored 
band reveals which species is present. The major drawback of these methods is 
the fact that an identification result is based on hybridization with a small part 
of a single gene or spacer. As a result, divergence within the rest of the target 
gene, spacer, or in fact in the entire mycobacterial genome is disregarded. 
This creates a situation comparable to identification of a person by the color 
of the eyes only. Although these systems offer identification results within 24 
hours after DNA isolation, the result should probably be considered as an 
approximate.  
As automated liquid culture systems were introduced, Mycobacterium cultures 
and identification finally became a matter of weeks instead of months. 
 Source 2000 2001 2002 2003 2004 2005 2006 Total
Pulmonary 401 416 382 403 491 532 631 3256
Lymph node 24 18 12 33 79 59 42 267
Skin 10 10 11 7 20 9 15 82
Feces 5 12 5 2 11 11 3 49
Urine 9 7 5 3 6 8 4 42
Blood 2 11 4 3 7 3 11 41
Gastric juice 8 1 2 4 4 4 4 27
Joint 3 2 2 1 2 7 3 20
Ear 1 2 1 1 0 3 5 13
Bone marrow 1 2 2 3 1 2 1 12
Eye 1 0 0 0 0 5 1 7
Other 15 12 12 11 13 25 27 115
Total 480 493 438 471 634 668 747 3931
Table 3: Sources of NTM isolates submitted to the RIVM in the 2000-2006 period
20
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Moreover, the liquid media proved far more sensitive and saw the number of 
cultures yielding NTM rise in many laboratories.34,35
Drug susceptibility testing (DST) of nontuberculous mycobacteria has always 
been a difficult issue in the laboratory diagnosis of NTM disease. For most 
drugs, the in vitro susceptibility does not correlate with in vivo outcome of 
treatment; susceptibility breakpoints have not been confirmed to be clinically 
meaningful There is ongoing debate on the preferential testing method. 
Currently, the Clinical and Laboratory Standards Institute (CLSI; formerly 
National Committee for Clinical Laboratory Standards, NCCLS) propagates 
the broth microdilution method for most NTM species.36 The RIVM currently 
uses an agar dilution method, since this same platform is also in use for M. 
tuberculosis complex bacteria.37 The fact that, in the Netherlands, only the 
RIVM routinely performs DST for NTM is testimony to the fact that this 
technique is difficult both to perform and to interpret.
The changing isolation frequency of nontuberculous mycobacteria
The advent and spread of the improved laboratory diagnostic tools facilitated 
robust studies of the isolation frequency of NTM. Consequently, many 
studies reported rising isolation frequencies.38-41 This observation however, 
had already been made prior to the advent of these improved detection and 
identification techniques.38,39 In the Netherlands, the number of clinically 
isolated NTM submitted to the RIVM has also risen since the late 1990’s. In 
the same period, the number of submitted M. tuberculosis complex isolates has 
decreased (Figure 2). 
Although it is tempting to conclude that this increasing isolation frequency is 
essentially a result of the technical improvements, there are various reasons 
for the increase in NTM isolation frequency. Of course, the recent technical 
developments such as liquid culture systems have had a major impact,34,35 but 
there may also be a growing number of patients who get infected by NTM 
and develop true NTM disease. Repetitive skin testing surveys using a purified 
protein derivative of M. scrofulaceum in elementary school children in the 
Netherlands recorded sensitization rates rising from 4 to 13% over the 1965 
to 1985 period.42 Recently, Marras and co-workers demonstrated that the 
sensitization to M. intracellulare in the United States, also assessed by skin 
testing, rose from 11% in 1971-72 to 17% in 1999-2000.43
Several medical and social factors could lead to an increase in the prevalence 
of NTM disease. The population in the Netherlands is ageing and with 
growing age there is an increase in the prevalence of chronic disease (the 
“epidemiological transition”). Chronic pulmonary disease is also common 
due to the (past) smoking habits and work-related exposure to harmful 
compounds. Chronic pulmonary diseases, especially COPD, are well known 
risk factors for pulmonary NTM disease.1,14,17 Hence, the number of patients 
at risk has increased. The aspects of smoking and work-related exposure to 
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harmful compounds also explain the predominance of males among patients 
with pulmonary NTM disease.1,14 A recent chronic pulmonary disease 
prevalence survey (among 358741 persons) in the Netherlands found that 
1.3% of the Dutch population is formally diagnosed with COPD.44 In a country 
of 16.2 million inhabitants, that makes for 210600 COPD patients. The life 
expectancy of patients  with cystic fibrosis has also risen. Patients with cystic 
fibrosis are also highly susceptible to NTM disease, frequently caused by M. 
abscessus.45,46 The HIV epidemic is another cause of the increasing numbers of 
patients with NTM disease, although this situation has now stabilized; highly 
active antiretroviral therapy (HAART) significantly reduced the number 
of patients with HIV-related NTM disease13,14 and the prevalence of HIV in 
the Netherlands is relatively low.47 More recently, a new category of patients 
susceptible to mycobacterial disease was recognized. Patients using the new 
immunosuppressive agents for rheumatic disease, mainly the tumor necrosis 
factor alpha-neutralizing (anti-TNF) agents, are at increased risk to develop 
mycobacterial disease.48
Mass BCG vaccination was never applied in the Netherlands, so an increasing 
NTM disease incidence can not be related to cessation of BCG vaccination. 
The increasing isolation frequency may also result from non-medical factors. 
The use of showers for personal hygiene means that many people are exposed 
to aerosols on a daily basis. Many NTM have been demonstrated to be present 
in tap water and aerosol formation favors their inhalation.12,13,49 Recently, 
DNA fingerprinting techniques clearly demonstrated that M. avium disease 
in a patient could be linked to presence of the same M. avium strain in his 
shower.50 Due to their presence in natural and man-made environments, it has 
been estimated that humans are exposed to 50 to 500 NTM bacilli per day.51 
In the light of the large number of patients with NTM disease in whom no 
predisposing conditions are found, it has also been suggested that the NTM 
may be becoming more virulent.52
Figure 2:
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A growing interest in nontuberculous mycobacteria in the 
Netherlands
Alongside the increase in sample volume (Figure 2 & Table 3), the RIVM received 
a growing number of questions on the clinical relevance of these isolates and 
diagnosis and treatment of NTM disease. A similar trend of increasing interest 
in NTM was noted at the University Lung Centre Dekkerswald, one of two 
reference hospitals for mycobacterial disease in the Netherlands. The number of 
patients referred to Dekkerswald for treatment of their NTM infection started 
to rise, alongside a growing number of questions on clinical management of 
NTM disease from pulmonary physicians and infectious diseases specialists 
throughout the Netherlands. The apparent difficulties in the diagnosis and 
treatment of NTM disease led to a collaboration between Dekkerswald and the 
RIVM, focusing on the clinical relevance of NTM isolation. The first action of the 
research group, referred to as the Research Atypical Mycobacteria (RAM)-team, 
was to explore the current standards of bacteriological handling of NTM. These 
were explored during interviews with bacteriologists of all clinical laboratories 
with facilities to culture mycobacteria. Then, as a pilot project, 2 separate studies 
started. The first was a retrospective analysis of the clinical relevance of NTM 
isolated in four associated hospital within a single region, in the 1999-2004 
period. This regional study confirmed the rising isolation frequencies of NTM 
(Chapter 2.1). The second was an exploration of the clinical relevance of a new 
NTM species, which had previously been considered a variant of M. xenopi 
(Chapter 5.2). Both studies unambiguously demonstrated serious flaws in the 
diagnosis and treatment for NTM disease in the Netherlands. Very few cultures 
were performed, even in patients with prior positive cultures and some centers 
only identified cultured NTM upon request of the acting physician. During 
a meeting in which we presented the findings of our initial clinical studies, a 
microbiologist from a sizeable institute in the Netherlands stated: “whenever 
we have a negative PCR result [for Mycobacterium tuberculosis complex] on an 
isolated Mycobacterium, we discard the culture outright”. 
During both pilot studies, we recorded that some patients received treatment 
in absence of evidence of NTM disease; other did not receive treatment despite 
such evidence. Apparently, not all clinicians were able to define true NTM 
disease. This definition is troublesome, due to various reasons. Firstly, the NTM 
are environmental pathogens, present in natural water, soil and tap water and 
resistant to common disinfectants such as glutaraldehyde.14,53-55 Therefore, a 
positive culture from a non-sterile source, such as the respiratory and digestive 
tract, alone does not prove NTM disease. In fact it may result from recent 
environmental exposure, thus coincidental presence in the respiratory tract, 
or even contamination of the sample during collection or processing. Even 
rinsing of the mouth with water, prior to sputum collection, may lead to 
contamination of the sputum sample with the NTM present in the tap water. 
Contamination may also take place in the microbiological laboratory.56
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The most notorious sources of NTM (pseudo-)outbreaks are contaminated 
medical instruments. The common resistance to disinfectants allows NTM 
to survive in washers for bronchoscopes and other medical instruments.57,58 
Pseudo-outbreaks of NTM have also been noted in the Netherlands.54 Using 
contaminated instruments may lead to false-positive cultures or even inoculate 
NTM into tissues and thus cause true NTM disease, for instance during surgery 
with contaminated materials.59
Thus, the clinical relevance of a positive culture yielding NTM should always 
be assessed by compiling clinical and microbiological data. To aid in the 
differentiation between coincidental culture positivity of a respiratory sample 
and true pulmonary NTM disease, both the British Thoracic Society (BTS) 
and American Thoracic Society (ATS) have published diagnostic criteria.17,60,61 
The clinical relevance of an isolated NTM can be assessed using these criteria, 
which all combine clinical features, mainly symptoms and radiological 
features, with microbiological data regarding the number of positive cultures 
and results of microscopy for acid-fast bacilli of the original clinical samples. 
The most recent ATS diagnostic criteria are summarized in Box 1. 
Clinical.
1. Pulmonary symptoms, nodular or cavitary opacities on chest radiograph, or an 
HRCT scan that shows multifocal bronchiectasis with multiple small nodules.
and
2. Appropriate exclusion of other diagnoses.
Microbiological.
1. Positive culture results from at least two separate expectorated sputum samples. 
(If the results from the initial sputum samples are nondiagnostic, consider repeat 
sputum AFB smears and cultures.)
or
2. Positive culture results from at least one bronchial wash or lavage.
or
3. Transbronchial or other lung biopsy with mycobacterial histopathologic features 
(granulomatous inflammation or AFB) and positive culture for NTM or biopsy show-
ing mycobacterial histopathologic features (granulomatous inflammation or AFB) 
and one or more sputum or bronchial washings that are culture positive for NTM.
4. Expert consultation should be obtained when NTM are recovered that are either 
infrequently encountered or that usually represent environmental contamination.
5. Patients who are suspected of having NTM lung disease but who do not meet the 
diagnostic criteria should be followed until the diagnosis is firmly established or 
excluded.
6. Making the diagnosis of NTM lung disease does not, per se, necessitate the institu-
tion of therapy, which is a decision based on potential risks and benefits of therapy 
for individual patients.
Patients who meet these criteria are likely to have true pulmonary NTM disease; their NTM 
isolates can be considered clinically relevant.
Box 1: Summary of the American Thoracic Society diagnostic criteria for pulmonary 
nontuberculous mycobacterial infection17
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Treatment of disease caused by nontuberculous mycobacteria
After the difficult diagnosis of NTM disease is made, treatment may be 
required. There has been significant progress in this field, and Manten’s 1965 
statement that “[effective] chemotherapy for these infections is an illusion”6 
can be partially refuted. Initially, pulmonary NTM disease was treated as 
conventional tuberculosis, with isoniazid and para-aminosalicylic acid, 
though this proved ineffective.1,6 Surgical resection was the therapy of choice 
until newer drugs including cycloserine, viomycin and ethionamide became 
available. The efficacy of regimens including these drugs was reviewed by 
Selkon, who noted a 56% cure rate for M. kansasii disease; cure rates for M. 
avium complex disease were disappointing, these ranged between 17 and 43%.7 
The original studies were observational in nature, rather than comparative 
or even randomized and controlled. In 1981 Hunter reviewed the results 
of treatment for pulmonary disease caused by M. avium complex bacteria. 
Various treatment regimens were used, though only combinations of isoniazid, 
rifampicin, and either ethambutol or streptomycin of 24 months duration were 
successful. Eighty-four percent of all patients treated with these combinations 
converted to negative cultures, although 14% relapsed within a year after 
treatment. Treatment regimens using multiple second line drugs were less 
effective and highly toxic.62 
The use of treatment regimens including rifampicin and ethambutol became 
more widespread after the in vitro studies by Banks, who clearly demonstrated 
synergy between these two drugs.63 The first prospective trial was done for 
pulmonary M. kansasii disease and used a rifampicin and ethambutol regimen 
of nine months duration; of 175 patients, all but one converted to negative 
cultures, although 10% suffered a relapse within 4 years of follow-up after 
treatment.64 In the same period, the first studies of macrolide-based multi-
drug therapy for M. avium complex disease were published. In 50 patients 
with pulmonary M. avium complex disease, 92% achieved prolonged culture 
conversion.65 The macrolide-based regimens also proved highly effective in 
HIV-related disseminated M. avium disease.66 The BTS published another 
important randomized controlled trial in 2001, which compared rifampicin 
and ethambutol regimens with and without isoniazid of 24 months duration 
in pulmonary disease caused by the NTM species important in North-Western 
Europe: M. avium, M. xenopi and M. malmoense. Generally, addition of 
isoniazid added little benefit, but resulted in more reported adverse events.67 
This trial was followed by a comparative trial of the rifampicin and ethambutol 
regimen with adjunctive ciprofloxacin or clarithromycin. Interestingly, this 
recently published trial failed to demonstrate superiority of a macrolide or 
fluoroquinolones based regimen over rifampicin and ethambutol only.68 
Combined, the BTS trials observed cure rates of 28% after five years of follow-
up, with 14% relapses.68 These results frankly conflict with previous North 
American studies of macrolide-based regimens, the causes of which remain 
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to be investigated. The added benefit of clarithromycin for treatment of 
pulmonary NTM disease remains controversial. In HIV-related disseminated 
disease, the macrolide based regimens are the recommended treatment.17,66
For a select group of patients, surgical excision of the affected part of the 
lung, combined with multi-drug treatment before and after surgery can prove 
successful.17
For extrapulmonary NTM disease, there is even less evidence on efficacy of 
treatment regimens. Pediatric NTM lymphadenitis usually responds well 
to excisional surgery alone;69 this is the recommended treatment.17,69 Other 
extrapulmonary disease types are generally treated by excisional surgery (or 
surgical debridement) combined with multi-drug treatment.17
A special reference should be made to disease caused by M. abscessus. Bacteria 
of this species are naturally resistant to virtually all classes of antibiotics, except 
the macrolides. Disease caused by M. abscessus is an enormous challenge for 
clinicians. Pulmonary M. abscessus disease is a virtually incurable disease for 
most patients and suppressive, instead of curative, treatment may be the only 
option,17 especially in CF patients. In pulmonary M. abscessus disease, too, 
surgery may be applied in selected cases.17 
Nontuberculous mycobacteria in areas with a high prevalence of 
tuberculosis
Traditionally, the NTM have been studied mainly in Europe, Australia and 
North America, where they were noted during the decline in the prevalence 
of tuberculosis. In Asia, Africa and South America the prevalence of 
tuberculosis has remained high. Moreover, many countries in these regions 
lack the financial and laboratory resources for Mycobacterium cultures at all. 
Diagnosing tuberculosis in these regions often depends on clinical assessment, 
including chest radiographs where available, and acid-fast bacilli microscopy. 
As a result, distinguishing TB from NTM disease is virtually impossible. 
The few historical studies that have looked at NTM isolation from patients 
suspected of pulmonary tuberculosis found very few; a survey of 7580 cultures 
from patients in various African countries identified only 86 (1.1%) as NTM.70 
Similarly, a prospective study early in the HIV-epidemic revealed that the 
prevalence of disseminated M. avium complex disease in Kenya was ten times 
lower than in the USA and Northern Europe;71 HIV-associated tuberculosis 
was more frequent in Kenya. Later studies in West Africa found prevalence 
rates very similar to those in the USA.72 Most recently, several studies were 
conducted in Zambia, which noted clinically relevant NTM disease in both 
HIV-positive and negative patients.73 Though the clinical relevance of NTM in 
areas with a high prevalence of tuberculosis remains unsettled, it may exceed 
previous expectations.
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Aims and outline of this thesis
Diagnosis and treatment of disease due to nontuberculous mycobacteria 
remains complicated. For most species, it is not clear whether their isolation 
is likely to be a sign of true NTM disease or whether they can be regarded as 
probable contaminants. Therefore, a single positive culture from a non-sterile 
source demands careful follow-up. 
Within this thesis, we have aimed to quantify the clinical relevance of the 
most frequently isolated NTM species in the Netherlands. To quantify 
clinical relevance, we assessed the percentage of patients that meet the ATS 
diagnostic criteria for pulmonary NTM disease, as well as the frequency and 
clinical features of extrapulmonary disease, per species (Chapter 2). Within 
Chapter 3, we focus on a new category of patients at risk for NTM disease, 
those with rheumatic or other inflammatory disease treated with the new 
immunosuppressive agents including the anti-TNF agents. The poor outcome 
of treatment for NTM disease is discussed in Chapter 4, where we study the 
role of drug susceptibility testing, adjunctive surgery and a potential novel 
drug. Hereafter, we shift the focus towards the pathogens. Chapter 5 details 
on the issue of unidentifiable mycobacteria. We have studied the prevalence 
of such unidentifiable mycobacteria in our reference laboratory. Selected 
groups of strains were studied in-depth and described as new species, with 
an assessment of their clinical relevance. In Chapter 6 we focus further, as we 
studied the genetic divergence within NTM species. This divergence could 
provide important insights in the bacterial factors in the issue of clinical 
relevance. We discuss our findings with an emphasis on the issue of clinical 
relevance. Finally, in Chapter 7, we have looked across our borders, to assess 
the clinical relevance of NTM isolation in very different geographical regions, 
with a different prevalence of tuberculosis and HIV.
Ultimately, our efforts should provide a basis for improved diagnosis and 
treatment of NTM disease. This is a clinical issue that can no longer be ignored. 
The period of considering NTM as possible but improbable causative agents 
of “atypical tuberculosis” needs to make way for a vision of NTM disease as 
a completely separate clinical entity, affecting different patients in different 
settings, to be treated in a way different from conventional tuberculosis.
Our data should assist in the creation of guidelines specifically for the clinical 
and laboratory diagnosis and treatment of NTM disease, in the Netherlands 
as well on an international level. Our pilot studies have clearly laid bare the 
necessity of such guidelines.
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Abstract
Background: The frequency of clinical isolation of nontuberculous 
mycobacteria (NTM) in the Netherlands is increasing, but its clinical relevance 
is often uncertain. 
Objectives: To assess the frequency and clinical relevance of isolation of NTM 
in four associated hospitals in a single region in the Netherlands.
Methods: Medical files of all patients from whom NTM were isolated between 
January 1999 and January 2005 were reviewed retrospectively. Diagnostic 
criteria for nontuberculous mycobacterial disease published by the American 
Thoracic Society (ATS) were used to determine clinical relevance. 
Results: 232 patients were found, from whom NTM were isolated from the 
respiratory tract in 91% of cases. Patients were mostly white men, with an 
average age of 60 years and pre-existing pulmonary disease. Fifty-three of 212 
patients (25%) with pulmonary isolates met the ATS diagnostic criteria for 
pulmonary NTM disease; this percentage differed by species. Most patients 
were treated with rifampicin, ethambutol and clarithromycin. Treatment 
outcome for pulmonary NTM disease was suboptimal but differed by species: 
overall improvement was seen in 67% of treated patients, but in only 50% of 
those with pulmonary M. avium disease. Lymphadenitis was the most common 
extrapulmonary disease type.
Conclusions: Twenty-five percent of all patients with pulmonary NTM isolates 
met the ATS criteria. Clinical relevance differs by species. NTM isolation 
increases over time. Species distribution differs from that of neighboring 
countries and the M. avium complex isolates have traits different from those 
reported in the USA. Adherence to diagnostic and treatment guidelines can be 
improved. 
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Introduction
The clinical isolation of nontuberculous mycobacteria (NTM) increases in 
many countries where the incidence of tuberculosis is decreasing, with marked 
geographic differences in the species encountered.1-3 The NTM are often 
opportunistic pathogens, capable of causing disease in patients with impaired 
immunity, either local due to pre-existing pulmonary disease or systemic – for 
example, hematological malignancy, immunosuppressive drug treatment or 
HIV/AIDS.1 The clinical relevance of isolated NTM is often unclear. The NTM 
are common in the environment and can survive in flowing water systems.4 
Moreover, NTM resist common disinfectants.5 Thus, pseudo-infection 
due to occasional presence of NTM in clinical samples as a consequence of 
contamination of medical tools should always be considered.1,6,7
To differentiate true infection from pseudo-infection, and establish the clinical 
relevance of an NTM isolate, is of paramount importance since treatment of NTM 
disease is time consuming and often complicated. To assist in this differentiation, 
the American Thoracic Society (ATS) established general criteria for the diagnosis 
of pulmonary nontuberculous mycobacterial infection (Box 1).1 
We performed a retrospective case study to assess the prevalence and clinical 
relevance of NTM isolated in the four associated training hospitals of the 
Nijmegen-Arnhem region, the Netherlands, using the ATS diagnostic criteria 
to differentiate NTM disease from pseudo-infection or contamination.
Methods
To determine clinical relevance, we examined medical records of all in- and 
outpatients in four collaborating hospitals in the Nijmegen-Arnhem region of 
the Netherlands from whom NTM were isolated between January 1999 and 
January 2005. We recorded demographic, clinical and microbiological data 
and status according to the diagnostic criteria for pulmonary NTM disease by 
the ATS.1 We considered pulmonary isolates clinically relevant if the patient 
met the ATS diagnostic criteria in absence of evidence of other pulmonary 
infections. 
For patients treated for NTM disease, we defined cure as symptomatic 
improvement and reversion to negative cultures sustained throughout our 
follow-up period. We focused on pulmonary isolates. 
The Dutch National Institute for Public Health and the Environment (RIVM) 
subjected isolates of all patients to laboratory diagnosis. The RIVM is the 
national reference laboratory that provides identification, drug susceptibility 
testing and genotyping of mycobacterial isolates for all hospitals in the 
Netherlands. To identify NTM,  the INNO-LiPA MYCOBACTERIA v2 
(Innogenetics, Ghent, Belgium) reverse line blot assay was used, after ruling 
out membership of the M. tuberculosis complex using a GenoType MTBC 
line probe assay (Hain Lifescience, Nehren, Germany). If no species-specific 
result was obtained, 16S rDNA gene sequencing (151bp hypervariable region A) 
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was performed. Prior to 2004, 16S rDNA gene sequencing was performed, 
after ruling out membership of the M. tuberculosis complex or M. avium 
complex using the AccuProbe MTB and M. avium complex DNA probe kits 
(GenProbe, San Diego, USA). Sequencing results were compared with the 
GenBank (National Center for Biotechnology Information, http://www.ncbi.
nlm.nih.gov) database. A Pearson χ2-test was used for statistical correlations. 
The regional ethics committee approved the study. 
Results
We found 232 patients with NTM isolates, mostly from the respiratory tract (n=212, 
91%). Primary isolates were cultured from sputum (n=158; 75%), broncho-alveolar 
lavages (n=47; 22%) and lung biopsy specimens (n=7; 3%). The annual number of 
patients from whom NTM were isolated rose during our research period, mainly 
owing to an increase in pulmonary isolates, especially M. avium complex (MAC) 
isolates (Figure 1). The annual percentage of patients meeting the ATS criteria did 
not change. 
Table 1 presents the baseline characteristics of the 212 patients with pulmonary 
NTM isolates.
Clinical.
1. Pulmonary symptoms, nodular or cavitary opacities on chest radiograph, or an 
HRCT scan that shows multifocal bronchiectasis with multiple small nodules.
and
2. Appropriate exclusion of other diagnoses.
Microbiological.
1. Positive culture results from at least two separate expectorated sputum samples. 
(If the results from the initial sputum samples are nondiagnostic, consider repeat 
sputum AFB smears and cultures.)
or
2. Positive culture results from at least one bronchial wash or lavage.
or
3. Transbronchial or other lung biopsy with mycobacterial histopathologic features 
(granulomatous inflammation or AFB) and positive culture for NTM or biopsy show-
ing mycobacterial histopathologic features (granulomatous inflammation or AFB) 
and one or more sputum or bronchial washings that are culture positive for NTM.
4. Expert consultation should be obtained when NTM are recovered that are either 
infrequently encountered or that usually represent environmental contamination.
5. Patients who are suspected of having NTM lung disease but who do not meet the 
diagnostic criteria should be followed until the diagnosis is firmly established or 
excluded.
6. Making the diagnosis of NTM lung disease does not, per se, necessitate the institu-
tion of therapy, which is a decision based on potential risks and benefits of therapy 
for individual patients.
Box 1: Summary of the American Thoracic Society diagnostic criteria for pulmonary 
nontuberculous mycobacterial infection.1
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Fifty-three patients (25%) met the ATS diagnostic criteria and were thus likely 
to have pulmonary NTM disease. Of the 159 patients who did not meet the 
ATS criteria, 146 (92%) failed to meet microbiological criteria and 149 (94%) 
failed to meet radiological criteria. For these patients, follow-up for a mean 
duration of 47 months (range 29-98 months) did not yield additional evidence 
of NTM disease.
Figure 2 visualizes the clinical relevance of the various NTM species, defined 
by the percentage of patients who met the ATS diagnostic criteria. Four cases 
of pulmonary NTM disease were actually relapses of disease episodes prior to 
our study period (two M. avium, one M. xenopi, one M. kansasii).
Eighty-five patients (40%) had MAC isolates (59 M. avium, 16 M. intracellulare, 
10 other MAC) of whom 26 (24 M. avium, 2 M. intracellulare; 31%) met the 
ATS diagnostic criteria. M. avium isolation was clinically more relevant than 
M. intracellulare (24/59=41% vs. 2/16=13% of patients met the ATS diagnostic 
criteria). A radiographic presentation with fibrosis and cavities was more 
prevalent than nodular bronchiectatic disease (12 vs. 3 cases for M. avium and 
1 case each for M. intracellulare). 
Whereas MAC was most frequently seen, the degree of clinical relevance was 
higher for isolation of M. malmoense (2/3), M. kansasii (12/17, 71%), M. xenopi 
(3/5), M. szulgai (4/4), M. celatum (2/2) and M. genavense (1/1; Figure 2).
Symptoms recorded at presentation varied widely; only fever (p=0.014, OR 
2.422, 95%CI 1.179-4.978) and fatigue (p<0.001, OR 3.477, 95%CI 1.721-
7.024) at presentation were associated with meeting the ATS diagnostic criteria 
(Table 1). Chest radiographs were performed for 206 of the 212 patients and 
abnormalities were noted in 161 patients (78%; Table 1). Abnormalities did 
not differ significantly by NTM species. Three patients with pulmonary NTM 
disease presented with a pulmonary mass, mimicking malignancy. Computed 
tomography (CT) scans were performed in 107 patients (50%); among patients 
Figure 1: Total number of patients with NTM isolates, per year and isolation site
MAC: M. avium complex
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meeting the ATS diagnostic criteria, five cases of fibrocavitary disease and six 
cases of nodular-bronchiectatic disease were noted in patients with inconclusive 
chest radiographs. On chest radiographs, these cases of fibrocavitary disease 
presented with dense airspace opacities; the nodular-bronchiectatic disease 
appeared as coarse linear scarring.
Drug treatment for mycobacterial infection was started in 44 patients; 31 
started treatment for tuberculosis (TB) and switched to an NTM treatment 
regimen, 13 patients received standard TB treatment only. Of these 44 patients, 
30 met the 1997 ATS diagnostic criteria available during the study period.8 
Among those 30, 20 (67%) were cured, defined by symptomatic improvement 
and reversion to negative cultures, five died during treatment (three with M. 
avium, one with M. intracellulare, one with M. xenopi disease; 17%) and five 
had a relapse after treatment (four with M. avium, one with M. celatum disease; 
17%). The mean interval between the end of treatment and culture-proven 
relapse was 31 months (range: 23-44). Of 14 patients treated for pulmonary M. 
avium disease, only seven improved. The regimens used mostly consisted of 
rifampicin and ethambutol, despite frequent in vitro resistance (15/25 primary 
isolates were resistant to rifampicin, 18/25 to ethambutol; 5 were not tested); 
isoniazid was added in 11 patients (despite in vitro resistance in all cases), 
clarithromycin in 19, ciprofloxacin in four. Clarithromycin and ciprofloxacin 
were only used in patients with susceptible isolates. Three patients received 6 
months of standardized TB treatment only. The mean treatment duration was 
13 months (range 1-37). Three patients received additional surgical treatment 
that consisted of resection of a solitary pulmonary mass in two and lobectomy 
for persisting fibrocavitary disease in one; all three were cured. The mean 
duration of follow-up after treatment was 34 months (range 17-91).
Figure 2: Clinical relevance of pulmonary NTM isolates in this study, per species
(x/y): number of patients that meet the ATS diagnostic criteria / total number of patients per species
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* >15mg prednisone/day for >3 months before primary NTM culture 
# anorexia nervosa, lymphopenia and complement C4 deficiency, diabetes mellitus (all n=1)
** intravenous drug abuse (n=2), azathioprine use (n=1)
† p=0.014, OR 2.422, 95%CI 1.179-4.978
§ p<0.001, OR 3.477, 95%CI 1.721-7.024 
¶ p<0.001, OR 23.583, 95%CI 8.777-63.125 
ATS+ 
(n=53)
ATS- 
(n=159)
Total 
(n=212)
Demography Males 37 (70%) 95 (60%)  132 (62%)
Mean age (yr) 57 61 60
Dutch origin 48 (91%) 145 (91%) 193 (91%)
Predisposing 
conditions
Pre-existing pulmonary disease 37 (70%) 125 (79%) 162 (76%)
COPD 23 (43%) 80 (50%) 103 (49%)
Lung cancer  4 (8%) 17 (11%) 21 (10%)
Healed Tuberculosis 6 (11%) 22 (14%) 28 (13%)
Previous pulmonary NTM disease 4 (8%) 0 4 (2%)
Asthma 4 (8%) 21 (13%) 25 (12%)
Bronchiectasis 8 (15%) 8 (5%) 16 (8%)
Current  or past smoker 35 (66%) 94 (59%) 129 (61%)
Alcohol abuse  8 (15%) 16 (10%) 24 (11%)
High dose steroid use* 2 (4%) 6 (4%) 8 (4%)
HIV infection 6 (11%) 7 (4%)  13 (6%)
Hematologic malignancy 1 (2%) 4 (3%) 5 (2%)
Anti TNF treatment 1 (2%) 1 (1%) 2 (1%)
Otherwise impaired immunity 3# 3 ** 6
Symptoms Productive cough 40 (75%) 126 (79%) 166 (78%)
Hemoptysis 10 (19%) 28 (18%) 38 (18%)
Dyspnea 29 (55%) 85 (54%) 114 (54%)
Fever 19 (36%)† 30 (19%) 49 (23%)
Night sweats 7 (13%) 16 (10%) 23 (11%)
Weight loss 14 (26%) 29 (18%) 43 (20%)
Fatigue 28 (53%)§ 37 (23%) 65 (31%)
Chest 
radiograph 
features
Airspace opacities 22 (42%) 42 (26%) 64 (30%)
Cavity 15 (28%) 2 (1%) 17 (8%)
Nodules 4 (8%) 2 (1%) 6 (3%)
Bronchiectasis 4 (8%) 5 (3%) 9 (4%)
Emphysema 14 (26%) 23 (15%) 37 (17%)
Microbiology Mean no of cultures performed 4.9 3.5 3.8
Mean no of positive cultures 2.9 1.1 1.5
AFB smear positive 26 (49%)¶ 6 (4%) 32 (15%)
Table 1: Baseline characteristics of patients with pulmonary NTM isolates
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Treatment was not given in 168 patients, though eight of them met the 1997 
ATS diagnostic criteria.8 Four patients were considered to have too few 
symptoms or radiographic deterioration, one refused treatment and one patient 
spontaneously reversed to negative cultures. Slow radiographic deterioration 
of pulmonary disease was apparent in all seven persistently symptomatic and 
culture-positive, untreated patients.
During the study period, NTM were isolated from extrapulmonary samples 
only of 20 patients. Lymphadenitis was the most common extrapulmonary 
NTM disease type; six children and one elderly female had cervical 
lymphadenitis (three M. avium, two M. malmoense, one M. intracellulare, one 
M. haemophilum) and one patient with AIDS (CD4 count 1) had axillar and 
mediastinal lymphadenitis with extensive abscess formation, caused by M. 
gordonae. We recorded three cases of skin infection: two caused by M. marinum 
in fish tank owners and one by M. malmoense in a patient with hematological 
malignancy. We also noted single cases of M. kansasii tenosynovitis in a 
gardener, M. abscessus otomastoiditis after tympanostomy tube placement in a 
child and disseminated M. avium disease in an AIDS patient (CD4 count 40).
The remaining six patients had MAC isolated from the digestive tract, in the 
absence of further evidence of NTM disease.
Discussion
Twenty-five percent of all patients in this study had pulmonary NTM disease 
according to the ATS diagnostic criteria, and the clinical relevance differed 
significantly by species (Figure 2). Isolation of M. malmoense, M. xenopi, M. 
szulgai, M. kansasii, M. celatum and M. genavense warrants special attention, as this 
usually reflects true NTM disease; an observation confirmed in previous studies.1 
Although in the current study the number of isolates of many species is too low to 
permit firm conclusions, similar rates of clinical relevance have already emerged 
for M. xenopi (21/45 patients; 47%), M. chelonae (7/35; 20%), M. abscessus (13/39; 
33%), M. simiae (3/28; 11%) and M. szulgai (11/15; 73%) in nationwide studies of 
pulmonary isolates in the Netherlands.9-12 These data and the additional data in 
our current study strengthen a presentation such as that shown in Figure 2.  The 
25% of patients that met the ATS criteria is similar to the 33% recently found in 
a Canadian referral center study, 25% recorded among patients in Korea, and the 
results of earlier studies reviewed by Marras and Daley.2,13,14 
A difference in clinical relevance by species has also been noted in the recently 
published Korean study with results similar to ours, except for a very limited 
relevance of M. szulgai (2/32 patients; 6%) and M. celatum (1/11; 9%).13 These 
differences in clinical relevance between NTM species emphasize the major 
role of the bacteriological laboratory in the management of these emerging 
infections; correct identification of NTM isolates is a prerequisite for correct 
patient handling. The apparent regional differences in clinical relevance of 
NTM species require further study. 
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The ATS diagnostic criteria are based on experience with M. avium, M. 
kansasii and M. abscessus;1 their applicability to less studied species may be 
limited.1,9 The clinical applicability of the ATS criteria is supported by those 
patients who did not meet the ATS criteria and which had no clinical event or 
new radiological events during follow-up. Very few follow-up cultures were 
performed (see Table 1), although this was advocated in the ATS statement 
available during the study period.8 
Although for some species the low number of isolates decreases the weight 
of the conclusions of the analysis, the difference in clinical relevance of the 
various NTM species may mean that for the species to the left of Figure 1 the 
ATS criteria should be very strictly applied or even be made more stringent, 
whereas among the upper half (50-“100”% clinical relevance) a diagnosis of 
NTM disease may be justified after the first positive culture. 
The increase in the annual number of patients from whom NTM were isolated 
(Figure 1) is a cause of concern and has also been noted in previous studies.1,2,13,15 
This increase was often thought to be related to improvements in laboratory 
techniques; in the Netherlands, the use of (automated) liquid culture systems 
increased during the study period.1,16 A recent study, however, demonstrated 
that skin sensitization to M. intracellulare has also increased significantly over 
recent decades in the USA, consistent with observed increases in the rate of 
pulmonary NTM infections.17 Several aspects may influence this increase in 
NTM isolation. First, the Dutch population, as in many developed countries, is 
ageing and an increasing prevalence of chronic obstructive pulmonary disease 
is observed.18-20 The baseline characteristics of our study group, predominantly 
men at an average age of 60 years, similar to previous NTM studies in societies 
with low HIV prevalence,1,13,15 reflect these changes. Second, for chronic 
inflammatory diseases, immunosuppressive drugs, including tumor necrosis 
factor α neutralizing agents, are increasingly used. Both aspects may have an 
impact on the future prevalence of NTM disease. In addition, the exposure to 
aerosols of tap water may have increased over time, as frequency of showering 
has risen dramatically over recent decades. The minor role of HIV infection 
probably reflects the low prevalence of HIV infection in the Netherlands, 
compared to chronic pulmonary disease, and the advent of highly active 
antiretroviral treatment (HAART). This limits the number of cases of severe 
HIV immunosuppression and its co-infections,21 which may be reflected in the 
decreasing NTM isolation from extrapulmonary samples (Figure 2). Besides, 
the hospitals participating in the study are situated in the eastern part of 
the Netherlands, where HIV incidence is lower than in the more urbanized 
western part.22
The limited associations between symptoms, chest radiograph results and 
NTM disease according to the ATS diagnostic criteria underline the fact that 
diagnosis of NTM disease remains difficult. Hence, the NTM merit special 
attention by doctors and microbiologists. 
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Despite inherent limitations, the species found in this study and their 
frequencies probably reflect the current epidemiological situation for NTM in 
the Netherlands. This situation is remarkably different from nearby southeast 
England, where M. xenopi is most frequent and Scotland and Scandinavia, 
where M. malmoense is especially prevalent.1,14,23 The species distribution 
and clinical relevance among MAC isolates seen in this study differs from 
recent reports from the USA where M. intracellulare is the more common 
respiratory pathogen,1 clinically more relevant than M. avium in non-HIV 
patients24 and nodular-bronchiectatic pulmonary MAC disease, associated 
with postmenopausal immunocompetent women, is as prevalent as cavitary 
disease.24 Possibly, the predominance of M. avium and cavitary disease in our 
study population are interrelated; different MAC subtypes are known to cause 
different disease types in humans.25 Cases of nodular-bronchiectatic disease 
may have also been missed owing to the infrequent use of CT scanning and low 
number of follow-up cultures performed; diagnosing this paucibacillary disease 
type generally demands prolonged, intense follow-up.1 Alternatively, since we 
used hospital in- and outpatient file review, cases of nodular-bronchiectatic 
disease may have been missed as they are less frequently referred to hospitals 
for diagnosis, owing to a more indolent clinical course compared with cavitary 
MAC disease.1
Previous studies have recorded high degrees of clinical relevance of M. 
kansasii, comparable to the 71% in the present study.14 Whereas the latest ATS 
statement states that for M. kansasii the treatment decision may be based on 
a single positive culture in select cases,1 we recorded single positive sputum 
cultures in five patients with non-suspect radiographic changes and repeatedly 
negative follow-up cultures. This would have meant an unnecessary treatment 
for these patients when applying the new ATS criteria.
We observed possible instances of both under-treatment (not treating those 
who meet the diagnostic criteria) and over-treatment (treatment of those who 
do not meet diagnostic criteria), as well as the use of treatment regimens that 
have never proved to be effective. This may harm patients. This, as well as the 
fact that few (high-resolution) CT scans and follow-up cultures, both strongly 
advocated in the ATS criteria,1,8 were performed in patients with NTM isolates 
in non-cavitary pulmonary disease, could reflect a lack of knowledge of and 
experience with the diagnosis and management of NTM disease in doctors, 
or clinical circumstances not captured in our file review. All these aspects 
emphasize the need for centralization of knowledge, experience and care for 
patients with (suspected) NTM disease or increased expert consultation.
Treatment duration recorded in our study was not in accordance with the British 
Thoracic Society (BTS) and ATS guidelines.1,26 A favorable outcome for 67% of 
patients with pulmonary NTM disease is higher than the 36% observed in the 
recently published BTS clinical trial comparing regimens with clarithromycin 
or ciprofloxacin as adjuncts to rifampicin and ethambutol.27 In that trial, 
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patients with MAC and M. xenopi had worse outcomes than those with M. 
malmoense.27 The differences in treatment outcome between our study and the 
BTS trial may result, first, from our more lenient definition of “cure”, second, 
our limited follow-up period and finally, the NTM species causing pulmonary 
disease in our patients. Whereas the first trials of macrolide-based regimens 
in pulmonary MAC disease in HIV-negative patients in the US reported 
cure rates of 59-92%, with comparable definitions of cure,1 the outcome of 
treatment for pulmonary MAC disease observed in our study and the BTS 
trial was disappointingly poorer. The treatment results, overrepresentation of 
men and cavitary disease, MAC species distribution and clinical relevance all 
suggest differences in MAC organisms encountered in the USA and Europe. 
Although generally, outcome of NTM treatment is suboptimal,1 various factors 
may have influenced our results. First, the conditions predisposing to NTM 
disease influence the outcome of the patient. Second, the 1997 ATS diagnostic 
criteria8 available to doctors in the study period, might not have selected the 
group of patients who would have benefited from treatment. More patients 
meet the recently published criteria,12 though herein it is stated that meeting 
the criteria does not of itself necessitate treatment.1 Still, this may lead to 
improved selection of patients to receive treatment and thus improve outcome 
rates. In this perspective, the term under-treatment will become invalid. Third, 
previous trials for pulmonary MAC disease have recorded superior treatment 
outcome using similar definitions, but in a different MAC population. In 
our group more patients had cavitary disease, which in general is associated 
with a worse treatment outcome.1 Finally, one of the centers incorporated in 
this study is a referral center for NTM disease treatment, which may create a 
selection bias.
Extrapulmonary disease was rare, though its overall frequency (9%) and 
distribution of disease types are in line with previous studies, summarized in 
the recent ATS statement.1 
In conclusion, clinical isolation of NTM was relevant in 25% of the 212 patients 
with pulmonary isolates. Clinical relevance differs markedly by species and 
there are important regional differences in species distribution and relevance. 
This, as well as the rising isolation rates of NTM, warrants special attention by 
doctors and microbiologists. Treatment outcome of pulmonary NTM disease 
was disappointing. Both over-treatment and insufficient treatment were noted. 
Extrapulmonary NTM disease is rare. Actions to increase awareness of the 
ATS diagnostic criteria and management guidelines and centralization of 
NTM disease management are strongly recommended. 
Clinical relevance of isolation of NTM in the Netherlands
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Abstract
In the Netherlands, isolation of Mycobacterium xenopi is infrequent, and 
its clinical relevance is often uncertain. To determine clinical relevance and 
determinants, we retrospectively reviewed medical files of all patients in the 
Netherlands in whom M. xenopi was isolated from January 1999 through 
March 2005, by using diagnostic criteria for nontuberculous mycobacterial 
infection published by the American Thoracic Society. We found 49 patients, 
mostly white men, with an average age of 60 years and pre-existing pulmonary 
disease; of these patients, 25 (51%) met the diagnostic criteria. Mycobacterial 
genotype, based on 16S rRNA gene sequencing, was associated with true 
infection. Most infections were pulmonary, but pleural and spinal infections 
(spinal in HIV-infected patients) were also noted. Treatment regimens varied in 
content and duration; some patients were overtreated and some undertreated.
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Introduction
Mycobacterium xenopi was first described by Schwabacher in 1959; it was isolated 
from skin lesions in a clawed frog and named after the official species designation 
of the frog, Xenopus laevis.1 Thereafter, these slow-growing mycobacteria have 
been recovered from heated water systems in many countries and more recently 
from natural waters in Finland.2 Transmission to humans is believed to originate 
from the environment, through aerosol inhalation or ingestion. Human-
to-human transmission and transmission from animal reservoirs remain 
controversial because these routes have not been proven by molecular typing.3,4 
Pulmonary M. xenopi infections are most common, but extrapulmonary and 
disseminated infections have also been recorded.5,6 A predisposing factor is 
impaired immunity, either local (e.g., pre-existing pulmonary disease) or 
systemic (e.g., hematologic malignancy, immunosuppressive medication, or 
HIV/AIDS).5,7
Its survival in flowing water systems and resistance to common disinfectants 
enables M. xenopi to contaminate laboratory samples and medical devices 
such as bronchoscopes, thus causing healthcare-acquired (pseudo)infections 
and laboratory cross-contaminations.3,6,8,9 Differentiating true infection from 
pseudoinfection is of paramount importance because treatment of M. xenopi 
infections is time-consuming and often complicated. The British Thoracic 
Society (BTS) trial in 2001 established that treatment for pulmonary infections 
should consist of a 2-year course of rifampicin and ethambutol; regimens 
including macrolides or fluoroquinolones are still being investigated.10 
The American Thoracic Society (ATS) established general criteria for the 
diagnosis and treatment of nontuberculous mycobacterial, not specifically 
M. xenopi, infections. The treatment guidelines are similar to those by the 
BTS, although the ATS guidelines advocate macrolide-containing regimens.5 
To assess frequency and clinical relevance of M. xenopi isolation and its 
determinants in the Netherlands, we performed a retrospective case study. 
We used the ATS diagnostic criteria available during the study period to 
differentiate true infection from pseudoinfection.
 
Methods
To determine clinical relevance, we examined medical records of all patients in 
the Netherlands from whom M. xenopi had been isolated from January 1999 
through March 2005. The following variables were extracted from the records: 
sex, age, predisposing factors, symptoms, chest imaging results, treatment and 
outcome, and drug susceptibility and status according to the ATS diagnostic 
criteria.5
Laboratory diagnosis of the isolates was made by the Dutch National Institute 
of Public Health and the Environment (RIVM) or by a local hospital laboratory. 
RIVM acts as the national reference laboratory that provides identification, 
drug-susceptibility testing, and genotyping of mycobacterial isolates for all 
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hospitals and other healthcare institutions in the Netherlands. To identify a 
mycobacterial isolate, a GenoType MTBC reverse line-blot (Hain Lifescience, 
Nehren, Germany) was used after PCR-based amplification to determine 
whether an isolate was a member of the M. tuberculosis complex. If the 
reaction was negative, an INNO-LiPA MYCOBACTERIA v2 (Innogenetics, 
Gent, Belgium) reverse hybridization multiple DNA probe assay was used 
to differentiate between the more common species of nontuberculous 
mycobacteria, including M. xenopi.11 Before 2004, 16S rDNA gene sequence 
analysis was performed, after ruling out membership in the M. tuberculosis 
complex, by using the AccuProbe MTB DNA probe kit (GenProbe, San Diego, 
CA, USA). The result was compared with the RIVM and GenBank (National 
Center for Biotechnology Information, www.ncbi.nlm.nih.gov) 16S rDNA 
gene sequence databases.12
On the basis of the results at position 90 in the 151bp hypervariable region 
of the 16S gene, two M. xenopi genotypes were discerned; a C at position 90 
distinguished M. xenopi I and a T distinguished M. xenopi II. Retrospectively, 
the 16S rRNA genes of all M. xenopi isolates at RIVM were sequenced and 
assigned to their respective genotypes.
Susceptibility testing was performed by using an agar dilution method.13 Drugs 
in the susceptibility testing panel were isoniazid, rifampicin, ethambutol, 
streptomycin, cycloserine, prothionamide, amikacin, ciprofloxacin, 
clofazimine, clarithromycin, and rifabutin. The Pearson χ2 test was used for 
statistical correlations. The local ethics committee approved the study.
Results
We found 49 patients with M. xenopi isolates (Table 1); of these, 25 (51%) 
met the ATS diagnostic criteria. Isolates from 46 patients were identified to 
the genotype level, I or II. Sequencing failed for two, and one was unavailable 
at RIVM. Mycobacterium xenopi I was found for 28 patients, M. xenopi II for 
13, and mixed (types I and II) for five. Isolation of type II was significantly 
associated with fulfillment of the ATS criteria compared with isolation of type 
I only (77% vs 39%; odds ratio [OR] 5.1, 95% confidence interval [CI] 1.2–23.0, 
p = 0.025). When we defined M. xenopi II cultures as “involving M. xenopi II,” 
and thus included the mixed cultures, the correlation increased in significance 
(OR 5.4, 95% CI 1.4–20.8, p = 0.011).
Clinical signs and symptoms varied widely and were not associated with 
fulfillment of the ATS diagnostic criteria (Table 1). Chest radiographs were 
taken for all patients, except for two who had spinal infection (Table 1). 
Cavitation was the only radiographic finding significantly associated with 
fulfillment of the ATS diagnostic criteria (OR 14.3, 95% CI 2.7–75.6, p = 
0.001). Results of additional computed tomography scanning, performed for 
27 patients, were not associated with fulfillment of the ATS diagnostic criteria 
(data not shown).
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Characteristic ATS+
(n = 25)
ATS–
(n = 24)
Total (%)
Demographics
Male sex 19 18 37 (76)
Mean age, y 60 60 60
Dutch origin 24 20 44 (90)
Concurrent and predisposing conditions
Pre-existing pulmonary disease 21 18 39 (80)
Chronic obstructive pulmonary disease 17 14 31 (63)
Lung cancer 1 3 4 (8)
Prior tuberculosis 0 2 2 (4)
Recurrent pulmonary infection† 5 2 7 (14)
Bronchiectasis 2 4 6 (12)
Smoker, current/ past 15/ 6 11/ 3 35 (71)
Alcohol abuse 2 3 5 (10)
High-dose steroid use‡ 3 5 8 (16)
HIV infection 2 5 7 (14)
Mean CD4 count in HIV-infected patients, 
cells/mL  
226 126 159
Hematologic malignancy 0 1 1 (2)
Otherwise impaired immunity§ 2 1 3 (6)
Signs and symptoms
Productive cough 21 20 41 (84)
Hemoptysis 5 4 9 (18)
Dyspnea 14 9 23 (47)
Fever 11 6 17 (35)
Weight loss 12 7 19 (39)
Malaise 16 10 26 (53)
Chest radiographic abnormalities
Infiltrate 15 12 27 (55)
Cavity 12¶ 3 15 (31)
Pleural thickening 3 4 7 (14)
Emphysema 9 9 18 (37)
Space-occupying lesion 1 3 4 (8)
*ATS+, American Thoracic Society diagnostic criteria for nontuberculous mycobacterial infection 
met; ATS–, ATS diagnostic criteria for nontuberculous mycobacterial infection not met.
†>3 requiring treatment in 6 months before primary M. xenopi culture.
‡>15 mg prednisone/day for >3 months before primary M. xenopi culture.
§Diabetes mellitus, cisplatinum chemotherapy, anorexia nervosa (all n = 1).
¶Significant association (odds ratio 14.3, 95% confidence interval 2.7–75.6, p = 0.001).
Table 1: Baseline population characteristics of 49 patients with M. xenopi isolates, the 
Netherlands, January 1999 through March 2005*
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We found four cases of extrapulmonary disease, two cases of pleural M. xenopi 
infection, and two cases of spondylodiscitis (the latter in HIV–co-infected 
patients). The pleural infections were diagnosed by biopsy of pleural tissue 
for one patient and repeated pleural fluid culture for the other, after chest 
radiograph demonstrated pleural thickening and fluid collection. The spinal 
infections were diagnosed by bone biopsy. In the pleural and bone biopsy 
specimens, granulomatous lesions with central necrosis were observed.
For most patients, M. xenopi was first isolated from sputum (51%), 
bronchoalveolar lavage fluid (35%), or lung biopsy sample (4%). Remaining 
isolates were from bone biopsy samples (4%), pleural fluid (2%), pleural biopsy 
samples (2%), and stool samples (2%). Acid-fast bacilli were detected with 
direct microscopy of primary samples for 39% of patients. An acid-fast bacilli–
positive primary sample, regardless of its nature, was significantly associated 
with fulfillment of the ATS diagnostic criteria (OR 8.2, 95% CI 2.1–31.6, 
p<0.001).
Treatment was started for 25 of 49 patients, of whom 19 met the ATS diagnostic 
criteria. Therapy consisted of medication for 21 patients, surgery for two, or 
both for two. Surgery consisted of lobectomy, pulmonary wedge resection, 
Clagett pleurostomy, and vertebral surgery with psoas muscle abscess drainage. 
Medication regimens varied widely but generally included rifampicin, 
isoniazid, ethambutol, clarithromycin, ciprofloxacin, and pyrazinamide in 
various 3- to 4-drug combinations. Duration of therapy varied between five 
days and 2.5 years, with a mean duration of nine months. Macrolides were 
included in regimens for 58% and quinolones for 37% of the patients who met 
the ATS diagnostic criteria and received drug treatment.
Antimycobacterial treatment cured 11 out of the 19 (58%) patients who met 
the ATS diagnostic criteria: seven with M. xenopi II, two with M. xenopi I, 
and two with M. xenopi I and II. We defined cure as resolution of symptoms 
and negative cultures after finishing treatment, until the end of our study 
period (range 0–60 months, median 25 months). Treatment failure, defined as 
protracted culture positivity for M. xenopi during and after adequate treatment, 
was noted for four (21%). Four other patients died. Treatment failure or 
death was not associated with genotype, susceptibility pattern, predisposing 
conditions, or radiographic imaging results.
Although they fulfilled the ATS diagnostic criteria, four patients did not receive 
treatment. Of these, one recovered spontaneously; two remained positive for 
acid-fast bacilli, culture, or both throughout the study period and one died. 
These outcomes were not associated with specific genotypes or patient factors.
Susceptibility testing was performed for 47 isolates from 42 patients. For five 
patients, cultures failed to grow for testing; for two others, cultures were not 
available. Results for isoniazid, rifampicin, and ethambutol are shown in Table 2. 
Isolates were susceptible to all other compounds tested. Susceptibility testing 
of follow-up cultures was performed for five patients. Mycobacterium xenopi 
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bacteria in two patients treated with rifampicin became resistant to rifampicin 
and to ethambutol in one patient. For nine patients, susceptibility testing 
results influenced the treatment regimens, mostly by inclusion or exclusion of 
rifampicin and ethambutol or by adding a quinolone or macrolide agent.
For six patients with cavitation visible on chest radiograph, of whom four met 
the ATS diagnostic criteria, fungi were cultured simultaneously (Aspergillus 
fumigatus from four, A. flavus from one, and Scedosporium apiospermum from 
one). Antifungal treatment was initiated for four patients, which meant true 
M. xenopi infection was left untreated for two.
Four patients who had received antimycobacterial treatment for M. xenopi 
infection before (mean duration eight months) had relapses. The mean 
interval between discontinuation of drug treatment and relapse was 28 months 
(range 12–39). We found no evidence of geographic clustering, which suggests 
nosocomial transmission or a pseudo-outbreak. The number of new isolates 
per year remained steady at ~8 per year. At least five patients were treated in 
preventive isolation for 2–15 days until M. tuberculosis complex infection was 
excluded by PCR.
 
Discussion
Clinical relevance of M. xenopi isolation, defined by fulfillment of the ATS 
diagnostic criteria, was likely in 51% of patients; mycobacterial genotype II 
was a major determinant. To our knowledge, this phenomenon and its causal 
mechanisms have not been described. If further evidence emerges, 16S rDNA 
gene sequencing may become a relevant addition to the diagnostic algorithm 
of M. xenopi infection.
The ATS diagnostic criteria are designed for M. avium, M. kansasii, and M. 
abscessus infections, although the authors state “there is no reason to believe 
these criteria would not be applicable to other species”.5 Because the BTS 
statement focuses on management rather than specific diagnostic criteria,14 
the ATS diagnostic criteria are recommended for the clinical setting. Of the 
main ATS diagnostic components, two were each significantly associated 
with true infection in our study (cavitary lesions on chest radiograph and 
acid-fast bacilli on primary samples), thereby supporting the ATS criteria. 
Susceptibility No. (%) susceptible to
Isoniazid Rifampicin Ethambutol
Susceptible 9 (21) MIC 0.2 mg/L 29 (69) MIC <1mg/L 5 (12) MIC 5 mg/L
Intermediate 32 (76) MIC 0.5–1.0 mg/L 11 (26) MIC 10 mg/L
Resistant 1 (2) MIC >1 mg/L 13 (31) MIC >1 mg/L 26 (62) MIC >10 mg/L
Table 2: Baseline in vitro susceptibility of primary isolates from 42 patients with M. 
xenopi infection, the Netherlands, January 1999 through March 2005
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The ATS diagnostic criteria, however, have one limitation. Patients with pre-
existing cavitary lesions are likely to have respiratory symptoms; they meet 
the radiologic criteria and are more likely to harbor mycobacteria in the 
cavity, which are not necessarily responsible for their symptoms and cavity 
formation. Cavity characteristics cannot reliably predict the cavity’s origin 
or pathogenesis.15 The uncertainty is compounded when fungi are cultured 
simultaneously, which suggests matching requirements for in vivo success of 
these microorganisms or selective impaired immunity. Determining which 
organism causes disease in the patient is difficult.
The undertreatment and overtreatment that we noted indicate a relative lack 
of knowledge in physicians, mainly those specializing in pulmonary diseases, 
concerning nontuberculous mycobacteria infections. Unnecessary drug 
treatment could harm the patient in terms of adverse effects and costs,16 and 
undertreatment of patients who fulfill the diagnostic criteria is potentially 
harmful to the patients’ health.
The baseline characteristics of our study group are similar to those in studies of 
nontuberculous mycobacteria patients in societies with low HIV prevalence.5,10 
The North American series included more HIV-infected patients, which 
lowered the mean age of patients in these studies.17,18 Pre-existing pulmonary 
diseases are major predisposing factors and may be causally associated with 
isolation of M. xenopi. However, M. xenopi may have been isolated more often 
because physicians were more focused on mycobacterial cultures for this 
category of patients.
Minor predisposing factors were HIV infection or other causes of impaired 
immunity, which, in addition to the causal relationship, probably reflects the 
low prevalence of HIV infection compared with chronic pulmonary disease in 
the Netherlands. Also, because most HIV-infected patients receive highly active 
antiretroviral therapy, fewer cases of severe HIV immunosuppression and its 
co-infections are seen. HIV infection predisposes patients to extrapulmonary 
M. xenopi infection, especially spinal infection.6,19 Those with HIV-associated 
spinal M. xenopi infection had rising CD4 counts after starting or changing 
highly active antiretroviral therapy regimens (Table 1). Possibly, their M. 
xenopi infection was an expression of immune reconstitution inflammatory 
syndrome.20 We found no previous reports of pleural infections.
Although the treatment regimens recorded in our study were not in 
accordance with the current standards of the BTS14 and ATS,5 cure rates were 
high. Although partly the result of the restricted definition of “cure” resulting 
from our research methods, this finding does bring the validity of the ATS 
diagnostic criteria into question. Despite meeting these criteria, some patients 
might have cleared M. xenopi infection without treatment. This possibility 
is also endorsed by the spontaneous recovery of a minority of patients who 
met the ATS criteria but were not treated. Alternatively, the regimen of 24 
months of rifampicin and ethambutol advised by the BTS may not be better 
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than similar regimens of shorter duration. The addition of macrolides and 
quinolones to therapy regimens might also account for the high cure rates after 
relatively short treatment durations.
Susceptibility testing results were similar to those published previously,21 but 
their value in clinical practice is uncertain. Interpretation of the laboratory 
results is difficult because of discrepancies between in vitro susceptibility 
and in vivo response to treatment.5,21 In our study, results rarely influenced 
treatment regimens; when they did, choice of regimen was controversial and 
not in accordance with ATS and BTS guidelines.5,14 Increasing use of PCR to 
rule out M. tuberculosis infection can be valuable for preventing or shortening 
patient isolation.
In conclusion, clinical isolation of M. xenopi was relevant for 51% of the 
patients; mycobacterial genotype was a major determinant. Currently, the 
ATS diagnostic criteria are the best tool for determining clinical relevance. 
We strongly recommend increased awareness of these diagnostic criteria and 
management guidelines by ATS and BTS.
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Abstract
The aim of the present study was to determine the clinical relevance of 
Mycobacterium simiae isolation from clinical samples. 
The medical files of patients in the Netherlands from whom M. simiae was 
isolated between 1999 and 2006 were reviewed in order to assess frequency 
and clinical relevance. Clinical relevance was defined as fulfilment of the 
diagnostic criteria of the American Thoracic Society. 
From the files, twenty-eight patients were identified, of whom six (21%) met the 
American Thoracic Society diagnostic criteria. A slight female predominance 
(54%) was observed, which is uncommon for NTM isolation. Fulfilment of 
the diagnostic criteria and initiation of treatment were not in agreement; 
treatment results were poor. 
Only a minority of clinical M. simiae isolates are clinically relevant and, applying 
the ATS diagnostic criteria, the number of true infections is overestimated. 
Physicians in the Netherlands do not always use these criteria in daily practice, 
resulting in both over- and underdiagnosis of M. simiae infection. Further 
studies are needed to improve diagnostic criteria and treatment regimens.
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Introduction
In 1965, Karassova et al. reported the isolation of a new species of nontuberculous 
Mycobacterium (NTM), which they named Mycobacterium simiae as it was isolated 
from Macacus rhesus monkeys (Latin; simiae: of monkeys).1 In 1975 Weiszfeiler 
and Karczag found that the previously described species M. habana was in reality 
also M. simiae.2
Clinical M. simiae isolation at first seemed restricted to the south of the USA, Israel 
and Cuba.3 However, in due course, M. simiae isolation has been reported from 
many places in the world.4-6
Mycobacterium simiae is present in the environment and can contaminate medical 
equipment and laboratory samples.3,7 Therefore, M. simiae isolation is not clinically 
relevant per se. Reports on M. simiae in the literature mainly describe single cases 
of infection; few authors have reported clinical relevance. The American Thoracic 
Society (ATS) has published guidelines for the diagnosis and treatment of NTM 
infections. Their diagnostic criteria are designed to distinguish between true and 
pseudo-infection, and thus to assess clinical relevance.8 
In the current study, the frequency and clinical relevance of M. simiae isolation 
in the Netherlands were determined using the ATS diagnostic criteria available 
during the study period.8
Methods
The medical records of all patients in the Netherlands from whom M. simiae was 
isolated between January 1999 and January 2006 were examined. We recorded 
demographic data, clinical data, drug susceptibility and whether the ATS diagnostic 
criteria available at the time were met.8 The impact of the renewed ATS diagnostic 
criteria published in 2007 was analyzed separately.9
The isolates of the patients were subjected to laboratory diagnosis by the Dutch 
National Institute of Public Health and the Environment (RIVM, Bilthoven, the 
Netherlands). This is the national reference laboratory, providing identification, 
drug susceptibility testing and genotyping of Mycobacterium isolates for all health-
sector institutions in the Netherlands. 
After ruling out membership of the M. tuberculosis complex, using the GenoType 
MTBC (Hain Lifescience, Nehren, Germany) reverse line blot, an INNO-LiPA 
MYCOBACTERIA v2 (Innogenetics, Gent, Belgium) reverse line blot was used to 
identify common species of NTM, including M. simiae. Prior to 2004, 16S rDNA 
gene sequence analysis (151bp) was performed after ruling out membership of the 
M. tuberculosis complex using the AccuProbe MTB DNA probe kit (GenProbe, 
San Diego, USA). 
Drug susceptibility testing was performed using the agar dilution method.10 The 
drugs tested were isoniazid, rifampicin, ethambutol, streptomycin, cycloserine, 
prothionamide, amikacin, ciprofloxacin, clofazimine, clarithromycin and rifabutin.
Pearson χ2 and Fisher exact tests were used for correlations. The study was approved 
by the regional ethics committee. 
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Results
Mycobacterium simiae was isolated from 28 patients during the study period. 
No extrapulmonary isolates or disease were noted during the study period. 
The baseline patient characteristics are shown in Table 1. Six patients (21 %) 
met the ATS diagnostic criteria, based on features detailed in Table 2. 
Patients who met the ATS diagnostic criteria for true NTM infection were 
significantly older than those who did not (73 vs. 63 years; 95%CI: 3.0-18.0; 
p=0.008; Table 1). 
Productive cough (96%), dyspnea (54%) and malaise (32%) were the most 
commonly reported symptoms, although only patients who reported weight 
loss were significantly more likely to meet the ATS diagnostic criteria (p=0.038 
OR 9.0; 95%CI 1.3-10.5). 
Chest radiographs at the time of primary sampling mostly showed infiltrates 
(54%), pre-existent emphysema (25%) or fibrosis (25%) and suspected 
malignant lesions (11%). Of the radiographic abnormalities, both nodular 
(p=0.040) and cavitary lesions (p=0.040) on chest X-ray were significantly 
associated with meeting the ATS diagnostic criteria. 
The M. simiae isolates were cultured from sputum (44%), bronchoalveolar 
lavage (BAL) fluid (52%) and lung biopsy specimens (4%). Of all primary 
samples, 22% were positive for acid fast bacilli (AFB) on direct microscopy. 
An AFB positive primary sample was significantly associated with meeting the 
ATS diagnostic criteria (p=0.010; OR 20.0; 95%CI 1.7-30.9).
ATS+ (n=6) ATS- (n=22) Total (n=28)
Male 2 11 13 (46%)
Female 4 11 15 (54%)
Mean age (yr) 73* 63 65
Dutch origin 6 20 26 (93%)
Pre-existing pulmonary disease 6 20 26 (93%)
COPD 5 16 21 (75%)
Lung cancer 0 2 2 (7%)
Prior tuberculosis 2 1 3 (11%)
Bronchiectasis 2 3 5 (18%)
Current smoker 0 3 3 (11%)
History of smoking 3 11 14 (50%)
Alcohol abuse 0 1 1 (4%)
HIV infection 0 1  1 (4%)
Hematologic malignancy 0 1 1 (4%)
Otherwise impaired immunity# 0 2 2 (7%)
* significant difference, 95%CI: 3.0-18.0; p=0.008
# methotrexate-associated pancytopenia, cystic fibrosis (both n=1)
Table 1: Baseline population characteristics
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Six patients started drug treatment; three of them had met the ATS diagnostic 
criteria. One of these three was cured (defined by improvement of symptoms 
and negative cultures until the end of the study period), one relapsed and 
one died due to progression of M. simiae disease (Table 2). Three received 
treatment without having met the ATS diagnostic criteria, for a mean duration 
of 30 days (range 14-56 days), until an alternative diagnosis was made 
(disseminated Histoplasma capsulatum infection and malignancy (each n=1)) 
or identification of the NTM as M. simiae was communicated (n=1).
Most commonly used drugs were rifampicin, ethambutol, ciprofloxacin and 
clarithromycin. Three patients met the ATS diagnostic criteria but did not 
receive treatment. In two, this decision was based on the estimated chance 
of successful treatment and the burden of treatment on the patients involved; 
in one the stable clinical picture was the main reason. Two of the patients 
remained clinically stable and one showed radiological deterioration (Table 2).
Drug susceptibility testing was performed for a single isolate of 25 patients, and 
invariably demonstrated in vitro resistance to rifampicin, ethambutol, isoniazid, 
streptomycin, amikacin and rifabutin. Resistance to ciprofloxacin (72% of 
isolates) and clarithromycin (84%) were frequent. Isolates were all susceptible to 
clofazimine and cycloserine and most (76%) were susceptible to prothionamide.
The ATS has recently published new diagnostic criteria for NTM infections with 
stricter radiological but less strict microbiological criteria for true infections. 
In addition, the criteria now state “making the diagnosis of NTM lung disease 
does not, per se, necessitate the institution of therapy”.9 Eight patients in our 
study (29%) met the new criteria, due to the less strict microbiological criteria.
Patient 1 2 3 4 5 6
Sex, Age F, 79 F, 68 M, 75 F,  72 M, 76 F, 70
Predisposing 
conditions
COPD TB COPD COPD, 
Bronchiectasis
COPD, TB, 
Bronchiectasis
Symptoms C,H,W,M C,H C,D,F,M C,W C,H,F,W,M C,H,W
Cultures/
positive
2/ 2 
(Smear+)
4/ 4 (Smear+) 5/ 3 
(Smear-)
9/ 6 (Smear+) 6/ 5 (Smear+) 3/3 
(Smear-)
Chest X-ray Infiltrate Cavities Infiltrate Nodular Cavities, 
Nodular
Infiltrate
Histiology - GI - NSI GI NSI
Treatment 2ECipCla 2HRZE6ECipCla None None 1HRZ3RbECla None
Outcome Improved Relapse Stable Deteriorated Relapse; died Stable
COPD=chronic obstructive pulmonary disease; TB=tuberculosis; C=productive cough; 
H=hemoptysis; W=weight loss; M: malaise/asthenia; F=fever; GI=granulomatous inflammation; 
NSI=non-specific inflammation; E=ethambutol; R=rifampicin; Rb=rifabutin; H=isoniazid; 
Z=pyrazinamide; Cip=ciprofloxacin; Cla=clarithromycin
Table 2: Characteristics of patients with true M. simiae infections
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Discussion
In 21% of the 28 patients, M. simiae isolation represented clinically relevant 
disease, as defined by the ATS diagnostic criteria. This low degree of clinical 
relevance demonstrates the probably limited pathogenicity of M. simiae in 
humans.
In contrast to other NTM species, a small majority of M. simiae isolates were 
cultured from samples in women. The low number of patients in the current 
study, however, prevents firm conclusions on gender distribution. Predisposing 
conditions, mainly pre-existent lung disease, were similar to those observed 
for other NTM species.8,11 During a nationwide survey in the USA, O’Brien 
et al. recorded a similar degree of clinical relevance (21%) and a comparable 
gender distribution (48% females) in 67 patients.11 The causes of this possibly 
unusual gender distribution remain unknown. Extrapulmonary infections 
are seldomly reported and restricted to immunocompromised hosts.8,11 Cases 
have occurred in the Netherlands before the present study period.12
In those patients who met the ATS diagnostic criteria, treatment results were 
poor, with frequent relapses (Table 2). Those who met the ATS diagnostic 
criteria but were left untreated remained clinically stable. Therefore, benefit 
of current drug treatment regimens may be questioned, although our study 
group is too small to draw firm conclusions. Alternatively, the ATS diagnostic 
criteria may not select the patients for whom treatment would be beneficial. 
Although designed for M. avium, M. kansasii and M. abscessus, the authors 
state that “there is no reason to believe these criteria would not be applicable 
to other species”.8 The present data, however, suggest that the ATS criteria are 
not applicable for M. simiae, as they over-diagnose true pulmonary M. simiae 
infections. Applying the latest ATS criteria,9 with more lenient microbiological 
criteria, further increased the number of true infections, since meeting 
the clinical and radiological criteria was common in our study group; the 
microbiological criteria were the major hurdle. 
Increasing the number of positive cultures required for diagnosis to more 
than three in one year, or reservation of the diagnosis for histologically proven 
infections alone, may lead to improved selection of patients to benefit from 
treatment. In the present study, this would result in three cases (11% of all 
patients) of true infection, requiring treatment (Table 2; patients 2,4,5). In line 
with this observation, Rynkiewicz et al., on the basis of stricter clinical and 
histological criteria, found 9% of 23 patients having true M. simiae infections.13 
Limited treatment results in the present study group demonstrate that the 
content and duration of treatment regimens require further study.
Although not suffering true infections, three patients in the present study were 
treated for NTM infection. This overtreatment may harm patients in terms of 
adverse effects and costs.14 Moreover, it indicates the difficulty in diagnosing 
true infections. The limited exposure of physicians in the Netherlands to 
NTM disease leads to limited experience with the currently available, albeit 
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imperfect, diagnostic criteria. Probably this is one of the main reasons of the 
observed over- and undertreatment. 
When considering treating a patient, age and concomitant diseases might 
be a factor in the decision; the significantly higher age of patients who 
met the ATS criteria complicates this situation. The contribution of drug 
susceptibility testing results to the drug treatment decision remains limited, 
as the association between in vitro susceptibility and the in vivo response has 
not been established for most drugs.8 Application of the new ATS criteria 
not only leads to diagnosis of more M. simiae infections, but also leaves the 
treatment decision more to the physician. For the infrequently encountered 
NTM, centralization of expertise and easily accessible expert consultation is 
therefore important, as acknowledged in the new statement.9
In conclusion, clinical M. simiae isolation occurs infrequently in the 
Netherlands, with a slight female predominance uncommon to other NTM. 
A minority of isolates represents true infection, which suggests limited 
pathogenicity in humans. The available diagnostic criteria are inadequate for 
the selection of patients for whom drug treatment for true M. simiae infection 
would be beneficial. Critical evaluation of more patients from whom NTM 
have been isolated will help to fine tune the criteria for improved diagnosis and 
treatment of NTM infection.
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Clinical relevance of Mycobacterium 
szulgai in the Netherlands
Jakko van Ingen1,2, Martin J. Boeree1, Wiel C.M. de Lange1, Petra E.W. de Haas2, 
P.N. Richard Dekhuijzen1, Dick van Soolingen2
1 Department of Pulmonary Diseases, Radboud University Nijmegen Medical Center, Nijmegen, 
the Netherlands; 2 National Mycobacteria Reference Laboratory, National Institute for Public 
Health and the Environment, Bilthoven, the Netherlands
Abstract
Background: The clinical relevance of Mycobacterium szulgai isolates is 
unknown, and available literature focuses on case reports of M. szulgai disease. 
We assessed the clinical relevance of M. szulgai isolated from patients in the 
Netherlands.
Methods: We reviewed medical files for all 21 patients in the Netherlands 
from whom M. szulgai was isolated during 1999-2006, applying the diagnostic 
criteria of the American Thoracic Society for nontuberculous mycobacterial 
infection. Random amplified polymorphic DNA genotyping was performed 
using IS986, OPA-2 and OPA-18 as primers. 
Results: Of the 21 patients, 16 (76%) met the American Thoracic Society 
diagnostic criteria and were thus likely to have M. szulgai disease. Pulmonary 
M. szulgai disease was the most common presentation, with extrapulmonary 
disease restricted to patients with an impaired systemic immunity. Although 
treatment regimens varied in content and duration, the outcomes were mostly 
favorable. Both overtreatment and undertreatment were noticed.
Random amplified polymorphic DNA genotyping revealed a higher degree 
of interpatient variability, with limited intrapatient variability, suggesting 
persisting monoclonal infection and good reproducibility. No genotype was 
associated with clinical relevance.
Conclusions: Clinical isolation of M. szulgai generally represents true disease 
and demands careful follow-up. Extrapulmonary disease occurs in patients 
with impaired immunity. Adherence to diagnostic guidelines can be improved.
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Introduction
Mycobacterium szulgai is a slow-growing nontuberculous mycobacterium 
(NTM) that was first described in 1972 by Marks et al. and that was named 
after Dr. T. Szulga, who developed the lipid analysis method that identified 
this NTM as a new species.1 Nontuberculous mycobacteria are opportunistic 
pathogens, with local events (e.g. chronic obstructive pulmonary disease 
[COPD] or healed tuberculosis) or systemic impaired immunity (e.g. receipt of 
immunosuppressive medication, HIV infection or hematological malignancy) 
as the predisposing condition.2 Pulmonary M. szulgai disease, which resembles 
tuberculosis, is the most common presentation, although extrapulmonary and 
disseminated disease has been recorded.1-6 
Mycobacterium szulgai has been recovered from environmental sources, 
including a snail, aquarium water, swimming pool water, and tropical fish.3-6 
The environment is the suspected source of human NTM infection.4,7 Therefore 
M. szulgai disease has to be distinguished from pseudoinfection because of 
the occasional presence of M. szulgai in clinical samples or contamination of 
samples in the laboratory.2,7
The American Thoracic Society (ATS) published guidelines for diagnosis 
and treatment of NTM infections, which consist of clinical, radiological and 
bacteriological criteria and are summarized in Box 1.2 
We reviewed the medical files of all patients in the Netherlands from whom 
M. szulgai was isolated during the period from January 1999 through January 
2006. We assessed the frequency and clinical relevance of M. szulgai isolation 
using the current ATS diagnostic criteria2 and we evaluated drug susceptibility, 
treatment regimens and outcome. In addition, we analyzed the genotypes of all 
clinical isolates that were evaluated, to study the molecular epidemiology of M. 
szulgai in The Netherlands.
Methods
To determine clinical relevance, we examined the medical records of all 
patients in the Netherlands from whom M. szulgai was isolated between 
January 1999 and January 2006. We recorded sex, age, predisposing factors, 
symptoms, chest imaging results, treatment and outcome, drug susceptibility 
and status in accordance with the diagnostic criteria of the ATS.2 We defined 
cure as clinical and radiographic improvement during treatment and absence 
of positive culture results after completion of treatment.
In all patients, the isolates were subjected to laboratory diagnosis by the Dutch 
National Institute for Public Health and the Environment (RIVM), or a self-
sufficient hospital laboratory. All self-sufficient hospitals used 16S rDNA gene 
sequence analysis for identification and granted access to their databases, to 
ensure full national coverage. The RIVM is the national reference laboratory 
that provides identification, drug susceptibility testing and epidemiological 
typing of mycobacterial isolates for all hospitals in the Netherlands. At the 
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RIVM we used 16S rDNA gene sequence analysis to identify mycobacteria, 
after ruling out membership of the M. tuberculosis complex, using a GenoType 
MTBC strip (Hain Lifescience, Nehren, Germany), or the more common 
species of NTM, with an INNO-LiPA MYCOBACTERIA v2 (Innogenetics, 
Gent, Belgium) reverse line blot. Mycobacterium szulgai is not incorporated 
in this line blot.
We used the agar dilution method for drug susceptibility testing. Drugs 
tested were isoniazid, rifampicin, ethambutol, streptomycin, cycloserine, 
prothionamide, amikacin, ciprofloxacin, clofazimine, clarithromycin and 
rifabutin.8
Genotypes were determined using Random Amplified Polymorphic DNA 
(RAPD) fingerprinting.9 We selected OPA2, OPA18 and IS986 as primers. The 
study was approved by the regional ethics committee.
Results
Files were reviewed for 21 patients. The patients’ clinical characteristics are 
detailed in table 1. Sixteen patients (76%) met the current ATS diagnostic 
criteria and therefore we considered them to have M. szulgai disease. Eighteen 
patients (86%) were male, and 20 (95%) were of Dutch origin; the mean age 
was 56 years. Most primary M. szulgai isolates were obtained from pulmonary 
samples (sputum samples, 7 isolates [33%]; bronchoalveolar lavage fluid 
samples, 8 isolates [38%]). Remaining primary isolates were obtained from 
skin specimens (two isolates [10%]) and from feces, joint aspirate, lymph 
node biopsy, and pleural fluid samples (one isolate each [5%]). Primary 
samples tested positive for acid-fast bacilli (AFB) by direct microscopy in 
Box 1: Summary of the 2007 American Thoracic Society diagnostic criteria 
American Thoracic Society Diagnostic Criteria of Nontuberculous 
Mycobacterial Lung Disease
Clinical criteria
1. Pulmonary symptoms, nodular or cavitary opacities on chest radiograph, or an HRCT scan 
that shows multifocal bronchiectasis with multiple small nodules.
and
2. Appropriate exclusion of other diagnoses.
Microbiological criteria
1. Positive culture results from at least two separate expectorated sputum samples. (If the 
results from the initial sputum samples are nondiagnostic, consider repeat sputum AFB 
smears and cultures.)
or
2. Positive culture results from at least one bronchial wash or lavage.
or
3. Transbronchial or other lung biopsy with mycobacterial histopathologic features 
(granulomatous inflammation or AFB) and positive culture for NTM or biopsy showing 
mycobacterial histopathologic features (granulomatous inflammation or AFB) and one or 
more sputum or bronchial washings that are culture positive for NTM.
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just four patients (19%). There were no relapses of prior M. szulgai disease. 
Remarkably, three patients had a history of Billroth II gastrojejunostomy; all 
three had M. szulgai disease. Impaired systemic immunity was associated with 
extrapulmonary disease (Odds ratio 4.0; 95% CI 1.71-9.35; p=0.006), but not 
with true disease overall (p=0.647).
Of the 15 patients with pulmonary isolates (table 1; patients 7-21), 11 (73%) had true 
disease (table 1). Thirteen patients (87%) were male, and all were of Dutch origin; 
the mean age was 60 years. Twelve patients (80%) had pre-existing pulmonary 
disease, mostly COPD (ten patients [67%]), and 11 patients (73%) were current 
or past smokers. Impaired immunity was noted in two patients (diabetes for one 
patient and use of tumor necrosis factor-α-neutralizing agents for the other).
Reported symptoms included productive cough (14 patients [93%]), 
hemoptysis (four patients [27%]), dyspnea (eight patients [53%]), weight loss 
(eight patients [53%]), and fever and malaise (six patients for each [40%]). 
All patients underwent chest radiography, and abnormalities were noted in 
14 patients. Infiltrates (seven patients [47%]), cavities (six patients [40%]), 
bronchiectasis (three patients [20%]), nodular opacities (one patient [7%]), 
pleural thickening (four patients [27%]), and scars of previous lung disease 
(seven patients [47%]) were observed. In ten patients, additional computed 
tomography (CT) scans of the thorax were performed, revealing one additional 
case of cavitary disease and one additional case of nodular bronchiectatic 
disease (in patients 7 and 20, respectively) (table 1). All other CT findings were 
concomitant with the findings on the chest radiograph.
Six patients (patients 1-6) had M. szulgai isolates from extrapulmonary sites 
(table 1). Five out of six (83%) patients met the ATS diagnostic criteria, having 
skin (two patients), joint, intestinal and lymph node infections (one patient 
each). The skin, joint and intestinal diseases represented disseminated disease. 
Five patients (83%) were male, and five (83%) were of Dutch origin; the mean 
age was 44 years. Predisposing conditions were HIV infection (two patients 
[33%]), interferon-γ receptor deficiency (two patients [33%]), and receipt of 
high-dose steroid treatment (one patient [17%]). Aside from local signs and 
symptoms, that are detailed in Table 1, patients reported a productive cough 
Table 1: Clinical characteristics of all 21 patients with Mycobacterium szulgai isolates
Note: M, male; F, female; Cult, cultures performed; Pos, total number of positive cultures; BAL, 
broncho-alveolar lavage; HIV, human immunodeficiency virus; IFN-γ RD, interferon γ receptor 
deficiency; B2G, Billroth II gastrojejunostomy; RTI, respiratory tract infection; COPD, chronic 
obstructive pulmonary disease; BR, bronchiectasis; TB, prior tuberculosis; anti-TNF, tumor 
necrosis factor alpha neutralizing treatment; PC, productive cough; H, hemoptysis; D, dyspnea; 
F, fever; WL, weight loss; M, malaise/fatigue; NS, night sweats; R, rifampicin, H, isoniazide, 
Z, pyrazinamide, E, ethambutol; Rb, rifabutin; Cla; clarithromycine; Cip, ciprofloxacin; Ofl, 
ofloxacin; Mer, meropenem; Dox, doxycyclin; n.a., not applicable.
 a  >15mg prednisone/day for >3 months
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(three patients [50%]), dyspnea (four patients [67%]), malaise (three patients 
[50%]), and weight loss (two patients [33%]). Three patients had abnormalities 
noted by chest radiography that consisted of nodular opacities in two patients 
(patients 4 and 6) and an infiltrate and pleural fluid collection in one patient 
(patient 3). Similar findings were noted in additional CTs of the thorax.
Reported symptoms and radiographic abnormalities were not significantly 
associated with fulfillment of the ATS diagnostic criteria, neither overall or 
specifically among patients with pulmonary or extrapulmonary isolates.
A total of 12 patients received antimycobacterial treatment, of whom 11 met 
the former ATS diagnostic criteria, which were available during the studied 
period.10 On average, treatment lasted for 12 months (range, 6-26 months) and 
consisted of rifampicin or rifabutin with ethambutol and clarithromycin and/
or a quinolone antibiotic. Two patients (patients 2 and 6) received concurrent 
treatment with interferon-γ, due to proven underlying interferon-γ receptor 
deficiency. Follow-up sputum microscopy or culture during treatment was not 
performed at regular intervals; five patients with pulmonary M. szulgai disease 
were known to have negative cultures after six months of treatment. Treatment 
outcomes are detailed in table 1; we recorded no failures or relapses. Two 
patients died: one during treatment, and the other died just after therapy (due 
to HIV-related cryptococcal meningitis in one and lung cancer in the other). 
The average duration of follow-up after treatment was 42 months (range, 9-84 
months). Three patients met the former ATS diagnostic criteria but were not 
treated; one died, one refused treatment, and one patient experienced conversion 
of culture results to negative. No signs of active NTM disease were noted during 
the follow-up for patients who did not meet the ATS criteria. Isolation measures 
were taken for four patients until PCR results for M. tuberculosis complex were 
proven to be negative.
In vitro, intermediate susceptibility to isoniazid (MIC 0.5-1 μg/ml) and 
susceptibility to all other compounds in the test panel was noted for all isolates. 
The MICs for rifampicin, ethambutol, and clarithromycin were 0.5-1, 2-5, and 
<2 μg/ml, respectively.
Genotyping of the isolates from our study period revealed little intrapatient 
and good interpatient variability (figure 1). Four major groups of strains are 
apparent. No associations between genotype and predisposing factors, patient 
origin, or clinical relevance were observed. Clustering that potentially indicates 
(pseudo-)epidemics or laboratory cross-contamination was not recorded. Two 
patients (patients 14 and 15, represented by lanes M and N in figure 1) had 
similar genotypes of M. szulgai, which was cultured in different laboratories 
and during different periods. They were not epidemiologically linked. In one 
patient (patient 5, represented by lanes W/X and Y in figure 1) two different M. 
szulgai strains were isolated; one sample (shown in lane Y) was cultured from 
feces, whereas the others (shown in lanes W and X) were from skin lesions. 
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Discussion
Mycobacterium szulgai isolation was found to be clinically relevant in 16 (76%) 
of the 21 patients included in this study. O’Brien et al. also reported a high rate of 
true M. szulgai infection (8 [57%] of 14 patients) in the first national survey from 
the United States.11 The current ATS criteria state “cultures yielding M. szulgai 
almost always have a pathological significance”;2 our findings are in accordance 
with this. No specific determinants significantly associated with M. szulgai disease 
were observed; the limited number of patients and the observed co-morbidities 
do not allow greater statistical certainty. Previous literature on M. szulgai disease 
focuses mainly on case reports.1,3-6,12,13 To our knowledge, we report the largest 
group of isolates examined thus far for their clinical relevance. Still, we may have 
missed M. szulgai isolates, because 16S rDNA gene sequencing is not a free service 
at the national reference laboratory, whereas identification by the INNO-LiPA 
MYCOBACTERIA v2 reverse line blot method - which does not recognize M. 
szulgai - is. However, few strains that are unidentifiable to the species level by this 
method are not sequenced, on the basis of an appraisal of the costs by the referring 
hospital. If cases of M. szulgai isolation have been missed, they will thus be very few. 
In addition, strains submitted for drug susceptibility testing are always identified to 
the species level, with 16S rDNA sequencing applied as appropriate.
Figure 1: RAPD genotyping results of 25 strains isolated from 19 patients
Four major strain types are discerned, type 1 in lanes A-E, type 2 in lanes F-R, type 3 in lanes 
S-V and type 4 in lanes W-Y; no association with geographical region, clinical relevance or 
specific predisposing conditions exists. Limited intra-patient variability is noted in patients with 
>2 year intervals between follow-up cultures (lanes A&B, I&J). Patient 5 has 2 distinct types 
from different body sites (lanes W/X&Y).
Note: DM, diabetes mellitus type 1; INFgRD, Interferon-γ receptor deficiency; Anti-TNF, tumor 
necrosis factor α neutralizing treatment; HIV, Human immunodeficiency virus. 
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The rate of extrapulmonary disease (31% of all cases of M. szulgai disease) was 
similar to that reported in prior publications by Marks et al. (43%),1 Benator et 
al. (29%)3 and Maloney et al. (33%).12 This may reflect the degree of impairment 
of immunity seen in this patient category, although it might also be a species-
specific phenomenon. We considered one positive pleural fluid culture for a 
patient with Streptococcus pneumoniae pneumonia with pleural effusion to 
have been contaminated on the basis of the patient’s clinical and radiographic 
improvement after receipt of treatment with penicillin, with complete 
resolution of the pleural fluid collection. The stool sample from one patient 
with HIV/AIDS was considered to be representative of a disseminated infection 
on the basis of a low CD4 count, symptoms, associated chest radiograph and 
CT abnormalities, which improved - as did the patient’s symptoms - after the 
initiation of antimycobacterial therapy; both interpretations remain debatable, 
because the pathway to diagnosis was not optimal.
The clinical and demographic features of our study group are comparable to 
those in previous reports.1-5,12,13 The number of patients with previous Billroth 
II gastrojejunostomy was an unexpected observation; gastric surgery has been 
recognized as a risk factor for the development of tuberculosis.14 Maloney et 
al. reported one case of M. szulgai disease with partial gastrectomy, smoking 
and alcohol abuse as predisposing factors.12 The three patients in our study 
also had multiple predisposing factors: they were smokers with AIDS, COPD 
and old age as individual risk factors. It remains controversial whether gastric 
surgery is a predisposing condition or a result of other predisposing conditions 
(e.g. heavy smoking and alcohol abuse) that cause gastric ulcers that require 
surgery. Contrary to reports of M. avium complex or M. abscessus pulmonary 
disease in the United States,2 we noted pulmonary M. szulgai disease only in 
patients with established predisposing conditions. This finding may reflect a 
difference in pathophysiology of infections with different NTMs.
In our cohort, we observed a favorable treatment outcome for all but two 
patients, and none of the cases in our study constituted relapses of prior M. 
szulgai disease. Previous studies recorded similar results, with the few relapses 
attributable to noncompliance with drug treatment or receipt of an inadequate 
drug regimen.1,3,12,13 Our findings imply that the observed average treatment 
regimen - 12 months of rifampicin, ethambutol and clarithromycin - leads to 
favorable outcomes without bacteriological relapse. In vitro drug susceptibility 
testing results supported this assumption. Randomized, controlled trials are 
needed to investigate optimal drug treatment and its duration. We realize, 
however, that these are difficult to perform, because they require a large, 
multiple-center approach to collect a large enough sample size. In our cohort, 
the treatment regimens were based on data from the available literature or 
expert consultation;10 the susceptibility of the isolates to the most frequently 
used drugs did not necessitate changes in therapy regimens.
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We observed possible instances of both undertreatment (i.e., patients who met 
the diagnostic criteria were not treated) and overtreatment (i.e., treatment 
of persons who did not meet diagnostic criteria). This, as well as the lack of 
bacteriological follow-up during treatment and handling of the uncertain cases 
of extrapulmonary disease discussed above, could reflect a lack of knowledge 
of and experience with the diagnosis and management of NTM disease in 
physicians or clinical circumstances that were not captured in our file review. 
Both over- and undertreatment can be harmful for patients.
The mostly unique genotypes imply acquisition of M. szulgai from the local 
environment rather than human-to-human transmission or laboratory 
contamination, as was found in previous studies.4,7,9 The uncertain pathogenesis 
and environmental reservoirs, as well as the low frequency of isolation are 
important drawbacks to these molecular epidemiological studies and to the 
interpretation of their results. The absence of an association between RAPD 
genotype and fulfillment of the ATS diagnostic criteria may reflect the 
importance of patient - rather than mycobacterial - factors in the etiology 
of M. szulgai disease. The limited intra-patient variability suggests good 
reproducibility and persisting monoclonal infections. In one patient (patient 
5), two infecting strains were found in specimens from separate body sites 
(as denoted in lanes W/X and Y in figure 1). The minor changes observed in 
serial isolates may hint at either limited reproducibility of RAPD genotyping 
or genetic drift of the infecting strain during chronic infection.
In conclusion, the vast majority (76%) of 21 patients with M. szulgai isolates 
in our study experienced true M. szulgai disease. Therefore, clinical M. szulgai 
isolation demands careful follow-up. Extrapulmonary disease occurs in 
patients with impaired immunity. Stricter adherence to diagnostic guidelines 
seems desirable. Treatment with rifampicin, ethambutol and a macrolide 
antibiotic leads to favorable outcomes; its optimal duration, as well as the 
efficacy of alternative regimens, requires additional study. Mycobacterium 
szulgai is most likely contracted from the environment, although this subject 
also requires further study. 
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Case Reports
The first patient, a 63-year-old Dutch male living in the south of the 
Netherlands, presented at a regional hospital with dyspnea and productive 
cough. No fever, malaise, hemoptysis, night sweats or weight loss was reported. 
His medical history included chronic obstructive pulmonary disease. Since a 
chest radiograph revealed a single opacity in the right upper lobe, computed 
tomography scanning (CT) was performed, demonstrating calcification in 
a mediastinal lymph node and a solid mass with spiculae in the right upper 
lobe, suggestive of malignancy. In the diagnostic work-up, a bronchoalveolar 
lavage was performed. No malignant cells were found in the cytology sample 
of the lavage fluid. Although no acid-fast bacilli (AFB) were seen on direct 
microscopy, the routine mycobacterial culture of the lavage fluid yielded 
Mycobacterium conspicuum. Serological examination lowered the suspicion of 
an infectious process, with an erythrocyte sedimentation rate (ESR) of 5mm/h 
and white blood cell (WBC) count of 7.8 per nl. Although no malignancy 
was cytologically proven, a mediastinoscopy was performed for staging of the 
suspected malignancy. No evidence of either malignancy or mycobacterial 
infection was found in the lymph node samples. Based on the radiographic 
image and mediastinoscopy result, the patient underwent a lobectomy of the 
right upper lobe and a squamous cell carcinoma was diagnosed histologically. 
No histological evidence of mycobacterial infection was found. Based on 
the single positive culture, nonsuspect radiographic image, and alternative 
diagnosis, the M. conspicuum isolate was considered a contaminant; hence, no 
antimycobacterial treatment was started. 
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The second patient was a 65-year-old Dutch male from the eastern part of 
the Netherlands whose medical history consisted of radiographic stage IV 
sarcoidosis. His sarcoidosis was not treated with immunosuppressive agents. 
The patient presented at another regional hospital with dyspnea and a productive 
cough, without a fever, night sweats, weight loss, or malaise. A chest radiograph 
and CT revealed further progression of pre-existent interstitial nodular 
opacities, thick septa, bronchiectasis, fibrotic scarring, bullae, emphysema, 
and a ground glass aspect. During the next two years, 13 mycobacterial 
sputum cultures were performed, 10 of which yielded M. conspicuum; three 
cultures remained negative, although two samples were initially PCR positive 
for a nontuberculous mycobacterium (NTM), identified as M. conspicuum by 
sequencing of the PCR product. All AFB smears were negative. Serological 
parameters of infection were slightly raised; the ESR ranged between 21 and 
32 mm/h, the C-reactive protein concentration ranged between 13 and 44 mg/
liter and the WBC counts were 12.2 per nl. The disease progressed in these 
two years, with increasingly frequent Pseudomonas aeruginosa infections and 
chronic hypoxia, making the patient oxygen-dependent. It was decided that 
the sarcoidosis, rather than the M. conspicuum infection, would be treated, 
and the patient underwent bilateral lung transplantation 2 years and 8 months 
after the first M. conspicuum culture. The last sputum culture yielding M. 
conspicuum was performed 8 weeks prior to transplantation. The patient 
died of respiratory failure 17 days after transplantation; the donor lungs were 
colonized by P. aeruginosa and an Acinetobacter species. Autopsy revealed an 
acute necrotizing pneumonia in both lungs, most likely caused by P. aeruginosa. 
The native lungs were not examined.
Based on the progression of symptoms and radiographic abnormalities as 
well as multiple positive cultures, this patient met the American Thoracic 
Society (ATS) diagnostic criteria,1 and thus was likely to have M. conspicuum 
pulmonary disease. However, fulfillment of these criteria does not necessitate 
treatment per se, this is a decision based on potential risks and benefits of 
therapy for the individual patient.1 In addition, the progression of symptoms 
and radiographic abnormalities may have been due to sarcoidosis alone. For 
these reasons, no antimycobacterial treatment was initiated. Histological 
examination of the native lungs could have provided additional proof of M. 
conspicuum infection. Previously, the condition of persistent culture positivity 
with little or no clinical and radiographic deterioration has been referred to as 
colonization. However, airway colonization without infection is an unproven 
condition for NTM and recent studies with high-resolution CT, summarized in 
the ATS statement, have revealed progressive nodular-bronchiectatic disease, 
as in our patient, considered to be due to the NTM.1 
Since its isolation and subsequent description as a novel Mycobacterium species 
in 1995 by Springer et al., no reports on clinical M. conspicuum isolation have 
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been recorded in the literature.2 Mycobacterium conspicuum is a rare clinical 
isolate phylogenetically most closely related to M. malmoense and M. szulgai 
on the basis of 16S rDNA gene sequences.2
In our country, over an eight year period, bacteria of this species have been 
isolated only from the pulmonary samples of the two patients presented. The 
mycobacteria were cultured in the MB/BacT system (Biomerieux, Boxtel, 
the Netherlands) as well as on Middlebrook 7H10, Ogawa and Coletsos-T 
(BioMerieux) solid media at 35° C. Growth was observed after 13 days in the 
MB/BacT liquid medium and after 28-35 days on the solid media. No growth 
was observed after 35 days on Löwenstein-Jensen media with and without 
pyruvate incubated at 35° C. On Middlebrook 7H10 media, colonies were 
small, smooth and white. 
Identification was performed at the Dutch national mycobacteria reference 
laboratory (RIVM) by sequencing of the 151bp hypervariable region in the 
16S rDNA gene, after ruling out membership of the M. tuberculosis complex 
using the GenoType MTBC (Hain Lifesciences GmbH, Nehren, Germany) 
line probe assay and the more common species of NTM using the INNO-
LiPA MYCOBACTERIA v2 (Innogenetics, Ghent, Belgium) reverse line blot 
assay. The obtained sequences were compared to those in the Ribosomal 
Differentiation of Medical Microorganisms database (http://rdna.ridom.de). 
All isolates from patient 2 had also been identified as M. conspicuum in the 
regional hospital laboratory, by 16S rDNA gene sequence analysis. 
We performed drug susceptibility testing for four M. conspicuum isolates 
(one from patient 1 and three from patient 2), using a previously published 
Middlebrook 7H10 agar dilution method.3 Drugs included in the panel, 
Drug
MIC (μg/ml) for indicated isolate
Overall 
status1 (patient 1) 2 (patient 2) 3 (patient 2) 4 (patient 2)
Isoniazid 10 2 5 5 Resistant
Rifampicin >5 5 >5 5 Resistant
Rifabutin 0.5 0.5 0.5 0.5 Susceptible
Ethambutol 5 =<1 2 2 Susceptible
Streptomycin 10 5 5-10 5 Variable
Amikacin 10 10 20 10 Resistant
Clarithromycin =<2 =<2 =<2 =<2 Susceptible
Ciprofloxacin =<1 =<1 =<1 =<1 Susceptible
Cycloserine 10 10 10 10 Susceptible
Prothionamide 5 5 5 2 Susceptible
Clofazimine 2 =<0.5 1 1 Susceptible
Table 1: In vitro drug susceptibility results for four Mycobacterium conspicuum strains
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with their breakpoint concentrations in parentheses, are isoniazid (1 μg/ml), 
rifampicin (1 μg/ml), ethambutol (5 μg/ml), streptomycin(5 μg/ml), cycloserine 
(50 μg/ml), prothionamide (5 μg/ml), amikacin (5 μg/ml), ciprofloxacin (2 μg/
ml), clofazimine (2 μg/ml), clarithromycin (16 μg/ml) and rifabutin (2 μg/ml). 
Growth at the breakpoint concentration is reported as susceptible, and growth 
at higher concentrations of the drug is considered resistant. The results are 
detailed in Table 1. 
The original species description featured two immunocompromised patients 
suffering from disseminated infections.1,2 The patients presented here were 
not known to suffer from impaired systemic immunity, but their preexisting 
pulmonary diseases predisposed them to NTM infection. For patient 1, follow-
up cultures in the three years since his M. conspicuum isolation have yielded 
other NTM (one M. avium and one M. kansasii isolate), indicative of increased 
susceptibility to mycobacterial infections in general. The demographics, with 
the patients being male, white and older than the average tuberculosis patient, 
are common for NTM infections and probably reflect the characteristics of the 
predisposing lung disease.
To assess the clinical relevance of the M. conspicuum isolation from these 
patients, we used the diagnostic criteria set in the recent ATS statement.1 
Although these criteria fit best with the M. avium complex, M. kansasii and 
M. abscessus, the authors state that “it is assumed, but not proven, that the 
concepts outlined in these guidelines are pertinent for other less common 
NTM respiratory pathogens”.1
Our findings indicate that M. conspicuum is not only a causative agent of 
disseminated infections in immunocompromised patients. This species may 
occasionally cause pulmonary infections in immunocompetent persons with 
pre-existing pulmonary diseases or be a mere contaminant. This is in line with 
most other NTM species.1
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Abstract
Uncertainty exists about the clinical relevance of Mycobacterium malmoense 
isolation, especially in pulmonary samples. We therefore determined 
clinical relevance, treatment and outcome of M. malmoense isolation in the 
Netherlands.
A retrospective medical file study was conducted for all patients in the 
Netherlands from whom Mycobacterium malmoense had been isolated between 
January 2002 and January 2006. Diagnostic criteria for nontuberculous 
mycobacterial (NTM) disease published by the American Thoracic Society 
(ATS) were used to determine clinical relevance. Treatment was compared 
with guidelines published by the British Thoracic Society.
We found 51 patients from whom M. malmoense was isolated. Forty patients 
(78%) had pulmonary isolates, 32 of them met the ATS diagnostic criteria 
(80%). Cavitary disease was most common (n=28; 88%). Patients with 
pulmonary disease were mostly males, with an average age of 56 years and 
pre-existing chronic obstructive pulmonary disease. Cervical lymphadenitis 
was the most common extrapulmonary disease type. Adherence to treatment 
guidelines was poor. A good clinical response to treatment was observed in 
70% and 73% of patients treated for pulmonary and extrapulmonary disease, 
respectively.
In conclusion, M. malmoense is a clinically highly relevant NTM in the 
Netherlands causing serious pulmonary morbidity. Adherence to treatment 
guidelines is not satisfactory. 
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Introduction
First described as a respiratory tract pathogen in 1977 by Schröder and 
Juhlin,1 Mycobacterium malmoense is among the most frequently isolated 
and clinically relevant nontuberculous mycobacteria (NTM) in northern 
Europe.2,3,4 The environment is the suspected source of transmission of NTM 
to humans through aerosols and ingestion. Person-to-person transmission or 
transmission from animal sources has not been proven.3,5,6 The presence of 
NTM in the environment implies that a NTM cultured from a non-sterile body 
site, such as the respiratory tract, may result from contamination or occasional 
presence of the NTM in a sample. Hence, it is important to distinguish 
contamination from true NTM disease. The American Thoracic Society (ATS) 
has published guidelines to assist in this distinction.3 The clinical relevance of 
a NTM species can be quantified by assessing the percentage of patients with 
positive cultures of the respective NTM who meet the ATS diagnostic criteria. 
In this study, we quantified the clinical relevance of M. malmoense isolation 
in the Netherlands between 2002 and 2006 by applying the ATS diagnostic 
criteria, and evaluated treatment and outcome.
Methods
We retrospectively reviewed medical records of all patients from whom 
Mycobacterium malmoense was cultured in the January 2002 to January 2006 
period. We recorded demographic data, clinical data, drug susceptibility, 
treatment and outcome, and status according to the 2007 ATS diagnostic 
criteria (summarized in Box 1).3 
Treatment was compared with guidelines published by the British Thoracic 
Society: a NTM based treatment regimen was defined as consisting of 
rifampicin or rifabutin and ethambutol.7 An adequate response to treatment 
was defined as symptomatic improvement and reversion to at least three 
subsequent negative cultures.
The National Institute for Public Health and the Environment (RIVM) 
subjected isolates of most patients to laboratory diagnosis. The RIVM is the 
national mycobacteria reference laboratory that provides identification and 
drug susceptibility testing for all hospitals in the Netherlands. All isolates 
were subcultured in both liquid and solid media and identified using the 
INNO-LiPA MYCOBACTERIA v2 (Innogenetics, Gent, Belgium) reverse 
line blot assay which has specific probes for M. malmoense. Prior to 2004, 
16S rDNA gene sequencing (151bp hypervariable region A) was performed, 
after ruling out membership of the M. tuberculosis or M. avium complex using 
the AccuProbe assays (GenProbe, San Diego, USA). Remaining isolates were 
identified at local hospitals, by 16S rDNA gene sequencing.
Drug susceptibility was tested using the agar dilution method.8 Drugs included in 
the test panel were isoniazid, rifampicin, ethambutol, streptomycin, cycloserine, 
prothionamide, amikacin, ciprofloxacin, clofazimine, clarithromycin, and rifabutin.
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Pearson χ2 and Fisher exact tests were used for statistical correlations. The 
regional ethics committee approved the study.
Results
Mycobacterium malmoense was isolated from 51 patients in the study period. 
Forty patients (78%) had pulmonary isolates, in 11 cases (22%) these were of 
extra-pulmonary origin. No patients in the study group were HIV-infected.
During the study period, no increase in the annual notification of M. malmoense 
isolation was observed.
Pulmonary isolates
Of all 40 patients with pulmonary M. malmoense isolates, 32 (80%) met the 
ATS diagnostic criteria and were likely to suffer M. malmoense lung disease. 
The baseline patient characteristics are detailed in Table 1. 
The predominant patient profile is a male with pre-existing pulmonary disease, 
mainly chronic obstructive pulmonary disease (COPD). The seven patients 
without a previous diagnosis of pre-existing pulmonary disease were mostly 
smokers, with radiographic features suggestive of pulmonary disease. Most 
patients reported productive cough (n=37; 93%), weight loss (n=24; 60%), 
and fatigue (23; 58%). Night sweats (n=10; 25%), hemoptysis (n=7; 8%) or 
fever (n=11; 28%) were infrequently reported. Only patients who reported 
weight loss were more likely to meet the ATS diagnostic criteria (p=0.048; OR 
American Thoracic Society Diagnostic Criteria of Nontuberculous 
Mycobacterial Lung Disease
Clinical criteria
1. Pulmonary symptoms, nodular or cavitary opacities on chest radiograph, or an 
HRCT scan that shows multifocal bronchiectasis with multiple small nodules.
and
2. Appropriate exclusion of other diagnoses.
Microbiological criteria
1. Positive culture results from at least two separate expectorated sputum samples. 
(If the results from the initial sputum samples are nondiagnostic, consider repeat 
sputum AFB smears and cultures.)
or
2. Positive culture results from at least one bronchial wash or lavage.
or
3. Transbronchial or other lung biopsy with mycobacterial histopathologic features 
(granulomatous inflammation or AFB) and positive culture for NTM or biopsy showing 
mycobacterial histopathologic features (granulomatous inflammation or AFB) and one 
or more sputum or bronchial washings that are culture positive for NTM.
Box 1: Summary of the 2007 American Thoracic Society diagnostic criteria
HRCT, High resolution computed tomography; NTM, nontuberculous mycobacteria; 
Note: Three or more pulmonary samples should be analyzed to apply these criteria.
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7.333; 95%CI 1.072-50.145). In the group of the patients that did not meet the 
ATS diagnostic criteria, four failed to meet the bacteriological criteria (three 
because only one sputum sample was collected) and four failed to meet the 
bacteriological and radiological criteria. Seventy-five percent (n=24) of the 32 
patients that met the ATS criteria for pulmonary NTM disease presented with 
cavitary lesions visible on chest radiographs. Additional computed tomography 
scanning revealed four extra cases of cavitary disease (total n=28; 88%), not 
identified as such using plain chest radiographs. Two patients presented with 
multiple nodular opacities on chest radiograph; two had a single pulmonary 
mass. 
Thirty patients who met the ATS diagnostic criteria for pulmonary NTM 
disease started treatment. Figure 1 summarizes treatment and outcome in the 
study group. The mean duration of antimycobacterial treatment was 12 months 
(range 1–26 months). Macrolides were added for 22 patients (clarithromycin 
for 18 and azithromycin for four patients; 92%), fluoroquinolones in six 
(ciprofloxacin for four and moxifloxacin for two patients; 25%). Nine patients 
received therapy for presumed tuberculosis, prior to the diagnosis of NTM 
disease, for a mean duration of 48 days (range 2-123 days), and completed a 
NTM based regimen afterwards. Six patients with M. malmoense pulmonary 
disease only received a complete first-line tuberculosis treatment. 
Of 30 patients treated, 21 patients (70%) showed an adequate response, five 
suffered a failure or relapse (17%; mean time to relapse 13 months, range 5-24 
months) and four died (13%) (Figure 1). Although the percentage of patients 
with an adequate response was lower in those receiving macrolide containing 
regimens (43 vs. 63%), this difference was not statistically significant (p=0.344). 
The mean duration of treatment among patients who later relapsed was shorter 
than for patients with an adequate response, though not significantly (320 vs. 
ATS criteria 
met
ATS criteria
not met Total P value
N 32 8 40
Males 21 (66) 7 (88) 28 0.67
Mean age (range) 56 (28-81yr) 57 (33-83yr) 56 (28-83yr) 0.84
Pre-existing pulmonary disease 26 (81) 7 (88) 33 0.57
COPD 21 (66) 5 (63) 26 0.59
Prior TB 2 (6) 2 (25) 4 0.18
AFB smear positive 27 (84) 2 (25) 29 0.03
Cavitary lesion 28 (88) 1 (13) 29 <0.001
Nodular lesion(s) 4 (13) 1 (13) 5 0.74
Data are presented as n or n (%). ATS, American Thoracic Society; COPD, Chronic obstructive 
pulmonary disease; TB, tuberculosis; AFB, acid-fast bacilli
Table 1: Baseline characteristics of patients with pulmonary M. malmoense isolates
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358 days; p=0.709). The frequency of adequate response was not significantly 
different between patients treated with a TB based regimen and those treated 
with a NTM regimen (p=0.260). Two patients who met the ATS criteria 
refused treatment, one patient died, the other showed progressive disease. 
Follow-up of patients not meeting ATS diagnostic criteria was uneventful; no 
more positive cultures have been recorded. Symptoms regressed in absence of 
antimycobacterial treatment.
Six (20%) patients received the 24 months of rifampicin and ethambutol 
regimen based on the British Thoracic Society (BTS) trials. This did not affect 
the percentage of patients with an adequate response (BTS regimen vs. other: 
83% vs. 71%; p=0.426). 
Contact-tracing studies were initiated for two patients with pulmonary M. 
malmoense isolates; both were presumed to have pulmonary tuberculosis. 
Some contacts received six months of isoniazid, based on a tuberculin skin 
test conversion.
In this study, one case of disseminated M. malmoense disease was noted in a 
patient who received immunosuppressive treatment after kidney transplantation. 
He presented with pulmonary M. malmoense disease, which extended to 
Figure 1: Frequency, treatment and outcome of pulmonary M. malmoense disease in 
the Netherlands between 2002 and 2006
NTM based, treatment given to treat nontuberculous mycobacteria; TB based, group of patients 
treated only for a presumed tuberculosis infection; ATS+, fulfillment of the criteria of the 
American Thoracic Society; PD, progressive disease; Abbreviations: AFB, Acid-fast bacilli
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histologically and bacteriologically proven lymphadenitis and mediastino-
esophageal fistula, with blood cultures yielding M. malmoense. Interestingly, 
this patient had strong epidemiological links to a patient diagnosed with smear 
positive pulmonary M. malmoense disease one year before. 
Extra-pulmonary isolates
Eleven patients had extra-pulmonary M. malmoense isolates; we noted 10 
cases of cervicofacial lymphadenitis, including two in elderly patients. One 
case of tenosynovitis of the 2nd and 3rd digit of the right hand was observed in 
a plant handler with a history of multiple wounds to the right wrist. He had an 
adequate response after surgical debridement followed by a macrolide based 
regimen of 13 months duration. The eight pediatric cases of lymphadenitis 
were three boys and five girls without predisposing conditions, with a mean 
age of 36 months (range 22-46 months). All presented with painless cervical or 
submandibular swelling, without fever or other symptoms. Surgical excision 
was the most frequent treatment and resulted in an adequate response in all 
patients. One of the elderly patients had a relapse after surgery, the other had 
an adequate response. Overall, eight patients (73%) with extra-pulmonary 
isolates had an adequate response after the initial therapy.
In vitro drug susceptibility testing was performed on the primary isolates 
from 46 patients. Isolates were resistant to isoniazid (all), streptomycin (70%), 
amikacin (70%), ciprofloxacin (61%); intermediately susceptible (39%) or 
resistant (46%) to ethambutol; and susceptible to rifampicin (72%), rifabutin 
(96%), clarithromycin (all), cycloserine (98%), prothionamide (96%) and 
clofazimine (all). 
Relapse or treatment failure among patients with pulmonary M. malmoense 
disease was not associated with in vitro rifampicin or ethambutol resistance 
(p=0.327 and p=0.405 respectively).
Discussion
Mycobacterium malmoense is one of the most clinically relevant NTM in 
the Netherlands. Eighty percent of patients with pulmonary isolates met the 
ATS diagnostic criteria, compared to 21 (47%) relevant infections among 45 
patients with pulmonary M. xenopi isolates, and 11 (73%) among 15 patients 
with pulmonary M. szulgai isolates.9,10 We observed M. malmoense disease 
exclusively in HIV-negative patients, which is in contrast to M. avium, M. 
kansasii, M. xenopi and M. szulgai.3,9,10 Patients were mainly males with pre-
existing pulmonary disease. The ATS diagnostic criteria were designed for 
infections with M. avium, M. kansasii and M. abscessus; they may be less 
applicable to M. malmoense. Because of the high degree of true pulmonary 
M. malmoense infections observed, judgment on the clinical relevance of 
pulmonary M. malmoense isolates could probably be based on less strict 
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criteria, as is advocated for M. kansasii,3 to prevent a prolonged period of 
inadequate treatment. The high degree of clinical relevance is in accordance 
with previous studies in northern Europe that reported 70% to 84% clinical 
relevance using either ATS criteria or a modification of these criteria.11-14 
Interestingly, a dramatically lower clinical relevance of 10% was found in a 
retrospective case study of 73 patients in the USA.15 There is no explanation 
for this difference; however, it suggests strains of M. malmoense in northern 
America are less pathogenic than those in northern Europe. There are no 
known bacterial virulence factors for M. malmoense. Phylogenetically related 
M. szulgai and M. kansasii, both of which are suggested to be among the most 
pathogenic NTM,3,9 are known to harbor a region of difference 1-like genetic 
element (including esat-6 and cfp-10 genes) which is a well-known virulence 
factor for M. tuberculosis.16 Mycobacterium malmoense, however, lacks this 
element.17 To date, immunological studies have focused on M. avium and M. 
abscessus,18,19 rather than M. malmoense. Studies of M. malmoense pathogenesis 
and virulence in murine models are warranted, as are studies on the role of 
host genetic factors in M. malmoense disease. 
In a recently published retrospective study of the prevalence of all NTM in 
Ontario, Canada, in the 1997 to 2003 period, M. malmoense was not isolated.20 
This observation is in contrast with the increase in M. malmoense notification 
in Europe since 1980, including increasing numbers of countries reporting 
isolation of M. malmoense.21 This contrast suggests environmental niches 
favoring transmission to humans in Europe. Whether this observation can be 
linked with the lower clinical relevance observed in the United Sates needs to 
be studied.
Human transmission has never been proven, even in a setting of geographic 
clustering of cases. In a study published by Doig and coworkers, small 
differences observed using pulsed-field gel electrophoresis were sufficient to 
show a lack of correlation between strain type and epidemiological or patient 
characteristics, making person-to-person spread unlikely.22 
Treatment regimens in the current study deviated from the BTS treatment 
guidelines for pulmonary M. malmoense disease, both in content and duration 
of treatment. Treatment of M. malmoense disease was often preceded by, or 
consisted only of, TB treatment. This observation reflects the similar clinical 
presentation of pulmonary M. malmoense and M. tuberculosis complex 
infection and is a cause of concern. Increasing the use of PCR to rule out M. 
tuberculosis, providing a quick and definite NTM diagnosis, will probably 
decrease morbidity and mortality and prevent initiation of unnecessary 
contact tracing studies. Although hampered by our limited study group size 
and duration of follow-up, successful clinical response in this study in the 
optimally treated group (83%) is comparable with a 75% successful outcome 
reported by Henry et al.23 The failure and relapse rates found in the recently 
published BTS trial (12% in the group treated with R and E, 5% in the group 
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treated with R and E combined with clarithromycin or ciprofloxacin) are 
lower compared to the rate found in our study (17%).24 Probably, the shorter 
mean duration of antimycobacterial therapy negatively influenced treatment 
outcome in our population.
The mortality rate found among adequately treated patients in this study (13%) 
is comparable to that found by Banks et al (15%)12 and Henry et al (11%).23 
The NTM disease related mortality after 5 years of follow-up is found to be low 
(3.6%).24 Mortality has been related to the length of delay between diagnosis 
and start of the treatment, while the occurrence of relapse has previously 
been associated with total time span of treatment.11 Other factors suggested 
to independently affect mortality are in vitro resistance to ethambutol and the 
involvement of more than one lung zone.15 In our study population, there was 
no significant association between ethambutol resistance and treatment failure. 
The recently published BTS trial showed no additional benefit of adjunctive 
clarithromycin or ciprofloxacin over the 24RE regimen for pulmonary M. 
malmoense disease. Addition of clarithromycin even led to more side-effects.24 
These data are clinically important considering the extent of adjunctive 
macrolide and/or fluoroquinolone use in our study group. 
The frequency and types of extrapulmonary disease in our study are similar 
to those found in a survey in Sweden in which 21% of 221 patients had extra-
pulmonary isolates, mainly lymphadenitis.14 Pediatric cases of cervicofacial 
lymphadenitis are most frequent and tend to affect children in a limited age 
range, which may be related to environmental exposures specific to this age 
category,25 or the state of development of the immune system in children. 
Contrary to pulmonary disease, M. malmoense lymphadenitis is a relatively 
benign condition. Surgery is considered to be the optimal treatment and yields 
good results.3,26
Tenosynovitis due to M. malmoense is rare, though case reports are available in 
the international literature.27 Extra-pulmonary infection with M. malmoense 
is rare and dissemination is only observed in patients with severely impaired 
immunity, although rarely in HIV/AIDS.
In conclusion, pulmonary Mycobacterium malmoense isolation is clinically 
relevant in 80% of all patients in the Netherlands, reflecting a level of virulence 
unmatched by other NTM species. Pulmonary disease resembling tuberculosis 
and pediatric lymphadenitis are the most common types of M. malmoense 
disease. Some patients are incorrectly treated for tuberculosis for a lengthy 
period. We recommend the use of molecular diagnostic tools for every sample 
positive for mycobacteria to enable quick initiation of adequate therapy. 
Treatment outcome is relatively favorable when compared to other NTM 
infections. Future studies are necessary to optimize treatment regimens and 
to discern host and pathogen factors determining virulence and transmission 
to humans. 
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abscessus isolation in 95 patients
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Abstract
Objectives: To determine the clinical relevance of Mycobacterium. abscessus 
and M. chelonae isolation from clinical samples.
Methods: We retrospectively reviewed medical files of all patients from whom 
these mycobacteria were isolated between January 1999 and January 2005. We 
applied the American Thoracic Society (ATS) diagnostic criteria to establish 
clinical relevance.
Results: Ninety-five patients were traced; 49 had M. abscessus and 46 M. 
chelonae isolates. Most isolates were cultured from pulmonary samples in 
patients with pre-existing pulmonary disease. Thirty-three percent (13/39) of 
patients with pulmonary M. abscessus isolates met the ATS criteria, opposed to 
twenty percent (7/35) for patients with M. chelonae isolates. Extrapulmonary 
disease usually presented as disseminated skin disease, with eye disease specific 
for M. chelonae and otomastoiditis for M. abscessus. Treatment, especially for 
pulmonary M. abscessus disease, yielded limited results.
Conclusions:  One third of the patients with pulmonary M. abscessus isolates 
meet the ATS criteria, versus one fifth for M. chelonae. Pre-existing pulmonary 
disease is the main predisposing condition, different from previous studies. 
Mycobacterium abscessus isolation in cystic fibrosis patients warrants special 
attention. The ATS criteria may be too lenient to diagnose M. chelonae or M. 
abscessus disease. Increased adherence to treatment guidelines may improve 
outcome.
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Introduction
For a long time, Mycobacterium chelonae and Mycobacterium abscessus have 
been thought to represent subgroups of a single species, due to overlap in 
biochemical and genetic properties; only in 1992 M. abscessus was granted 
a separate species status, supported by DNA-DNA hybridization of less than 
70%.1 In the Netherlands, these two species are the most frequently encountered 
rapidly growing nontuberculous mycobacteria (NTM), making up 55% of all 
referred rapid growers. (Source: National Mycobacteria Reference Laboratory).
In general, NTM are opportunistic pathogens and pulmonary infections mostly 
affect patients with pre-existing pulmonary disease. Extrapulmonary disease 
generally occurs after trauma or in patients with systemic impaired immunity, i.e. 
immunosuppressive medication, HIV infection or hematological malignancy.2 
Improvements in laboratory facilities for culture and species identification, 
increasing notification, and growing awareness of their pathogenic potential 
have led to increased interest in the NTM in general.2 Mycobacterium abscessus 
infections in cystic fibrosis (CF) patients, and the problematic resistance of 
these bacteria to antimycobacterial drugs, have received special attention.1-5 
The environment is the suspected source of infections by NTM, as man-to-
man transmission has not been proven.2,3 Bacteria of both species have been 
recovered from water and soil.1,2 Their presence in water and resistance to 
common disinfectants can result in pseudo-outbreaks due to contamination 
of laboratory materials6 or medical equipment such as bronchoscopes.7 Hence, 
clinical M. chelonae or M. abscessus isolation, especially from the respiratory 
tract, does not represent disease per se. To aid in the differentiation between 
NTM disease and pseudo-infection or contamination, the American Thoracic 
Society (ATS) provides diagnostic criteria, summarized in Box 1, with a 
specific emphasis on M. abscessus.2
In the current study we establish the clinical relevance of M. chelonae and M. 
abscessus isolation by studying the clinical and demographical data of patients 
from whom M. chelonae or M. abscessus was isolated and determining the 
percentage of patients that meet the ATS criteria. 
Methods
The medical records of all patients in the Netherlands from whom M. chelonae 
or M. abscessus was isolated between January 1999 and January 2005 were 
retrieved. We recorded demographical, clinical and microbiological data and 
status according to the diagnostic criteria by the ATS.2 
All patient isolates were subjected to laboratory diagnosis at the National 
Institute for Public Health and the Environment (RIVM, Bilthoven, the 
Netherlands). The RIVM is the national reference laboratory that provides 
identification and drug susceptibility testing of mycobacteria for all hospitals 
in the Netherlands. For identification, the GenoType MTBC (Hain Lifescience, 
Nehren, Germany) is used to determine whether an isolate is a member of the
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M. tuberculosis complex. If this test is negative, an INNO-LiPA 
MYCOBACTERIA v2 (Innogenetics, Ghent, Belgium) reverse line-blot is 
used to differentiate between the more common species of NTM, including 
M. chelonae and M. abscessus. Prior to 2004, 16S rRNA gene sequence 
analysis was performed for all isolates, after ruling out membership of the M. 
tuberculosis complex using the AccuProbe MTB DNA probe kit (GenProbe, 
San Diego, USA). The DNA sequence results were compared to the GenBank 
(National Center for Biotechnology Information, http://www.ncbi.nlm.nih.
gov) sequence database. Distinction between M. chelonae and M. abscessus 
was subsequently performed using the picric acid test.8 
Susceptibility to isoniazid, rifampicin, ethambutol, streptomycin, cycloserine, 
prothionamide, amikacin, ciprofloxacin, clofazimine, clarithromycin and 
rifabutin is tested using an agar dilution method.9 
Pearson χ2, Fisher exact and t-tests were used for statistical correlations. The 
regional ethics committee approved the study. 
Results
We found 95 patients, of whom 49 had M. abscessus isolates and 46 M. chelonae 
isolates. The baseline characteristics of all 95 patients are detailed in Table 1. 
Though more patients with M. abscessus than with M. chelonae isolates met 
the ATS diagnostic criteria (n=21; 43% vs. n=14; 30%) this was not statistically 
significant (p=0.210).
Most isolates were from pulmonary specimens. Thirty-three primary M. 
abscessus isolates were from sputum, 6 were from broncho-alveolar lavages; 
for M. chelonae this was 31 and 4, respectively. Thirty-three percent (n=13) 
of all patients with pulmonary M. abscessus isolates met the ATS diagnostic 
criteria. This percentage was lower for M. chelonae (20%; n=7), though not 
statistically significant (p=0.197). Primary samples were AFB smear positive in 
eight patients with pulmonary M. abscessus isolates (21%), opposed to 6 (17%) 
in those with pulmonary M. chelonae isolates (Table 2).
The clinical characteristics are detailed in Table 1; symptoms did not predict 
the results of microbiologic and radiographic diagnostic criteria, for both 
pulmonary and extrapulmonary patients. In patients with pulmonary M. 
abscessus isolates, bronchiectasis visible on chest radiograph (p=0.022; OR 
8.57; 95%CI 1.36-54.15) and smear positivity of the primary sample (p=0.001; 
OR 29.17; 95%CI 2.99-284.26) were significantly associated with meeting the 
ATS diagnostic criteria. No such associations were found for M. chelonae.
Pre-existing pulmonary disease was the most common predisposing condition 
for pulmonary M. abscessus and M. chelonae disease (Table 1). Pulmonary 
function was relatively preserved in the patients with pulmonary isolates, 
43% had an FEV1>70% predicted and another 28% scored within the 50-70% 
predicted range, compatible with GOLD I/II COPD.10 None of the patients 
were co-infected with HIV.
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M. chelonae M. abscessus Total
Pulm. EP Total Pulm. EP Total
Demography
N (%) 35 (76%) 11 46 39 (80%) 10 49 95
% males 60 36 54 62 50 59 57
Mean age 
(range)
57
(12-89)
51
(1-82)
56
(1-89)
51
(7-87)
52
(4-84)
51
(4-87)
53
(1-89)
AFB positive 6 (17%) 2 (18%) 8 (17%) 8 (21%) 6 (60%) 14 (29%) 24 (25%)
Predisposing conditions
Smoking 15 (43%) 1 (9%) 16 (35%) 19 (49%) 1 (10%) 20 (41%) 36 (38%)
Alcohol abuse 1 (3%) 1 (9%) 2 (4%) 1 (3%) 0 1 (2%) 3 (3%)
COPD 14 (40%) 1 (9%) 15 (33%) 11 (28%) 1 (10%) 12 (24%) 27 (28%)
Prior 
tuberculosis
1 (3%) 1 (9%) 2 (4%) 6 (15%) 1 (10%) 7 (14%) 9 (9%)
Cystic Fibrosis 2 (6%) 0 2 (4%) 5 (13%) 0 5 (10%) 7 (7%)
Non-CF 
bronchiectasis
3 (9%) 0 3 (7%) 6 (15%) 0 6 (12%) 9 (9%)
Hematol malign 1 (3%) 0 1 (2%) 2 (5%) 0 2 (4%) 3 (3%)
Steroids* 2 (6%) 3 (27%) 5 (11%) 1 (3%) 2 (20%) 3 (6%) 8 (8%)
Symptoms
Productive 
cough
33 (94%) 1 (9%) 34 (74%) 33 (85%) 1 (10%) 34 (69%) 68(72%)
Hemoptysis 6 (17%) 0 6 (13%) 7 (18%) 0 7 (14%) 13(14%)
Dyspnea 17 (49%) 0 17 (37%) 22 (56%) 1 (10%) 23 (47%) 40 (42%)
Weight loss 5 (14%) 1 (9%) 6 (13%) 9 (23%) 0 9 (18%) 15 (16%)
Night sweats 2 (6%) 0 2 (4%) 4 (10%) 0 4 (8%) 6 (6%)
Fever 3 (9%) 1 (9%) 4 (9%) 12 (31%) 2 (20%) 14 (29%) 18 (19%)
Malaise/ 
Fatigue
9 (26%) 1 (9%) 10 (22%) 13 (33%) 4 (40%) 17 (35%) 27 (28%)
Chest imaging
Infiltrate 10 (29%) 0 10(22%) 20 (51%) 0 20 (41%) 30 (32%)
Cavities 3 (9%) 0 3 (7%) 2 (5%) 0 2 (4%) 5 (5%)
Nodules 7 (20%) 0 7 (15%) 5 (13%) 1 (10%) 6 (12%) 13 (14%)
Bronchiectasis 3 (9%) 0 3 (7%) 7 (18%) 0 7 (14%) 10 (11%)
2007 ATS 
criteria met
7 (20%) 7 (64%) 14 (30%) 13 (33%) 8 (80%) 21 (43%) 35 (37%)
Pulm, Pulmonary; EP, extrapulmonary; AFB, acid-fast bacilli smear; COPD, chronic obstructive 
pulmonary disease; CF, cystic fibrosis; Hematol malign, hematological malignancy; ATS, 
American Thoracic Society
* >=15mg prednisone per day (or equivalent) for > 3months
Table 1: Baseline patient characteristics, by species
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Among cystic fibrosis patients, of M. abscessus was more commonly isolated than 
M. chelonae; four out of five CF patients (80%) with pulmonary M. abscessus 
isolates met the ATS diagnostic criteria; the two CF patients with M. chelonae 
isolates did not. Pulmonary M. abscessus isolates more often represented true 
infections in CF than in non-CF patients (p=0.035; OR 11.1; 95%CI 1.09-113.06). 
All cases of CF were diagnosed clinically and confirmed by CFTR genotyping.
Six (17%) patients with pulmonary M. chelonae and two (6%) patients with 
pulmonary M. abscessus isolates had esophageal disorders.
Ten patients started treatment for M. abscessus lung disease; regimens, duration 
and outcome are detailed in Table 2. The average duration of treatment in 
patients who met the ATS criteria was nine months. For four patients, these 
regimens were followed by long-term monotherapy with clarithromycin. 
Four patients were cured, which was defined by symptomatic improvement 
and conversion to negative cultures, three experienced treatment failure, i.e. 
persistent symptoms and positive cultures, and four patients died during 
treatment (Table 2); no autopsies were performed. Two patients were treated 
for M. chelonae lung disease. One failed, remaining symptomatic and culture 
positive, the other improved and converted to negative cultures (Table 2). 
Twelve patients (6 M. abscessus, 6 M. chelonae) started TB treatment, based on 
a clinical suspicion of tuberculosis. The average duration of TB treatment was 
1 month. One patient received nine months of standard TB treatment only and 
improved (Table 2, patient 2).
Extrapulmonary M. abscessus isolates represented disease in eight out of 
ten patients (80%), as opposed to 64% (n=7/11) for M. chelonae. The few 
extrapulmonary isolates that did not represent disease were cultured from the 
digestive tract without other signs of disease or were suspected contaminants 
that could not be repeatedly cultured from the original clinical sample. 
Extrapulmonary disease mostly followed trauma (n= 8) or immunosuppressive 
drug treatment (chronic high-dose steroid use, or post-transplantation; n=4). 
None of the patients were co-infected with HIV. Extrapulmonary infections 
with both species are detailed in Table 3. Among patients with extrapulmonary 
isolates, smear positivity was noted in 6 (60%) in the M. abscessus and 2 (18%) 
in the M. chelonae culture positive materials (Table 3). Disseminated skin 
infections by both species presented with multiple nodules, with various degrees 
of ulceration. Specific extrapulmonary disease types were seen for M. chelonae 
(eye disease; n=2) and M. abscessus (chronic otitis media; n=2; Table 3).
In vitro drug susceptibility testing was performed for 26 M. chelonae isolates 
from 20 patients and 46 M. abscessus isolates from 33 patients. Primary M. 
abscessus isolates were mostly susceptible to clarithromycin (67%) and 
occasionally to ciprofloxacin (18%), prothionamide (9%), amikacin (3%) 
and rifabutin (6%), though resistant to all other compounds tested. Acquired 
resistance to clarithromycin was noted in one patient after two months of 
clarithromycin treatment (Table 3, pt. 10). Primary M. chelonae isolates 
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were mostly susceptible to clarithromycin (60%), occasionally susceptible to 
ciprofloxacin (16%), prothionamide (10%) and amikacin (5%) and resistant to 
all other compounds in the test panel. No acquired resistance for bacteria of 
this species was noted. 
Three patients with pulmonary M. abscessus isolates had simultaneously 
obtained cultures yielding M. avium, M. interjectum and M. gordonae. Among 
those with pulmonary M. chelonae isolates, four patients had simultaneous 
positive pulmonary cultures yielding M. avium, M. kansasii, M. mucogenicum 
and an unidentifiable species, respectively. All were single isolates, none 
represented NTM disease.
We recorded no temporal or geographical clustering of isolates, suggesting 
(pseudo)outbreaks or contamination. 
Discussion
Mycobacterium chelonae and M. abscessus isolation and disease occur in almost 
equal frequency in the Netherlands. Pulmonary NTM disease as defined by 
the ATS criteria was likely in 20% of patients with M. chelonae isolates and 33% 
of those with M. abscessus isolates. Vigilance is warranted in specific patient 
categories such as cystic fibrosis patients; isolation of M. abscessus generally 
represents disease in this group.
The ATS criteria presumably fit well with pulmonary M. abscessus isolates.2 
However, short regimens, as well as regimens including mainly first-line anti-
tuberculosis drugs considered inactive against M. chelonae and M. abscessus, 
lead to favorable outcome in several pulmonary patients (Table 2; patients 
1, 2, 9 & 12). Although meeting the ATS criteria, it is doubtful whether 
these patients had true NTM disease. Despite the obvious drawbacks of our 
retrospective study design, this suggests that the ATS criteria are insufficiently 
stringent to diagnose true pulmonary M. chelonae or M. abscessus disease. 
Moreover, this demonstrates that knowledge on the treatment of disease due 
to these species is to be improved. If we do not consider the four patients 
with dubious pulmonary disease, true pulmonary disease was likely in only 
14% (5/35) of patients with M. chelonae and 28% (11/39) of patients with M. 
abscessus. Stricter criteria should be imposed, possibly including more positive 
cultures or histological evidence where appropriate.
MCH, Mycobacterium chelonae; MAB, M. abscessus; Cult/pos/(smear), Number of cultures 
performed/number of positive cultures/(acid-fast bacilli smear result); M, male; F, female; 
RTI respiratory tract infections (>=3 in 6 months); COPD, chronic obstructive pulmonary 
disease; ALS, amyotrophic lateral sclerosis; TB, tuberculosis; IVDA, intravenous drug abuse; 
PC, productive cough; H, hemoptysis; D, dyspnea; NS, night sweats; M, malaise/fatigue; WL, 
weight loss; F, fever; scar, coarse linear scarring; I; infiltrate; PT, pleural thickening; M/HLE, 
mediastinal/hilar lymph node enlargement; PF, pleural fluid; H, isoniazid; R, rifampicin; Z, 
pyrazinamide; E, ethambutol; Cla, clarithromycin; Pro, prothionamide; Ctm, co-trimoxazole; 
Ami, amikacin; Cef, cefoxitin; Imi, imipenem; Azi, azithromycin; Levo; levofloxacin
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Pt.
Species
Sex, 
A
ge
Cult/pos/
(sm
ear)
Predisposing conditions
Sym
ptom
s
Chest im
aging
Treatm
ent 
O
utcom
e
1
M
CH
M
, 76
4/3 (+)
N
one
PC
Scar
1H
RZE
Cured
2
M
CH
M
, 71
2/1 (+)
D
iabetes
PC, H
N
odules, PT
9H
RZE
Cured
3
M
CH
F, 29
6/4 (+)
A
sthm
a, Recurrent RTI
PC,D
,N
S,M
I, bronchiectasis
1H
RZE
Failure
4
M
CH
F, 71
7/2 (-)
A
sthm
a, Recurrent RTI
PC,D
,F,M
I, bronchiectasis
24RbClaPro
Cured
5
M
CH
M
, 57
8/6 (-)
CO
PD
, Recurrent RTI
PC
Solitary nodule, scar
N
one
D
eath
6
M
CH
M
, 78
7/4 (+)
CO
PD
, silicosis
PC
I, scar
8Cla 10Ctm
 
Failure
7
M
CH
M
, 48
5/5 (-)
A
LS, Recurrent RTI, ventilator
PC,D
,F,M
I, nodules
N
one
D
eath
8
M
A
B
M
, 87
2/2 (-)
Chest w
all traum
a
PC, W
L
I, cavities, M
LE, H
LE, PF
N
one
D
eath
9
M
A
B
M
, 47
9/2 (-)
CO
PD
, bronchiectasis
PC
Bronchiectasis, scar
N
one
Cured
10
M
A
B
M
, 21
3/3 (-)
N
one
PC
I, cavities
N
one
Lost
11
M
A
B
F, 42
8/8 (-)
A
sthm
a, bronchiectasis
PC,D
,N
S,W
L,M
I, cavities, bronchiectasis, nodules
Lobectom
y, 28ECla
Failure
12
M
A
B
F, 72
2/2 (+)
Prior TB, bronchiectasis
PC,D
,F,M
I, bronchiectasis
1H
RZE 1Ctm
 1RECla
Cured
13
M
A
B
M
, 80
5/5 (+)
Prior TB, CO
PD
PC,H
,D
I, scar
1H
RZE 1RECla
D
eath
14
M
A
B
M
, 47
9/4 (+)
Prior TB, CO
PD
PC,H
,D
I, cavities, nodules, PT, scar
2H
ZE
Failure
15
M
A
B
M
, 73
3/2 (+)
M
alignancy
PC,H
Cavities
1H
RZ
Failure
16
M
A
B
M
, 40
9/6 (-)
IV
D
A
, CO
PD
PC,F,D
, N
S
I, nodules, scar
1H
RZE 5H
RECla
Cured
17
M
A
B
M
, 28
24/18(+)
Cystic Fibrosis
PC,H
,D
,F,W
L,M
I, bronchiectasis, nodules, scar
12Cla
D
eath
18
M
A
B
M
, 7
6/6 (+)
Cystic Fibrosis
PC,D
,W
L,M
I, bronchiectasis, scar
16ClaA
m
iC
efIm
i 9Cla
D
eath
19
M
A
B
F, 28
7/4 (-)
Cystic Fibrosis
PC,D
,M
Bronchiectasis, nodules, scar
12A
ziLevo
Cured
20
M
A
B
M
, 12
3/1 (+)
Cystic Fibrosis
PC,W
L
I, bronchiectasis, scar
1Ctm
Cla 5Cla
Cured
Table 2: Clinical data of patients m
eeting the 2007 ATS criteria for pulm
onary N
TM
 disease
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Patients with bronchiectasis from whom M. abscessus was isolated were 
significantly more likely to meet the ATS diagnostic criteria, probably because 
bronchiectasis is a part of the criteria. Still, it remains uncertain whether 
bronchiectasis predisposes to, or results from, M. abscessus disease. 
Pulmonary M. abscessus or M. chelonae disease, although infrequent, is a clinical 
challenge, due to the extensive drug resistance that characterizes bacteria of 
these species. Pulmonary M. abscessus disease is difficult to treat and suppressive, 
instead of curative, treatment may be the only option,2 especially in CF patients. 
More than half of the patients treated for M. abscessus pulmonary disease 
in our study experienced treatment failure, relapsed after treatment or died 
during therapy. The low number of patients treated for M. chelonae pulmonary 
disease hampers analysis of their treatment outcome. The use of parenteral 
drugs (amikacin, cefoxitin, imipenem) was very limited in our study, despite 
their central role in the ATS and British Thoracic Society (BTS) treatment 
guidelines for disease due to rapidly growing mycobacteria.2,11 Increased use 
of multi-drug regimens including parenteral agents and more extensive testing 
of new drug classes, such as glycylcyclines and oxazolidinones, may provide 
additional therapeutic options and improve outcome of chemotherapy in the 
Netherlands. The recent finding that M. abscessus, but not M. chelonae, has an 
erm gene that induces macrolide resistance12 emphasizes the urgency of these 
issues. Surgical resection of the involved lung, combined with chemotherapy, 
may further improve treatment outcome in selected cases.2,11,13 However, the 
only patient in our study group who underwent adjunctive surgery ultimately 
experienced treatment failure (Table 2; patient 11).
Pre-existing pulmonary disease was the major predisposing condition for 
pulmonary NTM disease in our study, whereas in North American reports, M. 
abscessus or M. chelonae pulmonary disease is often associated with previously 
healthy women over 60 years of age.2,13,14 Its indolent course2,13 may prevent it 
from being diagnosed in this patient category in the Netherlands. Among our 
patients with pulmonary M. abscessus disease, the percentage of CF patients, 
whose susceptibility to M. abscessus disease has been widely published,4,5 is 
higher than the 6% recorded by Griffith et al.13 Moreover, M. chelonae and 
M. abscessus were isolated in equal frequency, while in the 154 patients with 
disease caused by rapid growing NTM studied by Griffith et al., only one had 
M. chelonae disease.13 The background of these differences demands further 
research.
The extent of pre-existing pulmonary disease in our patients meant that 
symptoms and radiographic abnormalities had limited value in diagnosing 
pulmonary M. chelonae or M. abscessus disease. The reported associations 
between esophageal disease and pulmonary disease due to rapidly growing 
NTM2,13,15 as well as concurrent recovery of other NTM species,2,13 were 
infrequent and statistically insignificant in our study group.
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Pt.
Species
Site 
Sex A
ge
Predisposing conditions
Treatm
ent
O
utcom
e
1
M
CH
Skin (single lesion)
M
58
Traum
a
Surgery, 1ClaCip
Cured
2
M
CH
Skin (diss.)
F
60
Prednison &
 cyclosporine use
Surgery, 3Cla
Cured
3
M
CH
Bone &
 joint
F
69
N
one
Surgical debridem
ent (2x), 5ClaO
flClz
Lost to follow up
4
M
CH
Lym
ph node
F
6
N
one
3RbCla
Cured
5
M
CH
Tendon
M
67
Steroid injection
Surgical debridem
ent, 6H
RZO
fl
Cured
6
M
CH
Eye (endophthalm
itis)
F
82
C
ornea transplantation
4CipCla w
ith topical ofloxacin
Cured; blind
7
M
CH
Eye (corneal ulcer)
F
47
Traum
a
3Cla w
ith topical tobram
ycin
Cured
8
M
A
B
Skin
F
35
Prior cosm
etic surgery (Caribbean region)
Surgical excision (3x)
Relapse
9
M
A
B
Skin (single lesion)
M
67
N
one
6ClaD
ox
Cured
10
M
A
B
Skin &
 bone &
 pleura (diss.)
M
65
CO
PD
; prior TB; Surgery, sternotom
y
4ClaCipIm
iLin, surgical debridem
ent
Failure, D
eath
11
M
A
B
Skin &
 joint (diss.)
F
44
Prednisone &
 cyclophospham
ide use
4ClaA
m
iLevo
Cured
12
M
A
B
Skin (diss.)
M
56
Prednisone, cyclosporine &
 
m
ycophenolate use
1RECla 1ClaA
m
iIm
i 4CipCla 4ECipCla 
1LinCipCla 1M
inCipCla 14Cla 
Relapse
13
M
A
B
Tendon
F
84
Steroid injection, thioguanine use
6Cla
Cured
14
M
A
B
Ear &
 m
astoid
F
11
Prior tym
panostom
y tube placem
ent
Surgical debridem
ent (2x), 2CipCla
Cured
15
M
A
B
Ear
M
4
PD
CD
; IgG
 deficiency 
3Cla
Cured
M
CH
, M
ycobacterium
 chelonae; M
AB, M
. abscessus; (diss.), dissem
inated disease; CO
PD
, chronic obstructive pulm
onary disease; TB, tuberculosis; PD
CD
, pyruvate 
dehydrogenase com
plex deficiency; Cla, clarithrom
ycin; Cip, ciprofloxacin; O
fl, ofloxacin; Clz, clofazim
ine; Rb, rifabutin; H
, isoniazid; R, rifam
picin; Z, pyrazinam
ide; 
D
ox, doxycyclin; E, etham
butol; Am
i, am
ikacin; Im
i, im
ipenem
; Levo, levofloxacin; Lin, linezolid; M
in, m
inocyclin
Table 3: Clinical data of patients w
ith extrapulm
onary disease
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The observed differences in clinical relevance of isolation of the two species 
may reflect a difference in pathogenicity, as recently indicated in a murine 
model.16 Among CF patients, the clinical relevance of M. abscessus pulmonary 
isolates is higher than that of M. chelonae and that of M. abscessus in non-CF 
patients. Apparently, infection and growth of M. abscessus in the lung requires 
pre-existing tissue damage, a changed biochemical environment, such as that 
resulting from CF, or both. This is in line with the observation in the murine 
model that, after systemic administration, M. abscessus fails to maintain itself 
in the lung.16
Extrapulmonary isolates were rare in our cohort, but almost invariably 
represented disease for both species. Immunosuppressive drug treatment and 
local trauma were the main predisposing conditions, which is line with the 
available literature.1,2 Mycobacterium abscessus skin infection after cosmetic 
surgery in the Caribbean (Table 3; patient 8) has also been recorded in previous 
studies.17 Mycobacterium chelonae and M. abscessus are uncommon isolates in 
HIV patients. Although in the Netherlands this is probably due to the low HIV 
prevalence, it could also have a causal relation.
Specific extrapulmonary disease types were seen for M. chelonae (eye disease) 
and M. abscessus (chronic otitis media). Both have been previously reported,18,19 
though the mechanism causing this species-specific tissue tropism is unknown.
The settling of the taxonomical positions of M. chelonae and M. abscessus 
seems short-lived. rpoB gene sequencing now allows distinction between M. 
American Thoracic Society Diagnostic Criteria of Nontuberculous 
Mycobacterial Lung Disease
Clinical criteria
1. Pulmonary symptoms, nodular or cavitary opacities on chest radiograph, or an HRCT scan 
that shows multifocal bronchiectasis with multiple small nodules.
and
2. Appropriate exclusion of other diagnoses.
Microbiological criteria
1. Positive culture results from at least two separate expectorated sputum samples. (If the 
results from the initial sputum samples are nondiagnostic, consider repeat sputum AFB 
smears and cultures.)
or
2. Positive culture results from at least one bronchial wash or lavage.
or
3. Transbronchial or other lung biopsy with mycobacterial histopathologic features 
(granulomatous inflammation or AFB) and positive culture for NTM or biopsy showing 
mycobacterial histopathologic features (granulomatous inflammation or AFB) and one or 
more sputum or bronchial washings that are culture positive for NTM.
HRCT, high resolution computed tomography; AFB, acid-fast bacilli; NTM, nontuberculous 
mycobacteria
Note: Three or more pulmonary samples should be analyzed to apply these criteria
Box 1: Summary of the 2007 American Thoracic Society diagnostic criteria
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abscessus and closely related M. bolletii and M. massiliense.20 The presence of 
these two novel species among strains labeled M. abscessus by our identification 
methods has not yet been studied in the Netherlands. These two species may 
have a different clinical relevance or cause specific disease types.
In conclusion, one third of all patients from whom M. abscessus is cultured 
from a respiratory specimen meets the ATS diagnostic criteria for pulmonary 
M. abscessus disease. For M. chelonae, this is the case in one fifth of all patients. 
Cystic fibrosis patients are highly susceptible to M. abscessus disease and 
warrant special attention. The ATS criteria may be too lenient, overdiagnosing 
true M. chelonae or M. abscessus disease. The characteristics of our study group 
differ from previous studies in the USA, mainly in age, gender distribution, 
extent of pre-existing pulmonary disease and the equal isolation frequency of 
M. chelonae and M. abscessus. Extrapulmonary isolates are rare, but should 
generally be considered indicative of NTM disease. Bacteria of both species 
cause specific extrapulmonary diseases. Treatment of these infections, 
especially pulmonary M. abscessus disease, yields limited results. Adherence to 
treatment guidelines and surgical treatment may improve treatment outcome.
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Impact of new American Thoracic 
Society diagnostic criteria on 
management of nontuberculous 
mycobacterial infection
Jakko van Ingen1,2, Martin J. Boeree1, Wiel C.M. de Lange1, P.N. Richard 
Dekhuijzen1 and Dick van Soolingen2 . 
1Dept. of Pulmonary Diseases, Radboud University Nijmegen Medical Center, Nijmegen; 
2National Mycobacteria Reference Laboratory, Bilthoven, the Netherlands
The American Thoracic Society has recently published new diagnostic criteria 
for nontuberculous mycobacterial (NTM) diseases.1 We retrospectively 
assessed the impact of the new criteria on clinical practice by reviewing 
medical files of all patients in whom Mycobacterium chelonae, M. abscessus, M. 
simiae or M. szulgai was isolated between January 1999 and January 2005 in 
the Netherlands. Isolates were earlier identified at the national mycobacteria 
reference laboratory (RIVM), by either reverse line blot assay (InnoLipa 
Mycobacteria v2, Innogenetics, Ghent, Belgium) or 16S gene sequencing, or 
by a self-sufficient hospital laboratory. 
7.7 % (9/117) more pulmonary patients met the 2007 diagnostic criteria,1 
compared to the 1997 criteria,2 although this differed by NTM species (Table 1).
The new diagnostic criteria contain more specific radiological criteria, whereas 
bacteriological criteria have become more lenient: a single NTM culture from 
bronchial washing fluid, in a well-defined class of patients, or two positive 
sputum cultures now suffice to establish the diagnosis.
As more patients are likely to meet the new criteria, more patients might receive 
antimycobacterial treatment. The authors, however, repeatedly state that 
meeting these criteria does not, per se, necessitate the institution of therapy.1 
This was not emphasized in the former statement. We believe such comments 
only add to the confusion for the clinician. Which factors should influence 
this treatment decision in individual patients? Ten years of experience with the 
former criteria apparently have not provided the answer to that question. More 
lenient criteria even increase the responsibility of physicians in the treatment 
decision.
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Increased exposure to antimycobacterial drugs can harm patients, both in 
terms of adverse events and cost.3 The variable cure rates achievable per type of 
NTM disease and persistence of the conditions predisposing to NTM infection 
further complicate the assessment of the benefit of treatment. Centralization 
of expertise and easily accessible expert consultation is important, as 
acknowledged in the new statement.
For extrapulmonary NTM isolates, no criteria for additional proof of infection 
are mentioned in the summarized criteria, contrary to the prior statement.2 
This complicates assessment of the significance of NTM isolated from pleural 
fluid, stool or gastric juice, without a context of disseminated disease, and in 
the HIV-negative patient, without histological proof of infection (Table 1). 
Extrapulmonary NTM warrant own diagnostic criteria.
More research is needed to improve diagnosis and treatment of this increasing 
problem in clinical practice.
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Species Site n Age (yr) 1997 ATS+, n (%) 2007 ATS+, n (%)
Mycobacterium 
chelonae
P 35 57 5 (14%) 7 (20%)
EP 11 51 8 (73%) 7 (64%)
M. abscessus P 39 51 11 (28%) 13 (33%)
EP 10 52 9 (90%) 8 (80%)
M. szulgai P 15 60 8 (53%) 11 (73%)
EP 6 44 6 (100%) 5 (83%)
M. simiae P 28 65 6 (21%) 8 (29%)
Definition of abbreviations: Age= mean age; ATS+= American Thoracic Society diagnostic 
criteria met; EP= extrapulmonary isolates; P= pulmonary isolates
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Abstract
Background: The isolation frequency of nontuberculous mycobacteria is 
increasing in the Netherlands. Laboratory improvements have been considered 
key factors in this increase. We assessed the role of factors other than laboratory 
improvements in the increasing isolation frequency of nontuberculous 
mycobacteria in the Netherlands.  
Methods: Retrospective laboratory database analysis. All clinically isolated 
nontuberculous mycobacteria referred to the national mycobacteria reference 
laboratory between January 2000 and January 2007 were retrieved from the 
laboratory database and divided by species, patient age group and sample 
origin. 
Results: Clinical Mycobacterium avium isolates accounted for most of the 
increase in referred nontuberculous mycobacteria. The number of respiratory 
M. avium samples in patients >40 years of age has increased over time. 
Mycobacterium avium isolation from lymph nodes in children remained 
stable, whereas extrapulmonary M. avium isolation in the middle age group, 
which includes HIV-associated bloodstream isolates, decreased.
Conclusions: The increasing nontuberculous mycobacteria notification in the 
Netherlands largely results from an increase of clinical M. avium isolation, 
especially from the emergence of M. avium in respiratory samples in patients 
over 40 years old. This specific increase is unlikely to result from laboratory 
improvements only; the ageing population with an increasing prevalence of 
chronic obstructive pulmonary disease and decreasing exposure to tuberculosis 
inferring cross-protection to nontuberculous mycobacterial disease as well as 
environmental changes may specifically favour M. avium.
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Introduction
Nontuberculous mycobacteria (NTM) are mostly opportunistic pathogens 
that are widely present in natural and man-made environments.1 The isolation 
frequency of nontuberculous mycobacteria (NTM) is increasing in many 
countries, mainly those where the incidence of tuberculosis is in decline.1-3 
This increase in isolation frequency has previously been related to laboratory 
improvements for detection and identification of NTM, including automated 
liquid culture systems and molecular identification kits.1,2 The pathogenic 
potential of these NTM, however, is increasingly recognized, especially in 
patients at risk due to local or systemic impaired immunity.1
At the Dutch national mycobacteria reference laboratory (RIVM), we also 
noted an increase in the number of referred nontuberculous mycobacteria, 
most notably isolates belonging to the Mycobacterium avium complex (MAC). 
In the current study, we explored the factors underlying this increase in NTM 
isolation.
Methods
Records of all clinical isolates of nontuberculous mycobacteria referred in 
between January 2000 and January 2007 were extracted from the reference 
laboratory database and divided by species, sample origin (respiratory, lymph 
node or other) and age group. Age was defined as the age at the date of primary 
sampling. We chose the following categories: 1-12yrs old to include mostly the 
children with lymphadenitis; 13-39yrs to include mostly immunocompromised 
patients, including co-infection with the Human Immunodeficiency Virus 
(HIV) and cystic fibrosis patients; over 40yrs to include mostly patients with 
pre-existent pulmonary disease, e.g. chronic obstructive pulmonary disease 
(COPD).4 The latter group was subdivided in the 40-60 and over 60yrs groups.
The isolates of all patients were subjected to laboratory diagnosis by the 
National Institute for Public Health and the Environment (RIVM). The 
RIVM is the national reference laboratory that provides identification, drug 
susceptibility testing and genotyping of Mycobacterium isolates for all hospitals 
in the Netherlands. To identify mycobacteria, a GenoType MTBC reverse 
line probe assay (Hain Lifesciences, Nehren, Germany) is used after PCR-
based amplification to determine whether an isolate is a member of the M. 
tuberculosis complex. If the reaction is negative, an Inno-LiPA Mycobacteria 
v2 (Innogenetics, Gent, Belgium) reverse line blot assay is used to differentiate 
between the more common species of NTM. If no species-specific result is 
obtained, 16S rDNA gene sequencing is performed. 
Prior to 2004, 16S rDNA gene sequence analysis was performed on request 
of referring physicians, if AccuProbe M. tuberculosis complex, M. avium 
complex, M. intracellulare and M. avium DNA probes (GenProbe, San Diego, 
USA) yielded negative results. 
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Figure 1: Total number of TB, NTM and MAC isolates received per year
Figure 2: MAC isolates referred per year, by species
Figure 4: The number of referred M. avium isolates per year, by sample site
Figure 3: The number of referred M. avium isolates per year, by age group
The number of referred NTM, including 
MAC, increases alongside a decrease in M. 
tuberculosis referral.
The increase in referral of MAC isolates is 
largely due to M. avium isolates. Laboratory 
improvements resulted in a decline in 
untyped MAC isolates, though insufficient to 
explain the rise in M. avium isolates.
The increasing M. avium isolation 
frequency is largely due to its isolation from 
patients >40 years of age.
The rising isolation frequency of M. avium 
is mainly due to a rising isolation frequency 
from pulmonary samples.
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Results
During the study period, the annual number of referred NTM rose in absolute 
terms, from 480 to 747 per year, as well as relative to M. tuberculosis isolation 
(Figure 1). Isolates belonging to the Mycobacterium avium complex (MAC), 
made up of M. avium and M. intracellulare, are the most commonly isolated 
NTM in the Netherlands and their number has risen sharply during the study 
period from 170 to 292 per year, making up 35% to 39% of annually referred 
NTM, respectively (Figure 1). 
During our study period, the increase in referred MAC isolates was caused 
mainly by an increase in M. avium isolates (Figure 2) from 60 isolates in the 
year 2000 to 210 in 2006. The number of M. intracellulare isolates was stable 
(Figure 2).
This rise in M. avium isolates has two important features. Firstly, it is most 
pronounced in patients over 40 years of age (Figure 3). Secondly, it is mainly 
caused by a rise in M. avium isolates from pulmonary samples (Figure 4). These 
pulmonary isolates are cultured almost exclusively from the patients over 40 
years of age; in general, the sample origin recorded was in agreement with the 
origins expected within the age group (Table 1). 
Numbers of extrapulmonary samples, including those from children with 
cervical lymphadenitis, have remained relatively stable throughout the study 
period (Figure 4). 
The increase in the annual number of referred isolates is not confined to 
M. avium, although for this species it is most pronounced. Mycobacterium 
gordonae isolates are also increasing in number, whereas isolation of other 
important species including M. intracellulare, M. malmoense and M. kansasii 
has been mostly stable (Figure 5).
Figure 5: The annual number of referred isolates of the most common NTM species
The increase in the isolation frequency of M. avium is not mirrored in other NTM species, 
including M. kansasii, M. malmoense and M. marinum. Many NTM species were referred in low 
numbers and not included in the graph to increase clarity.
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Discussion
The rise in isolation frequency of nontuberculous mycobacteria in the 
Netherlands is caused mostly by increasing numbers of Mycobacterium 
avium isolates from respiratory samples in patients over 40 years of age. 
These are probably patients suffering COPD, the most common predisposing 
condition for nontuberculous mycobacterial infection within this age group 
in the Netherlands and an argument for frequent culture of sputum samples.5 
A recent study in the Netherlands demonstrated that M. avium was more 
common than M. intracellulare in pulmonary samples. Moreover, pulmonary 
M. avium isolation represented true disease in 24 of 59 cases (41%) as opposed 
to 2 out of 16 cases (13%) for M. intracellulare, based on the 2007 ATS 
criteria.1,5 This study also demonstrated that among pulmonary MAC isolates, 
the percentage representing true MAC disease did not change significantly in 
the 1999-2004 period;5 this suggests that the increase in isolation frequency is 
not a mere result of an increased sample volume. Reports from the USA have 
noted that the nodular-bronchiectatic type of pulmonary MAC disease is most 
frequent there and M. intracellulare its most common causative agent.6 These 
differences remain largely unexplained. Possibly, M. avium bacteria isolated in 
the Netherlands differ in virulence from those isolated in the USA; previous 
studies have identified genetic differences in MAC isolates from different 
human and environmental sources.7,8
The improvements in culture and identification techniques often held 
responsible for rising NTM isolation frequencies1,2 are also relevant in the 
Netherlands. Automated liquid culture systems were introduced in 2003, to 
spread in the years following. Improvements in the identification methods in 
2004 led to a decrease in the number of untyped MAC strains and increase in 
the number of isolates identified as M. intracellulare or M. avium (Figure 2). 
It is evident from Figure 2 that this provides only a partial explanation of the 
increase in M. avium isolates in 2004. Figures 1-4 show that, although boosted 
by improved identification methods, the increase in M. avium isolation, 
especially among the oldest age groups, set in before the improvements 
in laboratory techniques. Moreover, the annual number of isolates of other 
species, including the commonly isolated M. kansasii, M. intracellulare and 
Age group Lymph node Other Pulmonary Total
0-12yrs 159 16 10 185
13-39yrs 7 70 112 189
40-60yrs 10 52 326 388
>60yrs 6 24 748 778
Total 182 162 1196 1540
Table: The number of MAC isolates by sample origin and age group
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M. malmoense did not benefit from these technical improvements (Figure 5), 
neither did the number of extrapulmonary M. avium isolates (Figure 4). Skin 
sensitization to M. intracellulare has increased over the last decades in the 
USA, along with the incidence of M. intracellulare infection.9 Combined, this 
suggests that laboratory techniques have a role in the increase in NTM, thus 
M. avium, isolation, but are not its sole explanation. 
Host factors provide a second partial explanation for the rise in NTM isolation 
frequency. The Dutch population is ageing and the prevalence of COPD is 
increasing.10 The COPD prevalence may partially explain the increase in NTM 
notification in pulmonary samples (Figure 5). Still, this offers no explanation 
for the rise in isolation specifically of M. avium unless COPD predisposes to 
infection by M. avium rather than other NTM species. In the Netherlands, the 
fibrocavitary disease type is more prevalent, primarily affects COPD patients 
and is mostly caused by M. avium.5 It is uncertain whether the predominance of 
cavitary MAC disease results from the strong presence of M. avium as opposed 
to M. intracellulare, or from host factors including COPD. Rather than rising 
COPD prevalence, the simultaneous decline in tuberculosis incidence (Figure 
1) may imply that exposure to tuberculosis infers cross-protection to NTM 
disease; this is supported by the fact that countries that halted Bacille Calmette-
Guerin (BCG) vaccination subsequently noticed an increase in the incidence 
of paediatric cervicofacial lymphadenitis caused by MAC.11,12
A third explanation for the increase in M. avium isolation in the Netherlands 
may be changes in the environment, either natural or man-made, that 
favour M. avium and impede or influence other NTM; these could result 
in increased exposure of humans specifically to M. avium. Similarly, in the 
1970’s M. scrofulaceum was replaced by MAC as the leading causative agent of 
cervical lymphadenitis in children. This phenomenon has been attributed to 
chlorination of tap water, which should select for the more chlorine resistant 
M. avium.3 Studies reviewed by Collins and co-workers, however, did not 
demonstrate important differences in chlorine susceptibility between NTM 
species and considered tap water chlorine levels too low to significantly reduce 
mycobacterial loads.13 
The number of M. avium isolates from lymph node samples referred to our 
reference laboratory has remained relatively stable; the temporary elevation 
in 2004-2005 results from a clinical trial in that period.14 The stable low 
numbers of other extrapulmonary M. avium isolates probably result, in part, 
from the availability of highly active antiretroviral therapy (HAART) and 
MAC prophylaxis for patients infected with HIV. A decline in the incidence 
of disseminated M. avium disease during and after HAART introduction has 
been recorded and reviewed before.15 Nontuberculous mycobacterial infection 
usually affects patients with very low CD4 counts and their numbers have been 
reduced after the introduction of HAART.
In summary, the rise in notification of nontuberculous mycobacteria at the 
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reference laboratory in the Netherlands was mainly caused by increasing 
isolation of M. avium from respiratory samples in patients over 40 years of 
age. This group most likely has pre-existent pulmonary disease, mainly COPD. 
Changes in laboratory techniques are unlikely to be the sole explanation of 
this increase; the ageing population with an increasing prevalence of chronic 
diseases including COPD and decreasing cross-protection to NTM disease 
from exposure to tuberculosis and environmental changes may specifically 
favour M. avium.
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Abstract
An increase in incidence of otomastoiditis caused by nontuberculous 
mycobacteria was noticed in the Netherlands. These infections affect children 
with tympanostomy tubes, a history of ear infection and ototopical antibiotic 
treatment and can result in permanent hearing loss. Diagnostic delay and 
limited adherence to available treatment guidelines warrant increased 
attention.
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Introduction
Nontuberculous mycobacteria (NTM) are common in the environment and 
increasingly recognized as mostly opportunistic human pathogens.1 NTM 
usually cause pulmonary disease. Extrapulmonary and disseminated disease 
is typically diagnosed in immunocompromised patients.1 Lymphadenitis and 
otomastoiditis in children are notable exceptions to this rule. 
Otomastoiditis is a rare extrapulmonary NTM disease type first described in 
1976 and mostly affecting children.1-3 In the Netherlands, we noted a sudden 
rise in NTM isolates derived from otological samples in 2006. This induced the 
current retrospective analysis of the clinical features, diagnosis and treatment 
of NTM otomastoiditis in the Netherlands.
The Study
We searched the national reference laboratory database and identified thirteen 
patients with otological samples yielding NTM over the January 1993 to June 
2007 period. We re-subjected their isolates to molecular identification applying 
the INNO-LiPA MYCOBACTERIA v2 (Innogenetics, Gent, Belgium) reverse 
line blot assay. Mycobacterium abscessus was the most frequent causative agent 
(10/13; 77%), followed by M. avium (n=2) and M. avium complex (MAC), 
though not M. avium or M. intracellulare (n=1). The latter three will be 
collectively referred to as MAC. Susceptibility testing was performed using the 
agar dilution method.4 All primary isolates were susceptible to clarithromycin 
and resistant to aminoglycosides and fluoroquinolones; M. abscessus bacteria 
in two patients acquired clarithromycin resistance during treatment. 
The peak in the number of patients in 2006 has only partly abated; Figure 1 
details the timing of the thirteen cases in this report, as well as two new cases 
from 2007 and three in the first half of 2008. 
Figure 1: Notification of NTM otomastoiditis over time, by species. After a prior 
emergence in 1999-2001, increased notification of cases was apparent from 2005 until 
May 2008
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We examined medical records of the thirteen patients; the main results are 
recorded in the Table. Two patients with M. abscessus otomastoiditis are 
siblings (Table, patients 5 & 6). Among immunocompetent patients, those 
with M. abscessus otomastoiditis were older than patients with MAC disease 
(6 vs. 2 years).
All patients had a history of ear infections and twelve had a history of 
tympanostomy tube placement. Eleven patients had used ototopical medication, 
including quinolone antibiotics (n=6), steroids and aminoglycosides (n=3) 
or both (n=2). The clinical presentation was non-specific, with persistent 
tympanic membrane perforation, chronic painless otorrhea resistant to 
antibiotic therapy and hearing loss.
The mean interval between first symptoms and diagnosis was 155 days for M. 
abscessus otomastoiditis (range 14-360) and 39 days for MAC otomastoiditis 
(range 28-49). In all thirteen patients acid-fast bacilli microscopy was 
performed; eleven were positive. In six cases the primary isolate was from 
biopsy material, in seven from otorrhea fluid. Seven patients had a computed 
tomography (CT)-scan performed which revealed fluid in the mastoid (n=6), 
bone erosion of the mastoid (n=3) and mucosal swelling (all); figure 2 displays 
typical findings.
The treatment regimens are detailed in the Table. Patients with M. abscessus 
infections received drug treatment for a mean duration of three months (range 
28-150 days) and 1.8 episodes of surgery, versus 14 months of drug therapy 
and one episode of surgery for those with MAC otomastoiditis. Five patients 
with M. abscessus otomastoiditis received clarithromycin monotherapy, five 
received multi-drug therapy with fluoroquinolones (n=3), fluoroquinolones 
Figure 2 (A+B): Computed tomography images of a patient with Mycobacterium 
abscessus otomastoiditis. There is extensive bone destruction in the right mastoid and 
associated right-sided mucosal swelling.
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and first-line anti-tuberculosis drugs (n=1) or meropenem (n=1; Table). The 
patients with MAC otomastoiditis received rifabutin and clarithromycin.
Complications of surgery comprised mainly delayed wound healing (n=5) and 
fistula formation (n=2; Table). For two patients, incus removal and later chain 
reconstruction surgery was necessary (Table, patient 7 and 8).
Although extrapulmonary NTM infections are considered localized infections, 
we recorded culture-proven regional spread of the infection to cervical lymph 
nodes (Table; patients 8 & 12) with a retro-auricular abscess, fistula and 
partially reversible facial nerve palsy in one patient (patient 8).
Ten patients are now considered to be cured. Two patients still received 
treatment at the time of the data collection. Cure was defined by symptomatic 
improvement and in some cases confirmed by negative cultures. One patient 
died after deliberately discontinuing treatment for multiple opportunistic 
infections (Table, patient 13). The mean interval between the start of the first 
treatment and cure was 341 days (range 202-570). Audiograms demonstrated 
persistent conductive hearing loss after treatment in five patients (42%; range 
30-80dB; Table 1). 
Conclusions
The number of cases of NTM otomastoiditis cases rose in 2006 and remained 
elevated, with three new cases in the first 6 months of 2008 (Figure 1). Whether 
this is a true increase or a result of improved laboratory facilities or awareness 
in clinicians remains uncertain. The latter seems unlikely as Dutch guidelines 
advise against performing cultures in children with chronic otorrhea. 
Laboratory improvements like liquid culture and molecular identification 
techniques predate the rise in notification. 
The predominance of M. abscessus is remarkable, as MAC is the overall most 
frequently isolated NTM and the most common causative agent of pulmonary 
and disseminated disease in adults as well as cervical lymphadenitis in 
children.1 Apparently, M. abscessus has a predilection to cause otomastoiditis. 
The patient characteristics and NTM species are similar to previous studies.5-7 
Early reports have identified M. fortuitum or M. chelonae as causative 
agents, which may be due to the fact that the taxonomy of the rapid growing 
mycobacteria has long been debated.8,9 
MAC otomastoiditis is usually diagnosed in patients younger than those 
with M. abscessus disease.5-7 Lindeboom et al. found similar associations 
between M. avium infection and young age, in their comparison of causative 
agents of pediatric NTM lymphadenitis.10 This may result from age-specific 
environmental exposure, e.g. playing in sandpits or swimming.10
American Thoracic Society (ATS) guidelines for treatment of skin, soft 
tissue and bone infections caused by M. abscessus advocate 4 to 6 months of 
triple-drug therapy with a macrolide, an aminoglycoside and cefoxitin or a 
carbapenem, based on in vitro drug susceptibility test results, combined with 
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surgical debridement when possible.1 Treatment regimens observed in our 
study deviated both in duration (3 months) and content; the clarithromycin 
monotherapy is likely to invoke resistance1 and simultaneously administered 
fluoroquinolones dampen clarithromycin activity.11 Moreover, use of 
parenteral agents was limited; its reasoning was not generally captured in our 
file review. Aminoglycosides may have been withheld due to their ototoxicity.1 
The patients with MAC otomastoiditis were treated with a combination of 
rifabutin and clarithromycin, without the ethambutol recommended by the 
ATS.1 The frequent deviation from treatment guidelines, necessity of multiple 
rounds of surgery to attain cure and acquired clarithromycin resistance may be 
interrelated, although our study group is too small for such conclusions. This 
situation may improve if adherence to ATS treatment guidelines increases.
We noted significant diagnostic delays. Otorrhea unresponsive to antibiotic 
therapy should raise a clinical suspicion of NTM otomastoiditis,3 especially in 
patients with bone destruction visible on CT images. Routine Mycobacterium 
cultures in such patients may reduce diagnostic delay, preventing further 
damage. Tissue biopsy is the most sensitive means of obtaining a specimen for 
culture.1
In summary, otomastoiditis caused by NTM is a rare but serious condition 
that may be emerging in the Netherlands. Mycobacterium abscessus and MAC 
are the predominant causative agents and affect children with previous ear 
infections, tympanostomy tubes and ototopical antibiotic or steroid use. The 
diagnostic delay and treatment regimens should be improved, mainly for M. 
abscessus disease. Treatment with surgery and evidence-based multi-drug 
regimens may prevent deterioration and prevent or limit permanent hearing 
loss.
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Summary
Background: A 54-year-old man with a 22-year history of rheumatoid arthritis 
and an 8-year history of chronic obstructive pulmonary disease presented with 
dyspnea on exertion, nonproductive cough and fatigue of 1 month’s duration. 
His medication at presentation consisted of etanercept, azathioprine, naproxen 
and inhaled fluticasone and salbutamol.
Investigations: At presentation, the patient underwent physical examination, 
chest X-ray and high-resolution CT, blood tests, and bronchoalveolar lavage 
fluid analysis including auramine stains and gene sequence analysis of 
cultured Mycobacterium szulgai. The patient underwent minithoracotomy 
after 6 months, and bronchoalveolar lavage fluid analysis, culture and chest 
X-ray after 18 months. Further chest imaging and culture of sputum samples 
were performed another year later.
Diagnosis: Pulmonary M. szulgai infection.
Management: Triple drug therapy with rifampicin, ethambutol hydrochloride 
and clarithromycin. Anti-tumor necrosis factor treatment was continued.
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The Case
A 54-year-old man presented to the respiratory department of a regional 
hospital with dyspnea on exertion, nonproductive cough and fatigue, which he 
had experienced for 1 month. The patient had a 22-year history of rheumatoid-
factor positive, severe, nodular, erosive rheumatoid arthritis (RA; Steinbrocker 
class III) and an 8-year history of chronic obstructive pulmonary disease 
(COPD; Global Initiative for Chronic Obstructive Lung Disease stage I). The 
patient’s RA had been treated with subcutaneous etanercept 25 mg twice weekly 
for 24 months, azathioprine 50 mg twice daily for 8 months and naproxen 
500 mg twice daily for over 10 years. Previous treatment with sub cutaneous 
methotrexate 30 mg once weekly had not been successful. The patient’s COPD 
had been treated for 3 years with inhaled fluticasone propionate 500 μg twice 
daily and salbutamol 100 μg 1-6 times daily, as needed.
Physical examination of the chest revealed decreased breath sounds but 
no wheezes, crackles or prolonged expiration. A chest X-ray (Figure 1A) 
and high-resolution CT at presentation showed generalized emphysema, 
an infiltrate in the lingula, apical bullae, cavities with fibrosis in the right 
upper lobe, and diffuse peribronchial alveolar consolidations. Chest X-rays, 
which had been performed before initiation of etanercept treatment, had 
not shown these abnormalities. Bronchoalveolar lavage fluid analysis at 
presentation revealed acute, nonspecific inflammation with an elevated cell 
count, lymphocytosis and an elevated CD4/CD8 T-lymphocyte ratio. Blood 
tests showed that the CD4/CD8 T-lymphocyte ratio was normal in the serum. 
Three auramine stains of the bronchoalveolar lavage fluid were negative; one of 
three corresponding cultures yielded Mycobacterium szulgai, a nontuberculous 
mycobacterium. No other micro-organisms were cultured. At this time, the M. 
szulgai was considered to be a contaminant in the culture, and a firm diagnosis 
of nontuberculous mycobacterial infection could not be made according to 
the American Thoracic Society 1997 criteria (Box 1).1 A minithoracotomy 
was performed 6 months later for histological diagnosis, which revealed 
panacinar emphysema, bronchiolitis and low-intensity granulomatous 
pneumonitis with epithelioid cell granuloma. The differential diagnosis now 
included sarcoidosis, tuberculosis, fungal infection, M. szulgai infection, and 
occupational pulmonary disease such as asbestosis, berylliosis and silicosis. At 
this stage, the patient’s stable pulmonary and rheumatologic condition did not 
warrant a therapy change.
At a routine follow-up visit 18 months later, bronchoalveolar lavage fluid analysis 
again yielded one positive culture for M. szulgai. Radiological progression of 
disease was noted, with progression of cavitary and fibrotic lesions, traction-
bronchiectasis and resolution of patchy consolidations (Figures 1B and 2A). 
A tentative diagnosis of stage IV sarcoidosis was made on the basis of results 
from chest X-rays and histology, and because the diagnostic criteria for 
nontuberculous mycobacterial infection according to the American Thoracic 
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Society had not been met (Box 1).1 Etanercept treatment was terminated, 
and treatment with adalimumab 40 mg every 2 weeks was started with the 
intention of treating both RA and the potential sarcoidosis.
Another year later, the patient returned with a mild cough, malaise and night 
sweats. Chest imaging (Figures 1C and 2B) revealed thickening of cavity walls, 
reappearance of consolidations, a nodular pattern in the right middle lobe, 
and ground glass appearance. Three sputum samples were positive for acid-
fast bacilli on microscopy, and corresponding cultures yielded M. szulgai. At 
this time, the patient met the American Thoracic Society diagnostic criteria for 
nontuberculous mycobacterial infection (Box 1).1 Treatment was started with 
rifampicin 600 mg once daily, ethambutol hydrochloride 1400 mg (20 mg/kg) 
once daily and clarithromycin 500 mg twice daily for a duration of 18 months. 
Adalimumab therapy was continued during the antimycobacterial treatment. 
The patient’s cough and dyspnea diminished within the first month after 
initiation of antimycobacterial treatment, constitutional symptoms resolved 
At least three respiratory samples should be evaluated from each patient. Other reasonable 
causes for the disease should be excluded. Expert consultation should be sought when 
diagnostic difficulties are encountered.
Patients can be diagnosed with nontuberculous mycobacterial infection if they 
fulfill the following criteria:
■ They have pulmonary symptoms
plus
■ Infiltrate
or
■ Nodular or cavitary disease
or
■ A high-resolution CT scan that shows multifocal bronchiectasis, with or without 
multiple small nodules
plus
■ If three sputum or bronchial wash results are available from the previous 12 
months: three positive cultures with negative AFB smear results, or two positive 
cultures and one positive AFB smear
or
■ If only one bronchial wash is available, and sputum samples can not be obtained: 
positive culture with a 2+, 3+, or 4+ AFB smear, or 2+, 3+, or 4+ growth on solid 
media
or
■ If sputum or bronchial wash evaluations are nondiagnostic or another disease 
cannot be excluded: transbronchial or lung biopsy yielding an NTM, or biopsy 
showing mycobacterial histopathologic features (granulomatous inflammation, 
with or without AFB) and one or more sputum samples or bronchial washings that 
are positive for an NTM even in low numbers
Abbreviations: AFB, acid-fast bacilli; NTM, nontuberculous mycobacteria.
Box 1 Summary of the American Thoracic Society diagnostic criteria for 
nontuberculous mycobacterial infection.1
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after 4 months, and radiological abnormalities had improved after 1 year of 
therapy (Figures 1D and 2C).
The patient’s erythrocyte sedimentation rate and serum C-reactive protein 
concentration were repeatedly measured during the course of the patient’s 
disease and after antimycobacterial treatment was initiated (Figure 3). 
Genotyping of all the patient’s M. szulgai isolates with random amplified 
polymorphic DNA analysis as previously described,2 using OPA18 and IS986 
FP as primers, was performed at the Dutch national tuberculosis reference 
Figure 2: The patient’s CT images
(A) 2 years after initial presentation and 1 year prior to antimycobacterial therapy. The image 
shows fibrotic and cavitary lesions. (B) 3 years after initial presentation and at the start 
of antimycobacterial therapy. The image shows that the fibrotic and cavitary lesions have 
worsened since the previous year. The smaller image in the bottom right-hand corner shows 
the anatomical position of the section displayed. (C) 4 years after initial presentation and 1 year 
after antimycobacterial treatment. The image shows that the fibrotic and cavitary lesions have 
partially regressed. The smaller image in the bottom right-hand corner shows the anatomical 
position of the section displayed
Figure 1: The patient’s chest X-rays
(A) At initial presentation. The image shows patchy consolidations in both lungs. (B) 2 years 
after initial presentation and 1 year prior to antimycobacterial therapy. The image shows 
progression of the patchy consolidations to fibrotic, cavitary lesions in the upper lobes. (C) 3 
years after initial presentation and at the start of antimycobacterial treatment. The image shows 
progression of the fibrotic and cavitary lesions in both upper lobes. (D) After antimycobacterial 
treatment. The image shows that the fibrotic, cavitary lesions in the upper lobes are slightly 
decreased in size.
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laboratory after the patient’s symptoms resolved. The results of the genotyping 
showed that all the M. szulgai isolates were of a similar, distinct genotype 
(Figure 4).
Mycobacterial smears and cultures were negative after 1 year of 
antimycobacterial treatment and remained negative on subsequent tests. This 
patient is still treated with adalimumab and his RA remains stable.
Discussion of Diagnosis
The patient developed a nontuberculous mycobacterial infection while 
receiving anti-tumor necrosis factor (TNF) therapy for the treatment of RA. 
The similar mycobacterial genotypes, which were obtained using random 
amplified polymorphic DNA analysis, indicated that the same strain of M. 
szulgai was isolated on all three occasions (Figure 4). Pulmonary M. szulgai 
isolates from other patients within the same geographical region and the same 
period, which were mostly cultured in the same hospital laboratory, seemed to 
be unrelated to those obtained from this patient; therefore, contamination of 
this patient’s cultures, or reinfection, is unlikely to have occurred. Theoretically, 
repeated exposure to a single environmental source might have caused 
monoclonal reinfections; however, this possibility is considered improbable. It 
is assumed, therefore, that the primary M. szulgai culture, which was cultured 
3 years prior to treatment, already represented true infection. The increases in 
erythrocyte sedimentation rate and serum C-reactive protein concentration in 
a period when RA was stable also supported this assumption.
The patient’s early symptoms, radiological features and M. szulgai isolates 
probably represented subclinical or latent nontuberculous mycobacterial 
infection; however, the American Thoracic Society diagnostic criteria for 
nontuberculous mycobacterial infection (Box 1)1 were not met, and the patient 
was not treated for nontuberculous mycobacterial infection at this time. 
Histological samples were obtained from the patient at the initial presentation, 
and the results of the samples were interpreted as sarcoidosis. The differential 
diagnosis also included tuberculosis, M. szulgai infection, fungal infection, and 
occupational pulmonary disease such as asbestosis, berylliosis and silicosis. 
The absence of asbestos, beryllium or silica exposure, and absence of cultured 
M. tuberculosis complex bacteria or fungi, however, narrowed the differential 
diagnosis to sarcoidosis and M. szulgai infection.
The possibility that the patient’s histological findings resulted from the 
nontuberculous mycobacterial infection, influenced by anti-TNF therapy, is 
supported by the finding that bronchiolitis and epithelioid cell granuloma, 
with or without central necrosis, have been recorded in histological studies 
of patients with nontuberculous mycobacterial infection.3 Also, the absence 
of radiological abnormalities 2 years prior to the initial presentation indicated 
that there was an association between the patient’s radiological features and 
the M. szulgai culture. Mycobacteria might have a role in the etiology of 
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Figure 4: A photograph of genotyping results of the patient’s Mycobacterium szulgai isolates.
The genotyping was performed using random amplified polymorphic DNA analysis with OPA18 
and IS986 FP as primers. Lanes A–D show the genotyping for pulmonary samples from four 
patients in the same geographical region as the case patient. Lanes E–G show the genotyping 
for the case patient’s pulmonary samples: 3 years after initial presentation and at the start of 
antimycobacterial therapy (E); 2 years after initial presentation and 1 year prior to the start of 
antimycobacterial therapy (F); and at initial presentation (G, extra band in IS986 FP). This figure 
shows that in the case patient, the same strain of M. szulgai was isolated on all three occasions. 
Pulmonary M. szulgai isolates from the four other patients within the same geographical region 
and the same period were unrelated to those obtained from the case patient.
Figure 3: Microbiological and serological parameters during the course of the patient’s disease.
This figure shows the culture results and the ESR and CRP levels, which rise after the first Mycobacterium 
szulgai culture, with CRP levels rising more pronouncedly after adalimumab treatment is started. Both 
ESR and CRP levels regress to their normal range during combined antimycobacterial and anti-TNF 
treatment. This figure indicates that the patient had chronic infection, which deteriorated during 
adalimumab therapy, but which was successfully treated without cessation of adalimumab therapy. 
Abbreviations: AFB, acid-fast bacilli (visible on direct microscopy); CRP, C-reactive protein; 
Cult, culture results for M. szulgai; ESR, erythrocyte sedimentation rate.
NTM disease in patients treated for rheumatic disease
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sarcoidosis;4 therefore, M. szulgai could theoretically have caused sarcoidosis 
in this patient. This possibility is unlikely, however, because mycobacterial 
DNA fragments, not viable mycobacteria, have been demonstrated in tissue 
samples of patients with sarcoidosis, and the bacteriological course of this 
patient’s disease is strongly indicative of mycobacterial infection rather than 
sarcoidosis.4
Treatment with etanercept was discontinued in this patient, and treatment 
with adalimumab was initiated. Adalimumab is closely related to the anti-
TNF agent infliximab, which is effective in the treatment of sarcoidosis.5 
Paradoxically, anti-TNF agents (mainly etanercept) have been described as a 
possible causative agent of sarcoidosis;6 this finding strengthened the diagnosis 
of sarcoidosis in this patient during the early stages, as he was being treated 
with etanercept at this time. Adalimumab inhibits the action of TNF and 
the production of interferon-γ (INFγ);7 these properties increase patients’ 
susceptibility to nontuberculous mycobacterial infection. This patient’s 
infection by M. szulgai, which was cultured at the initial presentation, was 
clinically stable during treatment with etanercept but slowly deteriorated after 
initiation of adalimumab therapy. This observation might demonstrate the 
high extent to which TNF and INFγ inhibition is achieved with adalimumab.
TNF has an important role in granuloma formation and maintenance, which 
is essential in host defense against mycobacteria;8 therefore, mycobacterial 
infection or reactivation of latent infection can be expected as a complication 
of anti-TNF treatment. Reports have documented the emergence of 
nontuberculous mycobacterial infection in patients who receive anti-TNF 
treatment. In 2004, Wallis et al.9 reported 29 unspecified nontuberculous 
mycobacterial infections in patients treated with anti-TNF agents from the 
FDA adverse events reporting system. These reports are not necessarily 29 true 
nontuberculous mycobacterial infections, as the reporting procedure might 
not be sufficient to fulfill the American Thoracic Society diagnostic criteria. 
Two true nontuberculous mycobacterial infections are described in separate 
case reports;10,11 one concerned a psoas muscle abscess caused by M. avium 
induced by etanercept use, and the other a M. abscessus skin infection induced 
by infliximab use. These infections occurred after 12 and 13 months of anti-TNF 
treatment, respectively, as in this patient, whose symptoms deteriorated after 
12 months of adalimumab therapy. These reports highlight that the length of 
time between the start of anti-TNF treatment and the onset of nontuberculous 
mycobacterial disease is longer than for the onset of tuberculosis, where a 
median interval of 12 weeks is observed.8,9 
Among patients who receive anti-TNF therapy, tuberculosis infection or 
reactivation is more common than nontuberculous mycobacterial infection or 
reactivation.8-11 Several possibilities exist for the cause of this finding, including 
a higher prevalence of latent tuberculosis compared with latent nontuberculous 
mycobacterial disease. Another explanation could be the ability of tuberculosis 
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to infect previously healthy individuals, whereas nontuberculous mycobacteria, 
being opportunistic pathogens, generally affect patients with local (e.g. COPD, 
as in this patient) or systemic impaired immunity. The finding could also arise 
from the possibility that TNF has a less prominent role in the pathogenesis 
of nontuberculous mycobacterial infection than it has in tuberculosis 
infection. The concept of ‘latent’ nontuberculous mycobacterial infection is 
controversial, and missed diagnoses of active nontuberculous mycobacterial 
infection might also contribute to a higher recorded prevalence of tuberculosis 
than nontuberculous mycobacterial infections in patients who receive anti-
TNF therapy.
Various authors have produced recommendations for the screening of latent 
tuberculosis in candidates eligible for anti-TNF therapy, which usually involves 
tuberculin skin testing and chest X-ray.8 For nontuberculous mycobacteria, 
these tests might not suffice: tuberculin skin test results are mostly negative in 
patients with nontuberculous mycobacterial infections, and chest X-rays show 
diverse, partly species-specific patterns.1 In candidates for anti-TNF treatment 
with known lung disease, specifically COPD and bronchiectasis, their sputum 
should be repeatedly cultured for mycobacteria. 
In this patient, it should be considered that COPD itself predisposed him to 
nontuberculous mycobacterial infection, independently of anti-TNF therapy. 
The localized pulmonary presentation in this patient, as opposed to the 
extrapulmonary or disseminated mycobacterial infections seen in patients 
who receive anti-TNF treatment, suggests that the host response to infection 
was relatively intact.8 It is not possible, therefore, to establish whether or not 
anti-TNF treatment was the sole, definite cause of his M. szulgai infection. 
As the number of indications for anti-TNF treatment increases, more patients 
with additional risk factors for nontuberculous mycobacterial infection might 
receive treatment with this class of agents; therefore, the case patient might 
represent an emerging issue of nontuberculous mycobacterial infection in 
anti-TNF recipients.
Discussion of treatment options
Whether or not anti-TNF agents can be safely continued during 
antimycobacterial treatment remains the subject of debate. Continuation 
of these agents might be feasible for the following three reasons. First, the 
disruption of granuloma achieved by anti-TNF agents could increase the 
exposure of mycobacteria to anti mycobacterial drugs, thereby resulting in 
improved treatment outcome for the infection.12 Second, although an increased 
risk of paradoxical response to antimycobacterial therapy has been reported 
in infliximab-treated patients with tuberculosis, which is characterized by 
clinical deterioration during treatment in patients who initially improve, 
maintenance of low doses of anti-TNF agents might produce immunologic 
regulation beneficial to this group.13 Third, rheumatologic complaints remain 
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well-controlled with anti-TNF therapy. A case reported by Matsumoto et al. 
showed that antimycobacterial therapy followed by anti-TNF therapy can 
be safe and effective for the treatment of mycobacterial infection; infliximab 
therapy was safely restarted after 2 months of antituberculosis treatment.14 
Anti-TNF treatment was not discontinued during antimycobacterial therapy in 
the patient described here, and his M. szulgai infection improved (Figures 1-3) 
while his rheumatologic complaints remained minimal and no paradoxical 
reaction occurred.
Both the American Thoracic Society and the British Thoracic Society have 
released management guidelines for nontuberculous mycobacterial infections. 
Although not designed for M. szulgai, both groups specifically mention this 
species. The American Thoracic Society advises treatment with rifampicin 600 
mg, ethambutol hydrochloride 25 mg/kg in the first 2 months, then 15 mg/kg, 
and streptomycin (dosage depending on weight, age and phase of therapy); 
the British Thoracic Society advises rifampicin 450 mg for patients who weigh 
<50 kg and 600 mg for those who weigh >50 kg, ethambutol hydrochloride 
15 mg/kg, clarithromycin 500 mg twice daily, and also the option of surgical 
treatment.1,15 Previous case series have reported an almost 100% cure rate of 
M. szulgai infection, with the few failures or relapses resulting from inadequate 
drug regimens or proven non-compliance.16 This patient was treated with 
clarithromycin to avoid the use of drugs that require injection. The optimal 
duration of therapy has not yet been established in clinical trials; however, 
both the American Thoracic Society and the British Thoracic Society currently 
advise 18-24 months of treatment if the patient has a satisfactory clinical and 
bacteriological response to chemotherapy, as this patient had.
Conclusions
The important role that TNF has in granuloma formation and maintenance, 
which is essential in host defense against mycobacteria, has been demonstrated 
by the many cases of tuberculosis reactivation described.7-9 Few cases of 
nontuberculous mycobacterial infections in patients receiving anti-TNF 
therapy have been reported.9-11 Given the low incidence and lack of good 
diagnostic instruments, specific screening for nontuberculous mycobacterial 
infections is currently not feasible; however, candidates for anti-TNF treatment 
with known lung disease, specifically COPD and bronchiectasis, should have 
their sputum repeatedly cultured for mycobacteria. Furthermore, clinicians 
involved in anti-TNF treatment should be aware of the potential emergence of 
nontuberculous mycobacterial infections in their patients. If a nontuberculous 
mycobacterial infection occurs, strictly supervised continuation of anti-TNF 
agents during antimycobacterial treatment might be safe and effective.
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Summary
This Review focuses on the emergence of mycobacterial disease in patients 
undergoing treatment for rheumatic disease with four new drug classes—
tumor necrosis factor (TNF) inhibitors, human interleukin (IL)-1 receptor 
antagonists, anti-CD20 antibodies and CD4+ T-cell costimulation 
modulators—collectively referred to as biologic agents. Mycobacterial disease 
is a major cause of severe infection in patients undergoing anti-TNF therapy. 
Reports are now emerging of an association between mycobacterial infection 
and antirheumatic treatment with anti-IL-1 or anti-CD20 antibodies. Although 
tuberculosis is the most common mycobacterial disease, nontuberculous 
mycobacterial (NTM) disease is an increasingly recognized problem in this 
setting. Among the antirheumatic drugs currently in development, agents 
that target IL-17, IL-23, Janus kinase–signal transducers and activators of 
transcription signaling, and metalloproteinases are likely to confer an increased 
risk of mycobacterial disease. Although screening and preventive treatments 
have lowered the incidence of active tuberculosis, these tools are not applicable 
to patients with NTM disease. All patients receiving drugs associated with an 
increased risk of mycobacterial disease should be carefully monitored, and 
suspect lesions should undergo Mycobacterium culture. Further studies are 
needed to determine the prevalence of NTM disease in this setting, and to 
evaluate the safety of simultaneous anti-TNF and antimycobacterial treatment.
Review Criteria
Relevant publications for this Review were identified using the PubMed da-
tabase. We reviewed English-language papers only. The following Medical 
Subject Heading (MeSH) terms were searched alone and in combination: 
“tuberculosis”, “mycobacterium infections, atypical”, “rheumatic disease”, 
“tumor necrosis factor-alpha” and “safety”.
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Introduction
Patients with rheumatic disease are at a higher risk of infection than the general 
population. Studies have focused mainly on the infection risk associated with 
the treatment of rheumatic disease.1 The advent of anti-tumor necrosis factor 
(TNF) therapy saw an increased incidence of active tuberculosis in patients 
undergoing antirheumatic therapy compared with the general population. 
Tuberculosis is among the most common severe infections seen in patients 
receiving anti-TNF treatment.1
The genus Mycobacterium comprises three main groups: the M. tuberculosis 
complex, M. leprae, which causes leprosy, and the nontuberculous mycobacteria 
(NTM). The most important causative agents of human tuberculosis are M. 
tuberculosis, M. bovis and M. africanum; M. microti, M. caprae, M. canettii, 
and M. pinnipedii are less frequent causative agents. The NTM include a 
highly divergent group of over 100 different species that are omnipresent in 
the environment (i.e. water and soil) and capable of causing opportunistic 
disease.2 Interestingly, reports are emerging of NTM-associated disease in 
patients receiving anti-TNF treatment.3,4 This Review focuses on the drug 
related risks, clinical presentation and new possibilities for screening and 
preventing mycobacterial disease in patients treated for rheumatic diseases.
Drug-related infection risk in antirheumatic therapy
The treatments currently available for rheumatic disease include six separate 
immunosuppressive drug classes, which all vary in their associated risk 
of infection.  Steroids and methotrexate are the oldest classes in active use. 
Although the elevated infection risk associated with steroids has been well 
documented, this association remains unproven for methotrexate.1
Four new drug classes have been developed over the past 10 years, based on 
human or chimeric antibodies against cytokines or receptors with pivotal 
roles in the inflammatory pathways of immune mediated inflammatory 
disease. These agents are collectively referred to as ‘biologics’; Table 1 shows 
all the biologic agents that are either currently approved for use or undergoing 
evaluation in clinical trials. Anti-TNF agents (the monoclonal antibodies 
etanercept, infliximab and adalimumab) pose the largest infection risk of 
all the biologics, and predispose patients to mycobacterial infection.1 In the 
prescreening era, the estimated rate of tuberculosis infection in infliximab-
treated patients with rheumatic disease in the US was 24.4 cases per 100,000 
patients, compared with 6.2 cases per 100,000 patients who had not received 
infliximab.5 This is not surprising, as TNF has an important role in granuloma 
formation and maintenance,6 which is essential for host defense against 
mycobacteria.5 Among the anti-TNF agents, infliximab and adalimumab are 
associated with a greater risk of infection than etanercept.7
In addition to the anti-TNF agents, three other new classes of drugs have become 
available for the treatment of rheumatic disease: human interleukin(IL)-1 
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receptor antagonists, anti-CD20 antibodies and CD4+ T-cell costimulation 
modulators. Anakinra is the first IL-1 receptor antagonist to be approved 
by the US FDA. A meta-analysis of randomized controlled trials revealed a 
significantly increased risk of serious infection with higher doses of anakinra 
(≥100 mg/day) compared with lower doses or placebo. The pooled odds ratio 
(OR) for serious infection in patients treated with anakinra versus placebo was 
2.75 (95% CI 0.90–8.35); however, no cases of mycobacterial infection were 
reported.8 A single case of nonspecified NTM infection has been reported 
in a patient receiving anakinra treatment and concomitant prednisone and 
methotrexate.9 For active tuberculosis, Brassard et al.10 found 19 cases among 
1,414 patients treated with anakinra in their cohort of 112,300 patients; 
however, the risk for tuberculosis was significantly increased only in past users 
of corticosteroids receiving anakinra (adjusted rate ratio 1.7, 95% CI 1.1–2.8). 
Additional case reports have described reactivation of previous tuberculosis 
infection in patients receiving anakinra monotherapy.11
Rituximab is the only available anti-CD20 antibody. A meta-analysis of three 
randomized controlled trials failed to demonstrate a significant increase in the 
rituximab-associated risk of serious infection (pooled OR 1.45, 95% CI 0.56–
3.73).8 However, the first cases of mycobacterial disease related to rituximab 
use have been reported this year.4
Abatacept is the only approved CD4+ T-cell costimulation modulator. A 
meta-analysis of five randomized controlled trials found no increase in the 
risk of serious infection associated with abatacept therapy (pooled OR 1.35, 
95% CI 0.78–2.32).8 However, the drug was shown to increase the infection 
risk in patients already using a biologic agent, and in patients with chronic 
obstructive pulmonary disease (COPD),12 but did not impair the capacity to 
control M. tuberculosis infection in a murine model.13 
Drug class Drug name Developmental phase
Tumor necrosis factor antagonists Etanercept, infliximab 
and adalimumab
Approved
Golimumab and 
certolizumab pegol
Phase III
IL-1 receptor antagonists Anakinra Approved
CD20+ B-cell antibodies Rituximab Approved
CD4-cell co-stimulation modulators Abatacept Approved
IL-6 receptor antibodies Tocilizumab Phase III
IL-17A antibodies NA Murine model / Phase I
Abbreviations: IL, interleukin; NA, not applicable
Table 1: Currently approved biological agents and new drugs in the pipeline for the 
treatment of rheumatic diseases.
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New drugs and new indications
New indications for biologic agents - particularly for anti-TNF therapy - are 
currently under intense investigation. Anti-TNF agents have already proven 
to be effective in the treatment of various immune-mediated inflammatory 
diseases, including juvenile dermatomyositis, psoriasis, sarcoidosis and 
Behçet’s disease.14-17 These agents, however, have proven ineffective in other 
conditions that are characterized by locally increased levels of TNF, including 
multiple sclerosis and COPD.18,19 Furthermore, although COPD is a risk factor 
for NTM disease, no NTM infections were observed during Phase III trials of 
anti-TNF therapy in patients with COPD.
The broadening spectrum of diseases treated with biologic agents stresses the 
need to implement mycobacterial infection screening strategies for patients 
who are candidates for anti-TNF treatment in all these settings. Current 
knowledge on the emergence of mycobacterial disease in patients treated with 
biologic agents needs to be disseminated to the users and prescribers of these 
new drugs.
As the indications diversify, so does the variety of biologic agents. Figure 1 
displays the current and future targets for the development of antirheumatic 
drugs, together with their immunological functions against mycobacteria. 
Golimumab and certolizumab are novel monoclonal antibodies against TNF, 
and are effective in the treatment of rheumatoid arthritis (RA) and Crohn’s 
disease, respectively. The infection risk associated with both of these agents is 
similar to that of other drugs in their class. Two trials, in which patients with 
evidence of previous or current tuberculosis were excluded, found one new 
case of pulmonary tuberculosis among 216 patients treated with certolizumab, 
despite tuberculin skin test (TST) screening, and no cases of mycobacterial 
disease among 137 patients who received golimumab therapy.20,21
IL-6 affects the function of T cells and B cells, and is overexpressed in the 
synovial tissue of patients with RA, making this cytokine a potential therapeutic 
target. In a 2008 Phase III trial, treatment with tocilizumab, a humanized 
monoclonalantibody that binds to the IL-6 receptor, was associated with an 
increased rate of infection, mainly of the respiratory tract, in patients with RA 
(101.9 and 98.7 per 100 patient years for high-dose and low-dose tocilizumab, 
respectively, compared with 96.1 per 100 patient years for placebo); no 
mycobacterial infections were noted.22 The role of IL-6 in the immune response 
to mycobacteria is not completely understood. Although IL-6 proved to be 
important in the initial containment of M. tuberculosis infection in a mouse 
model, late containment occurred in the absence of IL-6,23 suggesting that IL-6 
is not essential for the host defense against tuberculosis. Other researchers have 
found that IL-6 inhibits the macrophage activation necessary for infection 
eradication in murine tuberculosis.24 The issue of whether or not tocilizumab 
confers an increased risk of mycobacterial disease remains controversial, and 
demands careful investigation prior to approval of the drug.
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IL-17 and IL-23 also represent promising novel targets.25,26 IL-17 has the 
capacity to induce chronic destructive arthritis independent of IL-1 and TNF. 
Anti-IL-17A cytokine therapy was successful in mouse models of arthritis, but 
awaits clinical trials in humans.25 Both IL-17 and IL-23 have important roles 
in all stages of the immune response against mycobacterial infection, from 
neutrophil recruitment in the earliest phase, to granuloma formation and 
maintenance in later stages (Figure 1).27 Therapeutic agents that influence these 
cytokines, therefore, are likely to alter a patient’s susceptibility to mycobacterial 
disease, or could reactivate latent disease.
Modification of proinflammatory cytokine signaling pathways in the brain 
is a proposed mechanism of action for a new generation of antidepressants. 
These include the stress-activated/mitogen-activated protein kinases and Janus 
kinase-signal transducers and activators of transcription (JAK-STAT) signaling 
pathways, and could be useful in ameliorating peripheral inflammation in RA.28 
Similar to alterations in the interferon-γ and IL-12 signaling, however, JAK–
STAT signaling is an essential step in mycobacterial immunity, and modification 
leads to increased susceptibility to mycobacterial disease in humans.29
Figure 1: A basic representation of macrophage immune signaling after mycobacterial infection 
Engulfing of mycobacteria by macrophages induces a strong TH1 cell response. Macrophages 
activate TH1 cells by secretion of various interleukins, and induce their own activity via TNF 
and IL-1 secretion. IL-6 and IL-23 are secreted to induce differentiation of precursor cells to 
TH17 cells and to elicit the acute phase response. Activated TH1 cells, in turn, stimulate the 
macrophages by secretion of IFN-γ and TNF. This, combined with metalloproteinase secretion, 
leads to neutrophil recruitment, T-cell proliferation and finally granuloma formation. JAK-
STAT signaling mediates the activation of macrophages and TH1 cells. The current and future 
targets for antirheumatic drugs are shown in italics.
Abbreviations: IFN, interferon; IL, interleukin; JAK, Janus kinase; STAT, signal transducer and 
activator of transcription; TH, T helper; TNF, tumor necrosis factor.
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Another potential antirheumatic strategy is inhibition of the metalloproteinases, 
either directly or indirectly by modulating gene expression or preventing 
protein activation.30 In an animal model of pulmonary tuberculosis, 
metalloproteinase-9 was required for macrophage recruitment and granuloma 
formation;31 therefore, similar to the anti-TNF agents, metalloproteinase 
inhibition might disrupt granuloma formation and thus perturb the host 
defense against mycobacteria.
Mycobacterial disease in patients undergoing anti-TNF therapy
In most patients, tuberculosis represents reactivation of a previous infection, 
presenting after a median of 12 weeks of infliximab therapy, or after 12 months 
of treatment with etanercept.6,32-34 Diagnosing mycobacterial disease in 
patients treated with biologic agents is complicated. Patients often present with 
extrapulmonary mycobacterial disease,3,32,33 and require invasive diagnostic 
techniques. Extrapulmonary tuberculosis disease types are generally 
paucibacillary infections, which hampers confirmation of the diagnosis by 
Mycobacterium culture.
Few data on the emergence of NTM disease in patients undergoing anti-TNF 
therapy have been published. Wallis et al.34 reported 29 cases of unspecified 
NTM infections associated with anti-TNF therapy in 622 patients with 
granulomatous infectious diseases. Whether these patients had occasional 
NTM isolates or disease according to the American Thoracic Society diagnostic 
criteria (summarized in Box 1)2 cannot be substantiated from the report. 
Cases of NTM disease classified according to the American Thoracic Society 
criteria are described in separate case reports. Psoas muscle abscesses caused 
by M. avium,3 M. xenopi pulmonary disease,35 M. xenopi spondylodiscitis,36 
M. marinum tenosynovitis37 and fatal pulmonary M. abscessus disease38 have 
all been recorded in patients treated with etanercept. Furthermore, infliximab 
treatment has been associated with M. abscessus skin infection, disseminated 
M. avium complex disease, M. peregrinum pulmonary disease and M. fortuitum 
hepatitis,3 and there has been one reported case of M. szulgai pulmonary 
disease during adalimumab therapy.39
The number of patients with tuberculosis associated with biologic therapy is 
thought to outnumber that of NTM disease, although a recent report, based on 
the Emerging Infections Network of the Infectious Diseases Society of America, 
showed the opposite.3 Extrapulmonary and disseminated NTM disease seem 
to be the most common forms.3,35-37 Pulmonary disease might arise specifically 
in patients with additional risk factors, including bronchiectasis and COPD.35,39 
The range of NTM species involved in anti-TNF-associated mycobacterial 
disease is intriguing, as it includes species of both high pathogenicity (e.g. 
M. marinum, M. xenopi and M. szulgai)2,40,41 and low pathogenicity (e.g. M. 
fortuitum, M. peregrinum).2 This might reflect the importance of host factors 
in these infections.
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According to the WHO, one-third of the world’s population is thought to have 
a latent tuberculosis infection (LTBI). However, there is no evidence of a latent 
phase in NTM infections, which, in part, explains the low frequency of NTM 
disease compared with tuberculosis reactivation in patients undergoing anti-
TNF treatment. Furthermore, NTM infections usually present after at least 
12 months of anti-TNF treatment and are, therefore, considered to be new 
infections. The generally lower pathogenicity of NTM species, as opposed 
to M. tuberculosis, could further explain the lower frequency of anti-TNF-
associated NTM disease. Moreover, underdiagnosis of NTM disease due 
to insufficient awareness of the pathogenic potential of NTM species is a 
recognized problem.42 The prominent role of TNF in the pathogenesis of NTM 
infection was proven in mouse models, where anti-TNF treatment increased 
the mycobacterial burden.43
Screening and prevention of mycobacterial disease
If neglected, LTBI can progress rapidly to active and potentially fatal disease 
during immunosuppressive treatment, highlighting the importance of screening 
patients for deciding whether or not they should receive such therapy. Both the 
Clinical.
1. Pulmonary symptoms, nodular or cavitary opacities on chest radiograph, or an 
HRCT scan that shows multifocal bronchiectasis with multiple small nodules.
and
2. Appropriate exclusion of other diagnoses.
Microbiological.
1. Positive culture results from at least two separate expectorated sputum samples. 
(If the results from the initial sputum samples are nondiagnostic, consider repeat 
sputum AFB smears and cultures.)
or
2. Positive culture results from at least one bronchial wash or lavage.
or
3. Transbronchial or other lung biopsy with mycobacterial histopathologic features 
(granulomatous inflammation or AFB) and positive culture for NTM or biopsy show-
ing mycobacterial histopathologic features (granulomatous inflammation or AFB) 
and one or more sputum or bronchial washings that are culture positive for NTM.
4. Expert consultation should be obtained when NTM are recovered that are either 
infrequently encountered or that usually represent environmental contamination.
5. Patients who are suspected of having NTM lung disease but who do not meet the 
diagnostic criteria should be followed until the diagnosis is firmly established or 
excluded.
6. Making the diagnosis of NTM lung disease does not, per se, necessitate the institu-
tion of therapy, which is a decision based on potential risks and benefits of therapy 
for individual patients.
Abbreviations: AFB, acid-fast bacilli; NTM, nontuberculous mycobacteria
Box 1: Summary of the American Thoracic Society diagnostic criteria for 
nontuberculous mycobacterial infection2 
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US Centers for Disease Control and Prevention and the British Thoracic Society 
have produced recommendations for LTBI screening in patients who are eligible 
for anti-TNF therapy. These guidelines include an assessment of the infection 
risk through focused history taking, TST (Figure 2) and chest radiography.6,44,45 
However, interpretation of a TST is difficult in patients who are already receiving 
immunosuppressive treatment.44,45 The latest additions to these tools are the T-cell 
interferon-γ release assays (TIGRAs). These tests are based on the detection of 
interferon-γ production by T cells, stimulated by the recognition of mycobacterial 
antigens (Figures 1 and 2), from a whole blood sample.46 Although calculating 
the sensitivity and specificity of TIGRAs is hampered by the lack of an accurate 
‘gold standard’ diagnostic test for LTBI, the assays have demonstrated a better 
diagnostic performance than TST for LTBI screening in candidates for anti-
TNF therapy.47,48 Hence, these tests are increasingly incorporated into national 
screening guidelines, for instance in Switzerland.
As there is no evidence of the existence of a latent phase in NTM disease, 
screening for NTM before initiating immunosuppressive treatment might not 
be feasible. Thus, early detection during immunosuppressive therapy should be 
the goal in this setting. Currently, there are no specific tests for the detection of 
NTM infection. TSTs are mostly negative in patients with NTM infections, and 
chest radiography shows diverse, partly species-specific patterns;2 moreover, 
these features represent active NTM disease and cannot be used to identify 
Figure 2: Immunodiagnosis of latent tuberculosis is based on antigen recognition by 
previously sensitized T cells
(A) Antigens are delivered intradermally for the tuberculin skin test, and exposure takes place 
in sampled blood ex vivo for the IFN-γ release assays. (B) T cells produce many cytokines, 
including IFN-γ, upon recognition of the Mycobacterium tuberculosis complex antigens. (C) 
In the skin, T-cell recognition triggers a local inflammatory reaction leading to erythema and 
induration; IFN-γ production is analyzed by ELISPOT or ELISA in the IFN-γ release assay. 
Abbreviations: APC, antigen presenting cell; ELISA, enzyme linked immunosorbent assay; 
ELISPOT, enzyme-linked immunosorbent spot; IFN, interferon.
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early infection. TIGRAs are probably of no use for detecting NTM disease, 
as only a limited subset of NTM, including M. kansasii, M. szulgai and M. 
marinum, have antigens similar to those used in the TIGRAs, namely ESAT-6 
and CFP-10.49 The prevalence of TIGRA positivity in patients infected by these 
NTM is a focus of ongoing investigations in our institutes. Thus, in the absence 
of a specific test for early NTM disease, especially in patients with additional 
risk factors (such as COPD and bronchiectasis), sputum should be repeatedly 
cultured for mycobacteria.39,42 In patients suspected of such predisposing 
pulmonary diseases, chest radiography or CT could be considered. In addition, 
extrapulmonary disease should be carefully investigated, including staining of 
biopsy samples for acid-fast bacilli and performing mycobacterial cultures.
Preventive treatment, usually 6-9 months of isoniazid therapy, for those with 
assumed  LTBI is now advocated,1,6,43,44 and has been shown to be successful.1,33 
The first cases of anti-TNF-associated tuberculosis in patients who received 
preventive treatment have already been published: some could be related to 
noncompliance, and some are probably newly acquired infections based on 
the long interval (up to 35 months) between the initiation of anti-TNF therapy 
and disease onset, although this has not been proven by DNA-typing.50 
Paradoxically, isoniazid is used for tuberculosis prophylaxis, whereas it is more 
effective against actively replicating bacilli than the dormant bacilli of LTBI.51
Treatment of mycobacterial disease during anti-TNF therapy
The appropriate treatment of LTBI before initiation of anti-TNF therapy is the 
same as that for standard LTBI. Patients in whom active disease is encountered 
during pretreatment screening should complete their tuberculosis treatment 
before starting anti-TNF therapy. If necessary, anti-TNF therapy can begin in 
these patients after the first 2 months of tuberculosis treatment (the intensive 
phase), in case of infection by a fully susceptible tuberculosis strain.43,44 No specific 
recommendations exist for antimycobacterial treatment in the event of active 
tuberculosis disease during anti-TNF treatment; thus, the recommendations 
from the American Thoracic Society/ Centers for Disease Control and British 
Thoracic Society for treatment duration according to localization of disease 
apply in this setting. The experience of treating NTM disease in the setting of 
anti-TNF therapy is limited. Furthermore, the treatment of these patients is 
complicated because different regimens exist for the different bacterial species 
of NTM, based mostly on their varying growth rates. For disease caused by 
slow-growing NTM, the American Thoracic Society advocates that treatment 
with rifampicin and ethambutol should be continued until 12 months after 
culture conversion, with the addition of macrolides for M. avium complex 
disease.2 The results of a recent trial by the British Thoracic Society, however, 
demonstrated no additional effect of macrolides in this setting;52 hence, they 
still consider 2 years of rifampicin and ethambutol to be the optimal treatment 
approach in these patients.52
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For bacteria with a rapid growth rate, such as M. fortuitum and M. abscessus, 
a combination of macrolides, parenteral agents, quinolones or other broad-
spectrum antibiotics based on in vitro susceptibility of the isolate should be 
used.2 However, the outcome of NTM treatment is often disappointing,2,52 and 
expert consultation should always be sought in the setting of NTM disease 
during immunosuppressive therapy.2 
An increased risk of paradoxical response to antimycobacterial therapy, 
characterized by development of previously nonexistent tuberculosis lesions or 
worsening of pre-existing lesions during antituberculosis treatment in patients 
who initially improved, has been reported in infliximab-treated tuberculosis 
patients and in one case of NTM disease.3,53 Garcia Vidal et al.53 suggested 
that concurrent low-dose anti-TNF treatment might produce immunological 
regulation that is beneficial for this group of patients.53 Furthermore, the 
disruption of granuloma formation by anti-TNF agents could increase exposure 
of the bacteria to antimycobacterial drugs, resulting in improved outcomes for 
the infection.54 A 2008 report observed no complications in three patients who 
restarted anti-TNF treatment immediately after antituberculosis treatment.55 
Evidence that restarting anti-TNF therapy during antimycobacterial therapy 
is safe and effective for the treatment of mycobacterial infection first emerged 
from a case reported by Matsumoto and collegues,56 where infliximab therapy 
was safely restarted after 2 months of antituberculosis treatment. In one patient 
with pulmonary M. szulgai infection, anti-TNF treatment was continued during 
antimycobacterial therapy, which lead to a favorable outcome of the patient’s 
infection and control of his rheumatological complaints without unexpected 
reactions.39 However, in the absence of sufficient safety data, whether or not 
anti-TNF treatment can be continued during antimycobacterial treatment 
remains a matter of debate. The most recent American College of Rheumatology 
recommendations consider active tuberculosis infection prior to completing 
a standard regimen of antituberculosis therapy to be a contraindication for 
treatment with biologic agents; no information is available for NTM disease.57
Conclusions
Mycobacterial disease is a major cause of severe infection in patients receiving 
anti-TNF therapy, and is associated with anti-IL-1 and anti-CD20 antibody 
treatment for rheumatic disease. Although tuberculosis is the most frequently 
observed mycobacterial disease, NTM infection is an increasingly recognized 
condition in this setting. Among the drug classes currently in development 
for antirheumatic therapy, anti-IL-17 and anti-IL-23 antibodies, agents that 
modify JAK-STAT-signaling, and metalloproteinase inhibitors are likely to 
confer an increased risk of mycobacterial infection. The treatment of NTM 
disease is difficult, and the outcome is often disappointing. Screening and 
preventive treatments for LTBI have lowered the incidence of anti-TNF-
related tuberculosis; however, these treatments cannot be applied to NTM 
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disease. All patients receiving drugs that are associated with an increased 
risk of mycobacterial infection should be carefully monitored. Monitoring 
should include invasive techniques to diagnose extrapulmonary disease and 
repeated mycobacterial culture of pulmonary samples, especially in patients 
with a history of pulmonary disease. The prevalence of NTM disease and the 
possibility of simultaneous anti-TNF and antimycobacterial treatment in this 
setting should be the focus of future studies.
Supplementary information in the form of a Box is available on the Nature 
Clinical Practice Rheumatology website.
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In vitro drug susceptibility of 
2275 clinical nontuberculous 
Mycobacterium isolates of 49 species 
in the Netherlands
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Abstract
Objectives: To compile results of drug susceptibility testing on a wide 
variety of nontuberculous mycobacteria isolated from clinical samples in the 
Netherlands and discuss their implications for treatment regimens.
Methods: We subjected 2275 strains of 49 different species of nontuberculous 
mycobacteria, isolated from 2072 patients in the Netherlands between 2000 and 
2007, to drug susceptibility testing with the 25 wells Middlebrook 7H10 agar 
dilution method. Isoniazid, rifampicin, rifabutin, ethambutol, clarithromycin, 
ciprofloxacin, cycloserine, prothionamide, amikacin, clofazimine and 
streptomycin were included in the test panel. 
Results: The patterns of drug susceptibilities and minimum inhibitory 
concentrations were found conserved within species and differed significantly 
between species, revealing their value in taxonomy. Most nontuberculous 
mycobacteria were susceptible to clarithromycin. Susceptibility to ciprofloxacin 
and amikacin was less frequent and limited to Mycobacterium kansasii, M. 
xenopi, M. fortuitum and species phylogenetically related to these three species. 
Susceptibility to first-line anti-tuberculosis drugs was rare, except for M. 
kansasii and phylogenetically related species. Slowly growing nontuberculous 
mycobacteria were susceptible to second-line anti-tuberculosis drugs such 
as rifabutin, cycloserine, clofazimine and prothionamide; the latter also had 
activity against M. fortuitum and related rapid growers. 
Conclusions: Clarithromycin and rifabutin are most active against 
nontuberculous mycobacteria. The activity of other second-line anti-
tuberculosis drugs is not supported by clinical data. To improve the utility of 
drug susceptibility testing, the selection of drugs should be changed to more 
drugs with proven clinical efficacy, correlating with in vitro susceptibility.
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Introduction
There is an increasing number of clinical isolates of nontuberculous 
mycobacteria (NTM) in many countries and growing awareness of their 
ability to cause disease.1,2 Nontuberculous mycobacteria are opportunistic 
pathogens that occasionally can cause severe disease, usually in patients 
with pre-existent pulmonary disease or systemic impairment of immunity.1 
Treatment of NTM disease is time consuming and often complicated. 
Macrolide-based multi-drug regimens are currently advocated by the 
American Thoracic Society (ATS).1 In a recent trial of the British Thoracic 
Society (BTS) no beneficial effect of macrolides to treatment of patients 
with pulmonary M. avium complex (MAC), M. malmoense and M. xenopi 
disease was found.3 Overall, the degree of evidence to support the choice 
of treatment is limited since few clinical trials have been conducted, 
especially for disease due to less prevalent NTM species; current guidelines 
are mainly based on case reports and clinical experience.
Although there is a lack of correlation between in vitro drug susceptibility 
testing (DST) results and in vivo treatment outcome, DST is nevertheless 
valuable, especially in patients with no response to first line treatment, or 
with a relapse of prior NTM disease.1 For many of the infrequently isolated 
NTM species, no DST results have been published and there is little basis 
to predict a potentially successful treatment regimen.
A variety of DST methods have been applied to NTM. The Clinical and 
Laboratory Standards Institute (CLSI) currently recommends broth-based 
methods for MAC and related slowly growing NTM, with the broth micro-
dilution technique considered also suitable for rapid growers.4 Application 
of these techniques has highlighted the therapeutic potential of the 
macrolides, linezolid and tigecycline for disease due to both slow and rapid 
growing NTM.1,4-6
In the Netherlands, a Middlebrook 7H10 agar dilution method has 
been used for over a decade with favorable results for Mycobacterium 
tuberculosis complex isolates.7 This study reports the DST results on a wide 
variety of nontuberculous mycobacteria isolated from clinical samples 
in this country and discusses the implications of these findings for NTM 
treatment regimens.
Materials and Methods
We collected DST results of all clinical NTM isolates subjected to laboratory 
diagnosis at the Dutch National Institute for Public Health and the 
Environment (RIVM), which serves as the national mycobacteria reference 
laboratory, in the period between January 2000 and January 2007. 
Identification to the species level was performed by first ruling out 
membership of the M. tuberculosis complex, using the GenoType MTBC 
line-probe assay (Hain Lifesciences, Nehren, Germany), followed by 
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application of the INNO-LiPA MYCOBACTERIA v2 reverse line-blot 
(Innogenetics NV, Ghent, Belgium) for the more common NTM species. 
If identification to species level was not possible by these methods, 16S 
rDNA sequencing (151bp hypervariable region A) was performed. Its 
result was compared with the BLAST (National Center for Biotechnology 
Information, NCBI, http://www.ncbi.nlm.nih.gov) sequence database. 
Prior to 2004, 16S sequencing was performed for all isolates after ruling 
out the M. tuberculosis complex, M. avium complex and M. avium by the 
respective Accuprobe kits (GenProbe, San Diego, US).
Drug susceptibility testing was performed using the 25 wells agar dilution 
method, as recently published.7 In short, dilutions of antimycobacterial 
drugs are mixed in liquefied 7H10 agar and filled out in 25-well plates. 
After inoculation and incubation, the bacterial growth at different 
concentrations of the antimycobacterial drugs is compared to that on agar 
in a well without the drug and inoculated with 1/100 of the inoculum. 
The minimum inhibitory concentration (MIC) is the lowest concentration 
of antimycobacterial drugs that inhibits more than 99% of the growth of 
the mycobacterial inoculum. Dilutions of antimycobacterial drugs in 7H10 
agar are prepared with the following concentrations: 0.1, 0.2, 0.5, 1, 2, 5, 10 
and 20 mg/L isoniazid (Sigma Chemical Co., St. Louis, MO); 0.1, 0.2, 0.5, 
1, 2, and 5 mg/L rifampicin (Sigma); 1, 2, 5, 10, and 20 mg/L streptomycin 
(Sigma); 1, 2, 5, 10, and 20 mg/L ethambutol (Sigma); 1, 2, 5, 10 and 20 mg/L 
amikacin (ICN Biomedicals, Inc., OH); 1, 2, 4, 8 and 16 mg/L ciprofloxacin 
(Bayer, Mijdrecht, NL); 2, 4, 8, 16 and 32 mg/L for clarithromycin (Abbott, 
North Chicago, IL); 2, 5, 10, 20 and 50 mg/L cycloserine (Sigma); 1, 2, 5, 10 
and 20 mg/L prothionamide (Sanavita, Werne, Germany); 0.5, 1, 2, 5 and 
10 mg/L clofazimine (Novartis Pharma, Breda, NL); and 0.2, 0.5, 1, 2 and 5 
mg/L rifabutin (Pharmacia, Capelle a/d IJssel, NL).
The breakpoint concentrations are 1 mg/L for isoniazid and rifampicin, 5 
mg/L for ethambutol, streptomycin, prothionamide and amikacin, 2 mg/L 
for ciprofloxacin, rifabutin and clofazimin, 16 mg/L for clarithromycin and 
50 mg/L for cycloserine.4
Growth at the breakpoint concentration is reported as susceptible, and 
growth at higher concentrations of the drug is considered resistance. 
Isolates with MICs of 0.2 or 0.5 mg/L for isoniazid, or 5 or 10 mg/L for 
ethambutol and streptomycin, are reported as “intermediate resistant”.
For each series of isolates inoculated on DST plates, one Mycobacterium 
gordonae strain, one Mycobacterium avium strain and three M. tuberculosis 
control strains are included as internal controls. As a secondline quality 
control, strains are exchanged in a blind fashion with a peripheral laboratory 
and retested to test the reproducibility.
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Results
We performed DST on 2275 isolates of 49 different NTM species or species 
complexes, isolated from 2072 patients. The results obtained for published 
species of which five or more isolates were tested (2240 isolates of 29 species or 
complexes) are detailed qualitatively in Table 1. The median MIC’s measured 
for these isolates are recorded in Table 2. The results obtained in the least 
frequent (n<5) species are recorded in Table 3.
We found isolates of most species to be susceptible to the macrolide 
clarithromycin, most notably among the slow-growing NTM. Resistance to 
clarithromycin was only noted in the majority of M. simiae, M. mageritense 
and M. fortuitum isolates (Table 1 & 2).
Clarithromycin susceptibility was variable among M. avium complex and 
M. fortuitum complex strains. Most M. avium strains had MICs around the 
breakpoint (16 mg/L; Table 2), with a separate grouping (20%) exhibiting 
true clarithromycin-resistance (MIC>32 mg/L). For separate M. intracellulare 
sequevars and MAC-X (MAC unidentified by the Inno-Lipa Mycobacteria v2 
reverse line blot) median MICs were lower (Table 2). Within the M. fortuitum 
complex, M. fortuitum and M. peregrinum could be separated as M. fortuitum 
is resistant to clarithromycin and rifabutin, whereas M. peregrinum was found 
susceptible (Table 1).
Resistance to the fluoroquinolone ciprofloxacin was more frequent and noted 
in the majority of M. avium complex, M. chelonae and M. abscessus, the 
phylogenetically related M. malmoense and M. bohemicum, as well as in M. 
simiae, M. terrae and M. celatum isolates (Table 1). 
Ciprofloxacin susceptibility was variable among M. simiae, M. terrae, M. 
malmoense and M. mucogenicum isolates. The MICs were either around the 
breakpoint concentration (M. terrae, M. malmoense; Table 2), or there were 
separate strains with low and high MICs (M. simiae, M. mucogenicum).
We found in vitro susceptibility to first line anti-tuberculosis drugs, especially 
isoniazid and rifampicin, to be rare among NTM. However, susceptibility to 
rifabutin was frequent (Table 1). The phylogenetically related M. kansasii, M. 
szulgai and M. marinum are susceptible to most classes of antimycobacterial 
drugs, as are the phylogenetically more distant M. xenopi and M. gordonae.
The M. marinum, M. kansasii, M. szulgai group and M. xenopi, M. noviomagense 
and M. celatum were susceptible to amikacin. Susceptibility to the second line 
anti-tuberculosis drugs (clofazimin, cycloserine and prothionamide) was 
common, especially among slow-growing NTM. Slow and rapid growing NTM 
are divided by cycloserine susceptibility, with in vitro resistance restricted to 
the rapid growers, except for M. holsaticum.
Serial isolates were available for 237 patients (n=587; 2.5 per patient). For 
serial isolates, two-fold changes in MICs for any drug were common. Four-
fold changes in MICs for any drug occurred in 5% of patients. This percentage 
was consistent among the different drugs tested.
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Acquired resistance, defined as a resistant follow-up isolate after a susceptible 
primary isolate, was noted in 28 patients; acquired macrolide resistance 
was most frequent (22 patients; 11 M. avium, 3 M. intracellulare, 2 MAC, 3 
M. abscessus, 1 M. chelonae, 1 M. kansasii and 1 M. malmoense), followed 
by acquired rifampicin resistance (n=5; 4 M. malmoense, 1 M. szulgai) and 
acquired ciprofloxacin resistance (n=3; 1 M. malmoense, 1 M. kansasii and 1 
M. szulgai)
Discussion
Analyzing the results of seven years of drug susceptibility testing for NTM 
using the 25 wells agar dilution method, it is evident that the results yield 
important clues for optimization of NTM species-specific therapy. 
The debate on the role of DST in management of NTM disease is ongoing, 
mainly because of the observed discrepancies between in vitro susceptibility 
and in vivo response to treatment. These discrepancies need further study, 
especially for the newer antimicrobial drugs and less frequently isolated NTM 
species. Baseline testing for specific drugs such as rifampicin for M. kansasii and 
clarithromycin for M. avium complex isolates helps to understand treatment 
failure or relapse and to thereafter select second line treatment regimens.1
Our in vitro results confirm the potential efficacy of the macrolides in the 
treatment of NTM disease. Only M. fortuitum, M. mageritense and M. 
simiae isolates are usually macrolide resistant. Clinical trials of macrolide 
based treatment for M. avium complex disease in the United States have 
demonstrated superior results,8 compared to previous European trials using 
exclusively rifampicin and ethambutol only.9 However, recently published 
results of the BTS on a comparative trial of 2 years rifampicin, ethambutol 
and clarithromycin or ciprofloxacin for pulmonary MAC, M. malmoense 
and M. xenopi disease were unable to demonstrate superiority of either 
triple-drug regimen drug over a rifampicin and ethambutol only regimen3 
tested previously in a similar trial setting.9 Within this recent trial, in vitro 
susceptibility to ciprofloxacin or clarithromycin was not assessed.3 We found 
frequent ciprofloxacin resistance among MAC (92-99%) and M. malmoense 
(74%; Table 1) strains. While casting doubt on the efficacy of ciprofloxacin, 
our results offer no explanation for the limited results in the patients receiving 
a macrolide based regimen in the BTS study.3 This illustrates the necessity to 
acquire more clinical data that establish the correlation between in vitro and in 
vivo activity. There could be a role for macrolides in case of first-line treatment 
failure or relapse with susceptible strains.
Although clarithromycin resistance in primary isolates was rare, 9% (22/237) of our 
patients with serial isolates acquired clarithromycin resistance during treatment, or 
experienced a relapse with acquired clarithromycin resistance. In vitro resistance 
to macrolides has already been related to poor in vivo treatment outcome; for the 
first line anti-tuberculosis drugs this relationship has not been established.1 
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For the macrolide resistant species in our study, in vitro susceptibility to 
ciprofloxacin indicates a possible role for the fluoroquinolones. Most M. 
simiae isolates, however, are also resistant to ciprofloxacin (Table 1). Treatment 
results in M. simiae disease are, probably as a result, poor.10
The common in vitro resistance to ciprofloxacin (Table 1) may explain its 
limited in vivo activity in the latest BTS trial.3 Moxifloxacin is more active in 
vitro than ciprofloxacin1 and may be active against isolates that have median 
MICs just above the ciprofloxacin breakpoint (M. malmoense, M. chelonae). 
Combination therapy of moxifloxacin and clarithromycin may not be advisable, 
as fluoroquinolones were recently demonstrated to attenuate clarithromycin 
activity in a murine model of M. avium complex disease.11 How this translates 
to human disease remains to be determined.
The widespread amikacin resistance is contrary to results in available 
literature, at least for M. avium and M. abscessus.1,4 The discrepancies, which 
may result from the test methods or the applied breakpoint concentrations, 
are cumbersome since a recent trial of multi-drug MAC therapy demonstrated 
better sputum conversion rates in patients receiving an aminoglycoside as 
adjunctive therapy.12 Hence, reporting false amikacin resistance may negatively 
affect therapy choice and outcome. 
In vitro susceptibility to cycloserin, prothionamide and clofazimine was 
common, especially among slow-growing NTM. In vitro susceptibility of M. 
avium isolates to clofazimine and cycloserin, similar to our findings, was 
also found in patients in the USA with disseminated infections at the start 
of the HIV/AIDS epidemic.13 However, clinical efficacy of these drugs in 
NTM treatment has not been sufficiently proven and they are limited by their 
toxicity.1 Studies in murine models in the 1980s showed limited efficacy of 3-5 
drug combination therapy that included these drugs.14, 15
Similar DST results may hint at a phylogenetic relationship between various 
species, for example M. kansasii, M. szulgai and M. marinum (Table 1 & 2). The 
susceptibility to first line antituberculosis drugs, except isoniazid, observed in these 
three species hints at their close phylogenetic relationship with the M. tuberculosis 
complex, also observed by Devulder et al. in their multi-gene taxonomical model.16.
The currently available technique and the range of drugs tested offer too little 
therapy guidance for clinicians and need improvement. Our results call for a 
reconsideration of the drugs to be included in the test-panel and illustrate the 
necessity to acquire more clinical data that establishes the correlation between 
in vitro and in vivo information. There should be separate test panels for 
slow and rapid growing NTM and new, promising antimycobacterial drugs, 
such as moxifloxacin, linezolid, the carbapenems and tigecyclin should be 
included in test panels and their breakpoints established. Standardized control 
strains should be used to allow inter-laboratory comparisons. Application of 
liquid culture systems for DST may decrease the turnaround time. Recently, 
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susceptibility testing for M. tuberculosis complex bacteria in automated liquid 
culture systems has been standardized.17 
In summary, the 25 wells agar dilution method is an inexpensive and reliable 
method for drug susceptibility testing of nontuberculous mycobacteria. Results 
for the macrolides and fluoroquinolones appear useful for therapy guidance. 
DST can assist in selecting second line treatment regimens in cases of treatment 
failure or relapse. Most NTM species show in vitro susceptibility to macrolides. 
Against the background of the conflicting results of the clinical trials it is not 
clear what this means for clinical practice. This illustrates the necessity to 
acquire more clinical data that establish the correlation between in vitro and 
in vivo activity. One could defend a recommendation to use macrolides in case 
of treatment failure or relapse with susceptible strains. Acquired resistance, 
mainly to the macrolides, is a significant issue and was also recorded in our 
study. A reconsideration of the drugs included in the test is needed to improve 
its utility, especially for rapid growing mycobacteria. The utility of first and 
second line antituberculosis drug testing is very limited and this should be 
substituted for newer drugs with proven clinical efficacy correlating with in 
vitro susceptibility. The DST results have additional taxonomical value.
Species n INH RIF ETH STR RIB AMI CIP CLA CYC CLO PRO
M. conspicuum 4 R R S S S R S S S S S
M. palustre 4 R S I R S R S S S S S
M. gilvum 2 R S/R S S S S S S S S S
M. hiberniae 2 R R S S S S S S S S S
M. cosmeticum 1 R R I R R S R S S R R
M. florentinum 1 R R I R S R R S S R S
M. hassiacum 1 I S S S S S S S S S S
M. neoaurum 1 R S R S S S S S R S R
M. nonchromogenicum 2 R R S S S R S S S S/R S
M. novocastrense 1 I R S S S S S S S S S
M. obuense 2 R R R S S S S S R S S/R
M. phlei 3 R R S S S S S S S R R
M. porcinum 1 R R R R R S S R R R R
M. shimoidei 1 I R S S S S S S S S S
M. smegmatis 1 R R S S R S S R R S R
M. sphagni 1 R R S S S S S S S S R
M. vanbaalenii 1 R R S S S S S S S S S
M. wolinskyi 2 R R S S/R S R S R R S R
M. nebraskense 1 R S S R S R S S S S R
M. heidelbergense 3 I R I S S R S S S S S
R: resistant; S: susceptible; I: intermediate susceptibility
Table 3: DST results of seldom encountered NTM
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In vitro activity of thioridazine 
against mycobacteria
Jakko van Ingen1,2, Tridia van der Laan2, Leonard Amaral3, Richard Dekhuijzen1, 
Martin J. Boeree1, Dick van Soolingen2
1 Department of Pulmonary Diseases, Radboud University Nijmegen Medical Center, Nijmegen, 
the Netherlands; 2 National Mycobacteria Reference Laboratory, National Institute for Public 
Health and the Environment, Bilthoven, the Netherlands; 3 Unit of Mycobacteriology/UPMM, 
Institute of Hygiene and Tropical Medicine, Universidade Nova de Lisboa, Lisboa, Portugal
Thioridazine is an antipsychotic drug that is active against mycobacteria by 
targeting the type II NADH dehydrogenase, succinate dehydrogenase, and 
the binding of calcium to proteins as well as disruption of aerobic respiration 
under microaerobic conditions.1 
The activity of the thioridazine against mycobacteria has gained renewed 
attention due to the ongoing spread of multidrug-resistant tuberculosis 
(MDR-TB).2 The recent emergence of extensively drug-resistant (XDR-) TB 
only strengthened the search for new antimycobacterial drugs. Even aggressive 
treatment regimens including high numbers of drugs at maximum tolerable 
doses and adjunctive surgery result in cure rates of only 60% in XDR-TB.3 
Although tuberculosis is a major threat to public health, cure rates for 
nontuberculous mycobacterial (NTM) disease are comparable to those in XDR-
TB. In a recently published trial by the British Thoracic Society (BTS), cure 
rates after 5 years’ follow-up were only in the 20-40% range.4 These sobering 
rates are in part due to the pre-existing conditions that increased these patients’ 
susceptibility to NTM disease, e.g. chronic obstructive pulmonary disease. 
In MDR and XDR-TB, as well as in NTM disease, new drugs are needed to 
improve cure rates.3-5 However, most of the drugs currently in the pipeline are 
tested exclusively for their activity against Mycobacterium tuberculosis.
Thioridazine has a well-known safety profile owing to its extensive use in 
psychiatry and may represent a good candidate for drug trials for MDR-
TB, XDR-TB and NTM disease. To establish its possible efficacy, minimum 
inhibitory concentrations (MICs) of thioridazine were determined for clinical 
isolates of M. abscessus (n=3), M. avium (4), M. kansasii (1), M. malmoense (1), 
M. simiae (1), M. xenopi (1), M. gordonae (2), M. fortuitum (1), M. szulgai (2) 
and M. tuberculosis (8), applying a previously described 25-well agar dilution 
method.6 The M. tuberculosis isolates were four pan-susceptible isolates, three 
MDR isolates and one XDR isolate. 
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Susceptibility to thioridazine was tested at concentrations of 1, 2, 4, 8, 16, 32, 
64 and 128 mg/L. The MIC was defined as the concentration able to reduce 
bacterial growth by >99%; Growth on thioridazine-enriched Middlebrook 
7H10 medium was compared with an undiluted and a 1/100 diluted 
standardized bacterial suspension on drug free medium.
The MICs and the time of reading the plates are given in Table 1 for all isolates 
tested. For the rapid growers (M. abscessus and M. fortuitum) sufficient growth 
was noted after 4 days of incubation; most slow growers required 8 or 11 days.
Thioridazine is most active against M. tuberculosis. All M. tuberculosis isolates 
had MICs of 4 mg/L, regardless of their susceptibility to first- or second-line 
drugs. In humans, 0.5 mg/L is the acceptable maximum plasma concentration 
of thioridazine.2 However, M. tuberculosis bacteria residing in macrophages are 
Strain nr. Species MIC (mg/L) Incubation (days)
NLA000600658 M.avium 32 4
NLA000800431 M. avium 32 11
NLA000800441 M. avium 16 4
C687 M.avium 32 11
NLA000600659 M. avium complex 16 8
NLA000800050 M. malmoense 32 11
NLA000800280 M. kansasii type I 2 11
NLA000701790 M. szulgai 16 8
NLA000800062 M. szulgai 16 8
NLA000800549 M. xenopi 8 11
NLA000800295 M. simiae 16 8
NLA000600643 M. gordonae 16 11
C809 M. gordonae 16 8
NLA000600203 M. abscessus 64 4
NLA000800454 M. abscessus 64 4
NLA000800448 M. abscessus sv 16 4
NLA000800494 M. fortuitum 32 4
NLA000600443 XDR-M. tuberculosis 4 11
NLA000500538 MDR-M. tuberculosis 4 11
NLA000501371 MDR-M. tuberculosis 4 11
NLA000601463 MDR-M. tuberculosis 4 11
NLA000600523 M. tuberculosis 4 8
C100 M. tuberculosis 4 11
C2147 M. tuberculosis 4 11
C937 M. tuberculosis 4 11
sv, smooth colony variant; X/MDR, extensively/multi-drug resistant
Table 1: MICs (mg/L) and duration of incubation to obtain sufficient growth
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susceptible to thioridazine even at 0.1 mg/L, since macrophages concentrate 
thioridazine in the vacuoles where M. tuberculosis resides.2 
Thioridazine is less active against NTM, especially against rapid growers. 
Results were consistent among isolates of the same species, or differed by a 
single two-fold step, as for M. avium. MICs in the range of 16 to 32 mg/L, 
the most common MICs for NTM, appear to preclude a role for thioridazine 
in therapy of NTM disease. The low level of activity against M. abscessus is 
especially unfortunate. Bacteria of this species can cause severe disease and 
their level and extent of drug resistance demands new, active compounds.5 
Whether the concentrating effect within macrophages will lead to local drug 
concentrations capable of killing NTM remains to be established. Based on our 
in vitro results this seems less likely.
Although its cardiotoxicity is a significant drawback,7 thioridazine may add to 
the activity of regimens for MDR- or even XDR-TB, for which very few active 
drugs are currently available. A potential role for thioridazine in the treatment 
of latent TB, due to its disruption of aerobic respiration under microaerobic 
conditions, may warrant separate investigation.
Thioridazine appears less likely to add activity to the regimens for pulmonary 
NTM disease propagated by the American Thoracic Society and BTS.4,5
In summary, thioridazine is active in vitro against susceptible and MDR or 
XDR M. tuberculosis. Due to a concentrating effect within macrophages, there 
may be a role for thioridazine in the treatment of MDR- or even XDR-TB. With 
MICs at least four- to eight-fold higher than those observed for M. tuberculosis, 
its activity against NTM is significantly lower, thus a role in treatment of NTM 
disease is less likely.
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Abstract
Background: Drug therapy for nontuberculous mycobacterial (NTM) lung 
disease yields limited results. Adjunctive surgery is beneficial in selected cases, 
though its indication and timing are not well described in literature. Therefore, 
we describe our experiences with the adjunctive role and benefits of surgery 
for pulmonary NTM disease, specifically addressing its indications and timing. 
Methods: We performed a retrospective medical file review of eight patients 
who underwent surgical treatment for NTM lung disease in the period of 
January 2000 to January 2009, as well as a review of available literature.
Results: Therapy-resistant cavitary NTM disease was the most frequent 
indication for surgery; two patients underwent pneumonectomy for an infected 
destroyed lung. Mycobacterium avium was the most common causative agent. 
Surgery resulted in culture conversion in seven patients; one patient died two 
months after pneumonectomy. No relapses have been noted in the other seven 
after an average of 19 months of follow-up. 
Conclusions: Adjunctive surgical treatment for NTM lung disease yields 
encouraging results, similar to previously published case series. Careful patient 
selection, based on extent and type of disease as well as on cardiopulmonary 
fitness, is important. Potential benefits of surgery should be considered for 
every individual patient in whom NTM lung disease is diagnosed and re-
evaluated after six months of treatment. Where possible, surgery should be 
pursued and timely conducted.
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Introduction
Pulmonary disease due to nontuberculous mycobacteria (NTM) is a 
condition that has many faces, ranging from hypersensitivity pneumonitis 
to nodular-bronchiectatic disease in previously healthy women to the 
classical cavitary disease type that mostly affects males with pre-existing 
pulmonary disease.1 Cavitary disease is the most frequent disease type in 
the Netherlands. It is one of the factors contributing to a poor response to 
therapy, alongside previous treatment and a history of chronic obstructive 
lung disease or bronchiectasis.2
Drug therapy of NTM disease is long-term, cumbersome because of its side 
effects, and often yields poor results. In a recent trial by the British Thoracic 
Society (BTS), only 36% of 371 patients with mostly cavitary disease who 
received 24 months of multi-drug therapy for pulmonary NTM disease were 
alive and cured after five years of follow-up. Fifteen percent of the patients 
had treatment failure, relapsed or died due to NTM disease.3 Similar results 
have been observed recently in retrospective studies in the Netherlands.4 These 
data show striking similarities with those for multidrug-resistant tuberculosis 
and confirm that treatment needs to be improved. Previous authors have, for 
both conditions, suggested adjunctive surgical treatment, although important 
caveats are made.5-7 Surgery should be an adjunctive treatment modality, to be 
performed in a multidisciplinary program on a select category of patients.5,7
The University Lung Centre Dekkerswald is a third-line reference hospital for 
mycobacterial disease, and part of the Radboud University Nijmegen Medical 
Centre in Nijmegen, the Netherlands. Dekkerswald is the only centre in the 
Netherlands with experience in the field of surgery for pulmonary NTM 
disease and tuberculosis. In this study we explore the potential benefits, timing 
and in- and exclusion criteria of surgery for pulmonary NTM disease based on 
our experience in recent years and a review of available literature.
Methods
We reviewed the medical files of all patients who underwent surgical treatment 
for pulmonary NTM disease at the University Lung Centre Dekkerswald, in 
the January 2000 - January 2009 period. From the medical files we extracted 
demographic and clinical data, focusing on the timing of surgery, pre- and 
post-surgery drug therapy and final outcome. 
Nontuberculous mycobacterial disease was diagnosed using the American 
Thoracic Society (ATS) diagnostic criteria available at the time of patient 
referral.1,8 
Identification of the NTM isolates was performed at the Dutch National 
Mycobacteria Reference Laboratory, by the INNO-LiPA MYCOBACTERIA 
v2 reverse-line blot. Drug susceptibility testing was performed using the agar 
dilution method.9
No ethical approval was required for the current study.
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Preoperative assessment
Patients’ eligibility for surgery was discussed in multidisciplinary meetings 
with anaesthesiologists, thoracic surgeons and respiratory physicians. In 
absence of specific criteria for patient selection, the BTS and the American 
College of Chest Physicians’ (ACCP) guidelines for patient selection for lung 
cancer resection were followed,10,11 as suggested in the recent ATS statement 
on NTM disease.1 Thus, patients were evaluated by maximal cycle ergometry, 
ventilation perfusion scanning and spirometry, to estimate postoperative FEV1 
and DLCO, as well as by body mass index (BMI) measurement, nutritional 
assessment, with dietary supplementation when indicated, and exclusion of 
significant cardiac disease. 
Peroperatively, all patients received three intravenous doses of amoxicillin/
clavulanic acid 1000/200mg.
Results
In the study period eight patients underwent surgical treatment at Dekkerswald. 
The baseline characteristics of the patients are outlined in Table 1. Six patients were 
referred to our hospital because of therapy resistant cavitary NTM disease, two 
for NTM infection of a destroyed lung due to prior tuberculosis (Figures 1 and 2); 
Figure 1: Chest radiographs of patients who underwent surgical treatment
A&B: Right upper lobe cavitary disease caused by M. avium (Table 1: patient 2) and M. xenopi 
(patient 5); C: Destroyed right lung caused by prior tuberculosis, super-infected by M. avium 
(patient 1)
Figure 2: Computed Tomography images of patients who underwent surgical 
treatment
A&B: Right upper lobe cavitary disease caused by M. avium (Table 1: patient 2) and M. xenopi (patient 
5); C: Destroyed right lung caused by prior tuberculosis, super-infected by M. avium (patient 1)
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none had disease related complications necessitating surgery, e.g. hemoptysis. 
Mycobacterium avium was the causative agent of disease in six patients; two 
patients had clarithromycin resistant isolates. M. xenopi and M. avium complex, 
other than M. avium or M. intracellulare, bacteria were causative agents in one 
patient each. All patients were HIV-negative and had intact interferon-γ/IL-12 
pathways. 
The average duration of treatment at the time of surgery was 22 months, 
although three patients had received previous cycles of treatment for NTM 
disease (Table 1). The four patients that are currently alive and completed 
post-surgical chemotherapy received an average of 9 months of treatment after 
surgery. The average duration of follow-up is 19 months.
The procedures performed are detailed in Table 1. Two pneumonectomies 
were performed, both in patients who did not meet the BTS/ACCP eligibility 
criteria (Table 1). Surgery and post-surgical chemotherapy resulted in 
persistent culture-negative status in all but one patient (88%). This patient 
was oxygen-dependent and had a FEV1 of 0.58L (23% predicted), far below 
the 2L limit for pneumonectomy.10,11 After right pneumonectomy, the patient 
developed respiratory failure and was temporarily re-admitted to the intensive 
care unit for non-invasive positive pressure ventilation; she died of pulmonary 
embolism two months after surgery and was not sampled for Mycobacterium 
culture (Table 1, patient 4). 
Five out of eight patients experienced a complication of surgery (63%), mostly 
persisting pneumothorax that could be treated conservatively (n=3; 38%). One 
case of respiratory failure, one case of pneumonia and one case of collapse of 
the right lower lobe, due to stasis of pulmonary secretions and resolved by 
suction during bronchoscopy, were noted (Table 1).
Discussion
Surgical treatment adjunctive to multi-drug therapy resulted in culture 
conversion in seven of eight complicated cases of pulmonary NTM disease. No 
relapses have yet been noted. Our results, based on a small series of patients, are 
in line with the few case series published from other centres and recorded in 
Table 2.7,12-22 Conversion rates are generally very high (90-100%) and few relapses 
are noted, marking the efficacy of combined medical and surgical treatment.7,12-22 
Moreover, the current results compare positively to the 67% overall and 50% 
culture conversion in M. avium disease observed after medical treatment in a 
recent study that included many patients from our centre.4 Similar outcomes 
How can we improve treatment outcome in NTM disease?
M, male; F, female; BMI, body mass index; #, with persistent obstruction; Pulm. TB, pulmonary 
tuberculosis; PE, pulmonary embolism; COPD, chronic obstructive pulmonary disease; ND, 
not determined; L, left; R, right; UL, upper lobe; LL, lower lobe; MLE, mediastinal lymphnode 
enlargement; x(H)RECla, (isoniazid+) rifampicin+ethambutol+ clarithromycin regimen of 
x months duration; Rb, rifabutin; Mox, moxifloxacin; Pro, prothionamide; Ami, amikacin; Z, 
pyrazinamide; ~x, treatment ongoing, x months completed at the time of data collection.
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have been observed in series of adjunctive surgical treatment for multidrug-
resistant tuberculosis.5 Still, retrospective case series are inadequate to determine 
optimal therapies and comparative trials of drug treatment versus drug and 
surgical treatment are needed to establish its true benefit. Moreover, culture 
conversion alone may not be the appropriate endpoint in these complex patients 
with pre-existing pulmonary conditions. Quality of life and all-cause mortality 
should be included as endpoints in future trials. 
The most critical issues in the decision on this intervention are the selection of 
patients eligible for surgery and its exact timing. There are no published patient 
selection criteria for this type of surgery1 and available case series generally 
have not reported pulmonary function test results or other physiological 
parameters such as BMI of their patients.
Timing is essential to prevent disease progression into a stage where safe 
and effective surgery is no longer possible. Development of cavitary lesions 
in the contralateral lung, deterioration of patient condition and acquisition 
of further drug resistance may render adjunctive surgery and post-operative 
chemotherapy ineffective, as we have noted in patient 4 (Table 1). Mitchell and 
co-workers considered surgery either at the initial consultation, if evidence of 
irreversible, focal parenchymal injury emerged during radiologic evaluation, 
or after failure of adequate therapy.7 They operated on 236 patients after 2 to 
6 months of multi-drug therapy, similar to the three months advocated by 
Shiraishy and the 6 months advocated by Watanabe.7,19,22 Clinical improvement 
and culture conversion are to be expected within 6 months of treatment with 
macrolide-based regimens.23 Expert consultation, including assessment of the 
potential role of surgery, should be sought in this time-frame. In our patients, 
however, this was not the case. Our patients had already received an average 
of 22 months of multi-drug therapy, mostly at their regional hospital. Expert 
consultation is strongly encouraged in the ATS statement on NTM disease1 
and should be commonplace, especially in case of possible treatment failure. 
Our reference hospital was only consulted after these, sometimes multiple, 
prolonged treatment courses had failed. Early expert consultation needs to be 
propagated in the Netherlands. Surgery in an earlier phase of the disease offers 
the advantage that lesions may be smaller and easier to resect,15,16,19,22 further 
lung tissue damage may be prevented and the duration of antimycobacterial 
drug exposure, with its inherent risks, may be limited.
The possible role of surgery must be considered, in communication with a 
specialized centre, for every patient who is about to start multi-drug therapy. 
Even if patients show an initially favorable response to treatment, lesions of 
their pre-existing pulmonary disease or the cavitary lesions resulting from 
NTM disease may provide a niche for NTM and eradication by chemotherapy 
alone may be impossible. The study by Lam et al. clearly demonstrated the 
negative impact of cavitary lesions on culture conversion (hazard ratio 4.00; 
95% CI 1.74-9.19; p=0.001);2 cavitary disease is the most prevalent pulmonary 
How can we improve treatment outcome in NTM disease?
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NTM disease type in the Netherlands.4 Drug concentrations inside inside 
cavities may be sub-therapeutic, as within tuberculous pleural effusions and 
psoas abscesses.24 Compliance with chemotherapy may decrease during the 
long treatment of NTM disease. Surgery may thus be best performed when a 
patient is still motivated and compliant with therapy. 
To evaluate a patient’s eligibility for surgery, two main aspects are relevant. The 
first is the localization and extent of disease. Previous studies have proposed 
cavitary disease, destroyed lung tissue and continued sputum positivity 
despite maximal drug therapy as indications for surgery.7,14,16,19,20 Lobectomy or 
bilobectomy is a possibility if cavitary lesions in an upper lobe are accompanied 
only by minor nodular lesions. In eligible patients who present with a destroyed 
lung, either due to NTM or super-infected by NTM, pneumonectomy is the 
procedure of choice (Table 1).7 
The second aspect influencing patient eligibility for NTM surgery is the 
physical condition of the patient. This must be assessed through lung function 
measurements and radiographic assessment of remaining lung volumes. 
Moreover, patients should be motivated and their expectations of surgery 
should be clear. 
Extrapolation of the BTS and ACCP guidelines for patient selection for 
lung cancer resection is reinforced by our single patient who underwent 
pneumonectomy despite insufficient pulmonary function; this patient (Table 
1, patient 4) experienced severe complications (respiratory failure) and died 
2 months post-surgery. With the benefit of hindsight, this patient should 
not have been operated. Besides the clinical aspects of eligibility for surgery, 
surgical treatment must be performed in a centre that has thoracic surgeons, 
infectious disease specialists and pulmonary physicians with experience in 
Publication No. of 
patients
Predominant 
species
Sputum culture 
conversion rate
Long term 
relapse rate
Corpe et al. 1981 11 124 M. avium complex 93% 5%
Moran et al. 1983 12 37 M. intracellulare 94% 5%
Pomerantz et al. 1991 13 38 M. avium complex* 84% 0%
Ono et al. 1997 14 8 M. avium complex 100% 13%
Shiraishi et al. 1998 15 33 M. avium complex 94% 6%
Nelson et al. 1998 16 28 M. avium complex 90% 4%
Lang-Lazdunski et al. 2001 17 18 M. xenopi 89% 0%
Shiraishi et al. 2002 18 21 M. avium complex 100% 10%
Shiraishi et al. 2004 19 11 M. avium complex* 100% 9%
Sherwood et al. 2005 20 26 M. avium complex* 82% 0%
Watanabe et al. 2006 21 22 M. avium complex 100% 5%
Mitchell et al. 2008 6 236 M. avium complex* 100% 0%
Table 2: Outcome of surgical treatment for pulmonary NTM disease in previous 
reports. *other species were present
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NTM disease as well as general pulmonary surgery and capable of providing 
long-term follow-up. The impact of experience is shown by Mitchell et al. who 
demonstrated a decrease in mortality rate associated with an increase in case 
volume.7 In Box 1, we have translated the three eligibility criteria into proposed 
indications for adjunctive surgery in patients with pulmonary NTM disease.
Our overall complication rate is high, compared to the 50% (19/38) in the 
case series by Pomerantz et al.,14 44% (4/9) reported by Lang-Lazdunski et 
al.,18 28.6% (6/21) reported by Shiraishi et al.,20 or the 18.5% (49/236) reported 
by Mitchell et al.7 The predominance of persisting pneumothorax, which 
could be treated conservatively in our patients, is also recorded by other 
authors.7,14,16,18 Interestingly, we have noted no bronchopleural fistula, the most 
severe complication associated with right pneumonectomy.7,14,16,18,20 Surgery 
in an earlier phase of NTM disease may limit the number and severity of 
complications.16,19,22
There are no trials on the duration of post-surgical drug treatment; previous 
studies recorded good results using 6-12 months of post-surgery drug treatment 
with macrolide based regimens.19,22 The ATS currently advocates treatment for 
twelve months after culture conversion.1 Thus, if culture conversion is only 
obtained after surgery, 12 months of post-surgical treatment is conceivable. 
It is striking that surgical series predominantly feature patients with pulmonary 
MAC or, to a lesser extent, M. xenopi disease.7,12-22 This may be related to the 
fact that these two species are most difficult to eradicate by drug therapy, 
as demonstrated in the recent BTS trial.3 Whether this results from host or 
pathogen factors remains unknown.
In conclusion, a select category of patients can benefit from adjunctive 
surgical treatment for pulmonary NTM disease. The predominance of cavitary 
pulmonary NTM disease in Western Europe and its poor response to drug 
therapy stresses the potential role for surgical treatment. Careful patient 
selection and expert consultation is of the utmost importance. Possible benefits 
For patients culture positive after 6 months of optimal multidrug therapy, 
surgery should be considered if
the disease is 
1. limited to one lung, or 
2. a maximum of one lobe in each lung, with only nodules in other lobes,
while the patient is
1. in a cardiopulmonary condition that allows for pulmonary surgery and
2. in a nutritional state that allows for surgery (BMI) and 
3. motivated
and there is effective post-operative
1. multi-drug treatment possible, as well as 
2. care by experienced physicians in a centre that can offer long-term follow-up
Box 1: Proposed indications for adjunctive surgery in patients with pulmonary disease 
caused by nontuberculous mycobacteria
How can we improve treatment outcome in NTM disease?
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of surgery should be considered for every patient in whom pulmonary NTM 
disease is diagnosed and re-evaluated after six months of treatment. Where 
possible, surgery should be pursued; Dekkerswald aspires to provide this type 
of surgery for the Netherlands. 
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Re-analysis of 178 previously 
unidentifiable Mycobacterium 
isolates in the Netherlands from the 
1999-2007 period
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and D. van Soolingen2
1Department of Pulmonary Diseases, Radboud University Nijmegen Medical Center, Nijmegen, 
the Netherlands; 2National Mycobacteria Reference Laboratory, National Institute for Public 
Health and the Environment, Bilthoven, the Netherlands
Abstract
Nontuberculous mycobacteria that can not be identified to the species level 
by reverse hybridization assays and sequencing of the 16S rDNA gene are a 
challenge for reference laboratories. However, the number of 16S gene sequences 
added to online public databases is growing rapidly and so is the number of 
Mycobacterium species. Therefore, we re-analyzed 178 Mycobacterium isolates 
with 53 previously unmatched 16S rDNA gene sequences, submitted to 
our national reference laboratory in the 1999 tot 2007 period. We repeated 
molecular identification using two commercially available identification 
kits, targeting separate genetic loci, and repeated 16S rDNA gene sequence 
comparisons using the GenBank database. 
Ninety-three out of 178 isolates (52%) with 20 different 16S rDNA sequences 
could now be assigned to validly published species. The two reverse 
hybridization assays provided false identifications for five recently described 
species and we recorded discrepancies in identification results between the 
two reverse hybridization assays.
Identification by reverse hybridization assays underestimates the genetic 
heterogeneity among NTM. This heterogeneity can be clinically relevant as 
particular sub-groupings of species can cause specific disease types. Therefore, 
sequence-based identification is preferable, at least at reference laboratory 
level. The targets needed for clinically useful results remain to be established. 
The number of NTM species in the environment is probably so high that 
unidentifiable clinical isolates should be designated a separate species status 
only if this is clinically meaningful.
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Introduction
The isolation frequency of nontuberculous mycobacteria (NTM) increases in 
many countries where the incidence of tuberculosis is in decline.1,2 The NTM 
are ubiquitous in the environment and their presence in clinical samples does 
not necessarily indicate NTM disease. Assessment of the clinical relevance of 
these isolates is not straightforward. As an important support, the American 
Thoracic Society (ATS) has published statements to aid in this assessment.3
Clinical relevance differs significantly by species, which makes species 
identification crucial.3 NTM are nowadays mostly identified using molecular 
tools, such as species-specific probes, often incorporated in commercial line 
probe assays, or direct sequencing of semi-conserved genes with proven 
taxonomic values. Among these, the 16S rDNA, rpoB and hsp65 genes and 
16S-23S internal transcribed spacer (ITS) region are most commonly used.4-7 
Not all clinical NTM isolates can be convincingly identified by molecular 
identification tools. The ongoing increase in the number of newly recognized 
species is testimony to this phenomenon.8 
To establish the magnitude of the problem of unidentifiable NTM, we re-
investigated all NTM, submitted to the national reference laboratory in 
the Netherlands in the 1999 tot 2007 period that could previously not be 
convincingly identified by partial 16S rDNA gene sequencing. All 16S sequences 
were reanalyzed and the isolates re-identified applying two commercially 
available identification kits, targeting two separate genetic loci.
Methods
At the national mycobacteria reference laboratory (National Institute for Public 
Health and the Environment [RIVM]), NTM are identified using the INNO-
LiPA MYCOBACTERIA v2 (Innogenetics, Ghent, Belgium) reverse-line blot 
assay, according to the manufacturer’s instructions. If no identification to the 
species level is obtained, additional sequencing of the hypervariable region A 
(151 base pairs) of the 16S rDNA gene is performed, but only upon request by 
the referring clinician. Prior to 2004, we used the AccuProbe (GenProbe, San 
Diego, USA) assays as a first line of NTM identification. 
If the 16S sequences yielded a less than 100% match in the GenBank (National 
Center for Biotechnology Information, NCBI, http://www.ncbi.nlm.nih.gov) 
sequence database or a match with a species not validly published at the time 
of referral, the respective isolates were designated ‘Unknown Mycobacterium 
Species (UMS)’ and numbered consecutively. We extracted these sequences 
from our database and subjected these to a new comparison with the GenBank 
sequence database in June 2008. We performed multi-sequence alignment 
with sequences of reference strains of the closest related mycobacteria using 
Clustal X software.9 The resulting topology and tree, inferred by neighbour 
joining and visualized using the MEGA software package,10 were evaluated by 
bootstrap analyses based on 1000 re-samplings.
Unidentifiable mycobacteria in a national reference laboratory
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UMS n 16S hypervariable region A 
(GenBank)
GenoType 
CM/AS
Inno-
LiPA
Interpretation
1 18 100% M. noviomagense NLA000500338T Myc Myc M. noviomagense
2 2 99% M. intracellulare W249st MSC MAIS MAC
3 2 100% M. nonchromogenicum FI-06254 Myc Myc M. nonchromogenicum
7 9 100% M. arupense DSM 44942 Myc Myc M. arupense
10 6 99% M. colombiense CIP108962 MINT MAIS MAC
11 3 99% M. interjectum DSM 44064 MIJ MAIS M. interjectum sqv.
12 4 100% M. saskatchewanense 00-250 MINT Myc M. saskatchewanense
13 4 100% M. seoulense 03-19 MSC MAIS M. seoulense
14 1 96% M. pyrenivorans DSM 44605 Myc Myc RGM
15 3 100% M. pulveris CIP 106804 Myc Myc M. pulveris
16 5 98% M. saskatchewanense 00-250 MSC Myc MAC
17 2 99% M. smegmatis ATCC 700504 MSM MSM M. smegmatis sqv
18 3 100% M. holsaticum 1406 Myc MGO M. holsaticum
19 4 100% M. hiberniae DSM44241 Myc Myc M. hiberniae
20 2 95% M. nonchromogenicum ATCC 19530 Myc Myc M. terrae related sp.
22 4 98% M. szulgai CIP 104532 Myc Myc SGM
23 6 99% M. chlorophenolicum CIP 104189 Myc Myc RGM
24 9 99% M. kumamotonense CCUG 51961 Myc Myc M. terrae related sp.
25 2 98% M. fallax ATCC 35219 MGO Myc RGM
26 4 95% M. botniense DSM 44537 MFO2 Myc M. xenopi related sp.
27 24 100% M. gordonae FI-06271 MGO MGO M. gordonae
28 5 100%  M. fortuitum ATCC 49403 MFO2 MFO M. fortuitum
29 1 96% M. doricum DSM 44339 Myc MFO RGM
30 3 98% M. mucogenicum ATCC 49650 MFO2 MFO M. fortuitum complex
31 1 100% M. avium 104 MAV MAV M. avium
32 4 99% M. terrae ATCC 15755 Myc Myc M. terrae related sp.
33 4 99% M. mucogenicum ATCC 49650 MMC Myc RGM
34 4 98% M.gordonae CIP 104529 MGO MGO M. gordonae related sp.
35 1 100% M. triviale ATCC 23290 Myc Myc M. triviale
36 1 98% M. simiae CIP 104531 MLE Myc M. simiae related sp.
37 1 98% M. simiae CIP 104531 Myc MAIS M. simiae related sp.
38 4 100% M. palustre DSM 44572 M. palustre Myc M. palustre
39 1 100% M. lentiflavum CIP 105465 MLE Myc M. lentiflavum
40 1 99% M. gordonae CIP 104529 MGO MGO M. gordonae sqv.
41 1 98% M. asiaticum DSM 44297 MGO Myc M. gordonae related sp.
42 4 99% M. holsaticum 1406 Myc Myc SGM
43 3 100% M. branderi CIP 104592 Myc Myc M. branderi
44 2 100% M. nebraskense DSM 44803 Myc MAIS M. nebraskense
45 2 100% M. aurum N196 Myc Myc M. aurum
46 1 98% M. avium ATCC 25291 MSC Myc MAC
48 2 94% M. branderi CIP 104592 Myc Myc SGM
49 1 99% M. scrofulaceum CIP 105416 MSC MINT1 MAC
50 1 100% M. cosmeticum CIP 108169 MFO MFO M. cosmeticum
52 1 98% M. sphagni DSM44076 MPE MFO M. fortuitum complex
53 1 97% M. doricum DSM 44339 Myc Myc RGM
54 3 99% M. fortuitum ATCC 49404 MPE MFO M. fortuitum complex
59 2 99% M. sphagni DSM 44076 MMC Myc M. fortuitum complex
60 1 94% M. tusciae CIP106367 Myc Myc RGM
61 1 100% M. florentium DSM 44852 Myc Myc M. florentinum
62 1 98% M. porcinum CIP 105392 MMC Myc M. fortuitum complex
63 1 100% M. monacense B9-21-178 Myc Myc M. monacense
64 1 99% M. interjectum DSM 44064 MIJ Myc M. interjectum sqv.
65 1 98% M. celatum CIP 106109 Myc Myc M. terrae related sp.
Myc: Mycobacterium species; MSC: M. scrofulaceum; MAIS: M. avium-intracellulare-scrofulaceum complex; 
MINT: M. intracellulare; MIJ: M. interjectum; MSM: M. smegmatis; MGO: M. gordonae; MFO: M. fortuitum; 
MAV: M. avium; MPE: M. peregrinum; MMC: M. mucogenicum; MLE: M. lentiflavum; MAC: M. avium complex; 
RGM: Rapid-growing Mycobacterium; SGM: Slow-growing Mycobacterium; sqv.: sequevar; sp.: species. Bold face 
indicates that identification to species level was obtained after re-analysis of the 16S gene sequence. Italics indicate 
identification by hybridization assays not in accordance with partial 16S sequence result.
Table 1: Identification results of previously unidentifiable NTM species.
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To assess the impact of (reverse) hybridization assays on the disclosure of 
genetic diversity among NTM, at least one isolate from each UMS was subjected 
to additional identification using the GenoType Mycobacterium CM/AS 
(Hain Lifescience, Nehren, Germany) and INNO-LiPA MYCOBACTERIA v2 
identification kits, used according to the manufacturer’s instructions.
We considered UMS with a >1% sequence difference from a species type strain 
or with a reverse line blot identification conflicting with the 16S sequence 
result as related to that species. UMS with 16S sequences 1% divergent from 
established species were considered sequevars of that species, unless the 
reverse line blot identification results was discordant.
Results
We found 178 clinical isolates with 53 different 16S rDNA gene sequences, 
not matching with sequences of validly published species available in the 
GenBank database at the time of referral to the RIVM. These made up 4% of 
the 4481 NTM isolates referred to the RIVM in the studied period. During 
this period, another 913 NTM isolates (20%) were no further identified than 
as M. avium complex, other than M. avium or M. intracellulare (n=392), M. 
fortuitum complex (104), NTM not reacting with the M. avium complex and 
the M. tuberculosis complex AccuProbe kits (347) or NTM reacting only with 
the Mycobacterium species probe of the INNO-LiPA assay (70). More detailed 
identification for these 913 isolates was not requested by the referring clinicians 
and thus not conducted.
The isolation frequency of the UMS and results of the new identification efforts 
are detailed in Table 1. Multi-sequence alignment of the partial 16S rDNA 
gene sequences resulted in the phylogenetic tree visualized in Figure 1.
Based on our re-analysis of the partial 16S gene sequence, 20 UMS (yielding 
93 isolates; 52%) could be assigned to validly published species, including 
our recently described Mycobacterium noviomagense (UMS1; Table 1).11 The 
remaining 85 isolates, making up 33 UMS, were related to the M. avium 
complex (n=10), M. fortuitum complex (n=7), M. xenopi (n=3), M. terrae 
complex (n=4), M. gordonae (n=3), M. simiae (n=2), M. interjectum (n=2) 
or were assigned to the slow or rapid growers, distantly related to established 
species (Table 1 & Figure 1).
The GenoType CM/AS assay identified 28 of the 53 UMS (53%) to species 
(n=24) or complex level (M. fortuitum complex; n=4). Twelve of these 
identifications were not in accordance with species or complex identifications 
based on the partial 16S gene sequence (Table 1, italics). The Inno-LiPA assay 
identified 19 UMS (36%) to species (n=7) or complex level (n=12; 6 M. avium 
complex, 6 M. fortuitum complex). Eight identification results were discordant 
with species or complex identifications based on the partial 16S gene sequence 
(Table 1, italics). Identifications as M. fortuitum complex or M. gordonae by the 
two assays were especially frequent.
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Figure 1: Phylogenetic relationships of the UMS and related species of Mycobacterium, 
based on partial 16S rDNA gene sequences.
Neighbour-joining (NJ) tree was created and bootstrapped 1000x with CLUSTAL X9 and 
visualized with MEGA 4.0.10 Bootstrap values are indicated at the nodes.
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Discordance between species or complex identifications by the two 
hybridization assays was noted in 6 different UMS (UMS 2, 10, 11, 13, 49 and 
64, Table 1). This mainly involved isolates related to the M. avium complex, M. 
interjectum or M. scrofulaceum. 
Twenty six (49%) of the UMS were only encountered once; the average number 
of isolates considering all UMS was 3.4 (range 1-24). Most UMS isolates were 
cultured from respiratory samples (n=162; 129 sputa, 33 broncho-alveolar 
lavage fluid samples; 91%). Sixteen UMS isolates (9%) were cultured from 
normally sterile samples, including bone marrow (n=1), lung (2), lymph node 
(4), pleura (1) and joint biopsies (1), as well as urine (4), gastric aspirate (2) 
and maxillary sinus lavage fluid (1). 
Discussion
Unidentifiable NTM are a significant phenomenon, making up at least 4% of 
all NTM submitted to our national reference laboratory. This is well above the 
1% estimated by Tortoli and co-workers.12 Still, we most likely underestimate 
the number of UMS isolates. For isolates identified to species or complex level 
by the hybridization assays, additional 16S rDNA gene sequencing is not free 
of charge and therefore not routinely performed. Yet, this may reveal novel 16S 
rDNA sequences and thus UMS. In our situation, this seems most prominent 
in isolates identified by hybridization assays as M. fortuitum complex, M. 
avium complex or M. gordonae. In the 20% of all submitted isolates that were 
not identified to species level many additional UMS may be identified.
Reanalysis of the 16S rDNA sequence identified 20 of our 53 UMS as validly 
published NTM species. Forty-eight percent of the unidentifiable isolates (n= 
85) represent 33 novel species or variants of established species. 
UMS encountered in this study are clustered in specific parts of the phylogenetic 
tree of mycobacteria. Referral to our reference lab may be more likely for 
strains considered possible pathogens and this creates a potential selection 
bias. Still, this implies that in specific branches of the phylogenetic tree, such 
as within the M. avium and M. fortuitum complexes, more species exist than 
are currently described.
Most of the UMS were single pulmonary isolates, which may reflect limited 
clinical relevance, i.e. patients failed to meet the ATS diagnostic criteria 
for pulmonary NTM disease,3 or a reluctance to submit further isolates for 
identification. In nine cases, UMS were isolated from normally sterile sites, 
thus likely causative agents of true NTM disease. 
The current hybridization assays can only recognize a limited number of 
species. For manufacturers, it is a matter of choice to decide whether recently 
described species should be added or replace species currently included in 
the assay. Moreover, the hybridization assays are based on the detection of 
short DNA sequences. This mono-phasic approach precludes a high degree 
of genetic variation among identically identified strains and thus misses 
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the distinction between related (sub)species. Our results demonstrate that 
hybridization assays provide false identifications for recently described species 
including M. monacense, M. florentinum, M. holsaticum, M. cosmeticum and 
M. saskatchewanense (Table 1). Importantly, we also recorded differences in 
identification results between the two hybridization assays tested. Since clinical 
relevance and drug susceptibility of NTM species differs, correct identification 
is important.3,8,11-13 Sequence based identification is more reliable than the 
limited approach of hybridization assays, although this requires sophisticated 
and expensive laboratory equipment and may be most suitable for reference 
laboratories.
For UMS, the 16S sequence similarity to an established species does not provide 
guidance for clinicians. Our previous identification of M. noviomagense pointed 
out that close genetic relationships with M. xenopi were associated with very 
different phenotypical features, drug susceptibility and clinical relevance.11 
Genetic relationships, based on a partial single target should therefore be 
interpreted with caution. 
Identification based on DNA sequence analysis of a (partial) single gene 
disregards genetic variation in the rest of the genome. Multi-gene identification 
may improve our understanding of mycobacterial taxonomy and result in 
clinically relevant distinctions within species. Mycobacterium kansasii is a good 
example in this respect, as five subtypes have been described based on multiple 
genetic targets; one subtype causes pulmonary disease, one is a causative agent 
of HIV-related disseminated disease, while the three remaining types are 
environmental bacteria, not associated with human disease.14 The maximum 
resolution of genetic identification will only be achieved after the introduction 
of routine sequencing of whole genomes of all available Mycobacterium isolates. 
This will lead to a robust phylogenetic tree that can be enriched with clinical 
data as a self-learning model to improve our understanding of mycobacterial 
virulence. It is conceivable that this will also lead to a complete re-consideration 
of the ever growing list of new species that are described on basis of limited 
variation on semi-conserved genes and some degree of phenotypic variation.
It is questionable whether our UMS isolates with novel partial 16S rDNA 
sequences represent new species or variants of established species. 
Heterogeneity within the 16S rDNA gene has been described for multiple 
species including M. gordonae.15 Conversely, among rapid growers, new species 
have been described which share identical 16S rDNA gene sequences but differ 
in other genetic and biochemical traits.8,16 With regard to this, rpoB sequences 
are increasingly used to define novel species.16
What should make up a new species? A unique 16S rDNA gene sequence 
remains the gold standard, although an exact cut-off point indicating distinct 
taxa has not been established for mycobacteria. A separate species status based 
entirely on unique 16S rDNA sequences would result in hundreds, if not 
thousands, of new species; it is doubtful whether this would serve clinicians 
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or only add to the confusion. Our results demonstrate the presence of a large 
number of potentially new species. Moreover, human isolates represent only 
the tip of the ‘NTM-iceberg’.8 Here, we agree with Telenti, who has proposed 
that “clinical meaningfulness should be the key to taxonomic precision”.17 
Amidst an ever increasing number of species, a classification of NTM based 
on virulence factors, not unlike Runyon’s classification based on growth rate 
and pigmentation,18 may be a future strategy. Such a classification could begin 
if more NTM have their entire genomes sequenced.19
In conclusion, four percent of NTM isolates submitted to our reference 
laboratory are unidentifiable Mycobacterium species. A minority is isolated 
from normally sterile sites and may be causative agents of human disease. 
Periodical reanalysis of UMS is warranted to reclassify them. Identification by 
hybridization assays underestimates the genetic heterogeneity among NTM. 
This heterogeneity can be clinically relevant as specific (sub)species can cause 
specific disease types. Sequence based identification is preferable, at least at 
reference laboratory level, although the exact target and number of targets 
needed for clinically useful results remains to be established. The number 
of NTM species in the environment is probably so high, that clinical UMS 
isolates should be analyzed and designated a separate species status only if this 
is clinically meaningful.
References
1. Martín-Casabona N, Bahrmand AR, Bennedsen J, Thomsen VO, Curcio M, 
Fauville-Dufaux M, Feldman K, Havelkova M, Katila ML, Köksalan K, Pereira 
MF, Rodrigues F, Pfyffer GE, Portaels F, Urgell JR, Rüsch-Gerdes S, Tortoli E, 
Vincent V, Watt B; Spanish Group for Non-Tuberculosis Mycobacteria. 2004. Non-
tuberculous mycobacteria: patterns of isolation. A multi-country retrospective 
survey. Int. J. Tuberc. Lung Dis. 8:1186-93.
2. Marras TK, Chedore P, Ying AM, Jamieson F. 2007. Isolation prevalence of 
pulmonary non-tuberculous mycobacteria in Ontario, 1997-2003. Thorax. 
62:661-6.
3. Griffith DE, Aksamit T, Brown-Elliot BA, Catanzaro A, Daley C, Gordin F, 
Holland SM, Horsburgh R, Huitt G, Iademarco MF, Iseman M, Olivier K, Ruoss 
S, Fordham von Reyn C, Wallace RJ Jr, Winthrop K. 2007. An official ATS/IDSA 
statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial 
diseases. Am. J. Respir. Crit. Care. Med. 175:367-416.
4. Kirschner P, Springer B, Vogel U, Meier A, Wrede A, Kiekenbeck M, Bange 
FC, Böttger EC. 1993. Genotypic identification of mycobacteria by nucleic acid 
sequence determination: report of a 2-year experience in a clinical laboratory. J. 
Clin. Microbiol. 31:2882-9.
5. Adékambi T, Colson P, Drancourt M. 2003. rpoB-based identification of 
nonpigmented and late-pigmenting rapidly growing mycobacteria. J. Clin. 
Microbiol. 41:5699-708.
6. Telenti A, Marchesi F, Balz M, Bally F, Böttger EC, Bodmer T. 1993. Rapid 
identification of mycobacteria to the species level by polymerase chain reaction 
Unidentifiable mycobacteria in a national reference laboratory
Chapter 5.1
187
and restriction enzyme analysis. J. Clin. Microbiol. 31:175-8.
7. Roth A, Fischer M, Hamid ME, Michalke S, Ludwig W, Mauch H. 1998. 
Differentiation of phylogenetically related slowly growing mycobacteria based 
on 16S-23S rRNA gene internal transcribed spacer sequences. J. Clin. Microbiol. 
36:139-47.
8. Tortoli E. 2006. The new mycobacteria: an update. FEMS Immunol. Med. 
Microbiol. 48:159-78.
9. Thompson JD, Gibson TJ, Plewniak F, Jeanmougin F, Higgins DG. 1997. 
The CLUSTAL X windows interface: flexible strategies for multiple sequence 
alignment aided by quality analysis tools. Nucleic Acids Res. 25:4876-82.
10. Tamura K, Dudley J, Nei M, Kumar S. 2007. MEGA4: Molecular Evolutionary 
Genetics Analysis (MEGA) software version 4.0. Mol. Biol. Evol. 24:1596-1599.
11. van Ingen J, Boeree MJ, de Lange WCM, de Haas PEW, van der Zanden AGM, 
Mijs W, Rigouts L, Dekhuijzen PNR, van Soolingen D. 2009. Mycobacterium 
noviomagense sp. nov.; clinical relevance evaluated in 17 patients. Int. J. Syst. Evol. 
Microbiol. 59:845-9.
12. Tortoli E, Bartolini A, Böttger EC, Emler S, Garzelli C, Magliano E, Mantella 
A, Rastogi N, Rindi L, Scarparo C, Urbano P. 2001. Burden of unidentifiable 
mycobacteria in a reference laboratory. J. Clin. Microbiol. 39: 4058-65.
13. van Ingen J, Bendien SA, de Lange WCM, Hoefsloot W, Dekhuijzen PNR, Boeree 
MJ, van Soolingen D. The clinical relevance of nontuberculous mycobacteria 
isolated in the Nijmegen-Arnhem region, the Netherlands. Thorax 2009; 64(6): 
502-6.
14. Taillard C, Greub G, Weber R, Pfyffer GE, Bodmer T, Zimmerli S, Frei R, Bassetti 
S, Rohner P, Piffaretti JC, Bernasconi E, Bille J, Telenti A, Prod’hom G. 2003. 
Clinical implications of Mycobacterium kansasii species heterogeneity: Swiss 
national survey. J. Clin. Microbiol. 41:1240-4.
15. Kirschner P, Böttger EC. 1992. Microheterogeneity within rRNA of Mycobacterium 
gordonae. J. Clin. Microbiol. 30:1049-50.
16. Adékambi T, Berger P, Raoult D, Drancourt M. 2006. rpoB gene sequence-based 
characterization of emerging non-tuberculous mycobacteria with descriptions 
of Mycobacterium bolletii sp. nov., Mycobacterium phocaicum sp. nov. and 
Mycobacterium aubagnense sp. nov. Int. J. Syst. Evol. Microbiol. 56:133-43.
17. Telenti A. 1998. More on `What’s in a name…’- pragmatism in mycobacterial 
taxonomy. Int. J. Tuberc. Lung Dis. 2:182-3.
18. Runyon EH. 1959. Anonymous mycobacteria in pulmonary disease. Med. Clin. 
North Am. 43: 273-90.
19. Behr MA. 2008. Mycobacterium du jour: what’s on tomorrow’s menu? Microbes 
Infect. 10:968-72. 
188
Chapter 5.2Unidentifiable mycobacteria in a national reference laboratory
Chapter 5.2
189
Mycobacterium noviomagense sp. 
nov.; clinical relevance evaluated in 
17 patients
Jakko van Ingen1,2, Martin J. Boeree1, Wiel C.M. de Lange1, Petra E.W. de 
Haas2, Adri G.M. van der Zanden3, Wouter Mijs4, Leen Rigouts5, P.N. Richard 
Dekhuijzen1 and Dick van Soolingen2
1 Radboud University Nijmegen Medical Center, Department of Pulmonary Diseases, 
Nijmegen, the Netherlands; 2 National Institute for Public Health and the Environment, 
National Mycobacteria Reference Laboratory, Bilthoven, the Netherlands; 3 Laboratory 
for Medical Microbiology and Public Health, Enschede, The Netherlands; 4 Innogenetics 
N.V., Department of Diagnostics, Gent, Belgium; 5 Institute of Tropical Medicine, 
Department of Mycobacteriology, Antwerp, Belgium
Summary
Eighteen isolates of a nonchromogenic, slowly growing, non-tuberculous 
species of the genus Mycobacterium were cultured from respiratory specimens 
obtained over the last eight years from 17 patients in the Netherlands. 
These isolates were grouped because they revealed a unique 16S rDNA gene 
sequence and were related to Mycobacterium xenopi. None of the 17 patients 
met the American Thoracic Society diagnostic criteria for non-tuberculous 
mycobacterial disease, which distinguishes the novel isolates from the related 
species M. xenopi. A polyphasic taxonomic approach, including identification 
by biochemical and phenotypical analysis, hsp65 gene sequencing and PCR 
restriction enzyme pattern analysis, and sequence analyses of the rpoB gene 
and 16S-23S internal transcribed spacer supported the separate species 
status of the novel isolates. The name Mycobacterium noviomagense sp. nov. 
is proposed for the novel strains. The type strain is NLA000500338T (=DSM 
45145T =CIP 109766 T). A more distinctive taxonomy of NTM is a prerequisite 
for the assessment of their clinical relevance.
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Improved detection and identification techniques have triggered renewed 
interest in non-tuberculous mycobacteria (NTM) and their role as 
opportunistic pathogens. Polymerase chain reaction (PCR) techniques and 
16S rDNA gene sequence analysis have brought to light a series of novel NTM 
species. However, the clinical relevance of these species is not always clear.1-3 
NTM infections present predominantly as chronic pulmonary disease, although 
extrapulmonary and disseminated infections have also been described.3 Local 
immunosuppression due to pre-existing pulmonary disease and systemic 
immunosuppression, e.g. in haematological malignancy, immunosuppressive 
medication and HIV/AIDS, have been identified as predisposing factors for 
NTM infections.3 Infection has to be differentiated from contamination and 
pseudo-infection, characterised by single NTM isolates from the respiratory 
or digestive tract without signs of disease.3,4 Their ubiquitous presence 
in the environment, survival in flowing water systems and resistance to 
disinfectants implies that NTM often represent laboratory or medical 
equipment contamination.3-5 The diagnostic criteria proposed in a Statement 
by the American Thoracic Society (ATS) are designed to differentiate between 
true infection and pseudo-infection or contamination, based on clinical, 
radiological and microbiological features.3
This study describes the grouping of 18 previously unknown Mycobacterium 
isolates with identical 16S rDNA sequences and with a high degree of gene 
sequence similarity to strains of M. xenopi. As other features of these bacteria 
were highly distinct from M. xenopi and the clinical relevance differed 
significantly between the newly recognised bacteria and M. xenopi, the 18 
isolates are proposed to represent a novel species of the genus Mycobacterium.
The 18 novel isolates were acquired from pulmonary samples (13 from sputum, 
4 from broncho-alveolar lavage fluid and 1 from a post-mortem lung biopsy) 
of 17 patients in the Netherlands between January 1999 and January 2007. To 
determine clinical relevance, we examined the medical records of all 17 patients; 
their baseline characteristics are displayed in Table 1. The predominance of male 
patients, mean age and history of chronic pulmonary disease are comparable 
with previous NTM studies.3,6 None of the patients had clinical and radiographic 
features suggestive of mycobacterial lung disease; one was systemically 
immunocompromised due to HIV co-infection. The post-mortem lung biopsy 
sample showed histological features of bronchopneumonia and invading 
bacteria, without features of mycobacterial disease such as granuloma formation. 
All patient samples were negative for acid-fast bacilli (AFB) on direct microscopy 
which suggests the presence of a low number of NTM in the original sample 
or contamination after sample division for culture and microscopy. Although 
follow-up sputum cultures were performed for 16 patients, only one patient 
produced another culture that was positive for the novel strains. All others had 
a single positive culture. Based these findings, none of the patients from whom 
the novel strains were isolated met the American Thoracic Society criteria for 
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pulmonary NTM disease.3 Good clinical response to non-antimycobacterial 
regimes, the subsequent establishment of an alternative diagnosis and the 
observed spontaneous conversion to negative cultures suggested that the novel 
strains were not the causative agent of these patients’ symptoms. The novel 
strains therefore seem to have no clinical relevance, which distinguishes them 
from phylogenetically related, but more pathogenic species such as M. xenopi 
and M. heckeshornense.3,7,8 
Two patients received antituberculosis treatment for an average period of 10 
weeks, after a presumptive diagnosis of TB. Treatment of patients not meeting 
the ATS diagnostic criteria is potentially harmful to patients in terms of 
adverse effects and costs.9
Geographical clustering of the patients was observed, favouring the South-east 
of the Netherlands, in adjacent areas of the Limburg (7 cases), Gelderland (5 
cases) and Noord-Brabant (2 cases) provinces. This clustering suggested the 
presence of the novel strains in specific local environments or tap water. Since 
the clustering was seen geographically, but not over time, contamination from 
medical machinery or the laboratories involved seemed less likely.
All of the novel isolates were subjected to laboratory diagnosis by the National 
Mycobacteria Reference Laboratory of the National Institute for Public Health 
and the Environment (RIVM). The RIVM provides molecular identification, 
drug susceptibility testing and epidemiological typing of mycobacterial isolates 
for all healthcare institutions in the Netherlands. 
Biochemical identification and high performance liquid chromatography 
(HPLC) analysis of cell wall mycolic acid content were performed using 
Characteristic No. of patients
Male 13 (77%)
Mean age (yr) (range) 53 (29-86)
Dutch origin 16 (94%)
Pre-existing pulmonary 
disease 15 (88%)
COPD 8 (47%)
Lung cancer 4 (24%)
Healed Tuberculosis 2 (12%)
Recurrent pulmonary 
infection* 3 (18%)
Bronchiectasis 2 (12%)
Current smoker 5 (29%)
Past smoker 3 (18%)
Alcohol abuse 3 (18%)
HIV infection 1 (6%)
Table 1:
Characteristics of the patients 
in the study group
The total number of patients was 
17. COPD: chronic obstructive 
pulmonary disease 
*  >3 in 6 months prior to sampling
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previously described approaches.10,11 Eight isolates (4 M. xenopi, 4 of the novel 
strains) were subjected to biochemical testing. The results are detailed in Table 
2. Morphologically, two patterns were clearly discernible; on Middlebrook 
7H10 media, the M. xenopi isolates were scotochromogenic, showing yellow 
pigmentation, whereas the colonies of the novel species were smaller and 
nonchromogenic. All M. xenopi isolates grew at 45°C, as previously reported,12 
but the novel strains were unable to grow at this temperature (Table 2). 
Biochemically, the novel isolates were indistinguishable from the cluster 
comprising M. xenopi, M. botniense and M. heckeshornense, with negative 
results for urease, Tween 80 hydrolysis, niacin production, nitrate reductase, 
acid phosphatase and semi-quantative catalase. HPLC of the novel isolates 
revealed a pattern characterized by one early and one late cluster of peaks, 
a profile similar to that of M. xenopi, M. heckeshornense and M. botniense 
(Figure 1). The HPLC mycobacterium library (available online at http://www.
MycobacToscana.it) was used for this comparison.
Susceptibility testing was performed for eleven of the novel isolates from eleven 
patients using the agar dilution method.13 For the novel isolates, we recorded 
in vitro resistance to rifampicin (MIC 2mg/L), resistance or intermediate 
susceptibility to ethambutol (MIC 10-20 mg/L) and intermediate susceptibility 
to isoniazid (MIC 0.5-1mg/L). The novel species proved susceptible in vitro 
to streptomycin, cycloserine, prothionamide, amikacin, ciprofloxacin, 
clofazimine, clarithromycin and rifabutin. The drug susceptibility pattern for 
the novel isolates differed slightly from clinical isolates of M. xenopi tested 
at RIVM which were mostly susceptible, in vitro, to rifampicin (MIC 0.5-1 
mg/l).8 These results for M. xenopi are in accordance with previous reports.14
For molecular identification, sequencing of the full 16S rDNA gene and 
16S-23S internal transcribed spacer (ITS), partial rpoB and hsp65 gene, 
Characteristic 1 2 3 4
Growth at 45°C - + + +
Morphology
Colony size
NC
Small 
SC
Large
SC
NP
SC
Small 
Tolerance to (in LJ medium):
Isoniazid 10 μg/ml - - - NP
Thiophen-2-carboxylic acid + + NP NP
Hydroxylamine 250 μg/ml Variable + NP NP
Para-nitrobenzoate 500 μg/ml + Variable NP NP
5% NaCl - - - -
Taxa: 1, M. noviomagense sp. nov.; 2, M. xenopi; 3, M. heckeshornense;7 4, M. botniense.12
+, positive; -, negative; NC, nonchromogenic; SC, scotochromogenic; NP, not published
Table 2: Biochemical identification results for the novel isolates and closely related species
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and PCR restriction enzyme pattern analysis (PRA) of the hsp65 gene were 
performed, using previously published methods.15-18 The sequences obtained 
were compared with the GenBank/EMBL (National Centre for Biotechnology 
Information, NCBI, http://www.ncbi.nlm.nih.gov) gene sequence databases. 
The full 16S rDNA gene sequence for the new species showed 96% sequence 
similarity with that of M. xenopi and was 97% similar to those of M. heckeshornense 
and M. shimoidei. A sequence difference of 1% has been proposed in the literature 
as the threshold for the designation of a novel species.1,19 
The full 16S rDNA gene sequence of the of the novel strains was aligned with 
those of reference strains of the closest related mycobacteria using Clustal X 
software.20 The resulting topology and tree, inferred by neighbour-joining and 
visualized using the LOFT software package21 were evaluated by bootstrap 
analyses based on 1000 resamplings (Figure 2). 
Analysing only the hypervariable region A of the 16S rDNA gene (151 bp), we 
found a 100% match in the GenBank/EMBL database, to a strain designated 
“most closely resembling M. xenopi”, reported by Hall et al.19 Analysis of 
phenotypic and genetic characteristics of the new species (Table 2, Figure 1, 2 
and 3) demonstrates that very subtle 16S rDNA gene sequence differences can 
be associated with extensive divergence from the closest related species. This 
brings into question the use of monophasic identification methods.
Analysis of the 16S-23S ITS region revealed mixed sequence patterns for all 18 
novel isolates, even from single colony cultures, and necessitated cloning. For 
cloning of the ITS, amplicons were generated using primers provided with the 
Inno-LiPA Mycobacteria v2 kit (Innogenetics), and cloned in the PGEM-T Easy 
vector (Promega, Leiden, The Netherlands) according to the manufacturer’s 
Figure 1: Mycolic acid patterns of M. noviomagense sp. nov. obtained by HPLC analysis. 
One early and one late cluster of peaks are present, similar to M. xenopi. The first (left) and last 
(right) peaks are the low and high weight molecular standards
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instructions. Thirty colonies of transformed Escherichia coli strain DH5F were 
picked for each sample, cultured, and used to prepare plasmid DNA using 
the QIAprep 96 Turbo BioRobot Kit (Qiagen, Venlo, the Netherlands). For 
sequencing of the ITS region cloned into the pGEM-T vector, the universal vector 
primers M13(-21) and M13rev were used on the plasmid preparation as target. 
Cloning resulted in recognition of two distinct copies of the ITS, both with <68% 
sequence similarity to M. xenopi. A 93% sequence similarity was noted between 
the two ITS copies. The presence of multiple copies of the 16S-23S ITS region, 
thus possibly multiple rRNA operons, is unexpected. This phenomenon has not 
been described for M. xenopi or closely related slow-growing NTM species and 
thus supports the separate species status of the novel isolates.
The rpoB sequence was 95% similar to that of the recently described species M. 
seoulense and only 92% similar to that of M. xenopi. For the hsp65 sequence, 
the most closely related sequences (95%) were found among members of 
the M. avium complex and M. branderi, with <93% similarity to M. xenopi. 
The considerable divergence in these two targets from the otherwise related 
Figure 2: Phylogenetic relationship of the type strain of the novel species, M. 
noviomagense sp. nov., and related species of the genus Mycobacterium, based on 16S 
rDNA gene sequences. The neighbour-joining tree was created and bootstrapped 1000 
times with CLUSTAL X20 and visualized with LOFT (Levels of Orthology through 
Phylogenetic Trees).21 Bootstrap values are indicated at the nodes.
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cluster comprising M. xenopi, M. botniense and M. heckeshornense supports 
the separate species status of the novel isolates. The hsp65 and rpoB sequences 
were aligned with those of related mycobacterial species, as for the 16S rDNA 
sequence. The resulting topologies and trees are available as Supplementary 
Figures S1 and S2 (in IJSEM Online).
The hsp65 PRA results for the novel isolates, M. xenopi, M. tuberculosis H37RvT 
and M. botniense ATCC 700701T are shown in Figure 3. For the novel isolates, 
digestion with BstEII resulted in fragments of 240/120/100 bp, digestion with 
HaeIII gave fragments of 130/10/70/45 bp. A PRAsite (http://app.chuv.ch/
prasite/index.html) comparison showed this to be a unique fragment length 
combination. Isolates of M. xenopi and M. tuberculosis tested simultaneously 
were correctly identified using the PRAsite database; no entry was found for 
M. botniense.
Description of M. noviomagense sp. nov.
Mycobacterium noviomagense (no.vi.o.ma.gen’se. N.L. neut. adj., pertaining 
to Noviomagus, the Roman name of the major city in the endemic region 
in the Netherlands and the location of the reference hospital; current name: 
Nijmegen). Acid-fast and Gram-positive rods. Colonies are nonchromogenic 
and appear after 4 weeks of culture at 37°C, no growth occurs at 45°C. Negative 
in tests for urease, Tween 80 hydrolysis, niacin production, nitrate reductase, 
acid phosphatase and semi-quantative catalase. Can be readily identified by its 
unique rDNA sequences.
The type strain, NLA000500338T (=CIP 109766T; =DSM 45145T), was 
recovered from sputum. 
Figure 3: PRA typing results for the hsp65 gene. Different fragment length patterns are 
observed for M. botniense (lane 1), M. xenopi (lanes 2–5), M. tuberculosis H37RvT (lane 
6) and strain NLA000500338T (M. noviomagense sp. nov.; lanes 7–10)
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Supplementary Figure S1: Phylogenetic relationship of the type strain of the novel 
species, M. noviomagense sp. nov., and related species of the genus Mycobacterium, 
based on rpoB gene sequences. The neighbour-joining tree was created and 
bootstrapped 1000 times with CLUSTAL X20 and visualized with LOFT (Levels of 
Orthology through Phylogenetic Trees).21 Bootstrap values are indicated at the nodes.
Note: GenBank/EMBL/DDBJ accession numbers for the 16S rRNA, 16S-23S ITS 1 and 
2, hsp65 and rpoB gene sequences are EU239955, EU439248, EU439249, EU600390 
and EU810775. Phylogenetic trees based on hsp65 and rpoB sequences of selected 
mycobacterial species are available as supplementary material in IJSEM Online.
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Proposal to elevate Mycobacterium 
avium complex ITS sequevar MAC-Q 
to Mycobacterium vulneris sp. nov.
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Summary
The Mycobacterium avium complex consists of four validly published species, M. 
avium, M. colombiense, M. intracellulare and M. chimaera, and a variety of other 
strains that may be members of undescribed taxa. We report on two isolates of 
a scotochromogenic, slowly growing non-tuberculous Mycobacterium species 
within the M. avium complex from a lymphnode and an infected wound after a 
dogbite of separate patients in the Netherlands. The extrapulmonary infections 
in immunocompetent patients suggest a high level of virulence. These isolates 
are characterized by a unique nucleotide sequence in the 16S rDNA gene, 
99% similar to Mycobacterium colombiense, and the MAC-Q 16S-23S internal 
transcribed spacer sequence. Sequence analyses of the hsp65 gene revealed 
97% similarity to M. avium. The rpoB gene sequence was 98% similar to 
M. colombiense. Phenotypically, the scotochromogenicity, positive semi-
quantitative catalase and heat-stable catalase tests, negative tellurite reductase 
and urease tests and susceptibility to hydroxylamine and oleic acid set these 
isolates apart from related species. High performance liquid chromatography 
analysis of cell wall mycolic acid content revealed a unique pattern, related to 
that of M. avium and M. colombiense. Combined, these findings supported a 
separate species status within the Mycobacterium avium complex. 
We propose elevation of scotochromogenic M. avium complex strains sharing 
this 16S gene and MAC-Q internal transcribed spacer sequence to separate 
species status under the name Mycobacterium vulneris. The type strain is 
NLA000700772T (=DSM 45247T; =CIP 109859T).
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Mycobacterium avium complex (MAC) bacteria are the most frequently 
isolated nontuberculous mycobacteria (NTM) worldwide and are capable of 
causing a wide spectrum of clinical disease. Pulmonary disease, mostly in 
patients with pre-existent pulmonary diseases, is most common, followed by 
lymphadenitis in immunocompetent children and disseminated disease in 
systemically immunocompromised patients.1
The taxonomy of the MAC has been a subject of debate for decades. The 
MAC was long divided into two species, M. avium and M. intracellulare, and 
a number of unnamed bacteria not belonging to these two taxa. Frothingham 
and Wilson noted that sequencing of the 16S-23S internal transcribed spacer 
(ITS) revealed a wide range of genetic diversity among reference strains of those 
unnamed MAC bacteria, suggesting the presence of several as yet undefined 
species.2 Two such groups have recently been elevated to species rank, M. 
chimaera and M. colombiense.3,4 Within this study, we report on a novel M. 
avium complex member, related to M. colombiense, which was isolated from 
two patients in the Netherlands.
Case reports
A previously healthy, 42 year old woman presented with a painful wound in the 
left lower leg seven weeks after a dogbite. Several small white lesions with limited 
ulceration were noted. Surgical wound excision and oral amoxicillin and clavulanic 
acid had limited success. An abscess with fistula to the skin and spontaneous 
wound rupture prompted renewed surgical debridement, Mycobacterium culture, 
and vacuum therapy. The cultures yielded a nontuberculous Mycobacterium. A 
third wound debridement and vacuum therapy eventually led to symptomatic 
improvement and wound closure. Mycobacterium cultures from samples of the 
third debridement remained negative.
A previously healthy, two year old girl presented at another hospital with 
painless swelling of a right cervical lymph node and violaceous overlying 
skin. No other symptoms were reported. A biopsy revealed granulomatous 
inflammation, but no acid-fast bacilli were visible on direct microscopy. 
Cultures of the biopsy material yielded a nontuberculous Mycobacterium and 
surgery was successfully performed. No relapse has been noted since.
Both isolates were sent to the National Institute for Public Health and the 
Environment (RIVM), Bilthoven, the Netherlands. The RIVM is the national 
mycobacteria reference laboratory, which provides identification, typing and 
drug susceptibility testing. 
We investigated biochemical and phenotypical features and performed high 
performance liquid chromatography (HPLC) analysis of cell wall mycolic 
acid content, using previously described procedures.5,6 We used the HPLC 
mycobacterium library (available online at http://www.MycobacToscana.it) 
for visual comparisons.
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For primary identification we used the INNO-LiPA MYCOBACTERIA v2 
(Innogenetics, Ghent, Belgium) and GenoType CM/AS (Hain Lifesciences, 
Nehren, Germany) reverse line-blots. To identify the isolates to the species level 
we sequenced the complete 16S rDNA gene, the 16S-23S internal transcribed 
spacer (ITS) region and partial hsp65 and rpoB gene, using previously published 
primers and methods.7-10 The DNA sequences obtained were compared with 
the GenBank/EMBL (National Center for Biotechnology Information: http://
www.ncbi.nlm.nih.gov) sequence database. 
The 16S rDNA gene sequence of the Mycobacterium isolates of the two cases 
was aligned with those of reference strains in the M. avium complex using 
Clustal X software.11 The resulting topology and tree, inferred by neighbour 
joining and visualized using the MEGA 4.0 software package12 were evaluated 
by bootstrap analyses based on 1000 resamplings (Figure 1). The tree was 
rooted with M. tuberculosis H37Rv as an out-group.
We tested the presence of the IS1245 element by amplification of a 427bp 
internal fragment, using P1 and P2 primers, as previously described.13
Drug susceptibility testing was performed using the 25 wells agar dilution 
method.14 We included isoniazid, rifampicin, rifabutin, ethambutol, 
clarithromycine, ciprofloxacin, cycloserine, prothionamide, amikacin, 
clofazimine and streptomycin in the test panel. 
On Middlebrook 7H10, Ogawa and Stonebrink media, the bacteria produce 
film-like growth with small, smooth, bright yellow pigmented colonies after 
3 weeks of incubation at 36°C. Growth on Middlebrook 7H10 agar was only 
observed at 24, 30 and 36°C. Optimal growth occurred at 36°C. Colony 
morphology on Middlebrook 7H10 was similar at all temperatures.
Figure 1: Phylogenetic relationship of the new species (M. vulneris) type strain and 
related species of Mycobacterium, based on 16S rDNA gene sequences.
Neighbour-joining (NJ) tree was created, bootstrapped 1000x and visualized with MEGA 4.0.12 
Bootstrap values are indicated at the nodes.
202
Chapter 5.3
The INNO-LiPA MYCOBACTERIA v2 assay revealed only reaction with the 
MAIS (M. avium-intracellulare-scrofulaceum) complex probe, thus identifying 
the isolates as M. avium complex members, different from M. avium, M. 
intracellulare and M. scrofulaceum. Analysis using the GenoType CM assay 
(which uses the 23S rDNA gene as its target) incorrectly identified the strain as 
M. intracellulare. This may reflect 23S gene sequence similarity of our isolates 
with M. intracellulare. Currently available commercial identification kits for 
nontuberculous mycobacteria do not have sufficient discriminative power to 
recognize particular sub-groupings among the MAC isolates. This may suffice 
in the clinical setting, as the treatment of MAC disease, so far, is independent 
of exact speciation results.1 However, an improved recognition of clinically 
relevant sub-groupings within the complex may improve clinical management 
and eventually support research on the epidemiology and pathogenesis of 
MAC disease. 
Sequencing of the complete 16S rDNA gene of both isolates revealed a unique 
sequence most closely related to M. avium complex bacteria (Table 1). The 
multisequence alignment results of the 16S rDNA gene sequence clarified its 
taxonomical position within the M. avium complex (MAC) as most closely 
related to M. colombiense (Figure 1). The 16S-23S internal transcribed spacer 
sequence of both strains was identical to the previously described MAC-Q ITS 
sequevar (GenBank: AF315833); it is 6bp different from the M. colombiense ITS 
sequevar (Table 1). The previously published MAC-Q strain15 is the one isolated 
from patient two, the girl with lymphadenitis. We performed multisequence 
alignment of all published MAC ITS sequevars currently available in GenBank 
(Figure 2). Additional sequencing of the hsp65 and rpoB genes revealed unique 
Target Results of GenBank/EMBL comparison
16S (1471 bp)
GenBank EU834055
99% M. colombiense 10BT (1436/1439 bp)
99% M. chimaera FI-0169T (1432/1439 bp) 
99% M. avium 104 (1463/1471 bp)
99% M. paratuberculosis ATCC 19698T (1463/1471bp)
16S-23S ITS (281 bp) 
GenBank AF315833
MAC-Q
99% MAC-R, AF315834 (279/281bp)
98% MAC-E (ATCC 35847), L07852 (278/281 bp)
98% MAC-F, L07853 (277/281 bp)
97% M. colombiense 10BT (275/281bp)
rpoB (726 bp)
GenBank EU834057
98% M. colombiense CIP 108962T (690/701 bp)
95% M. chimaera DSM 446232T (669/701 bp)
94% M. avium 104 (678/714 bp)
94% M. avium ATCC 25291T (665/701 bp)
hsp65 (424 bp)
GenBank EU834054
97% M. avium ATCC 25291T (415/424 bp)
97% M. avium 104 (415/424bp)
97% M chimaera CIP 107892T (414/424 bp)
97% M. intracellulare ATCC 13950T (412/424 bp)
Table 1: Sequence comparison results for M. vulneris NLA000700772T
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sequences, detailed in Table 1. Sequences were, again, most similar to MAC 
members and related to M. avium rather than M. intracellulare (Table 1). Both 
strains had unique hsp65 sequences, the difference being a G =>A substitution 
at position 140 (corresponding to codon 538 of the M. tuberculosis H37Rv hsp65 
gene). The rpoB sequence related the isolates specifically to M. colombiense, in 
line with the 16S results (Table 1). We aligned the rpoB and hsp65 sequences 
with those of related Mycobacterium species, by the same methods as for the 
16S sequence.  In addition, we concatenated 16S, hsp65 and rpoB sequences 
and aligned these with concatenated sequences of the related Mycobacterium 
Figure 2: Phylogenetic tree based on ITS sequences showing the relationships of the 
new species (M. vulneris) type strain and other sequevars of MAC. 
Each organism is indicated by the sequevar name and GenBank accession number. Neighbour-
joining (NJ) tree was created, bootstrapped 1000x and visualized with MEGA 4.0.12 Bootstrap 
values are indicated at the nodes.
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species.16 Resulting topologies and trees are available as supplementary material 
in IJSEM Online (Supplementary Figures S1 ,S2 and S3).
We were able to demonstrate, by PCR, the presence of the IS1245 element in the 
genomes of the two isolates (results not shown). This supported its taxonomic 
position within the MAC, related to M. avium rather than M. intracellulare, 
although a minority of the M. intracellulare and other MAC strains are known 
to harbour this element.15
Phenotypical identification revealed a pattern generally similar to MAC 
strains, with negative tests for niacin accumulation, nitrate reduction, beta 
glucosidase, Tween 80 hydrolysis, 3-day arylsulfatase, urease and growth on 
MacConkey agar, but positive for 68° catalase. Our isolates are divergent in 
their positive semi-quantitave catalase test, susceptibility to hydroxylamine 
and oleic acid, as well as their scotochromogenicity. Positive semi-quantitative 
catalase tests are also noted for M. colombiense, which differs from our isolates 
in its negative urease test and colony morphology and pigmentation (Table 2).
Test item M. vulneris M. colombiense M. avium M. intracellulare M. chimaera
Niacin accumulation - - - - -
Nitrate reduction - - - - -
68°C catalase + +/- +/- +/- +
Catalase >45 mm + + - - -
Beta glucosidase - NP - - -
Tween 80 hydrolysis - - - - -
Tellurite reduction - NP + +/- +/-
3-day Arylsulfatase - +/- - - -
Urease - + - - -
Pigmentation SC NC NC NC NC
Colony morphology Smooth Rough Smooth Smooth Smooth
Growth rate Slow Slow Slow Slow Slow
Growth at 25°C + + + + +
Growth at 42°C - - +/- +/- -
Growth on MacConkey 
agar
- - - - -
Tolerance to:*
TCH 5μg/ml + NP + + +
Thiacetazone 10μg/ml + NP + + +
Isoniazid 1μg/ml + NP + + +
p-Nitrobenzoic acid 
500μg/ml
+ NP + + +/-
Hydroxylamine 500μg/ml - NP +/- +/- +/-
Oleic acid 250μg/ml - NP + + +/-
+, positive; -, negative; +/-, variable; NP, not published; SC, scotochromogenic; NC, 
nonchromogenic; TCH, thiopen-2-carboxylic hydrazide. * all in Middlebrook 7H10 agar
Table 2: Biochemical identification results for M. vulneris sp. nov. and closely related species
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The HPLC pattern of the isolate comprises 3 clusters of peaks; the first cluster 
is the main one and includes four major peaks. The second and third emerge 
later and close to each other, presenting four and three peaks, respectively 
(Figure 3). This pattern is consistent among most strains included in the MAC, 
although the M. colombiense pattern is characterized by increasing peak heights 
within the first cluster and the second cluster is absent in M. chimaera.3,4 The 
relative heights of the peaks in the second and third cluster vary within the 
MAC. Mycobacterium avium mostly presents lower peaks in the third cluster, 
as in our isolates. Mycobacterium colombiense usually present lower peaks in 
the second cluster (Figure 3). 
Applying the 25-well agar dilution method for drug susceptibility testing,14 we 
recorded resistance to isoniazid (MIC >20 μg/ml), ethambutol (MIC 20 μg/ml), 
streptomycin (MIC >20 μg/ml), amikacin (MIC 20 μg/ml) and ciprofloxacin 
(MIC >16 μg/ml), with susceptibility to rifampicin (MIC 1 μg/ml), rifabutin 
(MIC 1 μg/ml), clarithromycin (MIC 4 μg/ml), clofazimine (MIC =<0.5 μg/
ml), cycloserin (MIC 20 μg/ml) and prothionamide (MIC 2 μg/ml).
Previous authors have suggested the presence of multiple species within MAC, 
based on various phenotypic and genetic traits.2,17,18 Based on the phenotypic 
and genotypic features reported above, we believe that our isolates represent 
one such species. The extrapulmonary infections in immunocompetent 
patients suggest a high level of virulence.
Figure 3:
Mycolic acid patterns of 
M. vulneris sp. nov., M. 
avium and M. colombiense 
obtained by HPLC analysis. 
The M. vulneris sp. nov. 
pattern is similar to that of 
other M. avium complex 
members, but does not 
share the increasing peak 
heights within the first 
cluster, typical for M. 
colombiense.
LMMIS, low molecular mass 
internal standard; HMMIS, 
high molecular mass internal 
standard
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Description of Mycobacterium vulneris sp. nov.
Mycobacterium vulneris (vu’lne.ris; L. gen. N., pertaining to the wound 
[vulnus] from which the type strain was recovered). The bacillus stains acid-
alcohol fast. Cells are short rods, with occasional coccoid forms. No cording, 
spores or filaments are present. On Middlebrook 7H10, Ogawa and Stonebrink 
media, mature growth develops after 28 days of incubation at 36°C; growth 
is slower at 25 and 30°C and no growth occurs at 42°C. Colonies are small, 
scotochromogenic and bright yellow in appearance.
Isolates are negative for niacin accumulation, nitrate reduction, beta 
glucosidase, Tween 80 hydrolysis, tellurite reduction, 3-day arylsulfatase, 
urease and growth on MacConkey agar, but positive for 68° catalase and semi-
quantitative catalase. Isolates are tolerant to isoniazid, TCH, p-nitrobenzoic 
acid and thiacetazone, but not to oleic acid and hydroxylamine.
Mycobacterium vulneris is readily identifiable by its unique HPLC pattern 
and 16S rDNA, hsp65 and rpoB gene sequences. The 16S-23S ITS region was 
previously described as the MAC-Q ITS sequevar.
The type strain, recovered from a wound debridement specimen, is 
NLA000700772T (=DSM 45247T; =CIP 109859T). 
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Supplementary Figure S1: Phylogenetic relationship of the new species (M. vulneris) 
type strain and related species of Mycobacterium, based on rpoB gene sequences. 
Neighbour-joining (NJ) tree was created, bootstrapped 1000x and visualized with MEGA 4.0.12 
Bootstrap values are indicated at the nodes.
Supplementary Figure S2: Phylogenetic relationship of the new species (M. vulneris) 
strains and related species of Mycobacterium, based on hsp65 gene sequences. 
Neighbour-joining (NJ) tree was created, bootstrapped 1000x and visualized with MEGA 4.0.12 
Bootstrap values are indicated at the nodes.
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Supplementary Figure S3: Phylogenetic relationship of the new species (M. vulneris) 
strains and related species of Mycobacterium, based on concatenated 16S, hsp65 and 
rpoB gene sequences. 
Neighbour-joining (NJ) tree was created, bootstrapped 1000x and visualized with MEGA 4.0.12 
Bootstrap values are indicated at the nodes.
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Mycobacterium mantenii sp. nov.; 
A novel pathogenic slowly growing 
scotochromogenic Mycobacterium 
species
Jakko van Ingen1,2, Jerome A. Lindeboom3,4, Nico G. Hartwig5, Rina de Zwaan2, 
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Soolingen2
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Paediatrics, Erasmus MC-Sophia, Rotterdam, The Netherlands. 6 Regional Reference Center for 
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Summary
Slow growing, scotochromogenic bacteria of a novel Mycobacterium species were 
isolated from lymph node samples in two children, pulmonary samples in two 
elderly patients from different regions in the Netherlands, as well as from a surface 
water sample in Zambia. Its 16S rDNA gene, 16S-23S internal transcribed spacer, 
hsp65 and rpoB gene sequences are unique in comparison to other mycobacteria. 
Phylogenetic analysis based on the 16S rDNA gene sequence most closely relates 
these micro-organisms to Mycobacterium scrofulaceum (8 bp difference; 0.6%). The 
hsp65 sequence shows 96% similarity to that of Mycobacterium saskatchewanense, 
the rpoB sequence shows 95% similarity to that of Mycobacterium chimaera. The 
16S-23S internal transcribed spacer (ITS) sequence places these micro-organisms 
within the Mycobacterium avium complex, as a novel ITS sequevar. This is not 
supported by the 16S, hsp65 and rpoB gene sequences. Their scotochromogenicity, 
combined with mostly positive urease, positive semi-quantitative catalase and 
negative tellurite reduction tests set these isolates apart from related species. The 
mycolic acid patterns, obtained by high-performance liquid chromatography, 
are similar to that of Mycobacterium scrofulaceum, though the peak heights and 
distribution present minor differences. We propose the name ‘Mycobacterium 
mantenii’. The type strain, NLA000401474T (=CIP 109863T; =DSM 45255T), was 
isolated from a lymph node biopsy sample.
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Nontuberculous mycobacteria (NTM) are common in the environment and 
can be opportunistic pathogens. The NTM are capable of causing a wide 
spectrum of clinical disease. Pulmonary NTM disease, mostly in patients 
with pre-existent chronic pulmonary diseases, is most common, followed by 
lymphadenitis in immunocompetent children and disseminated disease in 
immunocompromised patients.1 Mycobacterium scrofulaceum, first described 
by Prissick and Masson in 1956,2 is mainly a causative agent of paediatric 
cervicofacial lymphadenitis. The isolation frequency of M. scrofulaceum has 
decreased in the past decades, presumably due to competition with M. avium 
after chlorination of tap water became more commonplace.1 On the other hand, 
several scotochromogenic slow growing mycobacteria isolated from children 
with cervicofacial lymphadenitis have been elevated to separate species status. 
These may have previously been falsely identified as M. scrofulaceum.3 The 
International Working Group on Mycobacterial Taxonomy also found several 
isolates related to, but different from, M. scrofulaceum.4
We report on a group of five isolates with unique 16S rDNA, 16S-23S ITS, hsp65 
and rpoB gene sequences that represent a novel Mycobacterium species, related 
to M. scrofulaceum. The isolates were cultured from four patients, including 
two cases of paediatric cervicofacial lymphadenitis, in the Netherlands and 
from the Zambezi River, Zambia.
Case reports
In 2004, a previously healthy 2 ½-year-old girl presented with an 8 week history 
of right submandibular erythematous swelling, 3 cm in diameter with obvious 
fluctuation and a red skin. She was otherwise asymptomatic. A fine needle 
aspiration from the swelling was performed. The acid-fast stain of the material 
obtained was positive. A M. avium complex (MAC) strain was detected by 
real-time PCR, using the 16S-23S ITS as a target, and a scotochromogenic 
Mycobacterium grew in culture (isolate 04-1474). Antibiotic therapy with 
clarithromycin 15 mg/kg and rifabutin 5 mg/kg was started for a 12 week 
period. An open wound with persistent drainage developed and healed during 
therapy. After two years only a small scar remained. 
The second patient was a previously healthy 18-month old girl who presented 
at another hospital in the Netherlands in 2007 with a fluctuating, painless left-
sided submandibular swelling, 4 cm in diameter, with violaceous overlying 
skin. She had no other symptoms. A lymph node biopsy with drainage was 
performed and a scotochromogenic Mycobacterium was cultured from the 
biopsy material (isolate 07-937). Involution of the lymph node was noted 
during follow-up; no further therapy was necessary and after one year only a 
small scar remained. 
The third patient was a 92-year-old Dutch woman, who was evaluated by a 
respiratory physician in a regional hospital in the North of the Netherlands 
in 2008. Her medical history included bronchiectasis. She presented with a 
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productive cough and slight dyspnea. A scotochromogenic Mycobacterium was 
isolated from one of three sputum samples (isolate 08-224). Her symptoms and 
radiographic features were not suggestive of mycobacterial disease and follow-
up cultures remained negative, so this isolate was not considered clinically 
relevant, based on the American Thoracic Society diagnostic criteria.1
The fourth patient was a 68-year-old Dutch male, who reported with 
chronic cough and purulent sputum in 2008. His medical history included 
an α-1-antitrypsin deficiency and resulting pulmonary emphysema. A 
scotochromogenic Mycobacterium was isolated from a broncho-alveolar lavage 
(isolate 08-1102). In absence of radiographic features suggestive of pulmonary 
mycobacterial disease or positive follow-up cultures, this isolate was also not 
considered clinically relevant.
The fifth isolate was cultured from a water sample we took for other research 
purposes from the Zambezi river, Zambia, 150m upstream from the Victoria 
Falls in the year 2007.
All five isolates were subcultured on Middlebrook 7H10 and the egg-based 
Ogawa and Stonebrink solid media, as well in the Mycobacterial Growth 
Indicator Tube (MGIT) system. All media were incubated at 36°C; Middlebrook 
7H10 slants were also incubated at 25°C, 30°C and 45°C.
The INNO-LiPA MYCOBACTERIA v2 reverse hybridization test was used 
for primary identification, according to the manufacturer’s prescriptions. 
To obtain identification to the species level, we sequenced the full 16S gene, 
16S-23S internal transcribed spacer (ITS) and, partially, the hsp65 and rpoB 
genes, using previously published approaches.5-8
We compared the obtained sequences with the GenBank/EMBL sequence 
database. The full 16S rDNA gene sequences of the five isolates were aligned 
with those of reference strains of the closest related mycobacteria using Clustal 
X software.9 The resulting topology and tree, inferred by neighbour-joining 
and visualized using the MEGA 4.0 software package10 were evaluated by 
bootstrap analyses based on 1000 re-samplings (Figure 1). The tree was rooted 
with M. tuberculosis H37RvT as an out-group.
For biochemical and phenotypical identification we investigated colony 
morphology, ability to grow at temperatures ranging from 25 to 45°C, niacin 
accumulation, nitrate reduction, β-glucosidase, Tween 80 hydrolysis, 3-day 
arylsulfatase, urease, tellurite reduction, 68°C and semiquantitative catalase, 
growth rate, pigmentation, growth on MacConkey agar and tolerance to thiophen-
2-carboxylic hydrazide (TCH) 5 μg/ml, oleate 250 μg/ml, p-nitrobenzoic acid 500 
μg/ml, thiacetazone 10 μg/ml, hydroxylamine 500 μg/ml, and isoniazid 1 μg/ml, all 
in Middlebrook 7H10 agar, following previously published guidelines.11 HPLC was 
used to investigate the cell wall mycolic acid composition according to previously 
reported methods.12 We used the HPLC mycobacterium library (available online 
at http://www.MycobacToscana.it) for visual comparisons.
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Susceptibility testing was performed using the Middlebrook 7H10 agar dilution 
method.13 We tested susceptibility to rifampicin, rifabutin, isoniazid, ethambutol, 
streptomycin, amikacin, clarithromycin, ciprofloxacin, moxifloxacin, 
cycloserine, prothionamide, clofazimine and linezolid.
All five samples yielded small colonies with bright yellow pigmentation after 
3 weeks of incubation on solid media at 36°C; growth was slower at 25°C and 
30°C and no growth occurred at 45°C. 
Figure 1: Phylogenetic relationship of the type strain and environmental isolate of 
M. mantenii sp. nov. and related species of the genus Mycobacterium, based on 16S 
rDNA gene sequences. Neighbour-joining tree was created, bootstrapped 1000x and 
visualized with MEGA 4.0.10 Bootstrap values are indicated at the nodes.
Figure 2: Phylogenetic relationship of the type strain and environmental isolate of M. 
mantenii sp. nov. and related species of the genus Mycobacterium, based on hsp65 gene 
sequences. Neighbour-joining tree was created, bootstrapped 1000x and visualized 
with MEGA 4.0.10 Bootstrap values are indicated at the nodes.
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For all five isolates, the INNO-LiPA MYCOBACTERIA v2 reverse hybridization 
test revealed a reaction with the “M. avium-intracellulare-scrofulaceum complex” 
probe only. The full 16S rDNA gene (1437bp) revealed an 8bp difference (99.4% 
similarity) with M. scrofulaceum ATCC 19981 in all four clinical isolates (Table 1); 
the Zambezi river isolate had a single base pair difference with the four clinical 
isolates and differed 9 bp from M. scrofulaceum. All five isolates shared the 3 
bp deletion in the hypervariable region B of the 16S rDNA gene, typical for M. 
scrofulaceum and absent in MAC species.
We recorded identical ITS, hsp65 and rpoB gene sequences in all four clinical 
isolates; the GenBank comparison results are detailed in Table 1. The Zambezi 
river isolate sequences differed from the clinical isolates, the differences being 
11 bp (4%) in the 16S-23S ITS, 3 bp (1%) in the hsp65 and 5 bp (2%) in the 
rpoB sequence.
Based on the 1437bp 16S gene sequence the five isolates were most closely 
related to M. scrofulaceum and M. seoulense (Table 1 & Figure 1), which 
also are scotochromogenic slow-growing mycobacteria.2,14 The hsp65 and, 
to a lesser extent, rpoB sequences relate our isolates to M. saskatchewanense, 
another scotochromogenic slow growing NTM.15 These, as well as the more 
distant relation to the MAC, were confirmed in the phylogenetic trees based 
on multi-sequence alignment of hsp65 gene (Figure 2) and rpoB gene (Figure 
3) sequences. In addition, we concatenated 16S, hsp65 and rpoB sequences 
and aligned these with concatenated sequences of the related Mycobacterium 
species.16 Resulting topology and tree are available as supplementary material 
in IJSEM Online (Supplementary Figure S1). 
Target GenBank comparison results
16S (1437bp)
GenBank: FJ042897
99% M. scrofulaceum ATCC 19981T (1429/1437bp)
98% M. seoulense 03-19T (1422/1439bp)
98% M. avium ATCC 25291T (1422/1441bp)
97% M. saskatchewanense ATCC BAA-544T (1407/1440bp)
16S-23S ITS
281bp
GenBank: FJ232522
96% “M. vulneris sp. nov.” (MAC-Q) AF315833 (271/281bp)
96% M. avium complex ATCC 35847 (MAC-E) L07852 (270/281bp)
95% M. sp. RiVM 9701605 (MAC-R) AF315834 (269/281bp)
95% M. avium complex 5154-O’Connor (MAC-F) L07853 (269/281bp)
hsp65
424bp
GenBank: FJ232523
96% M. saskatchewanense MB54784 (410/424bp)
96% M. triplex CIP 106108T (410/424bp)
96% M. avium ATCC 25291T (408/424bp)
95% M. genavense DSM 44424T (408/424)
rpoB
301bp
GenBank: FJ232524
95% M. chimaera CIP 107892T (288/301bp)
95% M. intracellulare CIP 104243T (288/301bp)
95% M. saskatchewanense ATCC BAA-544T  (282/295 bp)
94% M. seoulense 03-19T (285/301 bp)
Table 1: Molecular identification results for Mycobacterium mantenii NLA000401474T
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The ITS sequence is most closely related to the MAC (Table 1, Tree available 
as Supplementary Figure S2 in IJSEM Online). This matches the Inno-LiPA 
results, which uses ITS as its target. The different phylogenetic relationships 
arising from the different genetic targets, as well as the extent of the differences 
add to our view that these isolates make up a separate species.
The five studied isolates tested negative for niacin accumulation, nitrate 
reduction, β-glucosidase, Tween 80 hydrolysis, tellurite reductase, 3-day 
arylsulfatase and growth on MacConkey agar, but positive for urease (3/5), 
68° catalase and semi-quantitative catalase. The isolates were tolerant to 
Test item 04-
1474T
07-
937
07-
1794
08-
224 
08-
1102
MSC MSE MSK MAV
Nitrate reduction - - - - - - + - -
68°C catalase + + + + + + + + ±
Catalase >45 mm + + + + + + NP ± -
Tellurite reduction - - - - - + ± ± +
Urease + - + - + + - - -
Pigmentation SC SC SC SC SC SC SC SC NC
Growth at 45°C - - - - - - - - ±
Tolerance to 
hydroxylamine 500μg/ml*
- - - - - NP NP NP ±
±, variable ; NP, not published; SC, scotochromogenic; NC, nonchromogenic; MSC, M. scrofulaceum; 
MSE, M. seoulense; MSK, M. saskatchewanense; MAV, M. avium;  Comparative data extracted from 
references 14 (M. seoulense),15 (M. saskatchewanense) and 17 (M. scrofulaceum & M. avium). *in 
Middlebrook 7H10 agar
Table 2: Biochemical features differentiating the five isolates from related species
04-1474 07-937 07-1794 08-1102
Isoniazid >2 >2 >2 >2
Rifampicin 1 1 1 1
Ethambutol 10 20 10 5-10 (I)
Streptomycin 20 20 10 5
Rifabutin =<0.2 =<0.2 =<0.2 =<0.2
Amikacin 20 >20 10 10
Ciprofloxacin 16 >16 16 16
Clarithromycin =<2 8 4 4
Cycloserine 20 50 10 10
Clofazimine =<0.5 5 =<0.5 =<0.5
Prothionamide 5 5 5 >20
Moxifloxacin >2 >2 >2 >2
Linezolid >2 >2 >2 >2
Table 3: Minimum inhibitory concentrations (μg/mL) in the agar dilution method
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Figure 3: Phylogenetic relationship of the type strain and environmental isolate of M. 
mantenii sp. nov. and related species of the genus Mycobacterium, based on rpoB gene 
sequences. Neighbour-joining tree was created, bootstrapped 1000x and visualized 
with MEGA 4.0.10 Bootstrap values are indicated at the nodes.
isoniazid, thiacetazone, para-nitrobenzoic acid, TCH and oleic acid, but not 
to hydroxylamine. The negative tellurite reduction tests and mixed urease 
results set the isolates apart from M. scrofulaceum, M. saskatchewanense and 
M. seoulense; our isolates also differ from the latter in their negative nitrate 
reduction tests. Their scotochromogenicity, combined with uniformly positive 
semi-quantitative and 68°C catalase tests, mostly positive urease and negative 
tellurite reduction tests and susceptibility to hydroxylamine set them apart 
from the MAC (Table 2).17 
The HPLC profiles of NLA000401474 and the other clinical isolates are 
identical and overlap that typical of MAC, M. scrofulaceum and M. seoulense, 
i.e. three clusters of peaks, one early, large cluster and two late smaller clusters 
(Figure 4), though the peak heights and distribution present minor differences. 
This profile differs from the single, late emerging cluster of peaks characteristic 
for M. saskatchewanense.15 The profile of the Zambezi river isolate is slightly 
divergent, with different peak heights in the first and higher peaks in the 
second cluster (Figure 4). A divergent HPLC profile in environmental isolates 
compared to clinical isolates has also been noted for M. bohemicum.18 
The clinical isolates were only susceptible, in vitro, to rifampicin, rifabutin, 
clarithromycin, cycloserine, clofazimine and prothionamide; MICs are 
recorded in Table 3. The drug susceptibility pattern is similar to M. scrofulaceum 
and the MAC members, except for the remarkable in vitro susceptibility to the 
rifamycins, i.e. rifampicin and rifabutin (Table 3).
Although there is a 1bp difference in the 16S gene sequence, we consider 
the Zambezi river isolate and our four clinical isolates to belong to a single 
species, based on the minor genetic differences and overlapping biochemical 
and phenotypical features. Microheterogeneity in the 16S rDNA gene has been 
previously described in NTM.19 The slight genetic differences may reflect the 
evolutionary divergence among nontuberculous mycobacteria.
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The five described isolates make up a new species, phylogenetically and 
phenotypically related to M. scrofulaceum, M. seoulense, M. saskatchewanense 
and, albeit more distantly, the MAC. Biochemical features, however, offer little 
distinction in the MAC and HPLC patterns in the MAC and M. scrofulaceum 
are known to overlap.4 The 16S-23S ITS sequence places the five isolates inside 
the MAC, although bootstrap levels are low (Supplementary Figure S2). This 
does result in misidentification as a MAC species by the Inno-Lipa assay, not 
unlike the identification of M. saskatchewanense as MAC by the Accuprobe 
assay.15 ITS sequences have been useful for taxonomic assignment within the 
MAC.20-23 Our isolates comprise two distinct MAC ITS sequevars, although 
for a species not likely to be part of the MAC, naming them as such would be 
misleading. The spectrum of human disease of the new species, represented by 
the five described isolates, appears similar to that of M. scrofulaceum.1,2
Based on all available genetic, phenotypical and clinical data we conclude 
that the five isolates make up a new NTM species most closely related to M 
scrofulaceum and related to, but not part of, the MAC. 
Description of Mycobacterium mantenii sp. nov.
Mycobacterium mantenii (man.ten’ii; N.L. gen. masc. n. mantenii, of Manten, in 
honour of Dr. A. Manten, microbiologist, who published the first cases of NTM 
disease in the Netherlands in 1957, as well as landmark reviews on the clinical 
relevance of NTM in the Netherlands). The bacillus stains acid-alcohol fast. Cells 
are short rods, with frequent coccoid forms. No cording, spores or filaments are 
Figure 4:
Mycolic acid patterns of M. 
manteniiT and M. mantenii 08-
224 (Zambezi), M. scrofulaceum 
and M. avium obtained by 
HPLC analysis.
One early and one late cluster 
of peaks are present in all three, 
although the peak heights and 
distribution are different. The 
Zambezi isolate is divergent, with 
a different peak distribution in 
the first cluster and a pronounced 
second cluster. HMMIS: high 
molecular mass internal standard 
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present. On Middlebrook 7H10, Ogawa and Stonebrink media, mature growth 
develops after 28 days of incubation at 25 to 36°C; no growth occurs at 45°C. 
Colonies are small, smooth, scotochromogenic and yellow in appearance. 
It is negative for niacin accumulation, nitrate reduction, beta glucosidase, 
Tween 80 hydrolysis, tellurite reduction, 3-day arylsulfatase and growth on 
MacConkey agar, but positive for urease, 68°C catalase and semi-quantitative 
catalase. It is tolerant to isoniazid, thiacetazone, para-nitrobenzoic acid, TCH 
and oleic acid, but not to hydroxylamine.
Mycobacterium mantenii is readily identifiable by its unique 16S rDNA, 16S-23S 
ITS, hsp65 and rpoB gene sequences. The type strain, recovered from a lymph 
node biopsy specimen, is NLA000401474T (=CIP 109863T; = DSM 45255T). 
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Supplementary Figure S1: Phylogenetic relationship of the type strain and 
environmental isolate of M. mantenii sp. nov. and related species of the genus 
Mycobacterium, based on concatenated 16S, hsp65 and rpoB gene sequences. 
Neighbour-joining tree was created, bootstrapped 1000x and visualized with MEGA 
4.0.10 Bootstrap values are indicated at the nodes.
Supplementary Figure S2: Phylogenetic relationship of the type strain and 
environmental isolate of M. mantenii sp. nov. and related species of the genus 
Mycobacterium, based on 16S-23S ITS sequences. Neighbour-joining tree was created, 
bootstrapped 1000x and visualized with MEGA 4.0.10 Bootstrap values are indicated 
at the nodes.
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Abstract
The isolation frequency of nontuberculous mycobacteria (NTM) increases in 
many countries. The clinical relevance of NTM isolation is often unclear. For 
some species, subtypes with increased clinical relevance have been identified. 
To assess the intraspecies genetic divergence within several NTM species, 
we subjected two sets of strains to 16S rDNA, 16S-23S internal transcribed 
spacer, hsp65, sodA, secA1 and rpoB gene sequencing. The first set consisted 
of clinical isolates of the M. chelonae complex (n=4), M. avium complex 
(n=4), M. malmoense (n=3), M. kansasii (n=3), M. gordonae (n=3) and M. 
tuberculosis H37Rv; the second part focused on M. malmoense (n=13) and M. 
xenopi (n=16) isolates with available clinical data. In the first set, concatenated 
sequence analysis revealed all unique sequences. In experiment two, we noted 
ten distinct types for M. xenopi and eight for M. malmoense. No subtype based 
on any of the six genetic targets was significantly associated with clinical 
disease or a specific source of isolation. In this study, we demonstrate that a 
substantial and not previously recognized intraspecies genetic divergence 
exists among NTM. The variance within the targeted genes has a mosaic rather 
than a stochastic pattern and its extent differs by species. The low number of M. 
xenopi and M. malmoense isolates in the current study hampered association 
of particular subtypes with increased clinical relevance. If this divergence can 
be extrapolated to genes associated with virulence, such associations are likely 
to exist.
226
Chapter 6.1
Introduction
Nontuberculous mycobacteria (NTM) are mostly opportunistic, environmental 
pathogens5; their isolation frequency has increased in many countries where 
the incidence of tuberculosis is in decline.6 The NTM are causative agents of 
pulmonary infections, mainly in patients with pre-existent pulmonary disease. 
Extrapulmonary NTM disease is rare and generally affects patients with 
impaired immunity.6
As the NTM are ubiquitous in the environment, a positive culture from a non-
sterile body site, including the respiratory tract, may reflect occasional presence 
of or contamination by NTM rather than infection. To assist clinicians in the 
assessment of clinical relevance of NTM isolates from the respiratory tract, the 
American Thoracic Society (ATS) has established diagnostic criteria, which fit 
best with Mycobacterium avium complex, M. kansasii and M. abscessus.6
Several host factors are known to increase the susceptibility to NTM disease, 
including pre-existent pulmonary diseases and interferon-γ pathway 
deficiencies.6 Bacterial virulence factors are mostly unknown. For M. 
kansasii and M. xenopi, subtypes with increased clinical relevance have been 
identified.15,19 Still, the true extent of genetic divergence within NTM species 
and its association with clinical relevance has not been studied.
In the current study, we first explored genetic divergence within NTM species 
by applying multi-gene sequencing to clinical isolates of five NTM species. In 
a second experiment, we focused on M. xenopi and M. malmoense. For these 
two species, we have linked subgroups with clinical data, to explore differences 
in clinical relevance.
 
Methods
In the first experiment we subjected randomly selected clinical isolates of the 
M. chelonae complex (n=4), M. avium complex (n=4), M. malmoense (n=3), 
M. kansasii (n=3), M. gordonae (n=3), previously identified by 16S gene 
sequencing (151bp hypervariable region A)11, as well as M. tuberculosis H37Rv 
to extensive multi-gene sequence analysis. We sequenced the forward and 
reverse strands of the 16S-23S internal transcribed spacer (ITS; 234-285bp) 
and the hsp65 (424 bp), sodA (427 bp), secA1 (660 bp) and rpoB gene (301 bp), 
using previously published primers.1,10,12,18,21
In the second experiment we subjected a larger number of clinical isolates of 
M. malmoense (n=13) and M. xenopi (n=16) to the same sequencing strategy; 
we selected isolates from pulmonary and extrapulmonary sources and different 
clinical relevance. Clinical data for the M. xenopi and M. malmoense isolates 
have been reviewed in two previous studies8,20, in which the ATS diagnostic 
criteria for pulmonary NTM disease were applied.6 Most extrapulmonary 
isolates were from cases of true NTM disease, with supportive clinical and 
histological features, whereas one M. xenopi isolate was from a faeces sample 
and not associated with true disease.
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Obtained sequences were compared to the GenBank/EMBL sequence database 
(National Center for Biotechnology Information, http://www.ncbi.nlm.nih.
gov); where applicable, GenBank accession numbers are provided in brackets. 
Sequences unmatched in the GenBank/EMBL database were assigned a 
sequevar number, with the lowest number for the sequence most closely 
related to the type strain sequence.
We performed multi-sequence alignment using Clustal X software.19 The 
resulting topology and tree, inferred by neighbour-joining and visualized 
using the MEGA 4.0 software package17 were evaluated by bootstrap analyses 
based on 1000 re-samplings. For phylogenetic analyses, we constructed trees 
based on concatenated sequences of all targets.14
Results
Experiment 1: For the 18 isolates in experiment 1, 16S gene sequencing 
revealed intraspecies divergence only for M. gordonae; the DNA sequence of 
isolate 1010301991 was identical to that of the M. gordonae CIP 104529 type 
strain; the others were identical to clinical isolates from Italy (EU022513). 
Intraspecies divergence among M. chelonae complex isolates was not discerned 
(Figure 1). Results for all targets are recorded in Table 1.
MML, Mycobacterium malmoense; MAV, M. avium; MKA, M. kansasii; Mgo, M. gordonae; 
MCC, M. chelonae complex; MCH, M. chelonae; MAB; M. abscessus; MBO, M. bolletii; MMS, 
M. massiliense; MTB, M. tuberculosis complex; *sequence that does not match exactly with a 
GenBank entry
Strain 16S ITS hsp65 sodA secA1 rpoB identification
1010300199 MML MML *ML2 *MML2 *MML2 *ML2 MML
1010301186 MML MML MML *MML1 *MML1 MML MML
1010301752 MML MML MML *MML3 *MML1 MML MML
1010300601 MAV Mav-A Mav-A *MAV2 *MAV3 MAV MAV
1010300986 MAV Mav-A Mav-A *MAV3 *MAV2 MAV MAV
1010300987 MAV Mav-B Mav-A MAV MAV MAV Mav-B
1010400161 MAV Mav-B Mav-A MAV MAV MAV Mav-B
1010302078 MKA Mka-I Mka-I Mka-I *MKA2 Mka-I MKA
1010302119 MKA Mka-I Mka-I Mka-I Mka-I Mka-I Mka-I
1010302197 MKA Mka-II Mka-II Mka-II *MKA3 *MKA2 MKA
1010301806 Mgo-II Mgo-C Mgo-II *MGO2 *MGO3 - MGO
1010301991 Mgo-I *MGO2 Mgo-I *MGO1 *MGO1 MGO MGO
1010302187 Mgo-II *MGO3 *MGO3 *MGO3 *MGO2 *MGO2 MGO
1010300639 MCC MCH MCH MCH *MCH MCH MCH
1010300866 MCC *MAB2 MMS MMS *MMS MMS MMS
1010301670 MCC Mab-A MBO *MBO MBO MBO MBO
1010302073 MCC Mab-A MAB MAB MAB MAB MAB
H37Rv MTB MTB MTB MTB MTB MTB MTB
Table 1: Sequencing results for experiment 1
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M. kansasii
All secondary targets except secA1 distinguished the M. kansasii isolates in 
two groups. Both 1010302078 and 1010302119 belonged to M. kansasii type I; 
1010302197 belonged to M. kansasii type II. Of the M. kansasii type I isolates, 
1010302119 had a secA1 sequence identical to the M. kansasii ATCC 12478 
type strain sequence; 1010302078 and 1010302197 differed only by 1bp and 
were both 2bp different from the M. gastri ATCC 15754 sequence, but 22bp 
(3%) from the M. kansasii ATCC 12478 type strain sequence.
M. avium
All four M. avium isolates had identical 16S, hsp65 and rpoB sequences. Based 
on the ITS sequence, two previously published sequevars were discerned: 
1010300601 and 1010300986 had a Mav-A sequevar, 1010400161 and 
1010300987 had a Mav-B sequevar. Both Mav-B isolates had identical sodA 
(identical to that of ATCC 25291, EU409983) and secA1 sequences. Both 
Mav-A isolates had unique sodA and secA1 sequences; for 1010300601, the 
sodA sequence differed 1bp and the secA1 sequence differed 10bp (2%) from 
the ATCC 25291 type strain sequence, for 1010300986 these differences were 
3bp (sodA) and 5bp (secA1). 
Figure 1: Experiment 1: Phylogeny based on 16S hypervariable region A sequences. 
Micro-heterogeneity is noted for M. gordonae; exact species identification within M. 
chelonae complex isolates is not possible.
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M. malmoense
The three M. malmoense isolates had identical ITS sequences. Based on hsp65, 
secA1 and rpoB sequencing, 1010300199 was distinct from the other two 
isolates; the secA1 sequences differed 2bp (1010300199) and 4bp (1010301186 
and 1010301752) from the ATCC 25971 type strain sequence (AY724718). 
All three isolates had distinct sodA sequences; 1010301186 differed 2bp and 
1010300199 and 1010301752 differed 6bp from the CIP 105775T type strain 
sequence.
M. gordonae
All three M. gordonae isolates had unique sequences for all the targets. Of the 
ITS sequences, one was unmatched in the GenBank database: the 1010301991 
sequence differed 3bp from the Mgo-A sequevar (L42258); 1010301806 was 
identical to the Mgo-C sequevar (L42260) 1010302187 matched a clinical 
isolate from Italy (EU497913). For isolate 1010301991, the hsp65 and rpoB 
sequences were identical to the ATCC 14470 type strain sequences (AF057468); 
for 1010302187 the hsp65 sequence differed 15bp (4%) and the rpoB sequence 
was 8bp (3%) different; for 1010301806, the hsp65 sequence was identical to 
previously published isolates (EF546780) and the rpoB gene repeatedly failed 
to amplify.
For the sodA 1010301991 differed 3bp (1%), 1010301806 differed 16bp 
(4%) and 1010302187 differed 26bp (6%) from the CIP 104529T type strain 
sequence. The secA1 sequences of 1010301991 differed 11bp (2%), 1010302187 
differed 24bp (4%) and 1010301806 differed 29bp (5%) from the ATCC 14470 
type strain sequence.
M. chelonae complex
Three out of four M. chelonae complex members were identified to species 
level by ITS sequencing, one as M. chelonae (DQ986509), two as M. abscessus 
(Mab-A: AJ291580); 1010300866 had a sequence 2bp different from the 
Mab-A sequence and 2bp divergent from the M. massiliense CCUG 48898 type 
strain sequence (AY593978). This isolate was subsequently identified as M. 
massiliense by hsp65 sequencing. The hsp65 sequence of 1010301670 was 2bp 
different from M. bolletii CIP 108541T (EU266576). The rpoB, sodA and secA1 
gene sequences confirmed the identifications as M. bolletii, M. massiliense, 
M. abscessus and M. chelonae. All sequences were identical to type strain 
sequences, except for the 1010301670 sodA sequence which differed 1bp from 
the M. bolletii CIP 108541T sequence and the 1010300866 secA1 sequence 
which differed 1bp from the M. massiliense CCUG 48898 type strain sequence. 
The secA1 sequence for 1010300639 differed 13bp (2%) from the M. chelonae 
ATCC 35752 sequence.
230
Chapter 6.1
The concatenated 16S, ITS, hsp65, sodA, secA1 and rpoB sequences revealed 
mostly unique strains (Figure 2); only the two M. avium ITS sequevar Mav-B 
isolates had identical sequences for all targets. The highest level of intraspecies 
genetic divergence was noted for M. gordonae (Figure 2). 
Experiment 2
In the second experiment we focused on two infrequently isolated species 
M. xenopi and M. malmoense, both often associated with clinical relevance. 
The sequencing results, sample origin and statements on clinical relevance are 
depicted in Table 2.
M. xenopi
The M. xenopi type I 16S sequence was identical to that of the CIP 104035 type 
strain (AF547982); type II differed in 1bp and matched multiple clinical isolates 
(AY215377). All three previously published ITS sequevars were also found in 
this study.11 The hsp65 sequences were all identical to the CIP 104035 type 
strain sequence (AF547891), all secA1 sequences were identical, but differed 
1bp from the ATCC 19250 type strain sequence (AY724734). Of the two sodA 
sequevars noted, type I is identical to the M. xenopi ATCC 19250 type strain 
sequence (X81391); type II differs 1bp. For rpoB, too, we noted two sequevars. 
Figure 2: Experiment 1; concatenated 16S, ITS, hsp65, sodA, secA1 and rpoB sequences. 
The two Mav-B ITS sequevars have identical sequences for all targets; all others have 
unique sequences, most notably M. gordonae.
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The majority matched with the ATCC 19250 type strain sequence (AF057493); 
1010302059 and 1010201356 differed in 1bp. All groupings based on single 
target sequevars were independent of other targets. No subtype based on any 
target was significantly associated with true NTM disease or pulmonary and 
extrapulmonary sources of isolation.
Based on the analysis of six concatenated genetic targets, the 16 M. xenopi 
isolates were divided into 5 clusters (Figure 3). Strains in the two major clusters 
are not all identical, but the differences were too subtle (below 0.1%) to form 
separate groupings. Table 2 illustrates that ten types were distinguished.  
MXE, M. xenopi; MML, M. malmoense; P, pulmonary; EP, extrapulmonary
#as defined by the American Thoracic Society diagnostic criteria6
*sequence that does not match exactly with a GenBank entry
Strain type 16S ITS hsp65 sodA secA1 rpoB Source Disease#
1010100061 I Mxe-I Mxe-A MXE MXE *MXE MXE P Yes
1010100209 Mxe-I Mxe-A MXE MXE *MXE MXE EP Yes
1010101945 Mxe-I Mxe-A MXE MXE *MXE MXE P No
1010101975 Mxe-I Mxe-A MXE MXE *MXE MXE P No
1010302059 II Mxe-I Mxe-A MXE MXE *MXE *MXE2 P Yes
1010101526 III Mxe-I Mxe-B MXE MXE *MXE MXE P Yes
1010001068 IV Mxe-I Mxe-C MXE MXE *MXE MXE P Yes
1019901047 V Mxe-I Mxe-C MXE *MXE2 *MXE MXE P Yes
1019900896 VI Mxe-I+II Mxe-A MXE *MXE2 *MXE MXE EP No
1019900986 VII Mxe-II Mxe-A MXE *MXE2 *MXE MXE P Yes
1010201356 VIII Mxe-II Mxe-B MXE MXE *MXE *MXE2 P No
1019900581 IX Mxe-II Mxe-C MXE MXE *MXE MXE EP Yes
1019900792 Mxe-II Mxe-C MXE MXE *MXE MXE P No
1010200040 Mxe-II Mxe-C MXE MXE *MXE MXE EP Yes
1010200822 X Mxe-II Mxe-C MXE *MXE2 *MXE MXE P Yes
1010201570 Mxe-II Mxe-C MXE *MXE2 *MXE MXE EP Yes
1010201707 I MML MML MML *MML1 *MML1 MML P Yes
1010401587 MML MML MML *MML1 *MML1 MML P No
1010401612 MML MML MML *MML1 *MML1 MML P No
1019901018 II MML MML MML *MML1 *MML2 MML EP Yes
1010401708 MML MML MML *MML1 *MML2 MML P Yes
1010300497 III MML MML MML *MML2 *MML2 MML P Yes
1010401293 IV MML MML MML *MML3 *MML2 MML P Yes
1010400984 V MML MML MML *MML4 *MML2 MML P Yes
1019902232 VI MML MML *Mml2 *MML1 *MML2 MML EP Yes
1010002047 VII MML MML *Mml2 *MML1 *MML2 *MML2 EP Yes
1019901374 VIII MML MML *Mml2 *MML4 *MML2 MML EP Yes
1010400945 MML MML *Mml2 *MML4 *MML2 MML P Yes
1010500414 MML MML *Mml2 *MML4 *MML2 MML P Yes
Table 2: Sequencing results for the M. xenopi and M. malmoense isolates
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M. malmoense
The 16S and ITS sequences were identical for all isolates and matched the 
ATCC 29571 type strain sequences. Two subtypes were discernable based on 
hsp65 sequences: eight isolates matched the CIP105775 type strain sequence 
(AF547854), five had identical sequences which differed in 2bp from the 
CIP105775 type strain sequence. The sodA sequences divided the isolates in 
four groupings, unrelated to the hsp65 types. None of these sequences matched 
the CIP105775 type strain sequence; type I (*MML1) differed in 1bp, *MML2 
differed in 3bp, *MML3 differed in 6bp and *MML4 differed in 7bp (2%) from 
the CIP 105775 sequence. Two secA1 sequence types were noted, not matching 
groupings based on the previous targets. The first group (*MML1) differed 
in 2bp from the ATCC 25971 type strain sequence (AY724718), the second 
differed in 4bp. All but one of our M. malmoense isolates matched the ATCC 
29571 type strain rpoB gene sequence (AF057475); 1010002047 differed in 
1bp. Again, no subtype based on any target was significantly associated with 
true NTM disease or pulmonary and extrapulmonary sources of isolation.
Based on the analysis of six concatenated genetic targets, the 13 M. malmoense 
isolates were divided into eight types (Figure 4; Table 2). 
Discussion
In experiment 1 we revealed that genetic divergence exists in all NTM species 
tested in the current study. This extent of divergence has not been previously 
recorded. The variance within the targeted genes has a mosaic rather than a 
Figure 3: 
M. xenopi; concatenated 16S, 
ITS, hsp65, sodA, secA1 and 
rpoB sequences. The 16 M. 
xenopi isolates are divided 
into five clusters. Strains 
in the two major clusters 
are not identical, though 
differences are too subtle to 
form separate groupings.  
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stochastic pattern, i.e. groupings based on polymorphism in one gene were 
not reflected in groupings based on any of the other genes. Therefore, these 
sequence analyses presumably indicate a long term, whole genome evolution 
that can be used to subdivide strains within a species into separate groupings, 
representing different branches of the evolutionary tree.
For the two species studied in more detail, M. xenopi and M. malmoense, we 
noted an equal extent of genetic divergence. We could not link any subtype 
with pulmonary or extrapulmonary sources of isolation or, more importantly, 
with true NTM disease based on the American Thoracic Society diagnostic 
criteria.6 In the current study only semi-conserved house keeping genes were 
analyzed, because they are believed to be most informative regarding the 
phylogeny of bacteria. However, virulence and pathogenicity may be based 
on highly subtle genetic differences between strains in genes essential in 
host-pathogen interactions. Therefore, it is conceivable that whole genome 
sequencing of multiple NTM isolates will be required to disclose associations 
between subtypes and clinical importance. In turn, these differences between 
subtypes may be utilized in relatively simple mono-target identification 
methods. 
For Mycobacterium kansasii, subtyping based on ITS sequences is known to 
contribute to the daily practice of clinical laboratories as M. kansasii type I is a 
pulmonary pathogen, type II is a causative agents of HIV-associated infection, 
whereas the remaining types are typically avirulent environmental bacteria.16 
We have previously noted a similar association between M. xenopi 16S type II 
Figure 4:
M. malmoense; 
concatenated 16S, 
ITS, hsp65, sodA, 
secA1 and rpoB 
sequences. The 
13 M. malmoense 
isolates are 
divided into eight 
clusters.
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and clinical disease.20 The number of isolates tested per species in the current 
study may have been too low to permit sound statistical analysis. For M. 
malmoense, clinically non-significant isolates are very rare7,8, which hampered 
our strain selection. This issue is also complicated by the emergence of 
intermediate types; we noted a M. kansasii type I isolate with a secA1 sequence 
closely related to an M. kansasii II isolate, similar to the intermediate type 
described by Iwamoto and co-workers based on hsp65 sequences.9
Most targets used in our study resulted in adequate species discrimination; 
only 16S sequencing revealed the well known lack of differentiation within the 
M. chelonae complex. In the group of isolates identified as M. chelonae complex 
by routine 16S rDNA gene sequencing, rpoB and hsp65 sequencing revealed 
the existence of multiple subgroupings that were elevated to separate species 
status by previous researchers.2 The presence of M. bolletii and M. massiliense 
has not been previously recorded in the Netherlands. 
An important limitation of sodA and secA1 sequencing is the paucity of 
sequence data available for comparison in GenBank. For secA1 little data 
has been added since the publication of the type strain sequences by Zelazny 
and co-workers.21 Aside from limited available data, the sodA sequences of 
M. abscessus CIP 104536T and M. gadium CIP 105388T stored in GenBank 
are identical. Based on their level of species recognition and availability of 
comparative data, 16S, ITS, hsp65 and rpoB may be the most suitable targets 
for NTM identification, the latter being especially relevant for distinction of 
rapid growers.2
The divergence from published type strain sequences may reflect a 
geographically determined genetic divergence within NTM species and this 
may be important in the production of rapid hybridization assays for NTM 
identification. Such assays should ideally be based on sequences obtained from 
NTM isolated in the area where the assays will be used.
It is interesting that for M. xenopi, the divergence was essentially limited to the 
rrn operon (of which we examined 16S and ITS), whereas for M. malmoense 
the reverse was true. The background of these differences should be subject of 
future studies. 
We also noted high (3-6%) levels of divergence among M. gordonae isolates 
in all targets and may result from long term evolutionary divergence; in the 
rrn operon this heterogeneity had been previously noted.11 Among the rapid 
growers, new species have now been described based on >3% divergence from 
established species in the rpoB sequence.2 An extrapolation of this cut-off value 
is likely to lead to the distinction of multiple species in the group now named 
M. gordonae. As M. gordonae is generally not of any clinical importance and, 
hence, the introduction of additional species designations may not be clinically 
meaningful, it may be more appropriate to introduce the term ‘M. gordonae 
complex’ for these bacteria.
The mosaic rather than a stochastic pattern of intraspecies genetic divergence 
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may reflect the enormous genetic divergence among these environmental 
bacteria, only some of which are studied after recovering them from humans. 
On the other hand, the level of intraspecies divergence in the targets used in this 
study seems too low to be the result of lateral transfer of genetic information 
between NTM or between NTM and other taxa. There are indications of a role 
for lateral gene transfer in the evolution of M. tuberculosis and M. marinum, 
stemming from their whole genome sequences.15 Despite our attempts, only 
whole genome sequencing will reveal the true extent of intra-(and in fact inter-)
species genetic divergence among NTM. Currently, however, the vast majority 
of mycobacteria subjected to whole genome sequencing are M. tuberculosis 
complex members.3
There is an additional clinical utility for this intraspecies genetic divergence. A 
recent study revealed intraspecies divergence in a group of M. mucogenicum 
and M. phocaicum isolates which proved useful in an outbreak investigation.4
In summary, a previously unrecognized and substantial intraspecies genetic 
divergence exists among NTM. The variance within the targeted genes has a 
mosaic rather than a stochastic pattern and its extent differs by species. Taking 
our findings and previous studies together, it seems unavoidable to move into 
the direction of more extended DNA sequencing of NTM isolates. The extent 
of such analyses depends on the extent of genetic diversity, which will differ by 
species, as well as the clinical importance of a NTM species. To improve our 
understanding of the importance of genetic divergence, a structural collection 
of clinical information is essential. An international, integrative database 
combining DNA sequence data of NTM isolates and clinical aspects may be 
most beneficial in this respect. Such a database may also be helpful in refining 
the phylogenetic tree of NTM. It is conceivable that clinical importance will 
differ by (intraspecies) branch and once such a tree has been established, a 
reliable recognition of such branches by renewed, simple identification 
methods comes into sight.
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The Region of Difference 1 in 
nontuberculous Mycobacterium 
species adds a phylogenetic and 
taxonomical character
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Dick van Soolingen1
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Summary 
The esat-6 and cfp-10 genes are essential for virulence in Mycobacterium 
tuberculosis. Among nontuberculous mycobacteria we found these genes 
only in M. kansasii, M. szulgai, M. marinum and M. riyadhense, with unique 
sequences. This adds a phylogenetic and taxonomical character and may 
represent a virulence factor for nontuberculous mycobacteria.
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The 6 kDa early secretory antigenic target (ESAT-6) and 10 kDa culture filtrate 
protein (CFP-10) of Mycobacterium tuberculosis are potent T-cell antigens.1,2 
The genes encoding ESAT-6 and CFP-10 are situated within the “region of 
difference 1” (RD1) of Mycobacterium tuberculosis, but are also present in some 
nontuberculous mycobacteria (NTM).1,2 Deletion of the RD1 in M. tuberculosis 
significantly decreases its virulence in animal models,3 suggesting that genes 
residing in the RD1 are involved in the pathogenesis. In M. tuberculosis the 
RD1 proteins effect translocation to the cytosol, a mechanism for survival 
within macrophages.4 Therefore, the RD1 in NTM may also play a crucial role 
in virulence.
To improve our understanding of the pathogenesis of NTM disease and the 
possible role of the RD1 in virulence, we screened a wide diversity of NTM for 
presence of the RD1.
From our laboratory database, we retrieved isolates of all 5 M. kansasii subtypes 
based on 16S-23S internal transcribed spacer sequencing (n=15), M. szulgai 
(4), M. marinum (4), M. avium (2), M. conspicuum (4), M. genavense (1), 
M. bohemicum (2), M. interjectum (2), M. flavescens (5), M. xenopi (2), M. 
malmoense (2), M. riyadhense (1) and M. tuberculosis H37Rv. The selection of 
strains was based on their phylogenetic relationship with the M. tuberculosis 
complex, in the multi-gene taxonomical model published by Devulder et al.5
To establish the presence of an RD1-like element and sequences of esat-6 
and cfp-10 genes, we used Esa-12 CATGACAGAGCAGCAGTG and Esa-
303 5’-GCCCTATGCGAACATCCC-3’ primers for esat-6 and opBR78 
5’-GTAGCCCGGGATGGCAGAGATGAAGACCGATGCC-3’ and opBR103 
5’-TCAGAAGCCCATTTGCGAGGACAGC-3’ primers for cfp-10.6 The M. 
smegmatis esat-6 and cfp-10 gene sequences were extracted from the whole 
genome sequence in the GenBank database (accession number CP000480).
Using these primers, we were able to demonstrate an RD1 for M. tuberculosis 
H37Rv, as well as for all M. kansasii subtypes, M. szulgai, M. marinum and 
M. riyadhense. The PCR was repeatedly negative for isolates of the remaining 
species M. avium, M. conspicuum, M. genavense, M. bohemicum, M. interjectum, 
M. flavescens, M. xenopi and M. malmoense. For these species, we performed 
southern blotting and hybridized DNA membranes using the purified M. 
tuberculosis H37Rv and M. kansasii type I esat-6 amplicon as a probe.6 None of 
the PCR negative species hybridized with either probe (data not shown).
Presence of an RD1, characterised by an esat-6-like and cfp-10-like gene, is a 
phylogenetic character among the nontuberculous mycobacteria. It is found 
mainly only among slowly growing NTM species that are phylogenetically 
related to the M. tuberculosis complex, based on the multi-gene taxonomical 
model by Devulder et al.5 and in the more distantly related rapid grower M. 
smegmatis. Possibly, presence of the RD1 reflects phylogenetic relationships to 
the M. tuberculosis complex. 
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Species esat-6 cfp-10
M. szulgai EU826486 FJ014490
M. marinum EU826487 FJ014491
M. riyadhense EU552926 EU552927
M. kansasii I EU888292 FJ014492
M. kansasii II EU888293 FJ014493
M. kansasii III EU888294 FJ014494
M. kansasii IIIb EU888295 FJ014495
M. kansasii IV EU888296 FJ014496
M. kansasii V EU888297 FJ014497
M. tuberculosis H37Rv FJ014499 FJ014498
Table 1: GenBank accession numbers of isolates sequenced in this study
Previous authors have recorded presence of the RD1 in M. flavescens.6 We were 
unable to demonstrate it in four reference strains (ATCC 23008, 23033, 23035 
and 23039) and a clinical isolate. Thus, with its presence of an RD1 region, M. 
smegmatis still stands out among the rapid growing NTM.
Gey van Pittius et al. have demonstrated the ESX-5 locus, which they assume 
is a product of duplication of the RD1 and its secretion system (ESX-1), in 
most slow growing NTM species.7 Our results seem to suggest that in many 
slow growers, after this duplication, the original ESX-1 was either lost or has 
undergone extensive mutation, barring hybridization.
All five subtypes of M. kansasii had distinct esat-6 and cfp-10 sequences; type 
three was subdivided in two separate lineages based on both esat-6 and cfp-
10 sequences. Among M. marinum and M. szulgai strains, no difference was 
noted and the sequences obtained for M. riyadhense were unique. All obtained 
sequences are deposited in the GenBank database; accession numbers are 
detailed in Table 1. We aligned the esat-6 and cfp-10 gene sequences separately 
and concatenated using Clustal X software.8 The resulting topology and tree, 
inferred by neighbor joining and visualized using the MEGA 4.0 software 
package,9 were evaluated by bootstrap analyses based on 1000 re-samplings. 
Resulting trees are shown in Figure 1A (esat-6), B (cfp-10) and C (esat-6 and 
cfp-10 concatenated). From these trees, it is obvious that the slow growing 
RD1-positive NTM have esat-6 and cfp-10 sequences much closer related to 
those of M. tuberculosis than those of M. smegmatis (Figure 1A-C).
Thus, the presence of the RD1 in these slow growers marks a genetically closely 
related Mycobacterium grouping, and sequencing of the RD1 is a tool for (sub)
species identification. Therefore, we propose that future introduction of new 
species phylogenetically related to the RD1-positive grouping should include 
an investigation of RD1 presence and gene sequences. 
Deletion of the RD1 lowers the virulence of M. tuberculosis complex bacteria.3,10,11 
Although presence of an RD1 may thus be important for virulence, we were 
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not able to detect this genomic region in well known causative agents of disease 
in humans, including M. avium and M. malmoense.1,12 In M. smegmatis, ESAT-
6 and CFP-10 secretion has a role in conjugation, rather than translocation 
to the cytosol, by which M. tuberculosis survives within macrophages.4,13 The 
remaining NTM species that harbour an RD1 are phylogenetically closer 
related to M. tuberculosis than to M. smegmatis,5 which is also expressed in 
their esat-6 and cfp-10 sequences (Figure 1). Moreover, M. kansasii, M. szulgai 
Figure 1: Phylogenetic trees based on multiple sequence alignment of esat-6 (A), cfp-
10 (B) and concatenated esat-6 and cfp-10 (C) sequences.
Neighbour-joining (NJ) tree was created and bootstrapped 1000x with CLUSTALX and 
visualized with MEGA 4.0.8,9 Bootstrap values are indicated at the nodes. 
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and M. marinum are considered most pathogenic among the NTM.6,14,15 
Therefore, the RD1 may play a role in virulence of these NTM. 
The RD1 sequences differed between M. kansasii type I, an important causative 
agent of NTM disease, and the other types which are less or not involved in 
human disease.6 Both clinically relevant and non-relevant M. szulgai isolates, 
determined using the American Thoracic Society diagnostic criteria,14,15 
shared identical sequences. The RD1 presence and gene sequences, thus 
protein structure, do not provide a complete explanation of the virulence of 
the different NTM. Presumably, host factors and pathogen factors other than 
RD1 presence are also important. In vitro infection experiments are necessary 
to clarify the role of the RD1 in slow growing NTM. 
Demonstration and characterization of an RD1 in NTM has gained significance 
with the advent of the interferon gamma release assays (IGRAs) for the diagnosis 
of (latent) tuberculosis. These assays measure interferon-γ production and 
release by patients’ T-lymphocytes after incubation with ESAT-6 and CFP-10 
antigens of M. tuberculosis.16 The presence of similar antigens in NTM, thus 
recognition of these antigens by patients infected by these NTM, theoretically 
lowers the specificity of the IGRAs in diagnosing latent tuberculosis.
In conclusion, an RD1 element, similar to M. tuberculosis, is present in M. 
kansasii, M. szulgai, M. marinum and M. riyadhense. Presence of an RD1 in 
general is a phylogenetic and taxonomical character of NTM, which hints at a 
phylogenetic relationship with the M. tuberculosis complex. The RD1 sequence 
analysis enables distinction to species or sub-species level. Future studies 
describing related new species should investigate RD1 presence and gene 
sequences. The role of the RD1 as a virulence factor and the impact of RD1-
containing NTM on functioning of the IGRAs should be subject of further 
studies.
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Presence of esat-6 and cfp-10 genes 
does not lead to phagolysosome 
translocation of Mycobacterium 
szulgai
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Abstract
Mycobacterium tuberculosis secretes the 6 kDa early secretory antigenic 
target (ESAT-6) and 10 kDa culture filtrate protein (CFP-10), which effect 
translocation of these bacteria from the phagolysosome to the cytosol in 
macrophages; a crucial step for its virulence. Mycobacterium szulgai, a 
relatively virulent nontuberculous Mycobacterium, also harbors esat-6 and 
cfp-10 genes. To explore whether its virulence results from translocation from 
the phagolysosome to the cytosol in macrophages, we infected THP-1 cells 
with M. szulgai and M. tuberculosis to monitor their subcellular localization. 
Seventy-two hours after infection, no cytosolic M. szulgai bacteria were found, 
while 53% of the M. tuberculosis bacteria had translocated to the cytosol. Thus, 
while M. szulgai harbors esat-6 and cfp-10 genes, there is no translocation 
of the bacteria to the cytosol in THP-1 cells. ESAT-6 and CFP-10 structure 
or secretion could be critical factors. Translocation does not seem to be the 
underlying mechanism of virulence for M. szulgai.
246
Chapter 6.3
Introduction
In Mycobacterium tuberculosis, the locus known as ESX-1 (ESAT-6 Secretion 
compleX 1) encodes a secretion system dedicated to secretion of the 6 kDa early 
secretory antigenic target (ESAT-6) and 10 kDa culture filtrate protein (CFP-
10).1,2 Genes encoding for ESAT-6 and CFP-10 like proteins are not limited to 
M. tuberculosis complex bacteria; the nontuberculous mycobacteria (NTM) M. 
kansasii, M. marinum, M. szulgai and M. smegmatis harbor similar genes.3,4 In M. 
tuberculosis and M. marinum ESAT-6 and CFP-10 are crucial for translocation of 
the bacteria from the phagolysosome to the cytosol in myeloid cells, resulting in 
a direct access to the MHC class I antigen presentation pathway and thus CD8 
T-cell activation. Translocation to the cytosol is not detected for the attenuated 
M. bovis BCG or M. tuberculosis ESX-1 knockout mutants. In M. smegmatis, 
ESAT-6 and CFP-10 have a role in conjugation.2,5 
In a previous study, we found M. szulgai to be clinically highly relevant, i.e. 
76% of the patients from whom M. szulgai is isolated have disease attributable 
to this organism.6 We hypothesized that this level of virulence in humans, 
which is uncommon in NTM, may partially result from translocation from 
the phagolysosome to the cytosol in macrophages effected by ESAT-6 and 
CFP-10, as previously observed for M. tuberculosis. To explore this hypothesis, 
we performed an in vitro infection of human macrophages (THP-1) with M. 
szulgai to monitor the subcellular localization.
Methods
Isolates
We used a clinical M. szulgai isolate (NLA000701790) from a patient with 
severe, cavitary pulmonary disease. The isolate was identified by sequencing 
of the 16S rDNA gene. For comparison, we included a clinical M. tuberculosis 
isolate (NLA000200230) from a patient with pulmonary tuberculosis.
We sequenced the esat-6 and cfp-10 genes of the M. szulgai isolate using 
previously published primers.7 The obtained sequences were aligned with those 
of M. tuberculosis H37Rv, M. smegmatis MC2 155 and previously investigated 
isolates of M. szulgai, M. marinum and M. kansasii, available in the GenBank/
EMBL (National Center for Biotechnology Information: http://www.ncbi.nlm.
nih.gov) sequence database using Clustal X software.8 The resulting topology 
and tree, inferred by neighbour joining and evaluated by bootstrap analyses 
based on 1000 re-samplings, was visualized using the MEGA 4.0 software 
package.9
Cell infections
THP-1 cells were cultured and maturation to macrophage like cells was 
induced by addition of PMA 24 hours before infection. Cells were infected 
with M. szulgai NLA000701790 and M. tuberculosis NLA000200230 cultures 
(Optical Density 0.5-1 McFarland) at a multiplicity of infection (MOI) of 10:1. 
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After incubation for 2 hrs, extracellular bacteria were washed away. The cells 
were fixed at 48 and 72 hrs after infection and processed for cryo-immunogold 
electron microscopy, using previously published approaches.2 We analyzed 
the intracellular localization of M. szulgai and M. tuberculosis using late 
endosomal markers cathepsin-D (clone 1C11, Zymed) LAMP-1 (clone H4B4, 
BD Biosciences) and CD63 (M1544, Sanquin, the Netherlands).  
Results and Discussion
At 48 hrs after infection, the majority of M. szulgai bacteria were located within 
phagosomes, whereas 40% of the M. tuberculosis bacteria had translocated 
to the cytosol of the THP-1 cells. At 72 hrs, no cytosolic M. szulgai bacteria 
could be found, while 53% of the M. tuberculosis bacteria had translocated 
to the cytosol (Figures 1 and 2). Thus, despite presence of esat-6 and cfp-10 
genes, translocation of M. szulgai from the phagolysosome to the cytosol of 
THP-1 cells could not be convincingly demonstrated. Although we noted a few 
cytosolic M. szulgai bacteria at 48 hrs after infection, these cytosolic bacteria 
were absent at 72 hrs post infection.
This finding suggests that presence of genes encoding for ESAT-6 and CFP-10-
like proteins does not explain the high level of virulence of M. szulgai; at least not 
through translocation. From prior studies with M. kansasii7 it is already known 
that the presence of ESAT-6 and CFP-10-like proteins can not explain the level 
of virulence. Conversely, this finding may explain the fact that M. szulgai disease 
is generally limited to hosts with an impairment of immunity or pre-existing 
tissue damage of affected organs.6 The cell culture system here used most 
likely corresponds to an infection in immunocompetent persons rather than 
immunocompromised patients, specifically since THP1 cells represent matured 
macrophages, cells active in the immune responses.
Possibly, ESAT-6 and CFP-10 secretion, rather than presence of the respective 
genes, is the critical factor for virulence in an immunocompetent host. 
0
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Cytosolic
Figure 1: Percentage of phagosomal and cytosolic bacteria
MSZ: Mycobacterium szulgai; MTB: M. tuberculosis
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Therefore, the ESX-1 secretion system of M. szulgai should be tested by 2D 
protein electrophoresis, to demonstrate the presence of ESAT-6 or CFP-10 in 
culture media on which M. szulgai is grown. ESAT-6 and CFP-10 secretion in 
host cells should also be monitored.
Figure 2: M. szulgai remains restricted in phagosome, while M. tuberculosis translocates 
into the cytosol of THP-1 cells.
THP1 cells were infected with M. szulgai (A) or M. tuberculosis (B) for 48 h, fixed and 
immunolabeled with lysosomal marker CD63 and 10 nm gold particles. Note that the 
magnification of A and B (all bars represent 200 nm) is the same. Mycobacterium szulgai 
bacteria are larger than M. tuberculosis and contain large electron lucent areas. Enlargement of 
the boxed region in A’ demonstrated that M. szulgai remains restricted in a membrane enclosed 
compartment (arrowhead). M. tuberculosis is present both in the cytosol (B’) and in membrane 
enclosed CD63 labeled compartments.  Bars represent 200 nm; Ms: M. szulgai, Mt: M. 
tuberculosis, Nu: nucleus, L: lysosome, m: mitochondria, arrowheads: phagosomal membrane.
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The esat-6 and cfp-10 gene sequences of the M. szulgai isolate were identical to 
those deposited in GenBank, EU826486 (esat-6) and FJ014490 (cfp-10). The 
esat-6 sequence is 82% (236/289 bp) identical to that of M. tuberculosis H37Rv. 
These polymorphisms give rise to substitutions in 14 of 96 amino acids. The M. 
szulgai cfp-10 sequence is 88% (267/303bp) identical to that of M. tuberculosis 
H37Rv, accounting for substitutions in 7 of 101 amino acids. The topology and 
tree resulting from the multi-sequence alignment are visualized in Figure 3.
These differences in the esat-6 and cfp-10 genes and their products in M. szulgai 
and M. tuberculosis are substantial and likely to result in changes in secondary 
and tertiary structure of ESAT-6 and CFP-10. The esat-6 and cfp-10 genes in M. 
smegmatis are very different from those in M. tuberculosis (figure 3) and their 
products have a very different role, i.e. in conjugation rather than translocation 
of the bacteria from the phagolysosome to the cytosol in myeloid cells.5 Hence, 
the exact structure and thus functionality of these proteins in M. szulgai could 
also be different from those in M. tuberculosis and warrant further study.
Interestingly, the electron microscopic appearance of the M. szulgai bacteria 
was different from M. tuberculosis. The M. szulgai bacteria were large (average 
width 720 nm versus 500 nm for M. tuberculosis) and contained numerous 
large electron lucent areas (Figure 2).
In summary, while M. szulgai harbors esat-6 and cfp-10 genes, their products do 
not induce translocation of the bacteria from the phagolysosome to the cytosol 
in THP-1 cells to the extent known for M. tuberculosis. ESAT-6 and CFP-10 
structure and functionality, as well as secretion could be the critical factors 
and should be addressed in future studies. The level of clinical relevance of M. 
szulgai cannot be explained by translocation of these bacteria to the cytosol.
Figure 3: Phylogeny of ESX-1 harboring mycobacteria
The phylogeny is based on concatenated esat-6 and cfp-10 sequences, aligned using Clustal X 
software.8 The Neighbour Joining tree was constructed and evaluated by bootstrap analyses 
based on 1000 re-samplings, using the MEGA 4.0 software package.9 Bootstrap values are given 
at the nodes.
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Summary
Little is known about the clinical relevance of nontuberculous mycobacteria 
in the Arabian Peninsula. We assessed the prevalence and studied a random 
sample of isolates at a reference laboratory in Muscat, Oman. Nontuberculous 
mycobacteria cause disease in this region and their prevalence has increased.
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Introduction
Nontuberculous mycobacteria (NTM) are common inhabitants of the 
environment and have been cultured from water, soil and animal sources 
worldwide. The NTM are opportunistic pathogens, mostly affecting patients 
with pre-existing pulmonary disease such as chronic obstructive pulmonary 
disease or prior tuberculosis (TB), or those with systemic impairment of 
immunity. The latter group includes those with HIV-infection, those using 
immunosuppressive drugs and those with leukemia.1
Because NTM are common in the environment and resistant to commonly 
used disinfectants, they can be present in non-sterile patient material such 
as sputum and contaminate medical equipment (bronchoscope washers or 
samples in the laboratory) and consequently cause pseudo-infection.1,2 To 
distinguish pseudo-infections from NTM disease and establish the clinical 
relevance of isolated NTM, the American Thoracic Society (ATS) has published 
diagnostic criteria.1
Studies on the clinical relevance of NTM have traditionally been restricted 
to western countries, where the incidence of TB is relatively low. More 
recently, research has been initiated in African and East Asian countries.1-5 
There have been no recent reports on isolation and clinical relevance of NTM 
on the Arabian Peninsula. We analyzed a random sample of NTM isolated 
from clinical samples in Oman by using molecular techniques. Their clinical 
relevance was retrospectively analyzed by applying the updated ATS diagnostic 
criteria for nontuberculous mycobacterial disease.1 
The Study
Prevalence of NTM at the Central Public Health Laboratory (CPHL), the 
national TB reference laboratory of the Ministry of Health in Muscat, Oman, 
was assessed from the laboratory database. The CPHL Institutional Review 
Board reviewed and approved this study. The CPHL received 5,488 samples 
submitted for Mycobacterium spp. culture during 2006-2007. Samples were 
subcultured on Lowenstein-Jensen medium and automated Mycobacterial 
Growth Indicator Tubes (MGIT960; Becton Dickinson, Franklin Lakes, NJ, 
USA) liquid culture system and incubated at 36°C. A total of 491 (9%) samples 
yielded positive cultures. Mycobacterium tuberculosis complex bacteria were 
isolated from 445 (91%) samples, and NTM were isolated from 46 samples 
(9%). Most NTM were cultured from respiratory samples (sputum, n=36, 78%; 
bronchial wash, n=2, 4%), the remainder were from lymph nodes (n=3; 6%), 
urine (n=2; 4%) or other sources (n=3; 6%). The percentage of NTM increased 
from 7.6% (18/235) in 2006 to 10.9% (28/256) in 2007. 
Thirteen samples were randomly selected from all NTM isolated at CPHL 
during January 2006-September 2007. Selected NTM were subjected to 
molecular identification at the Dutch National Mycobacteria Reference 
Laboratory (National Institute for Public Health and the Environment, 
Nontuberculous mycobacteria in other geographical areas
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Bilthoven, the Netherlands). To identify NTM, after eliminating isolates 
of the M. tuberculosis complex by using the GenoType MTBC assay (Hain 
Lifesciences, Nehren, Germany), we used the INNO-LiPA MYCOBACTERIA 
v2 reverse line blot (Innogenetics, Ghent, Belgium). Both assays were used 
according to the manufacturer’s instructions. If no species-specific result was 
obtained, additional sequencing of the hypervariable region A of the 16S 
rDNA gene was performed.6
The 13 samples were identified as nine M. avium complex (MAC; three M. 
intracellulare sequevars, three M. chimaera, one M. colombiense, one M. avium, 
and one untyped MAC), M. marinum, M. kansasii, M. simiae and M. flavescens 
(Table). One sample could not be identified beyond the M. avium-intracellulare-
scrofulaceum complex level because insufficient DNA was available for further 
analyses. Because our molecular identification method does not distinguish 
M. marinum from M. ulcerans, we performed a light exposure test, which 
prompted yellow colony pigmentation, typical for M. marinum. One sample 
yielded M. tuberculosis and M. intracellulare (Table 1).
We assessed the clinical relevance of isolates from 13 patients in a retrospective 
study, by applying ATS diagnostic criteria and scoring demographic and 
clinical data. Results are detailed in the Table. Seven (54%) of the patients 
were female (mean age 43 years). Eight (62%) of thirteen patients met the ATS 
diagnostic criteria and were thus likely to have NTM disease. Among nine 
patients with MAC isolates, six (67%) had MAC disease. Most (n=11; 85%) 
isolates were cultured from pulmonary samples. Fibrocavitary and nodular-
bronchiectatic pulmonary NTM disease were noted, with a predominance of 
fibrocavitary disease (Table). 
Information on predisposing conditions was not available for most patients, 
although a destroyed lung on chest radiographs suggested previous pulmonary 
disease. One patient was HIV-positive, and another patient had a relapse of 
pulmonary NTM disease.
Eight patients began treatment, mostly with first-line treatment for TB. 
Three patients with pulmonary MAC disease and one with M. marinum skin 
disease received regimens that included macrolides, fluoroquinolones or both. 
Therapy resulted in clinical improvement in all but one patient. Most patients 
are still receiving treatment. 
Conclusions
A total of 9% of all Mycobacterium-positive cultures at CPHL in Muscat, 
Oman, yielded NTM. Although this conclusion is based on limited data, the 
prevalence of NTM seems to be increasing in Oman. Few studies are available, 
but this increase may be true for the entire Middle East region. 
Eight of 13 patients met the ATS diagnostic criteria; this finding probably 
reflects a selection bias because CPHL is a reference laboratory. Nevertheless, 
these findings indicate that NTM isolation in Oman and throughout the 
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Middle East region is a serious issue that requires attention by clinicians and 
microbiologists. 
Most isolates were MAC members (9/13; 69%), a predominance also noted in 
previous studies in the USA, European and west Asian countries (25%),1,8 as 
well as in a recent study from South Korea (48%).9 MAC isolates from Oman 
were mostly M. intracellulare sequevars. Infrequent isolation of M. avium 
is noteworthy, despite the small number of isolates in the random sample. 
Previous North American studies have suggested that M. intracellulare is the 
more common pulmonary pathogen within the MAC.1 We identified three 
pulmonary samples as MAC-A strains, recently elevated to species rank 
and named M. chimaera.7 Two samples were clinically relevant. Although 
M. chimaera has been assumed to be highly virulent,7 a recent study in 
Germany found only 3.3% of 90 M. chimaera isolates to be clinically relevant.10 
Mycobacterium colombiense was first described as a causative agent of mostly 
disseminated disease in HIV patients from Colombia11 and was recently 
isolated from a child with lymphadenopathy in Spain.12 Its isolation in other 
countries and from respiratory samples in HIV-negative patients has not been 
previously reported. Isolation of M. simiae is of interest, as this species has been 
reported to be especially prevalent in the Middle East,1 and HIV-associated 
disease has been reported in the region.13
Most patients in our study received standard treatment for TB. Although 
treatment should be prolonged and pyrazinamide discontinued because of 
natural resistance to pyrazinamide in NTM, the choice of first-line treatment 
for TB, without companion drugs such as macrolides or fluoroquinolones, is 
supported by a recently published trial of the British Thoracic Society.14
In summary, NTM are a serious issue in Oman and their prevalence may be 
increasing. Our random sample demonstrates that MAC isolates are most 
frequently isolated. True NTM disease, on the basis of ATS diagnostic criteria, 
was diagnosed in 62% of the patients assessed. Isolation of NTM is clinically 
relevant on the Arabian Peninsula and warrants further study.
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Mycobacterium riyadhense sp. nov.; a 
non-tuberculous species identified as 
Mycobacterium tuberculosis complex 
by a commercial line-probe assay
Jakko van Ingen1,2, Sahal Al-Hajoj3, Martin Boeree2, Fahad Al-Rabiah4, 
Mimount Enaimi1, Rina de Zwaan1, Enrico Tortoli5, Richard Dekhuijzen2 and 
Dick van Soolingen1.
1 National Mycobacteria Reference Laboratory, Laboratories for Infectious Diseases and Perinatal 
Screening, National Institute for Public Health and the Environment, Bilthoven, the Netherlands; 
2 Department of Pulmonary Diseases, Radboud University Nijmegen Medical Center, Nijmegen, 
the Netherlands; 3 Department of Comparative Medicine, King Faisal Specialist Hospital and 
Research Centre, Riyadh, Saudi Arabia; 4 Department of Medicine, King Faisal Specialist Hospital 
and Research Centre, Riyadh, Saudi Arabia; 5 Regional Reference Center for Mycobacteria, 
Microbiology and Virology Laboratory, Careggi Hospital, Florence, Italy
Summary
A non-chromogenic, slowly growing Mycobacterium strain was isolated from 
a maxillary sinus lavage from a symptomatic patient in Riyadh, Saudi Arabia. 
It was initially identified as a member of the Mycobacterium tuberculosis 
complex by a commercial line-probe assay. Its 16S rDNA, hsp65 and rpoB 
gene and 16S-23S internal transcribed spacer sequences were unique; 
phylogenetic analysis based on the 16S rDNA sequence groups this organism 
close to M. szulgai and M. malmoense. Its unique biochemical properties and 
mycolic acid profile support separate species status. We propose the name 
Mycobacterium riyadhense sp. nov. to accommodate this strain. The type strain 
is NLA000201958T (=CIP 109808T; =DSM 45176T).
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A 19-year-old male reported to the otolaryngology department of the King 
Faisal Hospital with pain and swelling of the left side of his face with protrusion 
of the left eye after blunt trauma. A computed tomography scan of the sinuses 
was performed, which revealed a tumor in the left maxillary sinus. The tumor 
involved the nasal septum, extended into the left orbit and infiltrated the medial 
and inferior rectus as well as the optic nerve. A chest radiograph revealed no 
abnormalities. A lavage of both maxillary sinuses was performed for diagnosis. 
Mycobacterial cultures were performed on Lowenstein-Jensen (LJ) media and 
yielded an isolate with unusual colony morphology after 3 weeks of incubation 
at 36°C. 
The patient was presumed to have bone tuberculosis (TB) and started a nine 
month anti-tuberculosis regimen. The patient improved both clinically and 
radiologically. He has not suffered a relapse since. The isolated strain was sent 
to the Dutch National Mycobacteria Reference Laboratory (RIVM, Bilthoven, 
Netherlands) for identification, as part of a second-line quality control program. 
Identification of the strain was first attempted using three commercial line-probe 
assays, GenoType MTBC and GenoType CM/AS (Hain Lifescience GmbH, 
Nehren, Germany) and INNO-LiPA MYCOBACTERIA v2 (Innogenetics NV, 
Ghent, Belgium), all used according to manufacturer’s instructions. 
Gene/region GenBank RIDOM
16S rDNA 
(full)
M. malmoense (99%)
M. szulgai (99%)
M. bohemicum (98%)
M. szulgai DSM44166T (99.1%)
M. avium complex ATCC35770 (98.4%)
M. intracellulare ATCC35772 (98.4%)
M. haemophilum ATCC29548T (98.4%)
16S-23S ITS
(273bp) 
M. szulgai (91%)
M. kansasii (91%)
M. marinum (91%)
M. kansasii DSM44162T (92%)
M. gastri DSM43505T (91%)
M. marinum DSM44344T (90%)
23S rDNA (full) M. kansasii (97%)
M. avium (97%)
M. ulcerans agy99 (97%)
rpoB (472bp) M. avium 104 (93%)
M. paratuberculosis K-10 (93%)
M. tuberculosis H37RvT (91%)
hsp65 (421bp) M. genavense DSM44424T (95%)
M. bohemicum CIP105811T (95%)
M. malmoense CIP105775T (95%)
esat-6 M. kansasii (89%)
M. tuberculosis H37RvT (87%)
M. szulgai (85%)
cfp-10 M. tuberculosis H37RvT (88%)
M. marinum M (85%)
M. ulcerans (84%)
Note: Where no strain is indicated, multiple highly similar sequences are deposited in GenBank
Table 1: Sequence comparisons between strain NLA000201958T and its closest relatives
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To obtain identification to the species level, we sequenced the 16S rDNA 
gene, 16S-23S internal transcribed spacer (ITS), and rpoB and hsp65 genes, 
using previously described approaches.1-4 The DNA sequences obtained 
were compared with RIDOM (Ribosomal Differentiation of Medical 
Microorganisms: http://rdna.ridom.de) and GenBank (National Center for 
Biotechnology Information: http://www.ncbi.nlm.nih.gov) databases. 
To establish the presence of a region of difference 1 (RD1)-like element and 
the DNA sequences of the esat-6 and cfp-10 genes, we used primers from a 
previous study.5
The most commonly investigated biochemical and phenotypical features (colony 
morpholgy, ability to grow at temperatures ranging from 24 to 45 °C, niacin 
accumulation, nitrate reduction, β-glucosidase, Tween 80 hydrolysis, 3-day 
arylsulfatase, urease, tellurite reduction, 68 °C and semiquantitative catalase, 
growth rate, pigmentation, growth on MacConkey agar and tolerance to 5% NaCl 
[on LJ medium], thiophene-2-carboxylic hydrazide [TCH] 5 μg/ml, oleate 250 
μg/ml, p-nitrobenzoic acid 500 μg/ml, thiacetazone 10 μg/ml, hydroxylamine 
500 μg/ml, and isoniazid 1 μg/ml [all in Middlebrook 7H10 agar]) as well as high 
performance liquid chromatography (HPLC) analysis of cell wall mycolic acid 
content were tested by the Regional Reference Center for Mycobacteria (Careggi 
Hospital, Florence, Italy), using standard procedures described previously.6,7 
Drug susceptibility testing was performed using the 25-well agar dilution 
method.8 We included isoniazid, rifampicin, rifabutin, ethambutol, 
clarithromycine, ciprofloxacin, cycloserine, prothionamide, amikacin, 
clofazimine and streptomycin in the test panel. 
Applying the GenoType MTBC assay, a non-specific reaction was noted with 
hybridization of the M. tuberculosis complex band only (banding pattern 1, 2, 3). 
The InnoLipa MYCOBACTERIA v2 line-probe assay yielded a Mycobacterium 
genus probe reaction, though no species-specific result. The GenoType CM 
(Common Mycobacteria) kit identified the strain as M. tuberculosis complex 
based on a band 1,2,3,10,16 pattern. The supplementary AS (Additional 
Species) kit identified the strain as a non-specified Mycobacterium species, 
with banding pattern 1, 2, 3, 12. Sequencing of the full 23S rDNA gene, the 
assay’s target, established its identity as a nontuberculous mycobacterium 
(Table 1). Based on these findings, IS6110 and IS1081 RFLP were performed 
to confirm its identity as M. tuberculosis.9 No IS6110 or IS1081 element copies 
could be demonstrated (results not shown).
The sequencing results are listed in Table 1; the 16S, ITS, rpoB and hsp65 gene 
sequences were all unique. Sequencing of the full 16S rDNA gene identified 
the bacterium as a Mycobacterium szulgai-like species (Table 1). The 16S rDNA 
gene sequence was aligned with those of reference strains of the closest related 
mycobacteria using Clustal X.10 The resulting topology and tree, inferred by 
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neighbour joining and visualized using the MEGA 4.0 software package,11 were 
evaluated by bootstrap analyses based on 1000 resamplings (Figure 1). The tree 
was rooted with Nocardia abscessus ATCC BAA-279T as an outgroup. Similar 
multisequence alignments and trees were created based on the ITS and hsp65 
sequences (Supplementary Figures S1 and S2, available in IJSEM online).
We were able to amplify an RD1 region, including an esat-6 (270bp) and cfp-10 
(251bp) gene. Results of sequence comparisons for both genes are recorded in 
Table 1.
On Middlebrook 7H10, Ogawa and Stonebrink media, the strain produced 
small, rough, non-pigmented colonies after 28 days of incubation at 36 °C. 
After three days of exposure to light at ambient temperature, no pigmentation 
was observed. Growth on Middlebrook 7H10 agar was only observed at 24, 
30 and 36 °C. Optimal growth occurred at 36 °C. Colony morphology on 
Middlebrook 7H10 was similar at all temperatures.
Generally, the biochemical profile of the isolate is unique, although it shares 
characterstics with M. szulgai and M. malmoense.12 The isolate was negative for 
niacin accumulation, heat-stable catalase (pH 7, 68 °C), β-glucosidase, tellurite 
reduction, growth on MacConkey agar and tolerance to para-nitrobenzoic 
acid, hydroxylamine and oleic acid, but positive for nitrate reduction, semi-
quantitative catalase, Tween 80 hydrolysis, 3 day arylsulfatase and urease 
activity and tolerance to TCH, thiacetazone and isoniazid. A comparison with 
profiles of M. szulgai and M. malmoense is recorded in Table 2.
Figure 1: Phylogenetic relationship of NLA000201958T (Mycobacterium riyadhense 
sp. nov.) and related species of Mycobacterium, based on 16S rDNA gene sequences. 
Neighbour-joining tree created and bootstrapped 1000 times with CLUSTAL X10 and visualized 
with MEGA 4.0.11 Bootstrap values are indicated at nodes.
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HPLC revealed a pattern characterized by a single, narrow, late-emerging cluster 
of peaks. A similar profile is presented by a limited number of mycobacteria 
(M. brumae, M. fallax, M. triviale and M. tuberculosis complex) with none of 
them fully overlapping the pattern of the strain characterized here (Figure 2). 
We used the HPLC mycobacterium library (http://www.MycobacToscana.it/
english.htm) for this comparison.
Drug susceptibility testing revealed in vitro resistance to amikacin (minimum 
inhibitory concentration [MIC] 10 μg/ml) and para-amino-salicylate (MIC 
>1 μg/ml), intermediate susceptibility to isoniazide (MIC 1 μg/ml) and 
susceptibility to rifampicin (MIC 0.2 μg/ml), rifabutin (MIC ≤ 0.2 μg/ml), 
ethambutol (MIC 5 μg/ml), clarithromycine (MIC ≤ 2 μg/ml), ciprofloxacin 
(MIC 2 μg/ml), cycloserine (MIC 20 μg/ml), prothionamide (MIC ≤ 1 μg/ml), 
clofazimine (MIC ≤ 0.5 μg/ml) and streptomycin (MIC 5 μg/ml).
Although identification of M. tuberculosis complex is not the main use of 
the GenoType CM test, false-positive results may lead to incorrect diagnoses 
of TB and unwarranted TB treatment. Aside from the identification as M. 
tuberulosis by a line probe assay, which sparked this study, both the molecular 
and HPLC analyses of the novel strain suggest a phylogenetic relationship with 
M. tuberculosis; the presence of an RD1 region strengthens this assumption. 
Its identity as a nontuberculous mycobacterium is easily proven by sequencing 
of the 16S rDNA, rpoB, hsp65, or RD1 genes and the absence of IS6110 and 
IS1081 elements. The novel strain seems closely related to M. szulgai, based on 
16S rDNA gene and ITS sequences (Figure 1 and Supplementary Figure S1), 
Test Strain 
NLA000201958T
M. szulgai M. malmoense
Nitrate reduction + + -
68 °C catalase - + +/-
Catalase >45 mm + + -
β-glucosidase - +/- -
Tween 80 hydrolysis + +/- +
Tellurite reduction - +/- +
3 day Arylsulfatase + + -
Urease + + -
Pigmentation Absent Photochromogen Absent
Colony morphology Rough Smooth/rough Smooth
Growth at 25°C + + +/-
Tolerance to:*
  p-Nitrobenzoic acid 500 μg/ml - + +
  Isoniazid 1 μg/ml + +/- +
  Hydroxylamine 500 μg/ml - - +/-
Table 2: Biochemical identification results of strain NLA000201958T and related species
* In Middlebrook 7H10 agar
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although it is related more distantly to M. szulgai based on rpoB and hsp65 
sequences (Table 1 and Supplementary Figure S2). Its nonchromogenicity, 
however, is distinct from the photochromogenic M. szulgai. 
Retrospectively, this isolate seems clinically relevant, based on its isolation 
from a normally sterile body site and the symptomatic improvement of the 
patient after 9 months of TB therapy.13 This suggests that the novel strain was 
the causative agent of this patient’s disease. 
Both the close phylogenetic relationship with species such as M. szulgai 
and M. kansasii, which are among the most pathogenic nontuberculous 
mycobacteria,13,14 and the presence of an RD1 region with esat-6 and cfp-10 
genes, which is a virulence factor in M. tuberculosis,15 add to our view that 
this strain is a human pathogen. On the basis of the data presented here, we 
describe a novel species to accommodate strain NLA000201958T, for which we 
propose the name Mycobacterium riyadhense sp. nov.
Description of Mycobacterium riyadhense sp. nov.
Mycobacterium riyadhense (ri.ya.dhen’se; N.L. neut. adj., riyadhense after 
Riyadh, capital of the Kingdom of Saudi Arabia and origin of the patient from 
whom the type strain was isolated). 
Slowly growing, nontuberculous mycobacterium that produces rough, white 
colonies after 28 days of incubation at 36 °C; growth is slower at 25 and 30 
°C and no growth occurs at 42 °C. Incorrectly identified as M. tuberculosis 
complex by the GenoType CM assay. Negative for niacin accumulation, heat-
stable catalase, β-glucosidase, tellurite reduction, growth on MacConkey agar 
and tolerance to para-nitrobenzoic acid, hydroxylamine and oleic acid, but 
positive for nitrate reduction, semi-quantitative catalase, Tween 80 hydrolysis, 
arylsulfatase and urease activity and tolerance to TCH, thiacetazone and 
isoniazid. Readily identifiable by its unique rDNA sequences.
The type strain is NLA000201958T (=CIP 109808T; =DSM 45176T), recovered 
from maxillary sinus lavage fluid. 
Figure 2: Mycolic 
acid pattern of strain 
NLA000201958T (M. 
riyadhense sp. nov.) 
obtained by HPLC 
analysis. The single, 
narrow, late-emerging 
cluster of peaks is 
similar, though not 
identical, to results for 
M. brumae, M. fallax, 
M. triviale and M. 
tuberculosis complex.
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Supplementary Figure S1: Phylogenetic relationship of NLA000201958T 
(Mycobacterium riyadhense sp. nov.) and related species of Mycobacterium, based on 
ITS sequences. Neighbour-joining tree created and bootstrapped 1000 times with CLUSTAL 
X10 and visualized with MEGA 4.0.11 Bootstrap values are indicated at nodes.
Supplementary Figure S2: Phylogenetic relationship of NLA000201958T 
(Mycobacterium riyadhense sp. nov.) and related species of Mycobacterium, based on 
hsp65 gene sequences. Neighbour-joining tree created and bootstrapped 1000 times with 
CLUSTAL X10 and visualized with MEGA 4.0.11 Bootstrap values are indicated at nodes.
Note: The GenBank/EMBL/DDBJ accession numbers for the sequences of the 16S rRNA, 
16S-23S ITS, rpoB, hsp65, esat-6 and cfp-10 gene are EU274642, EU274643, EU274644, 
EU921671, EU552926 and EU552927. Phylogenetic trees based on 16S-23S internal transcribed 
spacer and hsp65 sequences of selected mycobacterial species are available as supplementary 
material in IJSEM Online.
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Nontuberculous mycobacteria in 
Vietnam; more than confounders of 
culture-based TB diagnosis
Jakko van Ingen1,2, Nguyen Van Hung3, P.N. Richard Dekhuijzen2, Martin J. 
Boeree2, Dick van Soolingen1
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Environment (RIVM), Bilthoven, the Netherlands; 2Department of Pulmonary Diseases, 
Radboud University Nijmegen Medical Center, Nijmegen, the Netherlands; 3National 
Tuberculosis Reference Laboratory, Department of Bacteriology, National Hospital of 
Tuberculosis and Respiratory Diseases, Hanoi, Vietnam
Abstract
Mycobacterium cultures applied during a recent survey in Vietnam yielded 
nontuberculous mycobacteria in 2.4% of all smear-positive tuberculosis 
suspects. We identified ten of these nontuberculous mycobacteria as M. 
abscessus (n=8), M. fortuitum and M. porcinum (both n=1). Based on a 
retrospective analysis of the ten respective case record forms, three patients 
might have had NTM disease. The predominance of rapid-growing NTM 
appears specific to the South East Asia region. Our findings stress the need 
for identification tools alongside culture facilities. The cost-effectiveness of 
treatment for these infections in a low-income setting is a major concern.
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Introduction
Nontuberculous mycobacteria (NTM) have been isolated from clinical 
and environmental samples worldwide.1 Most of the cases of human NTM 
disease, however, have been reported from countries where the incidence of 
tuberculosis is low. Their clinical relevance in a setting with a high incidence 
of tuberculosis remains to be resolved. In both settings, however, NTM can 
confuse the culture-based diagnosis of tuberculosis.1,2
In Vietnam, during a recent drug resistance survey among patients suspected 
of tuberculosis, Mycobacterium culture on Löwenstein-Jensen media was 
added to the diagnostic tools. Of all 1863 culture positive patients, 45 (2.4%) 
had a positive culture yielding NTM. We randomly selected ten NTM isolates, 
cultured in different laboratories, for identification by molecular methods. In 
addition, we reviewed their case record forms to assess the clinical relevance 
of the isolated NTM.
Methods
Sputum samples were decontaminated by the NALC-NaOH method and incubated 
on Löwenstein-Jensen media at 36 °C. All positive cultures were examined for growth 
characteristics and colony morphology; primary identification as M. tuberculosis 
complex was done using Ziehl-Neelsen staining and the niacin test. From the cultures 
yielding acid-fast bacilli with a negative niacin test, ten were heat-killed and sent to 
the Dutch National Mycobacteria Reference Laboratory, for molecular identification. 
We identified the isolates using the Inno-LiPA MYCOBACTERIA v2 reverse line 
blot (Innogenetics NV, Gent, Belgium). If no species-specific identification was 
obtained, we performed sequencing of the 151bp hypervariable region A of the 16S 
rDNA gene, using previously published methods.3
To assess the clinical relevance of the isolates NTM, we applied a simplified version 
of the American Thoracic Society diagnostic criteria for pulmonary NTM disease,1 
using clinical data retrieved from the case record forms made for the survey.
Pt. Sex, Age Species Symptoms Chest radiograph ATS
1 M, 21 M. abscessus PC NA Not met
2 M, 49 M. abscessus PC, WL, NS NA Not met
3 M, 58 M. abscessus PC NA Not met
4 M, 43 M. abscessus PC NA Not met
5 F, 25 M. abscessus PC, WL, NS NA Not met
6 F, 49 M. abscessus PC NA Not met
7 M, 30 M. abscessus PC NCL Met
8 F, 79 M. porcinum PC NCL Met
9 M, 49 M. fortuitum PC NCL Met
10 M, 29 M. abscessus PC, F NA Not met
M/F, male/female; PC, productive cough; WL, weight loss; NS, night sweats; F, fever; NA, no 
abnormalities; NCL, non-cavitary lesions; ATS, status according to American Thoracic Society 
diagnostic criteria
Table 1: Baseline patient characteristics
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Results
We identified the isolates of the ten patients as M. abscessus (n=8) and M. 
fortuitum complex (M. fortuitum and M. porcinum, both n=1). No cross-
reactions with the M. tuberculosis complex probe of the INNO-LiPA kit, 
suggestive of mixed M. tuberculosis complex and NTM culture, were observed.
The baseline clinical characteristics of the patients are detailed in Table 1. All 
patients were HIV-negative. All of their samples were positive for acid-fast 
bacilli on direct microscopy. Chest radiographs were made for the surveys, but 
their results were only reported as I) cavitary lesions, II) non-cavitary lesions 
or III) no abnormalities. Based on this apparent limitation, we considered 
both category one and two to be possible signs of mycobacterial disease. 
Three patients met the ATS diagnostic criteria based on their symptoms, 
chest radiograph abnormalities and smear and culture positivity for the NTM 
species. 
Discussion
NTM can confuse the diagnosis of tuberculosis in high-incidence settings. A 
minority of patients in the present study might have even had pulmonary NTM 
disease. A firm diagnosis of NTM disease, however, should be based on the 
examination of at least three separate sputum samples and chest radiograph 
abnormalities that are confirmed to be suggestive of mycobacterial disease.1 
The absence of cavitary lesions in these patients does not preclude a diagnosis 
of disease due to rapid growing NTM, as these are usually characterized by 
nodular-bronchiectatic rather than cavitary disease.1 Detection of acid-fast 
bacilli during direct microscopy further strengthened the diagnosis of NTM 
disease. For the purpose of the surveys, these patients were considered unlikely 
to have TB and received no treatment.
The 45 patients with cultures yielding NTM made up 2.4% of all 1863 culture 
positives in the survey. This is in line with the classical observation that 1-4% 
of all patients in high-incidence settings have at least a single culture yielding 
NTM.4
Our small sample suggests that rapid growers may predominate among NTM 
isolates in Vietnam. This finding has been previously reported from neighboring 
regions including Thailand, Southern China and Taiwan.5-7 The isolation 
of NTM has important implications for tuberculosis control in such high 
incidence settings. Together with the implementation of culture facilities, there 
should be (molecular) identification facilities available, especially where liquid 
culture systems are applied which bar the interpretation of colony morphology. 
Without identification, patients may receive unwarranted tuberculosis 
treatment and NTM isolates may be subjected to drug susceptibility testing. 
Their common resistance to first-line drugs, which is most pronounced in the 
rapid growing NTM as encountered in this study,1 may lead to false reports of 
multi-drug resistant tuberculosis and misguided treatment.
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Diagnosing NTM disease brings about the issue of whether or not to treat 
these infections in a low-income setting. Treatment results vary for the 
different NTM species and current treatment guidelines advocate the use of 
expensive drugs over a long period.1 Both aspects are highly problematic in 
a low-income setting. Mycobacterium abscessus, which was most prevalent 
among our isolates, is especially problematic due to its natural resistance to 
most classes of antibiotics.1
In conclusion, NTM are cultured from patients suspected of TB in Vietnam 
and may represent NTM disease, although a survey setting hampers a firm 
diagnosis. This stresses the need for identification tools alongside culture 
facilities. In our random sample we found rapid-growing NTM only, which 
appears specific to the South East Asia region. Diagnosing NTM disease raises 
of issue of the cost-effectiveness of treatment for these infections in a low-
income setting.
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Summary
Data on nontuberculous mycobacterial (NTM) disease in sub-Saharan Africa 
are limited. During 2006-2008, we identified 3 HIV-infected patients in 
northern Tanzania who had invasive NTM disease; two were infected with 
“Mycobacterium sherrisii” and one with M. avium complex sequevar MAC-D. 
Invasive NTM disease is present in HIV-infected patients in sub-Saharan 
Africa.
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In sub-Saharan Africa, mycobacterial infections are predominantly caused by 
Mycobacterium tuberculosis.1 In more developed countries, M. avium and M. 
simiae are responsible for disseminated disease in HIV-infected persons.2 To 
better understand invasive nontuberculous mycobacterial (NTM) infections in 
HIV-infected persons in sub-Saharan Africa, we studied patients at 2 hospitals 
in northern Tanzania.
The Study
From July 2006 through August 2008, we collected blood from 723 patients 
>13 years of age who had axillary temperatures >38ºC and who had been 
admitted to Kilimanjaro Christian Medical Centre and Mawenzi Regional 
Hospital in Moshi, Tanzania. Standardized clinical information was collected 
from all patients. For mycobacterial culture, 5 mL from each patient was 
inoculated into a BacT/ALERT MB bottle and monitored in a BacT/ALERT 
3D (bioMérieux, Durham, NC, USA) automated liquid culture instrument. 
Other tissue samples (not blood) were obtained from patients with suspected 
invasive mycobacterial disease and incubated on Middlebrook 7H10 and 
Lowenstein-Jensen media at 36°C. We used AccuProbe MTB and MAC kits 
(GenProbe, San Diego, CA, USA) to identify members of M. tuberculosis 
complex and M. avium complex. NTM were further identified by the INNO-
LiPA Mycobacteria v2 reverse line blot (Innogenetics, Gent, Belgium). All 
assays were used according to the manufacturer’s instructions. All reverse line 
blot identifications were confirmed by performing additional sequencing of 
the complete 16S rDNA gene, the 16S-23S internal transcribed spacer (ITS), 
and the 65 kDa heat shock protein (hsp65) gene.3,4
Of the 723 patients, 30 (4.1%) had mycobacterial bloodstream infections, of 
which two (9%) were NTM. In one additional patient, NTM were identified in 
a tissue specimen. We describe the 3 patients with NTM infections.
The first patient was a 49-year-old man with cough and weight loss. His sputum 
contained acid-fast bacilli, and he simultaneously received a diagnosis of HIV 
infection with a CD4-positive T-lymphocyte count (CD4 count) of 9 cells/
mm3. Tuberculosis therapy was begun and comprised isoniazid, rifampicin, 
pyrazinamide, and ethambutol; he was also started on a fixed-dose combination 
of zidovudine, lamivudine, and abacavir. DNA was extracted from the initial 
sputum smear taken at the time of presumptive tuberculosis diagnosis according 
to previously published methods.5 The GenoType CM/AS reverse line blot assay 
(Hain Lifesciences, Nehren, Germany) was weakly positive for M. tuberculosis 
complex. The patient’s cough resolved, and he completed a 9-month course of 
tuberculosis therapy. When fever subsequently developed, he was admitted to the 
hospital; CD4 count was 13 cells/mm3. Mycobacterial blood culture grew acid-
fast bacilli after 12 days of incubation; results of AccuProbe MTB and MAC tests 
were negative. Heat-killed cells from the positive blood culture were identified 
as M. simiae by the INNO-LiPA reverse-line blot. Sequencing of the full 16S 
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rDNA gene, ITS, and hsp65 gene identified the isolate as “M. sherrisii.” The 16S 
rDNA and hsp65 sequences were identical to the M. sherrisii American Type 
Culture Collection (ATCC; Manassas, VA, USA) BAA-832 type strain sequences 
deposited in the GenBank sequence database under accession nos. AY353699 
(16S rDNA) and AY365190 (hsp65). The ITS sequence was identical to that of 
M. sherrisii strain FI-95229 (accession no. DQ185132), isolated from sputum of 
a patient in Italy.6 The Tanzanian patient was treated with azithromycin, 500 mg/
day, and ethambutol, 800 mg/day. His fever abated and he remained well, with 
109 CD4 cells/mm3 as of last follow-up in 2008.
The second patient was a 36-year-old HIV-infected man with a three-month 
history of fever and weight loss and 31 CD4 cells/mm3. He had been taking 
fixed-dose combination stavudine, lamivudine, and nevirapine for five months, 
but his adherence to therapy was poor. A mycobacterial blood culture grew 
acid-fast bacilli after 15 days of incubation; AccuProbe MTB and MAC test 
results were negative. Heat-killed cells from the positive blood culture were 
identified as M. simiae by the INNO-LiPA reverse-line blot and again as M. 
sherrisii by sequencing of the full 16S rDNA gene, ITS, and the hsp65 gene. 
The 16S rDNA gene had a single base-pair difference when compared with the 
M. sherrisii ATCC BAA-832 type strain sequence in GenBank. We deposited 
the new 16S rDNA sequence in GenBank under accession no. EU883389. The 
hsp65 sequence was identical to the M. sherrisii ATCC BAA-832 strain sequence 
(accession no. AY365190); the ITS sequence was identical to the M. sherrisii 
strain FI-95229 (accession no. DQ185132) sequence.6 The patient was treated 
with azithromycin, 500 mg/day, and ethambutol, 800 mg/day; fever abated. At 
follow-up in 2008, the patient was continuing treatment with azithromycin 
and ethambutol but had abdominal pain and hepatosplenomegaly. Abdominal 
ultrasonography showed retroperitoneal lymphadenopathy. Follow-up 
mycobacterial blood cultures have been negative.
The third patient was a 36-year-old HIV-infected woman with a 4-month 
history of bilateral skin lesions affecting the lower extremities (Figure 1) and 206 
CD4 cells/mm3. HIV infection had been diagnosed 18 months earlier; baseline 
CD4 count was 6 cells/mm3. She began fixed-dose combination stavudine, 
lamivudine, and nevirapine soon after her HIV diagnosis. An incisional biopsy 
from the active margin of a leg lesion showed several foci of dermal necrosis 
with dense lymphocytic infiltrate and Langhans-type giant cells consistent with 
granulomatous inflammation (Figure 2). Culture of biopsy material was positive 
for M. avium complex. The isolate reacted only with the M. avium-intracellulare-
scrofulaceum complex probe of the INNO-LiPA reverse-line blot. The 16S rDNA 
gene and ITS sequences were identical to the M. avium complex ATCC 35770 
(Melnick) strain sequences published by Böddinghaus et al.7 and available in 
the Ribosomal Differentiation of Microorganisms database (http://rdna.ridom.
de). The ITS sequence was also identical to the M. avium complex ATCC 
35770 strain sequence available in GenBank (ITS sequevar MAC-D, accession 
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no. L07851). The hsp65 sequence was identical to the ATCC 35770 sequence 
(accession no. U85637). Because the full 16S rDNA gene sequence of this strain 
was not available in GenBank and only a small fragment of hsp65 was available, 
we deposited our sequences under accession nos. EU815938 (16S rDNA) and 
EU935586 (hsp65). This patient was treated with azithromycin, 500 mg/day, 
ethambutol, 800 mg/day, and rifampicin, 600 mg/day. Her lesions abated over 
the subsequent weeks, and she remained well as of follow-up in 2008.
Conclusions
Improved laboratory techniques enabled us to demonstrate that invasive 
NTM infections occur in northern Tanzania and include M. sherrisii and M. 
avium complex. Mycobacterium sherrisii still awaits official recognition.6 Of 
M. sherrisii infections reported to date,6,8-12 most have been in HIV-infected 
patients from Africa.8-10 Although recommendations for the antimicrobial 
drug management of these infections have not yet been established, our two 
patients with M. sherrisii disseminated disease responded clinically to the 
optimization of their antiretroviral therapy regimen and to the combination of 
ethambutol and azithromycin. 
The M. avium complex isolated from our third patient is remarkable for its 
ITS sequevar type. MAC-D has not previously been associated with invasive 
disease in HIV-infected patients, in whom M. avium sequevars, mainly Mav-A 
Figure 1: Photograph of skin lesions on right leg of patient 3, taken before treatment
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Figure 2: Histopathologic appearance of skin biopsy specimen of patient 3
Dermal necrosis with a dense lymphocytic infiltrate and Langhans-type giant cells, consistent 
with granulomatous inflammation (hematoxylin and eosin stain, magnification ×40).
and -B, are most common.12,13 The M. avium complex ATCC 35770 reference 
strain was the first reported strain with a MAC-D ITS. The ATCC 35770 strain, 
however, was isolated from a sputum sample in a symptomatic patient in the 
United States.14 The isolate from our third patient and the ATCC 35770 strain 
are genetically divergent from other M. avium complex members and may 
represent a separate species within the M. avium complex.
Invasive NTM disease in HIV-infected populations in sub-Saharan Africa 
demands more attention in terms of identification of etiologic agents, clinical 
relevance, and management. Further insights would be gained if current 
and future studies on tuberculosis in the region included liquid culture and 
molecular identification to confirm M. tuberculosis infection and establish the 
epidemiology and clinical relevance of NTM.
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General Discussion
“Een tuingrondsuspensie bij een cavia ingespoten zal ondanks het feit, dat vele 
honderden bacteriesoorten worden ingespoten op zijn hoogst gasphlegmonen 
doen ontstaan, een infectie wordt practisch gesproken nimmer op deze wijze 
opgewekt. Het spreekt dus vanzelf, dat ook de grondmycobacteriën zich als 
volkomen onschuldige saprophyten zullen gedragen.”
[“Injection of a potting soil suspension in guinea pigs will, despite injection of 
hundreds of bacterial species, merely lead to gas phlegmons; [mycobacterial] 
infections are generally not invoked. Hence, the environmental mycobacteria 
behave as harmless saprophytes.”]
- L.E. Den Dooren De Jong, Dutch bacteriologist, 1939 1
 
Within this thesis, four cardinal issues have been raised. Most important is 
the observation that the clinical relevance of nontuberculous mycobacteria 
(NTM) in the Netherlands differs significantly by species. This observation is 
important as it offers guidance in the treatment decision in individual patients 
from whom NTM have been isolated. Furthermore, this may serve as a starting 
point to unravel the interaction between NTM and the human host. Our second 
observation is that the outcome of treatment for NTM disease is generally 
disappointing, despite treatment adjustment to in vitro susceptibility testing 
results and clinical trial data. Third, currently used molecular identification 
tools provide an over-simplified view of the evolutionary divergence among 
nontuberculous mycobacteria, which may provide part of the reason for the 
differences in clinical relevance between strains of different species and within 
species. Lastly, NTM cause disease worldwide, including in settings with a 
high prevalence of tuberculosis (TB), where identification, drug susceptibility 
testing and even active drugs may be unavailable.
The rising isolation frequency of NTM in the Netherlands lead to the current 
studies; during these studies, the species distribution among NTM isolates 
was found to differ from neighbouring countries. Before addressing the four 
cardinal issues of this thesis, the isolation frequency and species distribution 
will be briefly discussed.
Isolation frequency of nontuberculous mycobacteria in the Netherlands
The isolation frequency of NTM has risen during the 2000 to 2008 period in the 
Netherlands, whereas in the same period the incidence of TB decreased. This 
rise is not limited to the Netherlands. Many developed countries in Europe, 
West Asia and North America have recorded rising NTM isolation frequencies.2 
Some authors have rightly claimed that the rising isolation frequency of NTM 
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reflects simultaneous improvements in laboratory facilities.3 Microbiological 
laboratories have benefited from a wide array of novel techniques and materials 
over the past decade. Highly sensitive automated liquid culture systems have 
been added to the conventional solid media for Mycobacterium culture.4 
Molecular detection and identification assays have been developed that offer 
rapid inexpensive identification of NTM to laboratories without access to DNA 
sequencers. These techniques have largely replaced the previous biochemical 
identification and high-performance liquid chromatography as first line 
identification methods.5-7 
There is increasing evidence that the technological advances are not the sole 
explanation for the rise in NTM isolation.2,7,8 First, it is important to note that 
in the Netherlands the percentage of TB cases that could not be confirmed by 
culture (stable at 33% over the 1999-2005 period) did not decrease, despite 
introduction of the more sensitive liquid culture systems and molecular 
detection and identification tools.9 
Second, the rise in isolation frequency does not affect all species equally; if this 
rise was based largely on technical improvements, one would expect a uniform 
rise in isolation of many, if not all, NTM species. In the Netherlands, the rising 
isolation frequency is largely explained by an increasing isolation frequency of 
M. avium complex (MAC) isolates, mainly M. avium in respiratory samples of 
elderly patients (Chapter 2.1, 2.9). For other species, including M. simiae, M. 
xenopi, M. szulgai and M. malmoense, such an increase was not apparent in the 
Netherlands (Chapter 2.2-2.7). Other European countries did report rising 
isolation frequencies for M. malmoense.10 
Third, the increasing isolation frequency of NTM seems to be particularly 
true for countries where the incidence of TB is in decline.2,7 This decline in 
TB incidence suggests that exposure to TB infers cross-protection to NTM 
disease. This is supported by the fact that countries that halted Bacille 
Calmette-Guerin (BCG) vaccination subsequently noticed an increase in 
the incidence of paediatric cervicofacial lymphadenitis caused by NTM.11,12 
Moreover, during decades of decreasing tuberculosis incidence rates, Bleiker 
and co-workers noted increased skin sensitization to M. scrofulaceum and 
decreasing sensitization to tuberculin in Dutch elementary school children.13 
A similar observation was recently made in the United States, were over the 
past three decades, the skin sensitization to M. intracellulare has increased, in 
conjunction with an increase in the incidence of M. intracellulare disease.14 
Still, pulmonary NTM disease is well known to affect patients with a destroyed 
lung or upper lobe bronchiectasis caused by prior pulmonary tuberculosis. 
Thus, several factors other than cross protection by tuberculosis exposure need 
to be considered responsible for the rise in NTM isolation frequency. 
One of the most important factors is probably the ageing population in the 
Netherlands and many other developed countries. With the increased life 
expectancy comes an increasing burden of chronic diseases, especially chronic 
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pulmonary disease. The most recent estimate is that 1.3% of the Dutch 
population has a formal diagnosis of chronic obstructive pulmonary disease 
(COPD).15 In a country of 16.2 million inhabitants, that makes for 210600 
COPD patients. Chronic pulmonary disease in itself increases the susceptibility 
to pulmonary NTM disease. For other chronic diseases, immunosuppressive 
therapy is applied, which will indirectly lead to increased susceptibility to NTM 
disease. Such increased susceptibility has been noted specifically in users of 
anti-tumor necrosis factor-α (TNF) therapy (Chapter 3).16 These demographic 
changes have probably also influenced the NTM isolation frequency in the 
Netherlands (Chapter 2.1, 2.9).
The increased use of showers for personal hygiene may also be a factor in the 
increasing prevalence of NTM disease.17 Showers produce fine aerosols of tap 
water that is known to contain NTM.18-20 As a result of showering and other 
environmental contacts, humans are thought to be exposed to 50 to 500 NTM 
bacilli on a daily basis.21
Although the background of the increased clinical NTM isolation may 
remain controversial, it has obviously led to increased interest in NTM among 
clinicians.7 Increasing knowledge of NTM disease in clinicians may, in turn, 
have lead to more patients being evaluated for and diagnosed with NTM 
disease. Still, a rise in the incidence of NTM disease has also been noted in 
populations where the number of patients evaluated remained stable.22 The 
increased number of clinical NTM isolates has led to an intense debate on the 
clinical relevance of this finding. In fact, this debate was the starting point for 
our studies.
Based on these studies, we now conservatively estimate that NTM are isolated 
from 800 patients annually in the Netherlands, or 5/100.000 persons per year. 
In our regional study we found that for one third of all patients with NTM 
isolates, the NTM could be classified as causative agents of disease (Chapter 
2.1). The incidence of disease due to NTM in the Netherlands would then be 
1.7/100.000 persons per year.
Species distribution among clinical NTM isolates in the Netherlands
Of all isolates submitted to the Dutch National Mycobacteria Reference 
Laboratory, part of the National Institute for Public Health and the Environment 
(RIVM), Mycobacterium avium is the most frequently encountered NTM 
species (23%), followed by M. gordonae (15%), M. kansasii (8%), M. 
intracellulare (7%) and the M. fortuitum complex (5%; see Table 1). Within 
the Netherlands, this species distribution is likely to differ by region due to 
varying environmental characteristics. Nonetheless, the species distribution in 
our clinical study in the Nijmegen-Arnhem region was very much in line with 
the general distribution of NTM species submitted to the RIVM (Table 1).
The species distribution in the Netherlands is different from that of neighbouring 
countries, although the paucity of recent, published data precludes in-depth 
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analysis. Mycobacterium xenopi has been linked to the English Channel 
region, based on data from the UK and Belgium.2,29 Prior studies in South-
East England have demonstrated a predominance of M. xenopi in that area; 
this has been linked to the fact that this is a coastal region, with many water 
birds, which may be a source of M. xenopi.29 A similar species distribution has 
recently been reported from Slovenia.25 Despite the Netherlands’ long North 
Sea coast line and its proximity to the English Channel, M. xenopi isolation 
is infrequent. Moreover, M. xenopi isolation is not linked to coastal areas of 
the Netherlands (Chapter 2.2). Based on currently available data, the species 
distribution in the Netherlands most closely resembles that of Denmark and is 
remarkably different from that of our direct neighbouring countries Germany 
and Belgium, as well as from the United Kingdom and North America (Table 
1). In North America M. intracellulare is the most frequent M. avium complex 
isolate and the most common causative agent of pulmonary NTM disease.7,30 
Conversely, M. avium predominates in the Netherlands, both in terms of 
isolation frequency and clinical relevance (Table 1 & Chapter 2.1). 
Of the 130 validly published NTM species,31 approximately 70 have been 
isolated from clinical samples in the Netherlands (Chapter 4.1, 5.1). It is not 
known whether the frequency of clinical isolation mirrors the NTM species 
distribution in the environment. Although the RIVM has data on species 
distribution in clinical samples, no recent environmental data are available. 
Country Setting N Species distribution (%)
MAC Mav Min Mka Mxe Mml Msz RGM Mab Mfc
NL NRL 4599 39 23 7 8 2 3 1 13 3 5
NL MC 232 41 28 9 8 2 1 2 11 2 5
England RL 6668 20 - - 15 23 2 <1 16 - 8
Scotland RL 248 33 - - 4 8 38 0 17 - -
Belgium MC 1180 12 - - 3 35 0 - - - 2
Germany MC 1390 26 - - 4 13 2 - - - 12
France MC 3200 41 - - 11 21 1 - - - 7
Denmark NRL 496 40 - - 1 3 4 <1 7 4 2
Slovenia NRL 1299 20 12 7 8 29 1 - 16 1 7
Canada RL 11186 59 - - 2 26 - - 13 - -
USA-NY SC 505 84 - - 2 3 0 0 9 3 3
USA MC 5469 50 - - 12 1 <1 <1 13 - 10
Korea SC 794 28 14 14 2 <1 0 4 54 18 27
NL, the Netherlands; USA, United States of America; (N)RL, (National) Reference Laboratory; 
MC, multi-centre; SC, single centre; MAC, M. avium complex; Mav, M. avium; Min, M. 
intracellulare; Mka, M. kansasii; Mxe, M. xenopi, Mml, M. malmoense; Msz, M. szulgai; RGM, 
rapid-growing mycobacteria; Mab, M. abscessus; Mfc, M. fortuitum complex; data are derived 
from Chapter 2.1 and references 2,8,23-28.
Table 1: NTM species distribution in clinical samples in various geographic locations
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Possibly, the human respiratory tract (the most common source of clinical 
NTM isolates) exerts a selective pressure. Furthermore, it is conceivable that 
not all environmental NTM can be cultured in vitro with the same rate of 
success. This should be a subject of future studies.
The NTM species distribution in the Netherlands during our study period 
not only differed from neighbouring countries; it also varied from earlier 
observations. In the 1960’s, M. kansasii was reported to be the most frequent 
causative agent of pulmonary NTM disease in the Netherlands.32-34 This was 
different from for example the USA, where at that time the nonchromogenic 
M. avium complex bacteria (or “Battey” bacilli, after the Battey State Hospital, 
Georgia, USA 35) were most frequently isolated. It seems that in the three 
decades between the studies by Manten, van Joost and Selkon, the species 
distribution in the Netherlands has changed. Here, technical advances and 
their impact on Mycobacterium taxonomy36,37 as well as environmental and 
host factors may play an important role. The latter will be covered in the 
“disease characteristics” section. 
Similarly, in the 1960’s, the causative agents of paediatric cervicofacial 
lymphadenitis were mostly M. scrofulaceum (21/40), followed by the 
nonchromogenic “Battey” bacilli. Mycobacterium scrofulaceum is now a rarely 
encountered pathogen and most cases of paediatric cervicofacial lymphadenitis 
are now caused by M. avium (Chapter 2.1).38 Mycobacterium malmoense and 
M. haemophilum are probably the second and third most common NTM 
causative agents of NTM lymphadenitis in the Netherlands (Chapter 2.1, 
2.6).38,39 This shift in causative agents, away from M. scrofulaceum, has been 
simultaneously noted in the USA.7 This phenomenon has been attributed to 
chlorination of tap water, which should select for M. avium, as M. scrofulaceum 
is more susceptible to chlorine.7,21 Studies reviewed by Collins and co-
workers, however, did not demonstrate important differences in chlorine 
susceptibility between NTM species and considered tap water chlorine levels 
too low to lead to significant reductions in mycobacterial load.40 Furthermore, 
in the Netherlands the same species shift was noted in absence of tap water 
chlorination. Second, after molecular identification tools became more 
widespread, several scotochromogenic slow growing mycobacteria isolated 
from children with cervicofacial lymphadenitis have been elevated to separate 
species status; these include M. bohemicum, M. interjectum, M. lentiflavum 
and M. palustre.37 Mycobacterium mantenii and M. vulneris, which we have 
described, fall into this same category (Chapter 5.3, 5.4). The International 
Working Group on Mycobacterial Taxonomy also studied several isolates 
related to, but different from, M. scrofulaceum.41 All these isolates and newly 
described scotochromogenic slow-growers may have previously been falsely 
identified as M. scrofulaceum.37
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The clinical relevance of nontuberculous mycobacteria
The first part of our studies focussed on the clinical relevance of NTM isolation. 
To quantify clinical relevance we assessed the fraction of patients with isolates 
of a particular species that had disease attributable to bacteria of this NTM 
species. This approach is novel; previous studies generally described reports 
of single or a few cases, or were laboratory driven and left the assessment of 
clinical relevance to the treating physician. In general, most reports focus on 
cases of true NTM disease and ignore the fraction of the isolates of that same 
species that could not be associated with clinical disease. So, the literature 
was not conclusive with regard to the average level of clinical relevance of the 
described NTM species. This implies that for clinicians faced with a patient 
from whom an uncommon NTM is isolated, a literature search would probably 
lead to an overestimation of its clinical relevance due to this publication bias.
Figure 1: Percentage of patients with NTM disease, per species 
Figure 2: Clinical relevance of pulmonary isolates of NTM species
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We used the American Thoracic Society diagnostic criteria for pulmonary NTM 
disease to assess the relevance of pulmonary isolates. For extrapulmonary isolates, 
we divided those from the normally sterile sites (e.g. lymph nodes, bone) from 
those from the non-sterile digestive tract. Whereas the former were considered 
relevant until proven otherwise (e.g. signs of laboratory contamination), the 
latter were considered irrelevant, unless accompanied by features suggestive 
of disseminated NTM disease. We applied these criteria in a regional study, to 
cover the major species such as M. avium, M. intracellulare and M. kansasii. Later 
we used these criteria in nation-wide studies focussed on the less frequently 
isolated M. xenopi, M. simiae, M. szulgai, M. malmoense, M. conspicuum and the 
rapid growers M. chelonae and M. abscessus. Lastly, we used the ATS diagnostic 
criteria while describing four new species of Mycobacterium: M. noviomagense, 
M. riyadhense, M. vulneris and M. mantenii. We have reviewed medical files of 
473 patients in the Netherlands with NTM isolates, to conclude that 192 patients 
(41%) were likely to have true NTM disease (Chapter 2).
The most important observation stemming from our regional and national 
studies is that the clinical relevance, expressed as the percentage of patients 
with NTM isolates that met the ATS diagnostic criteria for pulmonary NTM 
disease or were likely to have extrapulmonary NTM disease, differs by species. 
These differences can be visualized on a scale (Figure 1), to assist clinicians in 
their assessment of individual patients from whom an NTM is isolated.
The position on Figure 1 partly reflects the number of cases of extrapulmonary 
disease due to the respective NTM species because isolation of NTM from 
extrapulmonary sites is generally indicative of true NTM disease. Species 
that frequently cause extrapulmonary disease are thus more often clinically 
relevant than species that are rarely encountered in extrapulmonary samples. 
The ability to cause extrapulmonary and disseminated disease differs 
significantly by species. Mycobacterium avium is a common causative agent 
of pulmonary disease, paediatric cervicofacial lymphadenitis and HIV-
related disseminated infections. In contrast, M. malmoense causes pulmonary 
disease and lymphadenitis, M. chelonae and M. abscessus cause pulmonary 
and focal extrapulmonary disease, but rarely lymphadenitis and M. simiae 
almost exclusively causes pulmonary disease in the Netherlands (Chapter 2). 
Hence, it is fairer to compare the clinical relevance of pulmonary NTM isolates 
separately. Based on these data for the various species studied in our regional 
and nation-wide studies, we have constructed Figure 2.
 
Whereas M. avium is the most frequently isolated NTM in the Netherlands, 
M. xenopi, M. kansasii, M. szulgai and M. malmoense are more often clinically 
relevant. Although M. kansasii and M. szulgai are phylogenetically related 
(and, in fact, most closely related to the M. tuberculosis complex (Chapter 
6.2)), the level of clinical relevance is not higher for these species than for more 
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distantly related NTM such as M. malmoense. This implies that there is no 
direct correlation between the phylogenetic grouping and clinical relevance. 
In addition, in The Netherlands 47% of 45 patients from whom M. xenopi 
was cultured from respiratory samples met the American Thoracic Society 
diagnostic criteria. Contrarily, none of the 17 patients with M. noviomagense 
isolates did, while these two species are phylogenetically closely related 
(Chapter 2.2, 5.2). 
The difference in clinical relevance between NTM species can guide a clinician 
in his stance towards the symptomatic patient from whom a particular NTM 
has been isolated. Isolation of M. kansasii, M. malmoense or M. szulgai urges 
vigilance and intense follow-up, if not the institution of therapy; if one of a 
series of sputum cultures yields M. gordonae or M. noviomagense, a more 
observational stance is probably sufficient, as pulmonary NTM disease is far 
less likely. Based on small numbers of isolates noted in our regional study we 
presume that M. genavense and M. celatum fall into he same category as M. 
kansasii, M. szulgai and M. malmoense. Mycobacterium alvei, M. palustre, M. 
terrae and M. phlei are likely to be as non-relevant as M. gordonae and M. 
noviomagense (Chapter 2.1, 5.2). Still, these findings remain to be confirmed 
in nationwide studies with larger numbers of patients.
We think that the ATS diagnostic criteria should be changed to accommodate 
for this difference in clinical relevance. It is conceivable to introduce less strict 
criteria for the diagnosis of pulmonary M. kansasii, M. malmoense and M. 
szulgai disease, as their isolation frequently indicates true NTM disease. For 
M. kansasii, the ATS criteria already state that the treatment decision may 
be guided by a single positive culture, based on its established pathogenic 
potential.7 It is important, however, to make note of the subtype of M. kansasii 
isolated, as only one of five subtypes is strongly associated with pulmonary 
disease.42,43 Stricter diagnostic criteria for species like M. chelonae, M. abscessus 
and M. simiae may prevent unwarranted diagnoses of disease. For these three 
species, we noted several patients who met the ATS diagnostic criteria, while 
they were unlikely to suffer true NTM disease (Chapter 2.3, 2.7). Figure 2 can 
Country Year Setting N % clinical relevance by species
All MAC Mav Min Mka Mab Mfc Mxe
NL 99-04 MC 212 25 31 41 13 71 33 9 60
Korea 02-03 SC 794 25 43 34 52 50 45 10 0
USA-NY 00-03 SC 344 24 25 - - 57 - - 44
USA 81-83 MC 5469 38 47 - - 75 - 18 25
NL, the Netherlands; USA, United States of America; NY, New York; MC, multi-centre; SC, single 
centre; MAC, M. avium complex; Mav, M. avium; Min, M. intracellulare; Mka, M. kansasii; Mab, 
M. abscessus; Mfc, M. fortuitum complex; Mxe, M. xenopi; data are derived from Chapter 2.1 and 
references 26-28.
Table 2: Clinical relevance of pulmonary NTM isolates in different countries
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serve as a template to assign sets of different microbiological criteria to groups 
of species. The clinical and radiological criteria should be strictly maintained.
Despite a paucity of available data, we did find striking similarities between the 
clinical relevance of NTM species observed in our regional study and the few 
previous studies in other countries; they are visualized in Table 2. 
The clinical relevance among MAC isolates observed in this study differs from 
previous reports from the USA, where M. intracellulare was the more frequent 
respiratory pathogen and clinically more relevant than M. avium in non-HIV 
patients.7,30 The latter issue was debated in a recent study from another site in 
the United States, where M. avium was still less frequently isolated than M. 
intracellulare, though more frequently clinically relevant.44 Unfortunately, the 
nation-wide study performed by O’Brien and co-workers27 and the recently 
published study performed by Bodle and co-workers at the Presbyterian 
Hospital in New York26 did not distinguish between the MAC species.
Similarly, we found M. malmoense to be the most frequently clinically relevant 
NTM species; 80% of all patients with pulmonary isolates met the ATS 
criteria. These data roughly match those reported from nearby Scotland and 
Denmark,23,24 but differ strongly from the United States. A single study of 60 
patients has been performed in the United States, which concluded that true 
M. malmoense disease was likely in just six (10%) of the patients assessed.45 
Differences in clinical relevance of NTM species in various geographical areas 
suggest variation in host susceptibility or differences in the virulence of the 
circulating bacteria. Both issues will be discussed in separate paragraphs. 
One important limitation associated with our approach is the use of the 
American Thoracic Society diagnostic criteria. For M. abscessus, M. chelonae 
and M. simiae, we have noted that patients may meet these criteria while true 
NTM disease is, in fact, unlikely (Figure 2). Most frequently, these patients 
responded well to therapies that were highly unlikely to have any impact on an 
NTM infection. For these three species, the true degree of clinical relevance, 
hence their position in Figure 2, is likely to be lower than currently estimated 
(Chapter 2.3, 2.7, 2.8). Another important issue is the revision of the ATS 
diagnostic criteria in 2007. With more lenient bacteriological criteria, we 
found that more patients met the revised criteria, compared to the stricter 
previous criteria published in 1997 (Chapter 2.8).7,46 Whether this leads to 
an improved selection of patients for whom therapy is warranted and leads to 
clinical improvement is uncertain. The authors of the new criteria, however, 
repeatedly state that meeting these criteria does not, per se, necessitate the 
institution of therapy.7 This was not emphasized in the former statement. We 
believe that such comments added for the academic nuance only increase 
confusion for the clinician (Chapter 2.8). 
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A second issue which may have influenced our results is the fact that for NTM 
identification, we have frequently relied on reverse line blot hybridization 
assays. In later studies we have proven that these tests underestimate the 
genetic divergence and, albeit infrequently, can lead to false identifications. The 
identification of M. riyadhense as M. tuberculosis complex, the identification 
of M. sherrisii isolates as M. simiae and the incorrect identification of isolates 
with unique, novel 16S gene sequences to species level may mean that some of 
the isolates in our species-specific retrospective studies may not have been that 
exact species (Chapter 5.1, 7.2, 7.4). The results of our multi-gene sequencing 
study also revealed isolates of M. bolletii and M. massiliense among isolates 
previously designated M. abscessus. These species may also be present in the 
series previously identified as M. abscessus and examined in our retrospective 
study.
Lastly, our studies on clinical relevance were based on retrospective medical file 
studies. An assessment of clinical relevance based on retrospective data only 
is hampered by the fact that not all clinical circumstances can be convincingly 
captured in a retrospective medical file review.
NTM disease characteristics in the Netherlands
In the 1950’s, the NTM were first recognized as causative agents of pulmonary 
disease in the Netherlands. Now, it has become clear that the NTM are 
causative agents of various types of disease, each within specific populations, 
though pulmonary NTM disease is most frequently diagnosed. Of all 473 
patients with NTM isolates evaluated during our various studies, 407 (86%) 
had NTM isolated from pulmonary samples; of all 192 cases of NTM disease 
found during these studies, 138 (72%) were cases of pulmonary NTM disease.
Three distinct pulmonary NTM disease types have been distinguished: 
classical cavitary disease, nodular-bronchiectatic disease and hypersensitivity 
pneumonitis.7 From Manten’s early observations32,33 to our current findings, 
it has been clear that in the Netherlands, the upper lobe cavitary disease type 
(example in Figure 3) is most frequent (Chapter 2). 
The cavitary disease type resembles pulmonary tuberculosis both clinically and 
radiologically, though its clinical course is usually more prolonged. This disease 
type primarily affects patients with pre-existing pulmonary disease. Most 
patients in our studies who suffered pulmonary NTM disease had a history of 
chronic obstructive pulmonary disease (COPD); the percentage ranged from 
83% of patients from with M. simiae disease, to 66% for those with M. malmoense 
disease (Chapter 2). These differences suggest that not all NTM equally need a 
structurally damaged lung to thrive well. Perhaps this explains the differences 
in species distribution between our current studies and the studies by Manten 
in the 1960’s, when M. kansasii dominated.32 In our era, with the increasing 
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incidence of COPD, NTM other than M. kansasii succeed in causing pulmonary 
disease, in the population with pre-existing pulmonary disease. 
Many patients had mild to moderate COPD, stage I to II according to the 
Global initiative for chronic Obstructive Lung Disease (GOLD) criteria.47 
In our regional study, we already noted that those who met the ATS criteria 
for pulmonary NTM disease were generally younger than those who did not 
(Chapter 2.1). This suggests that the risk of NTM disease does not increase as 
COPD progresses. Perhaps NTM disease affects a specific subgroup of COPD 
patients with an underlying genetic predisposition. This polymorphism, 
in turn, may have a role in the emergence of COPD, or of a specific COPD 
phenotype in these patients. 
In the United States, nodular-bronchiectatic disease is the most frequent 
NTM disease type; its radiographic features are shown in Figure 4. This 
disease primarily affects post-menopausal women, who tend to be taller and 
leaner than controls and have a distinct body habitus with scoliosis, pectus 
excavatum and mitral valve prolapse: the “Lady Windermere syndrome”.7,48 
It has recently been found that among patients presenting with the Lady 
Windermere Syndrome, mutations in the Cystic Fibrosis transmembrane 
conductance regulator (CFTR) gene were significantly more frequently present 
than in the general population.49 This disease type is rare in the Netherlands; 
it is outnumbered 4:1 by cavitary NTM disease (Chapter 2.1). No cases of 
hypersensitivity pneumonitis were encountered during our retrospective 
studies. It is not certain whether this represents a reporting bias, or reflects a 
true absence.
We noted several cases of pulmonary M. abscessus disease in patients with cystic 
fibrosis (CF). CF patients are specifically at risk of developing M. abscessus 
disease. The background of this phenomenon is incompletely understood 
(Chapter 2.7).50,51 There are two possible explanations for this predilection. First, 
the fact that M. abscessus bacteria are resistant to most antibiotics classically 
used to treat CF implies they are progressively selected for by the repeated 
Figure 3: Examples of cavitary lesions caused by Mycobacterium malmoense lung disease
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antibiotic treatments, as has been shown for other CF pathogens, including 
Stenotrophomonas maltophilia and Alcaligenes xylosoxidans.52,53 Second, as a 
result of the dysfunction of the CFTR, CF patients have epithelial lining fluid 
with elevated sodium chloride (NaCl) concentrations.54 Interestingly, M. 
abscessus bacteria are characterized in the laboratory by their ability to grow 
in a saline environment. Ability to grow in 5% NaCl was, in fact, the available 
method to distinguish M. abscessus from related rapid growing NTM prior to 
the advent and spread of molecular tools for NTM identification.55 
Little is known of the mechanisms by which the pre-existing pulmonary 
diseases influence susceptibility to pulmonary NTM disease. It is, for instance, 
not known what happens directly after acquisition of these bacteria in the 
lung. Disease caused by NTM is the result of a complex interplay between 
bacterial virulence factors and host immunity. Interestingly, both sides of the 
story are currently composed of largely blank pages. In murine models, M. 
avium is able to establish pulmonary infection after intravenous challenge, 
similar to M. tuberculosis.56-58 Mycobacterium abscessus and M. chelonae, 
on the other hand, fail to establish pulmonary infection after intravenous59 
and even intratracheal challenge of Balb/c mice.60 There is an interesting 
parallel with an observation in humans. In a series of 200 AIDS patients 
with documented disseminated M. avium complex disease, only 5 patients 
(2.5%) were found to have concomitant pulmonary disease due to M. avium 
complex.61 This suggests that NTM have difficulty establishing an infection 
in healthy lung tissue. In 1959, Emanuel Wolinsky already reported that in a 
guinea pig model successful pulmonary infection with a variety of NTM was 
Figure 4: The chest radiograph (A) and corresponding chest CT (B) image of a female 
patient with pulmonary nodular bronchiectatic M. intracellulare disease. Chest radio-
graph reveals bilateral, predominantly mid to lower lung zone linear and nodular opaci-
ties; Chest CT scan reveals peripheral nodular opacities (tree-in-bud pattern), consoli-
dation and bronchiectasis in the right middle lobe, and bronchiectasis in the lingula.
Pictures were kindly provided by Professor Charles L. Daley, National Jewish Health, Denver, USA.
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possible, but only after having induced silicosis in these animals by quartz 
inhalation.62 The CFTR mutations in the Lady Windermere syndrome49 add 
to the suggestion that patients suffering pulmonary NTM disease without 
a formally diagnosed pre-existing lung disease, or other risk factors, may 
not be truly “immunocompetent” or “without predisposing conditions” as 
has been suggested in many case reports and series. Our clinical findings 
and the many questions arising from them suggest that more appropriate 
animal models, mimicking clinical situations including COPD and cystic 
fibrosis, should be used to investigate the pathophysiology and immunology 
of pulmonary NTM disease.
Paediatric cervicofacial lymphadenitis is the second most frequent NTM 
disease entity in the Netherlands; a relatively benign disease which primarily 
affects previously healthy children below the age of six with no known 
impairment of immunity. It is characterized clinically by painless swelling 
of a cervical or submandibular lymph node in the absence of generalized 
symptoms; other lymph nodes are rarely affected (Chapter 2.1, 2.6, 5.3, 5.4). 
In the Netherlands, M. avium is the most frequent causative agent, followed by 
M. malmoense (Chapter 2.1, 2.6). Surgical excision is the treatment of choice 
and is more effective than multi-drug treatment.7,38
In the Netherlands, 15 to 20 cases of localized skin disease by M. marinum 
are diagnosed annually. This disease is often called the “fish tank granuloma” 
as most infections nowadays are seen in owners of aquaria with tropical fish; 
the infection commonly emerges in wounds acquired during cleaning of the 
aquarium.7 No cases of M. ulcerans skin disease (Buruli Ulcer) were observed 
in the Netherlands in our study period.
Besides these three frequent NTM disease types, several rare forms of localized 
NTM disease exist. Bone, skin and soft tissue infections generally arise after 
trauma, including puncture wounds, surgical wounds and injection sites. Eye 
infection after laser in situ keratomileusis (LASIK) and ear infection in children 
with tympanostomy tubes are especially notorious;7 both are frequently caused 
by rapid growing and highly drug-resistant NTM (Chapter 2.7, 2.10). 
In our series of NTM otomastoiditis, we noted very long intervals between 
the emergence of symptoms and the final diagnosis of NTM disease. We 
even noted cases of NTM infection in the skin and subcutis, after a dog bite 
(Chapter 5.3) and after cosmetic surgery in the Caribbean (Chapter 2.7). In 
all these clinical settings, Mycobacterium culture may not always be performed 
and cases may have been missed. 
Disseminated NTM disease is very rare and primarily affects patients with 
impaired immunity. Most cases of disseminated disease have been recorded 
in patients with advanced HIV disease (CD4 counts <50 cells/ml);7 this is in 
agreement with our findings, mainly for M. szulgai and M. avium (Chapter 
2.1, 2.4). Another important HIV-related manifestation of NTM disease is 
the immune reconstitution syndrome. Here, successful institution or change 
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of antiretroviral therapy leads to a local or multifocal inflammatory process 
caused by underlying NTM disease.63 We have noted two cases of spinal 
M. xenopi disease that we considered to represent immune reconstitution 
syndromes (Chapter 2.2). Intriguingly, not all NTM pathogens cause HIV-
related disseminated disease. This even accounts for bacteria of species that 
are common causative agents of other NTM disease types. For instance, M. 
malmoense, M. szulgai, M. avium and M. abscessus cause pulmonary disease in 
similar clinical settings, but only M. avium and M. szulgai are associated with 
disseminated infection in patients with AIDS (Chapter 2). 
Recently, inherited genetic defects of the interferon-γ/IL-12/IL-23 pathway 
were discovered, which confer an increased risk of mostly disseminated NTM 
disease.64 These genetic defects are rare and we have only observed these in two 
patients with M. szulgai disease (Chapter 2.4). However, only a very minor 
subset of the patients in whom NTM disease is diagnosed are examined for 
disorders in these pathways. Infections by other NTM (M. avium, M.gordonae, 
M. peregrinum and M. mageritense) in these patients have been described by 
van Dissel and co-workers of the Leiden University Medical Centre.65,66 It is not 
yet known whether all NTM species can cause disease in these patients with 
inherited immunological disorders. In their murine model, Ehlers and Richter 
found that interferon-γ is a crucial determinant in the outcome of infection with 
most, but not all, nontuberculous mycobacteria tested.58
Other patient groups at risk for disseminated NTM disease include those 
with leukaemia or immunosuppressive drug use. Previously, this mainly 
concerned patients who received steroid treatment for chronic inflammatory 
diseases, or patients receiving steroids and other immunosuppressive agents 
after solid organ transplantation.7 We have noted several cases of NTM disease 
attributable to immunosuppressive drug use. We recorded three cases of 
pulmonary M. xenopi disease and one case of M. szulgai skin disease in patients 
receiving steroids for chronic inflammatory diseases. In addition, we observed 
two cases of disseminated M. abscessus skin and joint disease and single cases 
of pulmonary M. avium disease, disseminated M. malmoense disease, focal 
M. malmoense skin disease and disseminated M. chelonae skin disease, all in 
patients receiving immunosuppressive drugs for haematological malignancies 
or solid organ transplantation (Chapter 2).
Recently, the increasing application of the anti-TNF agents for rheumatic and 
other inflammatory diseases has created a new category of patients at increased 
risk for NTM disease (Chapter 3).16 TNF-α has an important role in granuloma 
formation and maintenance,67 which are essential in the immunity against 
mycobacteria. During the early trials with these agents, reactivation of latent 
M. tuberculosis infection was most frequently reported.68 The introduction 
of screening measures, first by tuberculin skin test and chest radiograph,68,69 
now often by interferon-γ release assays and chest radiograph (Chapter 3.2), 
has limited the number of active tuberculosis cases in this patient group. The 
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number of cases of NTM disease associated with anti-TNF treatment, however, 
has increased and may now be more frequent than tuberculosis in this patient 
category;16 many of these patients have extrapulmonary or disseminated NTM 
disease. The number of patients who develop NTM disease associated with 
treatment of their inflammatory disease is likely to increase even further 
in the future. First, the anti-TNF agents are increasingly used for a wide 
array of indications, not only in rheumatic disease, but also in sarcoidosis, 
inflammatory skin disease (e.g. psoriasis) and inflammatory bowel disease 
(e.g. Crohn’s disease). Second, many of the immunosuppressive agents that 
are currently being developed or tested in rheumatic disease are likely to have 
a profound impact on the immunity against mycobacteria (Chapter 3.2). 
Awareness of the possible emergence of NTM disease needs to be induced 
among future users and prescribers of these drugs. For the recently approved 
CD20+ B-cell antibody rituximab, the first cases of NTM disease have already 
been reported.16,70
Treatment and outcome of pulmonary disease due to nontuberculous 
mycobacteria
In 1965, Manten stated that “[effective] chemotherapy for these [NTM] 
infections is an illusion”; surgical resection was the preferred treatment for 
NTM disease.32 Considering the cure rates in the most recent BTS trial, 25-
40% after 5 years of follow-up, one may question the progress made since 1965. 
In our studies, cure rates differed by species. In the regional study we recorded 
an overall cure rate of 67% for pulmonary NTM disease, though as low as 50% 
for M. avium disease. Higher cure rates were observed in M. szulgai (82%) 
and pulmonary M. malmoense (70%) disease (Chapter 2), the latter is in line 
with the recent BTS trial.71 Our results are biased since treatment regimens 
and duration varied widely, our average duration of follow-up was limited and 
retrospective medical file review is not an optimal method to study treatment 
outcome.
The sobering cure rates in the recent BTS trial, as well as in our various studies, 
may partly be explained by host factors, including the pre-existent pulmonary 
diseases and impairment of immunity. Most deaths in the BTS trial, for 
example, were due to these conditions rather than NTM disease.71 Of course, 
the lack of evidence-based, effective treatment regimens also results from the 
lack of interest in NTM disease and the low incidence, which hampers the 
execution of clinical trials.
The introductions of the rifamycins and the newer drug classes, including 
the fluoroquinolones and macrolides, have not resulted in higher cure rates. 
Macrolide-based treatment regimens have shown promising results in M. 
avium complex disease in the United States (92% culture conversion)72 and 
Japan (84% culture conversion).7,73 This efficacy could not be reproduced in 
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studies in Europe conducted by the British Thoracic Society (BTS), where only 
24% of 83 patients with pulmonary M. avium complex disease were alive and 
cured after five years of follow-up.71 How to explain the apparent controversy 
surrounding in the efficacy of macrolides in pulmonary M. avium complex 
disease? Three aspects need to be considered.
First, the macrolides have been proven effective mostly in studies performed 
in the US, where the majority of patients present with nodular-bronchiectatic 
disease.7,30,72 This specific disease type may differ in pathogenesis from the 
cavitary disease that is most common in the Netherlands and other European 
countries (Chapter 2).71 The different patient demographics, with a majority 
of females without a history of pulmonary disease but with CFTR gene 
mutations,7,49 support a different pathogenesis. The lack of drug penetration in 
cavities may be less an issue in nodular-bronchiectatic disease; it is well known 
that cavitary disease is among the factors associated with poor outcome of 
intermittent treatment.74 Possibly, the anti-inflammatory activity of macrolides 
is an added benefit in nodular-bronchiectatic disease, more so than in cavitary 
disease. Cavitary and nodular-bronchiectatic pulmonary NTM disease are 
two separate entities that may need separate treatment regimens to achieve 
comparable cure rates.
Second, in the United States the term ‘M. avium complex’ is commonly used, 
although most of the isolates are identifiable to the species level and represent 
M. intracellulare.7,30 We found macrolides to be more active in vitro against M. 
intracellulare than against M. avium (Chapter 4.1). Hence, in Western Europe, 
where M. avium is isolated more frequently than M. intracellulare, one may 
expect that macrolides are less effective.
Last, death rates were high during treatment and 5 years of follow-up in the 
BTS trial, due to the extent of pre-existent pulmonary disease in the enrolled 
patients. The studies in the United States enrolled patients of older age, though 
their condition was less frequently impaired by chronic pulmonary disease 
Growth 
rate
Species Susceptibility to
Macrolides Quinolones Aminoglycosides Rifampicin
Slow M. avium S R R R
Slow M. kansasii S S R S
Slow M. malmoense S R R S
Slow M. xenopi S S S S
Slow M. simiae R R R R
Rapid M. abscessus S R R R
Rapid M. chelonae S R R R
Rapid M. fortuitum R S S R
Rapid M. peregrinum S S S R
S, Susceptible; R, resistant
Table 3: Common slow- and rapid growing NTM with susceptibility data
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and follow-up was considerable shorter (19 months); correspondingly, death 
rates were lower.7,72
For the fluoroquinolones, the BTS trial again demonstrated a limited role in 
treatment of NTM disease.7 In the light of our in vitro results, this comes to no 
surprise. The new fluoroquinolone moxifloxacin has been shown to be more 
active than ciprofloxacin against mycobacteria.7,75 Perhaps there may be a role 
for moxifloxacin in the treatment of disease due to some NTM species. For M. 
avium disease, however, we expect little efficacy (Chapter 4.1). A combination 
of fluoroquinolones and macrolides did not result in greater efficacy in the 
BTS trial.71 Kohno and co-workers demonstrated a dampening effect of the 
fluoroquinolones on macrolide activity, both in vitro and in vivo.76 For slow 
growing NTM, a combination of macrolides and fluoroquinolones will not be 
an effective regimen. Still, it is a regimen that we regularly encountered in our 
restrospective studies (Chapter 2).
The use of treatment regimens that were not evidence based, or used for too short 
periods was frequent in all our retrospective studies (Chapter 2). Combined 
with the frequently observed over- and underdiagnosis, leading to over- and 
undertreatment of NTM disease, this makes clear that national guidelines for 
appropriate diagnosis and treatment of NTM disease are urgently needed. 
Pulmonary NTM infections are most frequent and the Dutch Association of 
Physicians in Pulmonary Diseases and Tuberculosis (Nederlandse Vereniging 
van Artsen voor Longziekten en Tuberculose; NVALT) is the most likely 
candidate to supervise the establishment and dissemination of such guidelines.
Based on our retrospective analyses of clinical NTM disease and in vitro drug 
susceptibility, we believe the advice based on the results of the recent BTS 
trial can be extrapolated to the Netherlands. The rifampicin and ethambutol 
regimen should be used as an initial basic regimen for disease due to slow-
growing NTM (for frequently isolated slow- and rapid growing NTM, see 
Table 3). Macrolides may be added if the patient does not improve, or in case 
of a relapse. Future studies should address their place in the initial regimen in 
case of nodular-bronchiectatic disease. 
The additional value of aminoglycosides, advocated by the ATS for the first 
months of treatment of cavitary M. avium complex disease,7 remains to be 
established in European studies. For the rapid growers, a combination of a 
macrolide, an aminoglycoside and one or two companion drugs selected on 
basis of in vitro drug susceptibility patterns, as proposed by the ATS, is the 
preferred regimen.7 For most NTM species, however, no controlled trials have 
been done and little supportive evidence to facilitate guidelines exists.
The clinical utility of drug susceptibility testing (DST) of NTM isolates remains 
an open question; within the American Thoracic Society guidelines, DST is 
considered most beneficial in case of delayed culture conversion or failure of 
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therapy; baseline testing is only advised for M. avium complex isolates, against 
the macrolides and for M. kansasii, against rifampicin.7 The utility of DST in 
case of relapse or failure is increased if a baseline test is available, to discern 
acquired resistance. Hence, we believe baseline testing, i.e. DST prior to the 
institution of therapy, is appropriate for all NTM that are considered clinically 
relevant. Here, again, our quantification of clinical relevance of the various 
species (Figures 1 and 2) may prove useful. 
For the first-line anti-tuberculosis drugs (isoniazid, rifampicin, ethambutol, 
streptomycin), discrepancies between in vitro activity and in vivo treatment 
outcome complicate the interpretation of the DST result (Chapter 4.1).71,77 
Various factors may be involved in these discrepancies. First, Banks and co-
workers noted substantial synergism between rifampicin and ethambutol, 
which may partially explain good treatment outcome in cases of M. avium 
disease caused by bacteria resistant to both rifampicin and ethambutol. 
Similarly, synergism between streptomycin and rifampicin was recorded.78 
Perhaps a combined rifampicin/ethambutol susceptibility test is clinically 
more valuable than testing separate drugs, to which resistance is common 
(Chapter 4.1).78 Second, the drug concentrations within NTM disease lesions 
and macrophages, thus the actual exposure of the NTM to antimycobacterial 
drugs, may be higher than the concentration used in in vitro DST. Moreover, 
cut-off points for in vitro resistance of NTM are usually extrapolated from 
those of M. tuberculosis and may not be representative. 
Here, pharmacokinetic studies may provide useful data to reconsider 
the currently used breakpoint concentrations. It has been observed that 
patients with pulmonary M. avium complex disease achieve higher serum 
concentrations of rifampicin than tuberculosis patients.79 Similar studies in 
patients with cavitary NTM disease are warranted in the Netherlands, preferably 
correlating the concentrations to bacteriological and clinical improvement 
and treatment outcome in a pharmacodynamic study. To date, no such studies 
have been performed in NTM disease. Preferably, serum concentrations, the 
tissue diffusion and intracellular drug concentration within macrophages 
should be investigated. These are likely to increase our understanding of the 
discrepancies between in vitro activity and in vivo treatment outcome. 
The second line drugs (prothionamide, cycloserine, clofazimine) are highly 
toxic and their efficacy has not been proven.80,81 As a result, there is little reason 
to include them in standard DST schemes, especially as part of the isolates 
will not be considered clinically relevant and the respective patients will not 
be treated. For now, mainly for the slow-growing NTM, it may suffice to test 
macrolides, aminoglycosides and the newer drugs with established therapeutic 
potential (moxifloxacin, linezolid, tigecycline). For the rapid growers, where 
drug resistance is a grave issue, this set should be expanded with carbapenems 
and cefoxitin.82 
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The optimal DST method also remains subject of debate. The Clinical and 
Laboratory Standards Institute (formerly National Committee for Clinical 
Laboratory Standards) now advocates the use of broth microdilution 
methods, especially for the rapidly growing NTM. For slow growers, agar 
dilution and broth microdilution methods are considered appropriate.82 In 
the Netherlands, we use an agar dilution method for all NTM. This method 
was historically selected as it was the method of choice for M. tuberculosis 
DST, for both first and second-line drugs.83,84 This may partly explain the 
differences in drug susceptibility patterns between our study (Chapter 4.1) 
and previously published studies applying the broth microdilution techniques. 
The level of resistance to aminoglycosides (see Table 3) exceeds that observed 
in previous studies.7,82,85 Especially for the rapid growing NTM, this may have 
an undesirable impact on treatment regimens.
For M. tuberculosis complex bacteria, the RIVM now performs DST in the 
MGIT automated liquid culture system. The abolition of the agar dilution 
method for M. tuberculosis complex has led to renewed debate on the platform 
of choice for NTM. Currently, the CLSI recommended broth microdilution 
method is being tested at the RIVM.
To optimise treatment of NTM disease, newer and more active drugs are 
still strongly needed. Preferably, the in vitro activity of these drugs should be 
concordant with their clinical activity and thus treatment outcome. Within this 
thesis we have assessed the potential of the antipsychotic drug thioridazine. 
Strictly, thioridazine is not a new drug, as it has been used extensively to treat 
schizophrenia for several decades.86 Its antimycobacterial activity had not been 
fully explored, though. We found promising activity against M. tuberculosis, 
even against multi- and extensively drug-resistant strains; unfortunately, its 
activity against NTM was limited (Chapter 4.2). Although thioridazine is 
concentrated within macrophages,86 where the NTM reside during (early) 
infection (Chapter 6.3), this drug is unlikely to have any additional value in 
the treatment of NTM disease (Chapter 4.2).87
Combined chemotherapy and surgery may be the most effective intervention in 
a select category of patients that do not respond favourably to the initial therapy 
regimen; therapy-resistant cavitary disease, preferably of a single lobe of one 
lung is a good indication for surgery in operable patients.88,89 Pneumonectomy 
for those with an infected destroyed lung may be feasible, although if there are 
lesions in the other lung, they should be minimal. Cavitary lesions in the other 
lung are a contra-indication for pneumonectomy.90 Although it requires keen 
timing, eligible patients and centres with specialized surgeons, pulmonary 
physicians and good follow-up facilities, we believe that increased application 
of surgery for pulmonary NTM disease can greatly improve outcome (Chapter 
4.3).
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Genetic divergence: from gene sequence to clinical relevance
Our finding that the clinical relevance of NTM differs significantly by species is 
an indication that bacterial factors are associated with clinical relevance. Very 
little is known of bacterial virulence factors and their mode of action in NTM. 
In M. avium, two genes associated with virulence have been identified. In 1998 
a conserved coding sequence for the macrophage-induced gene mig was found 
to be associated with increased virulence of M. avium and human disease,91 
although this association could not be reproduced in a recently published 
study.92 Recently, a PPE gene related to Rv1787 of M. tuberculosis was shown to 
promote survival and growth of M. avium within human macrophages and in 
a murine disease model.93 Since NTM are environmental bacteria and humans 
are likely to be an accidental host, one may wonder whether something like a 
virulence factor actually exists. Is a mechanism that allows NTM to survive 
in the hostile environment of the human lung not merely a fortunate result 
of adaptation to varying environmental niches? This broad adaptation is well 
represented by the size of the genome; the generalists M. smegmatis (7.0 Mb) 
and M. marinum (6.6 Mb) have larger genomes than specialist, host-adapted 
bacteria such as M. leprae, M. tuberculosis and M. avium paratuberculosis 
(3.8, 4.4 and 4.8Mb respectively), which have adapted to a limited host range 
by reductive genomics and lateral gene transfer.94 Genomes of intracellular 
bacteria tend to lose genes for metabolic diversity, needed for survival in 
diverse and potentially nutrient-poor environments, but retain those encoding 
transcription, translation and other basic processes that are important 
regardless of ecological niche.95,96 
We have explored the bacterial factor associated with clinical relevance, by 
two separate approaches. At the macro level, we have explored differences in 
virulence between species. We have looked into the presence of the Region of 
Difference 1 (RD1) and its role as a virulence factor in NTM. The RD1 is an 
important virulence factor for M. tuberculosis.97 It is striking, in this respect, 
that most NTM species found to harbour an RD1 element in their genome (M. 
kansasii, M. szulgai, M. marinum, M. riyadhense) are clinically highly relevant 
(Figure 1 & 2) (Chapter 2.1, 2.4, 6.2, 7.2). On the other hand, this element is 
absent in other clinically relevant species, most notably M. malmoense and M. 
avium (Chapter 2.1, 2.6, 6.2). Moreover, the RD1 genes are thought to facilitate 
the translocation of mycobacteria from the phagolysosome to the cytosol 
of macrophages.98 Translocation to the cytosol could not be convincingly 
demonstrated for M. szulgai in our THP-1 cell infection model, despite 
presence of an RD1-like element (Chapter 6.3). Similarly, in M. smegmatis, 
the RD1 genes are thought to be involved in bacterial conjugation, rather than 
translocation from the phagolysosome to the cytosol of macrophages.99,100 The 
genetic differences between the M. tuberculosis complex and NTM in genes 
associated with virulence such as the RD1 or their expression and product 
secretion may explain the generally lower virulence of NTM (Chapter 6.2, 
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6.3). For now, presence of an RD1 remains merely a phylogenetic character 
(Chapter 6.2).
At the micro level, we have explored intraspecies genetic diversity within 
semi-conserved housekeeping genes, i.e. genes involved in important cellular 
processes whose disruption by genetic polymorphism would lead to loss of 
bacterial viability. Subdividing NTM species, based on variance in housekeeping 
genes, may not be merely an academic or taxonomic exercise. Different 
subgroups may show different levels of clinical relevance or even different types 
of disease. Mycobacterium kansasii is a good example; although five subtypes 
are known, only two cause disease in humans. One causes mainly pulmonary 
disease (type I), whereas the other is a causative agent of disseminated disease 
in immunocompromised patients (type II). The remaining types are considered 
non-pathogenic environmental bacteria.42,43 This intraspecies divergence was 
already noted by Coster in his animal inoculation experiments in the 1950s; 
not all Syrian gold hamsters inoculated with similar loads of various “yellow 
bacillus” (the contemporary name for M. kansasii) isolates developed disease, 
suggesting that more and less pathogenic strains existed.101 In our retrospective 
study on M. xenopi we noted a similar phenomenon. Strains of the M. xenopi 
II 16S sequence type were more often clinically relevant than the ones of type I 
(Chapter 2.2). In our multi-gene sequencing study, we noted interesting levels 
of intraspecies divergence in all species tested. Interestingly, the divergence 
followed a mosaic rather than stochastic pattern. Lateral gene transfer as a 
driving force in bacterial evolution is not a far-fetched option for NTM. 
Their environmental habitat provides for intense contact with other bacterial 
species and genera. Nevertheless, the extent of divergence was such that it was 
unlikely to result from lateral gene transfer (Chapter 6.1). A long evolutionary 
development through stochastic processes is more likely.
We were not able to discern a M. xenopi or M. malmoense subgrouping 
significantly associated with clinical disease; our study served as an exploration, 
rather than proof of concept, as the number of isolates was quite low (Chapter 
6.1). If the intraspecies genetic divergence within house-keeping genes can 
be extrapolated to virulence-associated genes, however, intraspecies genetic 
divergence may still influence clinical relevance. Some isolates of a certain 
species may or may not cause disease based on variance within genes (and 
their products) essential in the disease process.
Overall, the knowledge on virulence factors in NTM lags significantly behind 
in comparison to other environmental opportunistic pathogens. For instance, 
a variety of mechanism has been described for Pseudomonas aeruginosa, an 
environmental pathogen that affects categories of patients also at risk for NTM 
disease. Pseudomonas aeruginosa is known to create biofilms in which they are 
less susceptible to antimicrobials and these bacteria can switch to a mucoid 
phenotype and even a hypermutator state, associated with immune evasion and 
increased virulence. By quorum sensing, a system by which bacteria sense their 
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cumulative numbers and change their behaviour accordingly, the Pseudomonas 
bacteria can assess their numerical presence and time their phenotypical and 
genotypical change.53,102 A similar change in colony morphology, associated 
with increased virulence and drug resistance, has recently been observed for M. 
abscessus,103 although it is not known whether this change reflects a change in 
behaviour such as biofilm formation. Other fascinating assets, such as quorum 
sensing, have not been studied in NTM. Conjugation has been described as 
a function of ESAT-6 and CFP-10 secretion in M. smegmatis.99,100 This is the 
closest to quorum sensing known for NTM. The genetic divergence among 
NTM makes that these kinds of virulence factors are unlikely to be distributed 
throughout the genus, as we have noted for the RD1 (Chapter 6.2). A lot is still 
to be learned on the mechanisms involved in the actual establishment of NTM 
infections. Furthermore, it is unknown whether these are uniform in all NTM 
pathogenic to humans.
The genetic divergence among NTM questions our currently used identification 
tools. Perhaps replacement of the 16S rDNA gene by the rpoB gene sequence as 
the molecular target for identification to species level among rapid growing NTM 
is an improvement, because this gene offers a higher level of discrimination.104 
Instead of choosing a more variable target, it may be worthwhile to switch to a 
system that includes sequencing of multiple targets.105 As we have noted in our 
multi-gene sequencing study, this leads to distinction of particular subtypes 
within NTM species. These subtypes may have clinical correlates (Chapter 
6.1); systematic identification of NTM in a multi-gene sequencing scheme will 
shed light on these correlates. Here, the genetic divergence among NTM calls 
for new, more exact species definitions. Ultimately, whole genome sequencing 
will provide the best identification method and will reveal the true extent of 
intra- and inter-species genetic divergence among NTM, although it is for 
technical and financial reasons not yet within reach for this purpose.
Whole genome sequences of clinical isolates of the major NTM species, 
both clinically relevant and non-relevant, can be used to build the ultimate 
phylogenetic tree of the genus Mycobacterium. This tree can be appended 
with clinical data to allow systematic studies of virulence associated genes. 
Currently, however, the vast majority of mycobacteria subjected to whole 
genome sequencing are M. tuberculosis complex members.106
Given the fact that the clinical relevance of NTM differs by species, the 
description of new species can be clinically meaningful. A more distinctive 
taxonomy is frequently considered a nuisance by clinicians. The ongoing use 
of terms like ‘M. avium complex’ is testimony to this sentiment.107 Recognition 
of species of particular pathogenicity or causative agents of a particular disease 
type and their subsequent description as novel species may be of great help 
in clinical practice and can serve to unravel bacterial virulence factors. We 
have elevated the group of M. avium complex isolates characterised by the 
MAC-Q 16S-23S internal transcribed spacer sequevar to species status as they 
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were causative agents of extrapulmonary disease. If this is confirmed in larger 
case series, whole genome sequencing and comparison with M. avium and 
M. intracellulare may help to understand the aetiology of NTM disease and 
the apparent tropism of M. vulneris (Chapter 5.3).106 Alternatively, distinction 
of M. noviomagense as a novel species, genetically related to M. xenopi, is 
clinically meaningful as pulmonary M. noviomagense isolates were clinically 
not relevant, which is very different from the frequently clinically relevant M. 
xenopi (Figure 2) (Chapter 2.2, 5.2). Future comparative studies can reveal 
the causative mechanisms behind these clinical observations. Integration of 
clinical data in new species descriptions is helpful to clinicians to determine 
their stance towards patients with a pulmonary isolate of M. noviomagense, M. 
mantenii or other novel species.
For NTM, it may be important to use clinical utility as a criterion for 
description of novel species. We agree with Telenti, who has proposed that 
“clinical meaningfulness should be the key to taxonomic precision”.107 The 
number of validly published NTM species has exploded after the introduction 
and spread of molecular identification tools in the early 1990’s (Figure 5). 
In our re-analysis of previously unidentifiable NTM isolates, we recorded 
53 groups of isolates with novel 16S gene sequences, of which one third 
(n=18) could be assigned to recently published species. Still, that leaves 35 
groups of isolates that may represent novel species; some isolates were from 
extrapulmonary sources and thus likely causative agents of human disease. 
Hence, even if clinical meaningfulness is a decisive factor to describe new 
species, the number of NTM species is likely to reach 200 by the year 2010 
(Figure 5). Is such a large number of NTM species feasible in daily clinical 
practice? Based on the whole genome sequences appended with clinical data, a 
grouping of NTM into groups based on virulence factors, rather than specific 
species names, may be a worthwhile future strategy: from gene sequences to 
clinical relevance (Chapter 5.1, 6.1).106 
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published Mycobacterium 
species over time
Numbers were obtained from 
references 31,34,35,37,108,109.
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Clinical relevance of NTM isolation in other geographical regions
The number of countries that have reported NTM isolation or disease has 
increased. Marked regional differences in NTM species distribution exist. The 
species that seemed to be dominant in Oman are slightly different from those 
found in the Netherlands (Chapter 7.1). In a small study in Vietnam, however, 
we found a very different species distribution, marked by predominance of 
rapid growers similar to adjacent regions of China, Taiwan and Thailand 
(Chapter 7.2). Such differences are clinically important, as treatment can vary 
for different species. 
In areas with a high prevalence of tuberculosis (TB), it is often assumed that 
all acid-fast bacilli visualized by Ziehl-Neelsen staining of clinical samples 
or Mycobacterium cultures are M. tuberculosis complex bacteria. This is not 
always the case, though, and this has an impact on clinical care and surveillance 
of TB.110 The clinical relevance of NTM isolation from respiratory samples in 
areas with a high prevalence of TB remains uncertain. In most of these areas, 
physicians already struggle to cope with the high number of TB patients, 
leaving little attention to the possibility of NTM disease. In many such regions, 
culture and identification facilities are lacking, hampering even the diagnosis 
of TB and rendering distinction between TB and NTM disease impossible.
In many regions of Africa the high TB prevalence is further complicated by a 
high burden of HIV infection. For patients with HIV infection, distinguishing 
NTM disease from TB is important, as treatment of NTM disease is different 
from that of TB (Chapter 7.4). Still, the same lack of diagnostic tools bars 
diagnosing NTM disease. Several studies found NTM in clinical samples in 
Africa, although few have examined their clinical relevance.111 After the onset 
of the HIV epidemic, a few studies have reported cases of disseminated NTM 
disease.112,113 A recent study in Zambia clearly demonstrated extrapulmonary 
NTM disease, mostly in HIV-infected patients.114 Our work in Tanzania 
demonstrated that disseminated NTM disease is also prevalent there (Chapter 
7.4), though the causative agents are different from the Netherlands and the 
United States, where M. avium, M. kansasii and M. xenopi are important 
(Chapter 2.1, 2.2).115,116
The NTM species distribution differs by region and some NTM species are 
restricted to particular areas and not found elsewhere. The misidentification 
of M. sherrisii isolates as M. simiae in our Tanzanian study (Chapter 7.4) 
showed that currently available molecular identification tools, many of which 
are designed to identify NTM in Europe and the USA, may be of limited use 
in other parts of the world, where different NTM species exist. In addition, 
the data on clinical relevance obtained in our studies in the Netherlands can 
probably not be extrapolated to African or Asian countries. Similarly, we have 
noted that results from studies in the United States proved irreproducible in 
the Netherlands (Chapter 2.1). Therefore, each region should perform its own 
investigations into the NTM species present and their clinical relevance.
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Conclusions and strategies for future research
The clinical relevance of NTM differs by species. This provides guidance to 
clinical care. This guidance should be further improved by systematic study 
of additional species and re-evaluation of the already studied NTM species 
once their case volume has increased. Disease due to NTM results from a 
complex and incompletely understood interplay of host and pathogen factors. 
Several host factors, including advanced HIV infection, CFTR gene mutations 
and interferon-γ or interleukin-12 receptor deficiencies, have been shown 
to increase susceptibility to NTM disease.7,49,64,65 Bacterial virulence factors 
remain largely unknown. The role of ESAT-6 and CFP-10 as virulence factors 
in M. tuberculosis complex bacteria does not hold true for M. szulgai. The 
translocation by M. tuberculosis and M. marinum from the phagosomes to 
the cytosol in macrophages could not be convincingly demonstrated for M. 
szulgai (Chapter 6.2, 6.3). Whether this results from a lack of transcription 
or secretion, or whether these genes and their products have very different 
functions in M. szulgai remains to be investigated. Similar genes are also 
present in M. kansasii and M. riyadhense, but the functions of their products 
in these species remains to be investigated.
Despite the findings for ESAT-6 and CFP-10, it may prove worthwhile to 
perform whole genome sequencing of strains of the clinically relevant species 
(i.e. M. kansasii, M. szulgai, M. malmoense), most of which are phylogenetically 
related to the M. tuberculosis complex (Chapter 6.2), to assess the presence 
and absence of other virulence factors and their secretion mechanisms. The 
already sequenced M. tuberculosis, M. bovis and M. bovis BCG strains can 
serve as a template for these analyses. Interestingly, whole genome sequencing 
of NTM is performed now, though the choice of species has not been based on 
clinical relevance. Currently, sequences are available for M. avium hominissuis 
104, M. avium paratuberculosis K10, M. marinum, M. ulcerans, M. vanbaalenii 
and M. smegmatis. Whole genome sequences of M. abscessus and M. kansasii 
are currently determined.106
We do not know whether the clinical isolates mirror the NTM species 
distribution in the environment in the Netherlands. Perhaps, the human 
respiratory tract (the most common source of clinical NTM isolates) exerts 
a selective pressure. This would be important for the concept of clinical 
relevance and mycobacterial virulence. Sampling of natural and man-made 
environments, accompanied by molecular identification and preferably typing 
of encountered NTM should be performed in association with a prospective 
clinical study within a confined region.
We have used the degree of clinical relevance in humans as a measure of 
pathogenicity. Still, this concept has not been sufficiently validated. Animal 
infection experiments with isolates of various species and with relevant and 
non-relevant isolates of the same species may shed light on this issue. Such 
studies could reveal the relative importance of host and pathogen factors in 
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NTM disease. Simultaneously, this would offer the opportunity to study the 
consistency of the immunological reaction to various NTM species. The 
obvious differences in clinical relevance of M. malmoense and M. intracellulare 
between the United States and the Netherlands could also be studied by murine 
infection with clinical isolates from both countries. The choice of animals 
and infection route is very important and it may even be necessary to invoke 
conditions that predispose to NTM disease (e.g. silicosis, COPD, CF), similar 
to early guinea pig studies with silicosis induction to facilitate pulmonary M. 
kansasii infection.62
Outcome of treatment for NTM disease is often disappointing; the success 
with macrolide-based regimens observed in the United States72 is not observed 
in the Netherlands (Chapter 2.1), or in the recent BTS study.71 More trials are 
needed to address this issue. These must be multi-country trials and need to 
explore the additional effect of moxifloxacin, as well as novel compounds and 
combinations. Meanwhile, we recommend that regimens that proved most 
effective in previous trials should be increasingly used in the Netherlands. In 
our retrospective surveys we noted a widespread use of inferior regimens of 
too short duration. This is an unwanted situation in a country where access 
to up-to-date medical literature is easy. In addition, we noted both over- and 
undertreatment of NTM disease. This suggests that the use of diagnostic 
criteria, available from both the ATS and BTS,7,117 is not commonplace in the 
Netherlands. The limited use of available guidelines for diagnosis and treatment 
of NTM disease makes clear that national guidelines for appropriate diagnosis 
and treatment of NTM disease are needed. We believe that separate diagnostic 
guidelines are needed for pulmonary disease due to species of different 
clinical relevance. Strict criteria should be implemented for species generally 
of low clinical relevance (M. gordonae, M. noviomagense, M. chelonae) and 
more lenient criteria for the highly clinically relevant species (M. kansasii, M. 
szulgai, M. malmoense) (Chapter 2). Moreover, increased consultation and 
referral of patients to the two tuberculosis reference hospitals available in 
the Netherlands (Dekkerswald and Beatrixoord) would be beneficial. These 
centers have extensive knowledge and experience in handling NTM disease. 
Dekkerswald also offers surgery for pulmonary NTM disease. Surgery proved 
effective for patients who did not respond to optimal chemotherapy regimens 
in our pilot study; it may help to improve the cure rates, even though it is 
suitable for a select category of patients only (Chapter 4.3).  
We found substantial genetic divergence within NTM species. This may help 
to explain the bacterial side of the principle of clinical relevance; particular 
subtypes may be associated with clinical relevance, as we noted for M. xenopi 
(Chapter 2.2). The differences in clinical relevance of M. intracellulare and M. 
malmoense between the Netherlands and the United States are an interesting 
starting point for a multi-gene sequencing study of representative isolates of 
both species from both countries.
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It was difficult to obtain national coverage for our clinical relevance surveys; 
individual laboratories had to be contacted to obtain insight in their databases. 
NTM disease is not a reportable condition in the Netherlands and there is 
no obligation to send isolated NTM to the national reference laboratory 
(RIVM). Although obligatory strain referral may be impossible to arrange 
and superfluous, a laboratory reporting system would be of great benefit to 
monitor the NTM isolation in the Netherlands. We hope that our results will 
lead to such a reporting system and that this will encourage and facilitate 
future research.
We have been able to lift the carpet and demonstrate that NTM isolation is a 
relevant clinical and laboratory issue in the Netherlands and other countries, 
including countries with a high prevalence of tuberculosis. We hope to have 
encouraged researchers in many countries to survey the local NTM isolation 
frequency and the degree of clinical relevance. Such surveys will enable 
countries to develop their own diagnosis and treatment guidelines, using 
the ATS diagnostic criteria and both ATS and BTS treatment guidelines 
as a backbone. It is apparent that the American or British situation and its 
resulting guidelines7,117 can not be directly extrapolated to other countries, as 
acknowledged in the ATS document.7 
310
Chapter 8
References
1. Den Dooren de Jong LE. [Tuberculosis from the bacteriological standpoint]. 
Ned Tijdschr Geneesk 1939; 83: 5896-906. Dutch
2. Martín-Casabona N, Bahrmand AR, Bennedsen J, Thomsen VO, Curcio M, 
Fauville-Dufaux M, Feldman K, Havelkova M, Katila ML, Köksalan K, Pereira 
MF, Rodrigues F, Pfyffer GE, Portaels F, Urgell JR, Rüsch-Gerdes S, Tortoli E, 
Vincent V, Watt B; Spanish Group for Non-Tuberculosis Mycobacteria. Non-
tuberculous mycobacteria: patterns of isolation. A multi-country retrospective 
survey. Int J Tuberc Lung Dis 2004; 8: 1186-93.
3. Donnabella V, Salazar-Schicchi J, Bonk S, Hanna B, Rom WN. Increasing 
incidence of Mycobacterium xenopi at Bellevue Hospital. An emerging pathogen 
or a product of improved laboratory methods? Chest 2000; 118: 1365-70.
4. Alcaide F, Benítez MA, Escribà JM, Martín R. Evaluation of the BACTEC 
MGIT 960 and the MB/BacT systems for recovery of mycobacteria from clinical 
specimens and for species identification by DNA AccuProbe. J Clin Microbiol 
2000; 38: 398-401.
5. Devallois A, Picardeau M, Goh KS, Sola C, Vincent V, Rastogi N. Comparative 
evaluation of PCR and commercial DNA probes for detection and identification 
to species level of Mycobacterium avium and Mycobacterium intracellulare. J 
Clin Microbiol 1996; 34: 2756-9.
6. Springer B, Stockman L, Teschner K, Roberts GD, Böttger EC. Two-laboratory 
collaborative study on identification of mycobacteria: molecular versus 
phenotypic methods. J Clin Microbiol 1996; 34: 296–303.
7. Griffith DE, Aksamit T, Brown-Elliot BA, Catanzaro A, Daley C, Gordin 
F, Holland SM, Horsburgh R, Huitt G, Iademarco MF, Iseman M, Olivier K, 
Ruoss S, Fordham von Reyn C, Wallace RJ Jr., Winthrop K. An official ATS/
IDSA statement: diagnosis, treatment, and prevention of nontuberculous 
mycobacterial diseases. Am J Respir Crit Care Med 2007; 175: 367-416.
8. Marras TK, Chedore P, Ying AM, Jamieson F. Isolation prevalence of pulmonary 
non-tuberculous mycobacteria in Ontario, 1997-2003. Thorax 2007; 62: 661-6.
9. Tuberculose in Nederland 2005, Surveillancerapport over de tuberculosesituatie 
in Nederland. KNCV Tuberculosefonds, Den Haag, 2007. ISBN: 978907786
10. Hoefsloot W, Boeree MJ, van Ingen J, Bendien S, Magis C, de Lange W, 
Dekhuijzen PNR, van Soolingen D. The rising incidence and clinical relevance 
of Mycobacterium malmoense: a review of the literature. Int J Tuberc Lung Dis 
2008; 12: 987-93.
11. Trnka L, Dankova D, Svandova E. Six years’ experience with the discontinuation 
of BCG vaccination: 4. Protective effect of BCG vaccination against the 
Mycobacterium avium intracellulare complex. Tuberc Lung Dis 1994;75:348–52.
12. Romanus V, Hallander HO, Wåhlén P, Olinder-Nielsen AM, Magnusson PH, 
Juhlin I. Atypical mycobacteria in extrapulmonary disease among children. 
Incidence in Sweden from 1969 to 1990, related to changing BCG vaccination 
coverage. Tuberc Lung Dis 1995; 76: 300-10.
13. Bleiker MA. Nonspecific tuberculin sensitivity in schoolchildren in European 
countries. Z Erkrank Atm Org 1989; 173: 46-9. German
14. Khan K, Wang J, Marras TK. Nontuberculous mycobacterial sensitization in 
the United States: National trends over three decades. Am J Respir Crit Care 
Med 2007; 176: 306-13.
15. Uijen AA, Schermer TRJ, van den Hoogen HJM, Mulder J, Zantinge EM, 
Bottema BJAM. [Prevalence and health care consumption for asthma and 
Discussion, conclusions and strategies for future research
Chapter 8
311
COPD in relation to ethnicity]. Ned Tijdschr Geneesk 2008; 152: 1157-63. 
Dutch
16. Winthrop KL, Yamashita S, Beekmann SE, Polgreen PM. Infectious Diseases 
Society of America Emerging Infections Network. Mycobacterial and other 
serious infections in patients receiving anti-tumor necrosis factor and other 
newly approved biologic therapies: case finding through the Emerging 
Infections Network. Clin Infect Dis 2008; 46: 1738-40.
17. Marras TK, Daley CL. Epidemiology of human pulmonary infection with 
nontuberculous mycobacteria. Clin Chest Med 2002; 23: 553-67.
18. Engel HW, Berwald LG, Havelaar AH. The occurrence of Mycobacterium 
kansasii in tapwater. Tubercle 1980; 61: 21-6.
19. Havelaar AH, Berwald LG, Groothuis DG, Baas JG. Mycobacteria in semi-
public swimming-pools and whirlpools. Zentralbl Bakteriol Mikrobiol Hyg [B] 
1985; 180: 505-14.
20. Falkinham JO III, Iseman MD, de Haas P, van Soolingen D. Mycobacterium 
avium in a shower linked to pulmonary disease. J Water Health 2008; 6: 209-13.
21. Primm TP, Lucero CA, Falkinham JO III. Health impacts of environmental 
mycobacteria. Clin Microbiol Rev 2004; 17: 98-106.
22. Henry MT, Inamdar L, O’Riordain D, Schweiger M, Watson JP. Nontuberculous 
mycobacteria in non-HIV patients: epidemiology, treatment and response. Eur 
Respir J 2004; 23: 741-46.
23. Bollert FGE, Watt B, Greening AP, Crompton GK. Non-tuberculous pulmonary 
infection in Scotland: A cluster in Lothian? Thorax 1995; 50: 188-90.
24. Thomsen VØ, Andersen ÅB, Miörner H. Incidence and clinical significance of 
non-tuberculous mycobacteria isolated from clinical specimens during a 2-y 
nationwide survey. Scand J Infect Dis 2002; 34: 648-53.
25. Zolnir-Dovc M, Pate M, Ocepek M, Erzen D. Nontuberculous mycobacteria 
in Slovenia in 2000 to 2006 - a nation-wide study. European Society for 
Mycobacteriology meeting 2007; abstract PP029. Available at:  http://www.
esmycobacteriology.eu/abstracts/PP029.pdf
26. Bodle EE, Cunningham JA, Della-Latta P, Schluger NW, Saiman L. Epidemiology 
of nontuberculous mycobacteria in patients without HIV infection, New York 
City. Emerg Infect Dis 2008; 14: 390-6. 
27. O’Brien RJ, Geiter LJ, Snider DE Jr. The epidemiology of nontuberculous 
mycobacterial diseases in the United States. Am Rev Respir Dis 1987; 135: 
1007-14.
28. Koh WJ, Kwon OJ, Jeon K, Kim TS, Lee KS, Park YK, Bai GH. Clinical significance 
of nontuberculous mycobacteria isolated from respiratory specimens in Korea. 
Chest 2006; 129: 341-48.
29. Yates MD, Pozniak A, Uttley AHC, Clarke R, Grange JM. Isolation of 
environmental mycobacteria from clinical specimens in South-East England 
1973-1993. Int J Tuberc Lung Dis 1997; 1:75-80.
30. Han XY, Tarrand JJ, Infante R,  Jacobson KL, Truong M. Clinical significance 
and epidemiologic analyses of Mycobacterium avium and Mycobacterium 
intracellulare among patients without AIDS. J Clin Microbiol 2005; 43: 4407-12.
31. Euzéby JP. List of prokaryotic names with standing in nomenclature. http://
bacterio.cict.fr/m/mycobacterium.html; accessed 27-04-2008
32. Manten A. [Bacteriological and chemotherapeutic aspects of atypical 
mycobacteria]. Maandschr Kindergen 1965; 33: 309-19. Dutch
33. van Joost CRNF, Manten A, Beeuwkes H, Bleiker MA, Coster JF, Oosterbaan N, 
Polak MF. The occurrence in the Netherlands of infections caused by ‘atypical’ 
312
Chapter 8
mycobacteria. KNCV Selected Papers 1967; 10: 31.
34. Selkon JB. “Atypical” mycobacteria: a review. Tubercle 1969; 50(Suppl): 70-8.
35. Wolinsky E. Nontuberculous mycobacteria and associated diseases. Am Rev 
Respir Dis 1979; 119: 107-159.
36. Clarridge JE III. Impact of 16S rRNA gene sequence analysis for identification 
of bacteria on clinical microbiology and infectious diseases. Clin Microbiol Rev 
2004; 17: 840-62.
37. Tortoli E. Impact of genotypic methods on mycobacterial taxonomy: the new 
mycobacteria of the 1990’s. Clin Microbiol Rev 2003; 16: 319-54.
38. Lindeboom JA, Kuijper EJ, Bruijnesteijn van Coppenraet ES, Lindeboom R, 
Prins JM. Surgical excision versus antibiotic treatment for nontuberculous 
mycobacterial cervicofacial lymphadenitis in children: a multicenter, 
randomized, controlled trial. Clin Infect Dis 2007; 44: 1057-64.
39. Lindeboom JA, Prins JM, Bruijnesteijn van Coppenraet ES, Lindeboom R, 
Kuijper EJ. Cervicofacial lymphadenitis in children caused by Mycobacterium 
haemophilum. Clin Infect Dis 2005; 41: 1569-75.
40. Collins CH, Grange JM, Yates MD. Mycobacteria in water. J Appl Bacteriol 
1984; 57: 193-211.
41. Wayne LG, Good RC, Böttger EC, Butler R, Dorsch M, Ezaki T, Gross W, Jonas 
V, Kilburn J, Kirschner P, Krichevsky MI, Ridell M, Shinnick TM, Springer B, 
Stackebrandt E, Tarnok I, Tarnok Z, Tasaka H, Vincent V, Warren NG, Knott 
A, Johnson R. Semantide- and chemotaxonomy-based analyses of some 
problematic phenotypic clusters of slowly growing mycobacteria, a cooperative 
study of the International Working Group on Mycobacterial Taxonomy. Int J 
Syst Bacteriol 1996; 46: 280-297.
42. Taillard C, Greub G, Weber R, Pfyffer GE, Bodmer T, Zimmerli S, Frei R, 
Bassetti S, Rohner P, Piffaretti JC, Bernasconi E, Bille J, Telenti A, Prod’hom G. 
Clinical implications of Mycobacterium kansasii species heterogeneity: Swiss 
national survey. J Clin Microbiol 2003; 41: 1240-4.
43. Arend SM, de Haas PEW, Leyten E, Rosenkrands I, Rigouts L, Andersen P, 
Mijs W, van Dissel JT, van Soolingen D. ESAT-6 and CFP-10 in clinical versus 
environmental isolates of Mycobacterium kansasii. J Infect Dis 2005; 191: 1301-
10.
44. Stout JE, Hopkins GW, McDonald JR, Quinn A, Hamilton CD, Reller LB, 
Frothingham R. Association between 16S-23S internal transcribed spacer 
sequence groups of Mycobacterium avium complex and pulmonary disease. J 
Clin Microbiol 2008; 46: 2790-3.
45. Buchholz UT, McNeil MM, Keyes LE, Good RC. Mycobacterium malmoense 
infections in the United States, January 1993 through June 1995. Clin Infect Dis 
1998; 27: 551-558.
46. Wallace RJ Jr, Cook JL, Glassroth J, Griffith DE, Olivier KN, Gordin F. American 
Thoracic Society statement: diagnosis and treatment of disease caused by 
nontuberculous mycobacteria. Am J Respir Crit Care Med 1997; 156: S1-S25.
47. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, 
Jenkins C, Rodriguez-Roisin R, van Weel C, Zielinksi J. Global strategy for 
the diagnosis, management, and prevention of chronic obstructive pulmonary 
disease: GOLD Executive Summary. Am J Respir Crit Care Med 2007; 176: 
532–55.
48. Reich JM, Johnson RE. Mycobacterium avium complex pulmonary disease 
presenting as an isolated lingular or middle lobe pattern. The Lady Windermere 
syndrome. Chest 1992; 101: 1605-9.
Discussion, conclusions and strategies for future research
Chapter 8
313
49. Kim RD, Greenberg DE, Ehrmantraut ME, Guide SV, Ding L, Shea Y, Brown 
MR, Chernick M, Steagall WK, Glasgow CG, Lin J, Jolley C, Sorbara L, Raffeld 
M, Hill S, Avila N, Sachdev V, Barnhart LA, Anderson VL, Claypool R, 
Hilligoss DM, Garofalo M, Fitzgerald A, Anaya-O’Brien S, Darnell D, DeCastro 
R, Menning HM, Ricklefs SM, Porcella SF, Olivier KN, Moss J, Holland SM. 
Pulmonary nontuberculous mycobacterial disease: prospective study of a 
distinct preexisting syndrome.Am J Respir Crit Care Med 2008; 178: 1066-74.
50. Pierre-Audigier C, Ferroni A, Sermet-Gaudelus I, Le Bourgeois M, Offredo C, 
Vu-Thien H, Fauroux B, Mariani P, Munck A, Bingen E, Guillemot D, Quesne 
G, Vincent V, Berche P, Gaillard JL. Age-related prevalence and distribution 
of nontuberculous mycobacterial species among patients with cystic fibrosis. J 
Clin Microbiol 2005; 43: 3467-70.
51. Olivier KN, Weber DJ, Wallace RJ Jr., Faiz AR, Lee J, Zhang Y, Brown-Elliot BA, 
Handler A, Wilson RW, Schechter MS, Edwards LJ, Chakraborti S, Knowles MR. 
Nontuberculous Mycobacteria in Cystic Fibrosis Study Group. Nontuberculous 
Mycobacteria I: Multicenter prevalence study in Cystic Fibrosis. Am J Respir 
Crit Care Med 2003; 167: 828-834.
52. Gilligan PH. Microbiology of airway disease in patients with cystic fibrosis. 
Clin Microbiol Rev 1991; 4: 35-51.
53. Lyczak JB, Cannon CL, Pier GB. Lung infections associated with cystic fibrosis. 
Clin Microbiol Rev 2002; 15: 194-222.
54. Kozlova I, Nilsson H, Henriksnas J, Roomans GM. X-ray microanalysis of 
apical fluid in cystic fibrosis airway epithelial cell lines. Cell Physiol Biochem 
2006; 17: 13-20.
55. Kent PT, Kubica GP. Public Health Mycobacteriology. A Guide for the Level 
III Laboratory. U.S. Department of Health and Human Services, Atlanta, GA, 
1985. 
56. Doherty TM, Sher A. Defects in cell-mediated immunity affect chronic, but not 
innate, resistance of mice to Mycobacterium avium infection. J Immunol 1997; 
158: 4822-31.
57. Dunn PL, North RJ. Virulence ranking of some Mycobacterium tuberculosis and 
Mycobacterium bovis strains according to their ability to multiply in the lungs, 
induce lung pathology, and cause mortality in mice. Infect Immun 1995; 63: 
3428-37.
58. Ehlers S, Richter E. Differential requirement for interferon-gamma to restrict 
the growth of or eliminate some recently identified species of nontuberculous 
mycobacteria in vivo. Clin Exp Immunol 2001; 124: 229-38.
59. Rottman M, Catherinot E, Hochedez P, Emile J, Casanova J, Gaillard J, Soudais 
C. Immune control of the rapid-grower Mycobacterium abscessus in C57BL/6 
mice: importance of T cells, interferon γ and tumor necrosis factor. Infect 
Immun 2007; 75: 5898-907.
60. Byrd TF, Lyons CR. Preliminary characterization of a Mycobacterium abscessus 
mutant in human and murine models of infection. Infect Immun 1999; 67: 
4700-7.
61. Kalayjian RC, Toossi Z, Tomashefski JF Jr, Carey JT, Ross JA, Tomford JW, 
Blinkhorn RJ Jr. Pulmonary disease due to infection by Mycobacterium avium 
complex in patients with AIDS. Clin Infect Dis 1995; 20:1186-94.
62. Wolinsky E. Chemotherapy and pathology of experimental photochromogenic 
mycobacterial infections. Am Rev Respir Dis 1959; 80: 522-34.
63. Phillips P, Bonner S, Gataric N, Bai T, Wilcox P, Hogg R, O’Shaughnessy M, 
Montaner J. Nontuberculous mycobacterial immune reconstitution syndrome 
314
Chapter 8
in HIV-infected patients: spectrum of disease and long-term follow-up. Clin 
Infect Dis 2005; 41: 1483-97.
64. van de Vosse E, Hoeve MA, Ottenhoff TH. Human genetics of intracellular 
infectious diseases: molecular and cellular immunity against mycobacteria and 
salmonellae. Lancet Infect Dis 2004 ;4: 739-49.
65. Noordzij JG, Hartwig NG, Verreck FA, De Bruin-Versteeg S, De Boer T, 
Van Dissel JT, De Groot R, Ottenhoff TH, Van Dongen JJ. Two patients with 
complete defects in interferon gamma receptor-dependent signaling. J Clin 
Immunol 2007; 27: 490-6.
66. Koscielniak E, de Boer T, Dupuis S, Naumann L, Casanova JL, Ottenhoff TH. 
Disseminated Mycobacterium peregrinum infection in a child with complete 
interferon-gamma receptor-1 deficiency. Pediatr Infect Dis J 2003; 22:378-80.
67. Roach DR, Bean AGD, Demangel C, France MP, Briscoe H, Britton WJ. TNF 
α regulates chemokine induction essential for cell recruitment, granuloma 
formation and clearance of mycobacterial infection. J Immunol 2002; 168: 
4620-7.
68. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman 
WD, Siegel JN, Braun MM. Tuberculosis associated with infliximab, a tumor 
necrosis factor α-neutralizing agent. N Engl J Med 2001; 345: 1098-104.
69. Gardam MA, Keystone EC, Menzies R, Manners S, Skamene E, Long R, Vinh 
DC. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of 
action and clinical management. Lancet Infect Dis 2003;3:148-55.
70. Lutt JR, Pisculli ML, Weinblatt ME, Deodhar A, Winthrop KL. Severe 
nontuberculous mycobacterial infection in 2 patients receiving rituximab for 
refractory myositis. J Rheumatol 2008; 35: 1683-5.
71. Research Committee of the British Thoracic Society. Clarithromycin vs 
ciprofloxacin as adjuncts to rifampicin and ethambutol in treating opportunist 
mycobacterial lung diseases and an assessment of Mycobacterium vaccae 
immunotherapy. Thorax 2008; 63: 627-34.
72. Wallace RJ Jr, Brown BA, Griffith DE, Girard WM, Murphy DT. Clarithromycin 
regimens for pulmonary Mycobacterium avium complex: the first 50 patients. 
Am J Respir Crit Care Med 1996; 153: 1766-72.
73. Tanaka E, Kimoto T, Tsuyuguchi K, Watanabe I, Matsumoto H, Niimi A, 
Suzuki K, Murayama T, Amitani R, Kuze F. Effect of clarithromycin regimen 
for Mycobacterium avium complex pulmonary disease. Am J Respir Crit Care 
Med 1999; 160: 866-72.
74. Lam PK, Griffith DE, Aksamit TR, Ruoss SJ, Garay SM, Daley CL, Catanzaro A. 
Factors related to response to intermittent treatment of Mycobacterium avium 
complex lung disease. Am J Respir Crit Care Med 2006; 173: 1283-9.
75. Bakker-Woudenberg IA, van Vianen W, van Soolingen D, Verbrugh HA, van 
Agtmael MA. Antimycobacterial agents differ with respect to their bacteriostatic 
versus bactericidal activities in relation to time of exposure, mycobacterial 
growth phase, and their use in combination. Antimicrob Agents Chemother; 
2005; 49: 2387-98.
76. Kohno Y, Ohno H, Miyazaki Y, Higashiyama Y, Yanagihara K, Hirakata Y, 
Fukushima K, Kohno S. In vitro and in vivo activities of novel fluoroquinolones 
alone and in combination with clarithromycin against clinically isolated 
Mycobacterium avium complex strains in Japan. Antimicrob Agents Chemother 
2007; 51: 4071-6.
77. Research Committee of the British Thoracic Society. First randomised trial 
of treatments for pulmonary disease caused by M. avium intracellulare, M. 
Discussion, conclusions and strategies for future research
Chapter 8
315
malmoense, and M. xenopi in HIV negative patients: rifampicin, ethambutol 
and isoniazid versus rifampicin and ethambutol. Thorax 2001; 56: 167-72.
78. Banks J, Jenkins PA. Combined versus single antituberculosis drugs on the in 
vitro sensitivity patterns of non-tuberculous mycobacteria. Thorax 1987; 42: 
838-42.
79. Peloquin C. Clinical experience with high dose and high serum concentration 
rifampin. 2008. Abstract 13, p. 12, Abstracts of the 1st International Workshop 
on Clinical Pharmacology of Tuberculosis Therapy, Toronto, Canada.
80. Kuze F, Kurasawa T, Bando K, Lee Y, Maekawa N. In vitro and in vivo 
susceptibility of atypical mycobacteria to various drugs. Rev Infect Dis 1981; 
3: 885-97.
81. Kuze F. Experimental chemotherapy in chronic Mycobacterium avium-
intracellulare infection of mice. Am Rev Respir Dis 1984; 129: 453-9.
82. National Committee for Clinical Laboratory Standards. Susceptibility testing of 
mycobacteria, nocardiae and other aerobic actinomycetes. Approved standard. 
NCCLS Document no. M24-A. Wayne, PA, 2003.
83. van Klingeren B, Dessens-Kroon M, van der Laan T, Kremer K, van Soolingen 
D. Drug susceptibility testing of Mycobacterium tuberculosis complex using 
a high throughput, reproducible, absolute concentration method. J Clin 
Microbiol 2007; 45: 2662-8.
84. van Ingen J, Boeree MJ, Wright A, van der Laan T, Dekhuijzen PNR, van Soolingen 
D. Second line drug resistance in multi-drug resistant tuberculosis cases in the 
Netherlands, of various origin. Int J Tuberc Lung Dis 2008; 12: 1295-9.
85. Wallace RJ Jr, Nash DR, Steele LC, Steingrube VA. Susceptibility testing of 
slowly growing mycobacteria by a microdilution MIC method with 7H9 broth. 
J Clin Microbiol 1986; 24: 976-81.
86. Ordway D, Viveiros M, Leandro C, Bettencourt R, Almeida J, Martins M, 
Kristiansen JE, Molnar J, Amaral L. Clinical concentrations of thioridazine 
kill intracellular multidrug-resistant Mycobacterium tuberculosis. Antimicrob 
Agents Chemother 2003; 47: 917-22.
87. Sohaskey CD. Nitrate enhances the survival of Mycobacterium tuberculosis 
during inhibition of respiration. J Bacteriol 2008; 190: 2981-6.
88. Mitchell JD, Bishop A, Cafaro A, Weyant MJ, Pomerantz M. Anatomic lung 
resection for nontuberculous mycobacterial disease. Ann Thorac Surg 2008; 85: 
1887-93.
89. Shiraishi Y, Fukushima K, Komatsu H, Kurashima A. Early pulmonary resection 
for localized Mycobacterium avium complex disease. Ann Thorac Surg 1998; 
66: 183-6.
90. Sherwood JT, Mitchell JD, Pomerantz M. Completion pneumonectomy for 
chronic mycobacterial disease. J Thorac Cardiovasc Surg 2005; 129: 1258-65.
91. Meyer M, von Grunberg PW, Knoop T, Hartmann P, Plum G. The macrophage-
induced gene mig as a marker for clinical pathogenicity and in vitro virulence of 
Mycobacterium avium complex strains. Infect Immun 1998; 66: 4549-52.
92. Yoon JH, Kim EC, Kim JS, Song EY, Yi J, Shin S. Possession of the macrophage-
induced gene by isolates of the Mycobacterium avium complex is not associated 
with significant clinical disease. J Med Microbiol 2009; 58: 256-60.
93. Li Y, Miltner E, Wu M, Petrofsky M, Bermudez LE. A Mycobacterium avium 
PPE gene is associated with the ability of the bacterium to grow in macrophages 
and virulence in mice. Cell Microbiol 2005; 7: 539-48.
94. Stinear TP, Seemann T, Harrison PF, Jenkin GA, Davies JK, Johnson PDR, 
Abdellah Z, Arrowsmith C, Chillingworth T, Carol Churcher C, Clarke K, 
316
Chapter 8
Cronin A, Davis P, Goodhead I, Holroyd N, Jagels K, Lord A, Moule S, Mungall 
K, Norbertczak H, Quail MA, Rabbinowitsch E, Walker D, White B, Whitehead 
S,  Small PLC, Brosch R, Ramakrishnan L, Fischbach MA, Parkhill J, Cole ST. 
Insights from the complete genome sequence of Mycobacterium marinum on 
the evolution of Mycobacterium tuberculosis. Genome Res 2008; 18: 729-41.
95. Wernegreen JJ. For better or worse: genomic consequences of intracellular 
mutualism and parasitism. Curr Opin Genet Dev 2005; 15: 572-83.
96. Andersson SG, Kurland CG. Reductive evolution of resident genomes. Trends 
Microbiol 1998; 6: 263-8.
97. Lewis KN, Liao R, Guinn KM, Hickey MJ, Smith S, Behr MA, Sherman DR. 
Deletion of RD1 from Mycobacterium tuberculosis mimics bacille Calmette-
Guerin attenuation. J Infect Dis 2003; 187: 117-23.
98. van der Wel N, Hava D, Houben D, Fluitsma D, van Zon M, Pierson J, Brenner 
M, Peters PJ. M. tuberculosis and M. leprae translocate from the phagolysosome 
to the cytosol in myeloid cells. Cell 2007; 129: 1287-98.
99. Flint JL, Kowalski JC, Karnati PK, Derbyshire KM. The RD1 virulence locus 
of Mycobacterium tuberculosis regulates DNA transfer in Mycobacterium 
smegmatis. Proc Natl Acad Sci U S A 2004; 101: 12598-603.
100. Abdallah AM, Gey van Pittius NC, Champion PA, Cox J, Luirink J, 
Vandenbroucke-Grauls CM, Appelmelk BJ, Bitter W. Type VII secretion--
mycobacteria show the way. Nat Rev Microbiol 2007; 5: 883-91.
101. Coster JF. The identification of tubercle bacilli. Thesis. 1958. Drukkerij H.J. 
Smits, Oude Gracht 231 Utrecht, the Netherlands.
102. Waine DJ, Honeybourne D, Smith EG, Whitehouse JL, Dowson CG. Association 
between hypermutator phenotype, clinical variables, mucoid phenotype, and 
antimicrobial resistance in Pseudomonas aeruginosa. J Clin Microbiol. 2008; 
46: 3491-3. 
103. Greendyke R, Byrd TF. Differential antibiotic susceptibility of Mycobacterium 
abscessus variants in biofilms and macrophages compared to that of planktonic 
bacteria. Antimicrob Agents Chemother 2008; 52: 2019-26.
104. Adekambi T, Berger P, Raoult D, Drancourt M. rpoB gene sequence-based 
characterization of emerging non-tuberculous mycobacteria with descriptions 
of Mycobacterium bolletii sp. nov., Mycobacterium phocaicum sp. nov. and 
Mycobacterium aubagnense sp. nov. Int J Syst Evol Microbiol 2006; 56: 133-43.
105. Stackebrandt E, Frederiksen W, Garrity GM, Grimont PA, Kämpfer P, Maiden 
MC, Nesme X, Rosselló-Mora R, Swings J, Trüper HG, Vauterin L, Ward AC, 
Whitman WB. Report of the ad hoc committee for the re-evaluation of the 
species definition in bacteriology. Int J Syst Evol Microbiol 2002; 52: 1043-7.
106. Behr MA. Mycobacterium du jour; what’s on tomorrow’s menu? Microbes 
Infect 2008; 10: 968-72.
107. Telenti A. More on `What’s in a name…’- pragmatism in mycobacterial 
taxonomy. Int J Tuberc Lung Dis 1998; 2: 182-3.
108. Runyon EH. Anonymous mycobacteria in pulmonary disease. Med Clin North 
Am 1959; 43: 273-90. 
109. Wayne LG, Sramek HA. Agents of newly recognized or infrequently encountered 
mycobacterial diseases. Clin Microbiol Rev 1992; 5: 1-25.
110. Buijtels PC, van der Sande MA, de Graaff CS, Parkinson S, Verbrugh HA, Petit 
PL, van Soolingen D. Nontuberculous mycobacteria, Zambia. Emerg Infect Dis 
2009; 15: 242-9.
111. Zykov MP, Roulet H, Gaya N. Non-tuberculosis mycobacteria in Africa. I: 
Isolation and identification. Bull Wld Hlth Org 1967; 37: 927-38.
Discussion, conclusions and strategies for future research
Chapter 8
317
112. Gilks CF, Brindle RJ, Mwachari C, Batchelor B, Bwayo J, Kimari J, Arbeit RD, 
von Reyn CF. Disseminated Mycobacterium avium infection among HIV-
infected patients in Kenya. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 
8: 195-8.
113. Bonard D, Messou E, Seyler C, Vincent V, Gabillard D, Anglaret X. High 
incidence of atypical mycobacteriosis in African HIV-infected adults with low 
CD4 cell counts: a 6-year cohort study in Côte d’Ivoire. AIDS 2004; 18: 1961-4.
114. Buijtels PC, Petit PL, Verbrugh HA, van Belkum A, van Soolingen D. Isolation 
of nontuberculous mycobacteria in Zambia: eight case reports. J Clin Microbiol 
2005; 43: 6020-6.
115. van der Meer JT, Kerssemakers SP, van Steenwijk RP, Kuijper EJ. [Infections 
with Mycobacterium kansasii in the Academic Medical Center in Amsterdam: 
the changing clinical spectrum since the start of the HIV-epidemic]. Ned 
Tijdschr Geneesk 1998; 142: 965-9. Dutch
116. Juffermans NP, Verbon A, Danner SA, Kuijper EJ, Speelman P. Mycobacterium 
xenopi in HIV-infected patients: an emerging pathogen. AIDS 1998; 12: 1661-6.
117. Subcommittee of the Joint Tuberculosis Committee of the British Thoracic 
Society. Management of opportunist mycobacterial infections: Joint 
Tuberculosis Committee guidelines 1999. Thorax 2000; 55: 210-8.

Chapter 9
Summary
jakko 
was here
320
Chapter 9Summary
Chapter 9
321
This thesis summarizes joint studies on the clinical relevance of nontuberculous 
mycobacteria, by the University Lung Centre Dekkerswald (part of the 
Radboud University Nijmegen Medical Center) and the National Institute for 
Public Health and the Environment. 
In Chapter 1 we present a general introduction on nontuberculous 
mycobacterial disease, including a historical perspective. Our starting point 
is that the genus Mycobacterium consists of three main groupings: I) the 
Mycobacterium tuberculosis complex, II) Mycobacterium leprae and III) the 
nontuberculous mycobacteria. While clinical isolation of nontuberculous 
mycobacteria (NTM) has become increasingly frequent in recent years, their 
clinical relevance was largely unknown.
Whereas the M. tuberculosis complex and M. leprae bacteria are obligate 
pathogens for humans and other animals, the NTM, which consist of over 100 
validly published species, are mostly opportunistic environmental pathogens 
mainly affecting patients with impaired local or systemic immunity. Their 
omnipresence in the environment implies that if NTM are cultured from non-
sterile clinical samples, e.g. those from the respiratory and digestive tract, this 
does not indicate NTM infection per se; contamination or pseudo-infection 
should be ruled out. To accommodate for this, the American Thoracic Society 
(ATS) has developed diagnostic criteria for NTM lung disease, consisting of 
clinical and microbiological criteria.
In Chapter 2, we have quantified the clinical relevance of isolation of various 
NTM species. To determine the clinical relevance, we retrospectively assessed 
the percentage of patients that met the ATS diagnostic criteria for pulmonary 
NTM disease, as well as the frequency and clinical features of extrapulmonary 
disease, per species. In a regional study of all clinical NTM isolates we found that 
25% of all NTM isolated from respiratory tract samples were causative agents 
of pulmonary NTM disease. Taking both pulmonary and extrapulmonary 
isolates into account, 33% of all clinical NTM isolates were causative agents of 
true NTM disease. In the regional and subsequent national studies we found 
that this percentage differs significantly by species, from less than 5% (for M. 
noviomagense, M. gordonae), to well over 70% (M. kansasii, M. szulgai and M. 
malmoense). This finding has important implications for clinical practice. The 
identification of cultured NTM can assist the clinician in determining his stance 
towards the individual patient. We suggest that future ATS diagnostic criteria 
should accommodate for these differences in clinical relevance. For species of 
limited clinical relevance, the criteria should be stricter to prevent unwarranted 
diagnosis and treatment of NTM disease. Conversely, for highly relevant species, 
more lenient criteria can reduce diagnostic delay and undertreatment.
From the retrospective studies we learned that the diagnosis and treatment 
of NTM disease in the Netherlands can be improved. The use of available 
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diagnostic criteria and treatment guidelines seemed limited; we recorded 
significant over- and underdiagnosis, leading to over- and undertreatment 
of NTM disease. Moreover, the use of treatment regimens that were not 
evidence based, or of too short duration was frequent. Possibly as a result, 
cure rates for pulmonary NTM disease were suboptimal. In our regional 
study, we recorded an overall cure rate of 67%. Cure rates also differed by 
species and ranged from 50% (for M. avium) to 82% (M. szulgai). These 
cure rates are comparable to those of multi- or extensively drug-resistant 
tuberculosis and emphasize the strong need for new anti-mycobacterial 
drugs and adjunctive therapies.
From our retrospective studies, a rather homogeneous patient population 
emerged, characterized by a predominance of males, an average age of 60 
years and pre-existing pulmonary disease. Cavitary disease was the most 
common pulmonary NTM disease type in these patients. Pre-existing 
pulmonary disease and cavitary NTM disease are both major factors negatively 
influencing treatment outcome. The increasing isolation frequency of NTM in 
the Netherlands was largely due to a rise in M. avium isolates from pulmonary 
samples exactly in this patient category.
We consider the increased frequency of clinical NTM isolation to be mainly 
a result of the ageing of the Dutch population, with an increasing prevalence 
of chronic (pulmonary) diseases and immunosuppressive treatment for these 
diseases, as well as a decline in cross-protection from exposure to tuberculosis. 
Improvements in laboratory techniques and the increased use of showers for 
personal hygiene may have also had an impact.
Within Chapter 3, we focused on an emerging category of patients at risk for 
NTM disease, those with rheumatic or other immune-mediated inflammatory 
disease treated with antibodies against cytokines or receptors with pivotal roles 
in inflammatory pathways. These include the anti-tumor necrosis factor-α (anti-
TNF) agents and are collectively referred to as ‘biologicals’. The first clinical 
trials using anti-TNF agents revealed an increased risk of serious infections, 
including reactivation of latent tuberculosis. We described a case of pulmonary 
M. szulgai disease associated with anti-TNF therapy and reviewed the impact 
of the various biologicals on immunity against mycobacteria. NTM disease has 
already been recorded in patients undergoing anti-TNF, anti-IL-1 and CD20+ 
B-cell antibody treatment for rheumatic disease. Among the drug classes 
currently in development for anti-rheumatic therapy, the IL-17, IL-23 and JAK/
STAT-signaling modifying agents and metalloproteinases are also likely to 
confer an increased risk of mycobacterial infection. As the biologicals and the 
indications for their use diversify, associated cases of NTM disease are likely to 
become more frequent. All patients receiving biologicals should be screened for 
latent tuberculosis infection and carefully monitored for mycobacterial disease.
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With the clinical relevance of NTM established and populations at risk 
identified, it is sensible to shift the focus to treatment of NTM disease. In 
Chapter 2, we found the outcome of treatment was often poor. Therefore, 
in Chapter 4, we looked into potential improvements of therapy for NTM 
disease. We studied the role of drug susceptibility testing, a potential novel 
drug and adjunctive surgery.
Drug susceptibility testing demonstrated that clarithromycin and rifabutin are 
in vitro most active against NTM. The utility of testing other first and second 
line anti-tuberculosis drugs is limited. For the first line drugs (isoniazid, 
rifampicin and ethambutol) there are discrepancies between in vitro activity 
and in vivo outcome of treatment; the activity of the second line drugs 
(clofazimine, cycloserine, prothionamide) is not supported by clinical data. 
To improve therapy guidance, these should be substituted for drugs with 
proven clinical efficacy, correlating with in vitro susceptibility, especially for 
rapid growing NTM. Baseline testing, i.e. drug susceptibility testing prior to 
the institution of therapy, is appropriate for all clinically relevant NTM isolates; 
follow-up testing is warranted in case of therapy failure or relapse.
Considering the urgent need for new antimycobacterial drugs, we tested the 
activity of thioridazine, a widely available and out-of-patent antipsychotic 
drug with antimicrobial properties. We measured potent activity against M. 
tuberculosis; the activity against NTM was up to 8 times lower. This seems to 
preclude a role for thioridazine in treatment of NTM disease. 
In case of failure of conventional drug treatment for pulmonary NTM disease, 
adjunctive surgical resection of the affected parts of the lungs has been advised. 
We reviewed the outcomes of eight patients who underwent surgery for NTM 
lung disease in Dekkerswald. Surgery resulted in long-term culture conversion 
in all but one patient. The indications and timing of surgery were critical 
factors; these were insufficiently addressed in available literature. We conclude 
that benefits of surgery should be considered for every individual patient in 
whom NTM lung disease is diagnosed and re-evaluated after six months of 
treatment. Where possible, surgery should be pursued and timely conducted. 
To assist pulmonary physicians, we have proposed indications for surgery.
Clinical relevance and optimal treatment regimens have been defined for well-
established NTM species. In Chapter 5, we explored the heterogeneity among 
NTM and concluded that at least 4% of all NTM isolates submitted to the 
national reference laboratory can not be assigned to validly published species. 
Strains related to, but different from, the M. avium complex and M. fortuitum 
complex members were especially prevalent. 
Some groupings of previously unidentifiable mycobacteria stood out as 
they were frequently isolated, or isolated from extrapulmonary samples 
and were thus probably associated with clinical NTM disease. Four of these 
were studied in-depth and could be elevated to separate species status, with 
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an assessment of their clinical relevance. We discerned the clinically non-
relevant M. noviomagense from the closely related and frequently clinically 
relevant M. xenopi, described M. vulneris and (in Chapter 7) M. riyadhense as 
causative agents of extrapulmonary NTM disease and found that M. mantenii 
is a causative agent of pediatric cervicofacial lymphadenitis but not relevant in 
pulmonary samples. More discriminative mycobacterial taxonomy can be of 
clinical utility; in fact, we conclude that clinical meaningfulness should be the 
key to taxonomic precision in NTM.
In Chapter 6 we zoomed further in, on the genetic divergence within NTM 
species. Infectious diseases result from complex interplay of host and pathogen 
factors; genetic divergence within NTM could provide important insights in the 
bacterial factors in the issue of clinical relevance. Particular subgroups within 
species may be clinically more relevant than others. By sequencing multiple 
house-keeping genes in various NTM species, we were able to reveal, for the 
first time, the extensive genetic divergence within NTM species. Still, we could 
not correlate subgroups based on variation in any of the house-keeping genes 
with clinical disease. The next approach was to look at a specific virulence 
factor, a gene whose product is essential in the pathogenesis of NTM disease. 
We therefore explored the presence and role of the esat-6 and cfp-10 genes, 
which have central roles in virulence of M. tuberculosis. The proteins encoded 
by these genes allow M. tuberculosis to escape from the phagolysosome, where 
it should be neutralized, to the cytosol in human macrophages. We found 
similar genes in M. szulgai, M. kansasii, M. riyadhense and M. marinum, 
species that are highly clinically relevant and phylogenetically related to the 
M. tuberculosis complex. In M. szulgai, we tested the function of these genes 
in an in vitro macrophage infection. Here, however, we recorded by cryo-
immunogold electron microscopy that presence of esat-6 and cfp-10-like genes 
does not allow M. szulgai to escape from the phagolysosome to the cytosol 
in macrophages. The actual pathogenesis of NTM infection remains to be 
established.
Finally, in Chapter 7, we have looked across our borders to assess the 
occurrence and clinical relevance of NTM isolation in different settings in very 
different geographical regions. In Oman, we encountered a situation similar to 
the Netherlands, with similar species causing similar pulmonary NTM disease 
types. In nearby Saudi Arabia, we identified a novel NTM species causing a 
soft tissue infection after blunt trauma. In Tanzania, we identified NTM as 
causative agents of HIV-related disseminated disease. In Vietnam, we identified 
a random sample of NTM isolates in a tuberculosis drug susceptibility survey, 
a setting that hampers assessment of the clinical relevance of the isolates. In 
the Tanzanian and Vietnamese setting we noted a predominance of NTM that 
are rare or absent in the Netherlands. Hence, we conclude that identification 
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methods intended for use in the European or North American setting may not 
function optimally in other geographical regions, where different distributions 
of NTM species may be present. Although incidence and disease manifestations 
likely differ by setting, we concluded that NTM are present and cause disease 
worldwide, including in settings with a high prevalence of tuberculosis.
We have demonstrated that NTM isolation is a relevant clinical and laboratory 
issue in the Netherlands and other countries, including countries with a 
high prevalence of tuberculosis. In Chapter 8, the combined results of our 
studies are discussed within their scientific context. We conclude that future 
research on NTM should focus on three subjects. First and perhaps foremost, 
the pathogenesis of NTM infections is largely unknown. Prospective clinical 
studies should address host factors influencing susceptibility to NTM 
disease; whole genome sequencing of clinically relevant NTM as well as in 
vitro and in vivo infection experiments can help to reveal bacterial virulence 
factors. Second, improvement of treatment outcome is urgently needed. 
Pharmacokinetic studies are warranted to optimize therapy with currently 
available drugs. New antimicrobials should be tested for their activity against 
NTM and this specifically includes new antituberculosis drugs currently under 
development. Simultaneously, existing diagnostic and therapeutic guidelines 
should be disseminated and expert consultation should be propagated among 
respiratory and infectious diseases specialists. Third, the environmental 
sources of NTM infection remain uncertain and deserve further investigation. 
Water and soil samples have yielded NTM and some of these could be linked 
to human disease. Still, we do not know where these NTM actually reside and 
multiply.
Last, it is difficult to advocate increased attention for NTM disease when its true 
incidence, prevalence and the burden of disease remain to be quantified. As a 
start, we propose an obligatory, although not necessarily real-time, laboratory 
reporting system for the Netherlands. Combined with clinical data this will 
reveal the true burden of NTM disease in the Netherlands.
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Dit proefschrift omvat het eerste deel van een gezamenlijk onderzoek van 
het Universitair Longcentrum Dekkerswald (onderdeel van de vakgroep 
Longziekten van het UMC St. Radboud te Nijmegen) en de afdeling 
Mycobacteriën van het Rijksinstituut voor Volksgezondheid en Milieu te 
Bilthoven, naar de klinische relevantie van nontuberculeuze mycobacteriën.
In Hoofdstuk 1 introduceren wij de stand van de wetenschap aangaande ziekte 
door nontuberculeuze mycobacteriën voorafgaand aan dit onderzoek, inclusief 
een historisch overzicht. In het kort omvat het geslacht Mycobacterium drie 
hoofdgroepen: I) het Mycobacterium tuberculosis complex, II) Mycobacterium 
leprae en III) de nontuberculeuze mycobacteriën (NTM). Hoewel in 
Nederland het aantal klinische monsters waaruit NTM worden gekweekt is 
gestegen gedurende het afgelopen decennium is er nog weinig kennis omtrent 
de klinische relevantie hiervan.
Waar het M. tuberculosis complex en M. leprae obligate pathogenen zijn 
voor de mens en dier zijn de NTM, waarvan al meer dan 100 verschillende 
species zijn beschreven, doorgaans opportunistische pathogenen die vanuit 
milieubronnen infecties veroorzaken bij patiënten met verlaagde lokale of 
systemische immuniteit. Door hun veelvuldig voorkomen in ons milieu 
betekent het kweken van NTM vanuit een niet-steriel monster, bijvoorbeeld 
een monster uit de luchtwegen of het maag-darmstelsel, niet per definitie dat 
er sprake is van een infectie; contaminatie of pseudo-infectie dienen te worden 
uitgesloten. Om het maken van dit onderscheid te ondersteunen heeft de 
American Thoracic Society (ATS) criteria opgesteld voor het diagnosticeren 
van longinfecties door NTM, bestaande uit klinische en microbiologische 
criteria.
In Hoofdstuk 2 hebben wij de klinische relevantie van het isoleren van 
verscheidende NTM species gekwantificeerd. Hiertoe bepaalden wij per 
species retrospectief het percentage patiënten dat voldeed aan de ATS criteria 
voor NTM longinfecties, alsmede de frequentie en klinische uitingsvormen van 
extrapulmonale NTM infecties. In een regionaal onderzoek dat alle klinisch 
geïsoleerde NTM omvatte oordeelden wij dat 25% van alle uit longmaterialen 
gekweekte NTM veroorzakers waren van daadwerkelijke NTM longinfecties. 
Wanneer we ook de extrapulmonale monsters meenamen, konden we stellen 
dat 33% van alle klinische geïsoleerde NTM verwekkers waren van ware 
NTM infecties. In de regionale en hierop volgende nationale studies stelden 
wij vast dat dit percentage significant verschilt tussen de verschillende NTM 
species, variërend van minder dan 5% (M. noviomagense, M. gordonae) tot 
boven de 70% (M. kansasii, M. szulgai en M. malmoense). Deze bevinding 
heeft een belangrijke klinische weerklank. De identiteit van de NTM in 
een klinisch monster kan de clinicus ondersteunen in het bepalen van zijn 
grondhouding ten aanzien van een kweekpositieve patiënt. Wij suggereerden 
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dat toekomstige ATS criteria rekening moeten houden met deze verschillen 
in klinische relevantie tussen de verschillende NTM species. Voor de minder 
relevante species kunnen striktere diagnostische criteria onterechte diagnoses 
en behandelingen voorkomen. Voor de zeer relevante species daarentegen 
kunnen soepeler criteria het stellen van de definitieve diagnose bespoedigen.
Uit onze retrospectieve studies leerden wij ook dat de diagnostiek en 
behandeling van NTM infecties in Nederland verbetering behoeven. Het 
gebruik van bestaande richtlijnen voor diagnostiek en behandeling is geen 
gemeengoed; wij bemerkten zowel over- als onderdiagnostiek, leidend tot 
over- en onderbehandeling van NTM infecties. Daarbij viel het veelvuldig 
instellen van niet bewezen effectieve behandelingen, of behandelingen van te 
korte duur, op. Mogelijk als gevolg hiervan waren de uitkomsten van therapie 
voor NTM longinfecties vaak teleurstellend. In onze regionale studie zagen wij 
bij 67% van de behandelde patiënten een gunstige uitkomst. De uitkomst van 
therapie verschilde echter ook per species en varieerde van 50% (M. avium) 
tot 82% (M. szulgai) gunstige uitkomst. Deze uitkomsten zijn vergelijkbaar 
met die van multi- of extensief drugresistente tuberculose en benadrukken de 
sterke behoefte aan nieuwe antimycobacteriële middelen en ondersteunende 
therapieën.
De homogeniciteit binnen de patiëntenpopulaties van onze verschillende 
retrospectieve studies was opvallend; de populaties bestonden voornamelijk uit 
mannen, met een gemiddelde leeftijd van 60 jaar en pre-existente (chronische) 
longziekten. Holtevormende NTM longinfectie was de meest voorkomende 
vorm van NTM ziekte in deze patiënten. Zowel pre-existente longziekten als 
de holtevormende NTM longinfecties vergroten het risico op het falen van 
therapie. De toename in het aantal NTM isolaten in Nederland wordt ook 
grotendeels veroorzaakt door een toename in het aantal M. avium isolaten uit 
longmaterialen exact in deze patiëntcategorie.
We beschouwen deze toename in het aantal klinische NTM isolaten 
voornamelijk als een gevolg van de vergrijzing van de Nederlandse bevolking, 
met een toename van chronische (long)ziekten en immunosuppressieve 
behandelingen hiervan, maar ook van afnemende kruisbescherming door 
blootstelling aan tuberculose. Daarnaast hebben ook verbeteringen in de 
laboratoriumdiagnostiek en het toenemende gebruik van douches voor 
persoonlijke hygiëne een mogelijke invloed gehad.
In Hoofdstuk 3 hebben we extra aandacht besteed aan een nieuw opkomende 
groep patiënten met een verhoogd risico op NTM infecties, te weten patiënten 
met reumatische of andere immuun-gemedieerde inflammatoire ziekten 
die worden behandeld met antilichamen tegen cytokines of receptoren met 
belangrijke functies in het inflammatoir proces. De middelen omvatten o.a. 
de tumor necrosis factor-α (TNF-α) blokkers en worden in de Engelstalige 
literatuur vaak aangeduid als “biologicals”. De eerste klinische studies 
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met TNF-α blokkers toonden al een verhoogd risico op ernstige infecties, 
waaronder reactivaties van latente tuberculose. Wij beschreven een patiënt 
met een pulmonale M. szulgai infectie tijdens gebruik van TNF-α blokkers 
en schreven een overzichtsartikel over de impact van de verschillende 
“biologicals” op de afweer tegen mycobacteriën. Inmiddels zijn NTM infecties 
beschreven zowel bij patiënten die TNF-α blokkers gebruikten, als bij patiënten 
die anti-IL-1 en CD20+ B-cel antilichamen gebruikten voor reumatische 
aandoeningen. Onder de verschillende klassen antireumatische middelen die 
momenteel worden ontwikkeld mag van de IL-17 en IL-23 blokkers, de JAK/
STAT signaaltransductie-modificerende middelen en de metalloproteïnases 
worden verwacht dat zij de afweer tegen mycobacteriën negatief beïnvloeden. 
Aangezien het aantal “biologicals” en de indicaties voor hun gebruik snel 
uitbreiden is een toename in het aantal geassocieerde NTM infecties te 
verwachten. Alle patiënten die deze middelen gebruiken moeten worden 
gescreend op latente tuberculose en nauwlettend worden gecontroleerd op het 
optreden van mycobacteriële infecties.
Na het vaststellen van de klinische relevantie van NTM en het identificeren van 
risicopopulaties is het logisch de aandacht te verleggen naar de behandeling 
van NTM infecties. In Hoofdstuk 2 vonden we al dat de uitkomst van therapie 
vaak teleurstellend was. Daarom zijn we in Hoofdstuk 4 op zoek gegaan naar 
mogelijkheden om de uitkomst van therapie van NTM infecties te verbeteren. 
Hiertoe bestudeerden wij de rol van resistentiebepalingen, een mogelijk nieuw 
geneesmiddel voor mycobacteriële infecties en de waarde van chirurgie als 
toevoeging aan medicinale therapie.
Uit de door ons verzamelde resistentiedata kwam naar voren dat 
clarithromycine en rifabutin in vitro het meest actief zijn tegen NTM. 
Het nut van resistentiebepalingen tegen andere eerste- en tweedelijns 
antituberculose middelen is beperkt. Bij de eerstelijns middelen (isoniazide, 
rifampicine en ethambutol) zijn er discrepanties tussen de in vitro activiteit 
en de in vivo uitkomst van therapie; de activiteit van tweedelijnsmiddelen 
(clofazimine, cycloserine en prothionamide) wordt niet ondersteund door 
klinische gegevens. Om therapieadvies en begeleiding te verbeteren dient het 
testen van deze middelen te worden vervangen door resistentiebepalingen 
tegen middelen met een bewezen klinische effectiviteit, bij voorkeur 
overeenstemmend met de in vitro activiteit. Dit gaat in het bijzonder op voor 
de snel groeiende NTM waar resistentie een groot probleem is. Het bepalen 
van uitgangswaarden qua resistentie, voorafgaand aan therapie, is wenselijk 
voor alle klinische relevante NTM isolaten. Vervolgtesten zijn geïndiceerd 
bij falen van therapie of terugkeer van ziekte na therapie.
Gezien de urgente behoefte aan nieuwe antimycobacteriële middelen, 
testten wij de activiteit van thioridazine, een overal beschikbaar patentloos 
antipsychoticum met antimicrobiële eigenschappen. Wij maten een 
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veelbelovende activiteit tegen M. tuberculosis; de activiteit tegen NTM was 
echter tot wel 8 maal lager. Thioridazine lijkt dan ook geen rol van betekenis te 
kunnen spelen in het verbeteren van de behandeling van NTM infecties.
Wanneer medicinale therapie voor NTM infecties faalt, wordt chirurgische 
verwijdering van de aangedane longdelen als laatste redmiddel aangeraden. Wij 
bestudeerden de uitkomsten van dergelijke chirurgie bij acht patiënten die werden 
geopereerd voor NTM longinfecties in Dekkerswald. Chirurgie resulteerde in 
een langdurige omslag naar kweeknegativiteit in zeven van de acht patiënten die 
werden geopereerd. De indicatiestelling en timing van chirurgie bleken hierbij 
van doorslaggevend belang; juist deze zaken komen in de bestaande literatuur 
nauwelijks aan bod. Wij concluderen dat de toegevoegde waarde van chirurgie 
overwogen dient te worden bij iedere patiënt bij wie een NTM longinfectie wordt 
vastgesteld en dat dit opnieuw geëvalueerd dient te worden na zes maanden 
medicinale behandeling. Waar mogelijk dient chirurgische behandeling te 
worden nagestreefd en tijdig uitgevoerd. Ter ondersteuning van longartsen 
hebben wij indicaties voor chirurgie opgesteld.
De klinische relevantie en optimale therapie is vastgesteld voor beschreven 
NTM species. In Hoofdstuk 5 verkenden wij de heterogeniciteit onder NTM 
en concludeerden dat ten minste 4% van alle NTM isolaten ingezonden 
naar het nationale referentie laboratorium niet kon worden toegewezen aan 
een officieel beschreven species. In het bijzonder ging het hier om stammen 
verwant aan, maar niet behorend tot de leden van, het M. avium complex en 
M. fortuitum complex.
Enkele groepen van deze eerder niet identificeerbare mycobacteriën vielen 
op doordat zij frequent werden geïsoleerd, of omdat zij geïsoleerd werden uit 
normaal gesproken steriele materialen en dus zeer waarschijnlijk veroorzakers 
van NTM infecties waren. Vier van deze groepen werden intensief onderzocht 
en konden beschreven en erkend worden als nieuwe species, met een 
inschatting van hun klinische relevantie. Zo onderscheidden wij het klinisch 
niet relevante species M. noviomagense van het sterk verwante en wel frequent 
klinisch relevante species M. xenopi. Ook beschreven wij M. vulneris en 
(in Hoofdstuk 7) M. riyadhense als verwekkers van extrapulmonale NTM 
infecties en identificeerden wij M. mantenii als verwekker van cervicofaciale 
lymfadenitis bij kinderen, terwijl dit nieuwe species in longmaterialen klinisch 
niet relevant bleek. Een beter onderscheidende taxonomie binnen het genus 
Mycobacterium kan dus klinisch betekenisvol zijn; wij concluderen dan ook dat 
deze klinische betekenis een voorwaarde zou moeten zijn voor taxonomische 
precisie binnen de NTM.
In Hoofdstuk 6 zoomen we verder in, op de genetische divergentie binnen 
NTM species. Infectieziekten zijn het gevolg van een compelx samenspel van 
gastheer en pathogeenfactoren; genetische divergentie binnen NTM species 
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zou dus inzicht kunnen verschaffen in de bacteriële factoren verantwoordelijk 
voor klinische relevantie. Bepaalde subgroepen binnen species kunnen klinisch 
relevanter zijn dan andere. Door het sequencen van meerdere huishoudgenen 
in verscheidene NTM species konden wij, voor het eerst, de enorme genetische 
divergentie binnen deze species aantonen. Ondanks deze divergentie konden 
wij geen associaties vinden tussen subgroepen op basis van variatie in de 
huishoudgenen en klinische ziektevormen. De volgende stap bestond uit het 
bestuderen van een specifieke virulentiefactor, dat wil zeggen een gen waarvan 
het product een cruciale rol speelt in de pathogenese van NTM infecties. 
Hiertoe verkenden wij de aanwezigheid en functie van esat-6 en cfp-10 genen, 
die cruciale rollen spelen in de virulentie van M. tuberculosis. De eiwitten 
waarvoor deze twee genen coderen maken het M. tuberculosis mogelijk om 
te ontsnappen uit het fagolysosoom, waar de bacterie onschadelijk gemaakt 
dient te worden, naar het cytosol van humane macrofagen. Wij vonden sterk 
gelijkende genen in M. szulgai, M. kansasii, M. riyadhense en M. marinum, 
stuk voor stuk klinisch zeer relevante species en fylogenetisch verwant aan 
het M. tuberculosis complex. Middels een in vitro macrofaaginfectie testten 
wij de functie van deze genen in M. szulgai. Hier zagen wij, met behulp van 
cryo-immunogold elektronenmicroscopie, dat de aanwezigheid van esat-6 en 
cfp-10 genen het voor M. szulgai niet mogelijk maakt te ontsnappen uit het 
fagolysosoom naar het cytosol van macrofagen. De pathogenese van NTM 
infecties blijft dus vooralsnog onbekend.
Tenslotte hebben we, in Hoofdstuk 7, een blik over onze landsgrenzen 
geworpen om de klinische relevantie van NTM in zeer verschillende 
geografische gebieden in te schatten. In Oman troffen we een situatie aan 
met sterke gelijkenissen met de Nederlandse situatie, zowel qua aangetroffen 
species als qua manifestaties van NTM longinfecties. In Saoedi Arabië 
identificeerden wij een nieuw species dat een weke delen infectie veroorzaakte 
na stomp trauma. In Tanzania toonden we aan dat NTM verwekkers zijn 
van HIV-gerelateerde gedissemineerde infecties. In Vietnam identificeerden 
wij een groep willekeurig gekozen NTM die waren aangetroffen gedurende 
een surveillance studie naar drugresistentie onder M. tuberculosis complex 
bacteriën. Helaas bood deze setting weinig kansen om de klinische relevantie 
van deze isolaten goed in te schatten. Zowel in Tanzania als in Vietnam 
bemerkten wij dat species die in Nederland zeldzaam of afwezig zijn daar de 
overhand hadden. Hierop concluderen wij dat de identificatiemethoden die 
ontwikkeld zijn voor gebruik in de Europese of Noord-Amerikaanse setting 
minder kunnen functioneren in andere regio’s ware andere NTM species 
aanwezig kunnen zijn. Hoewel de incidentie en manifestaties van NTM 
infecties waarschijnlijk verschillen per setting, kunnen wij concluderen dat 
NTM wereldwijd aanwezig zijn en ziekte veroorzaken, ook in settings met 
een hoge prevalentie van tuberculose.
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Wij hebben aangetoond dat NTM een relevant klinisch en laboratorium-
technisch probleem vormen, zowel in Nederland als daarbuiten. Dit geldt 
ook voor landen met een hoge prevalentie van tuberculose. In Hoofdstuk 8 
bediscussiëren wij de bevindingen uit onze verschillende studies binnen hun 
wetenschappelijke context. Wij concluderen hieruit dat het onderzoek naar 
NTM zich toe dient te gaan spitsen op drie hoofdthema’s. Ten eerste blijft de 
pathogenese van NTM infecties goeddeels onbekend. Prospectieve klinische 
studies dienen gastheerfactoren te onderzoeken die de gevoeligheid voor NTM 
infecties beïnvloeden. Aan de kant van de pathogenen is het raadzaam om van 
enkele klinisch relevante NTM het volledige genoom te laten sequencen en in 
vitro en in vivo infectie-experimenten uit te voeren, teneinde meer inzicht te 
verwerven in virulentiefactoren. De tweede peiler dient de verbetering van de 
uitkomst van therapie te zijn. Farmacokinetische studies zijn van belang om 
de huidige therapie te optimaliseren. Daarnaast dienen nieuwe antibiotica ook 
te worden getest op hun activiteit tegen NTM en dit behelst in het bijzonder 
de nieuwe antituberculose middelen die op dit moment in ontwikkeling zijn. 
Gelijktijdig dienen de bestaande richtlijnen voor diagnostiek en behandeling 
verder te worden verspreid en dient het consulteren van experts gepropageerd 
te worden onder longartsen en infectiologen. Het derde belangrijke thema is 
het bestuderen van milieubronnen van NTM. Uit water- en grondmonsters 
worden veelvuldig NTM geïsoleerd en sporadisch zijn deze ook al gekoppeld 
aan ziektegevallen bij de mens. Toch weten we nog onvoldoende over 
waar deze bacteriën zich bevinden en waar zij zich daadwerkelijk kunnen 
vermenigvuldigen.
Tot besluit is het zeer lastig om meer aandacht voor de NTM infecties te 
genereren wanneer basale zaken als incidentie, prevalentie en ziektelast nog 
niet gekwantificeerd zijn. Als startpunt stellen wij voor om in Nederland een 
meldingsplicht, zij het niet real-time, in te stellen voor laboratoria die NTM 
aantreffen in klinische monsters. In combinatie met klinische gegevens zal dit 
de ware ziektelast door NTM in Nederland inzichtelijk maken.
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Dankwoord
dank de; m (betuiging van) goede gezindheid tegenover iemand vanwege 
een geschenk, bewezen dienst enz.
be·dan·ken -dankte, h -dankt 
1 dank betuigen: iemand voor iets ~ 
2 ontslag nemen of geven: ~ als lid 
3 afwijzen: daar bedank ik voor
Bedankt. Zeven letters. Het is een kort woord, een klein gebaar, maar toch van 
zo’n groot belang. Er zijn vele mensen die in de loop van dit promotietraject 
van mij een oprecht “bedankt” hebben moeten horen; ik hoop dat ik het jullie 
allemaal eens gezegd heb.
Vanzelfsprekend moet ik dit dankwoord bij mijn promotor Prof. Dr. Richard 
Dekhuijzen en co-promotoren Dr. Martin Boeree en Dr. Dick van Soolingen 
beginnen. Tenslotte heb ik vooral uitgevoerd wat jullie hebben bedacht.
Richard, ik moet beginnen je te bedanken voor het feit dat je me vers uit 
de co-schappen een AGNIO plaats met onderzoekstijd hebt aangeboden; 
daar is dit alles immers uit voortgekomen. Zodra het promotietraject vorm 
kreeg, heb je daar alle ruimte voor gecreëerd. Bedankt voor je supersnelle 
commentaren op de stukken, zelfs vanaf je vakantieadres, je heldere visie op 
de onderzoeksstrategie, maar zeker ook voor het stroomlijnen van het laatste, 
formele, deel van dit mooie traject.
Martin, tijdens het tuberculose onderwijs voorafgaand aan mijn co-schappen 
in Tanzania heb je mijn laatste twijfels weggenomen: ik moest iets gaan 
doen met mycobacteriele infecties. De wetenschappelijke stage die je me bij 
terugkomst aanbood bleek een opmaat voor vier prachtige jaren, eerst vooral 
in de kliniek op Dekkerswald, later meer vanuit het RIVM. Onze besprekingen 
op de vrijdagmiddag hebben de inhoud en vorm van dit proefschrift bepaald, 
maar verliepen zo ontspannen dat dat achteraf vaak als bijzaak aanvoelde. 
De humor en je eeuwige positiviteit zijn gelukkig wel van mens op mens 
overdraagbaar! Wanneer gaan we naar de Wakhan corridor?
Dick, het is alweer vier jaar geleden dat we elkaar voor het eerst ontmoetten en 
toch leer je me iedere dag nog zoveel nieuws. Bedankt voor de grote mate van 
vrijheid die ik heb gekregen en voor je bijdragen, op alle mogelijke manieren, 
aan dit proefschrift; ze waren van onschatbare waarde. Zowel je loopbaan als 
je werkwijze zijn een doorlopende bron van inspiratie voor me. Het is dan ook 
heerlijk om te weten dat ik nog meer dan een jaar in je fantastische team mag 
meedraaien, met hopelijk een mooi feest ergens in dat jaar. Als alles goed gaat 
ben je ook op je nieuwe post in Nijmegen nog niet van me af! 
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De overige leden van het Research Atypische Mycobacteriën (RAM)-team 
hebben een enorm belangrijke bijdrage aan dit proefschrift geleverd, op vele 
manieren.
Wiel de Lange, als ik teruglees door dit proefschrift zie ik veel terug van de 
vele namiddagen die we op je werkkamer achter de PC hebben doorgebracht. 
Alle casuïstiek die je, als consulent op NTM gebied, met me hebt gedeeld hield 
tijdens het rondreizen, de statusinzages en het labwerk het belang van al dit 
onderzoek altijd op mijn netvlies... maar gelukkig konden we het ook gewoon 
over drummen hebben.
Cecile Magis, bedankt voor je aanstekelijke enthousiasme, de vele bijdragen 
aan de stukken en de heel prettige supervisie tijdens mijn werk op de TB 
afdeling. Ik heb veel van je mogen leren waar ik zowel in de kliniek als in het 
onderzoek veel profijt van heb gehad. 
Wouter Hoefsloot, Mister M. malmoense, al vanaf het begin zijn we samen aan 
het werk aan de NTMs. Bedankt voor de fantastische samenwerking, of het nu 
was op de longrevalidatie of tijdens statusinzages voor de regio-studie. Dankzij 
de vele gedeelde interesses zijn onze etentjes altijd gezellig en van iets langere 
duur dan gepland. Heel erg bedankt dat je paranimf wilde zijn! 
 
Dit proefschrift is het resultaat van de samenwerking tussen twee fantastische 
clubs. Graag bedank ik iedereen binnen het Universitair Longcentrum 
Dekkerswald en de afdeling Longziekten van het UMC St. Radboud te 
Nijmegen. De twee jaar van klinisch werk gecombineerd met onderzoek 
waren een prachtige tijd. De destijds actieve longartsen Anton Cox, Erik 
van der Heijden, Johan Molema, Jolanda van Haren-Willems, Miep van der 
Drift, Monique Reijers, Olga Schuurbiers, Tewe Verhage en Yvonne Heijdra 
ben ik veel dank verschuldigd. Ik heb ontzettend veel van jullie mogen leren, 
van polysomnografie tot pleurapunctie en daar heb ik nog steeds veel profijt 
van! Ook bedank ik alle arts-assistenten met wie ik heb samengewerkt voor de 
leuke tijd en alle collegialiteit; ik besef me maar al te goed dat jullie nog een 
stap harder moesten lopen tijdens mijn onderzoeksdagen…
Saar van Nederveen-Bendien verdient, als RAM-team lid van het eerste uur, een 
extra woord van dank. Saar, bedankt voor al je bijdragen aan de verschillende 
stukken, in het bijzonder ons regio onderzoek; veel succes in Den Haag!
Vanuit de kliniek verhuisde ik naar de afdeling Mycobacteriën van het RIVM. 
Hoewel de overstap bijna niet groter kon zijn, werd ik vanaf dag één volledig 
in jullie hechte club opgenomen en mocht ik overal aan meedoen en denken. 
Anne-Marie van den Brandt, Arnold Herrewegh, Arnout Mulder, Jessica de 
Beer, Kristin Kremer, Mimount Enaimi, Miranda Kamst, Rina de Zwaan, 
Tridia van der Laan, zonder jullie was dit boekje er nooit geweest; heel erg 
bedankt, voor alles!
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Petra de Haas mag ik bedanken voor alle bijdragen aan de verschillende 
studies, veel plezier met je prachtige werk in Zambia (maar kom toch maar 
gauw weer terug!).
Mirjam Dessens, bedankt voor het ondersteboven keren van de 
laboratoriumdatabase op zoek naar al die isolaten die we later hebben kunnen 
bestuderen.
Dit proefschrift was onmogelijk geweest zonder de belangeloze medewerking 
van alle longartsen, infectiologen, oogartsen, KNO-artsen, huisartsen en 
neurologen die NTM “vingen” bij hun patiënten en de artsen-microbioloog 
die ze ook echt aan wisten te tonen en de schakel naar de behandelend 
artsen vormden. Hartelijk dank voor de altijd vriendelijke ontvangst en de 
mogelijkheid te leren van jullie ervaringen met NTM infecties.
Een special woord van dank ben ik verschuldigd aan alle co-auteurs van de 
verschillende stukken; jullie enthousiasme en inzet zijn bepalend geweest 
voor het verloop van dit promotietraject. Hier mag ik Adri van der Zanden 
in het bijzonder bedanken; je enthousiasme voor het onderwerp en eeuwige 
bereidheid om hier op alle mogelijke manieren aan bij te dragen waren 
fantastisch. Ook bedankt voor de vele uren lol tijdens de jaarlijkse ESM 
meetings!
Chapter Seven exists because of the great collaborations with equally great 
people from diverse parts of the world. A big word of thanks goes out to Sahal 
al-Hajoj and Fahad Al-Rabiah (Saudi Arabia), Sara Al-Mahruqi and Suleiman 
Al-Busaidy (Oman), John Crump (USA/Tanzania) and Nguyen Van Hung 
(Vietnam). 
Enrico Tortoli, thanks for the introduction into the fascinating world of 
mycobacterial taxonomy and the great and ongoing collaboration; I will make 
sure there will be a Mycobacterium tortolii one day, that’s a promise.
I could devote a full chapter to thanking the European Society for 
Mycobacteriology and all its members but prefer to do so personally during 
the next meeting. The annual meetings are fantastic in many ways. See you all 
in Slovenia, 2010!
For a lot of what I have learnt on NTM disease, I am indebted to my fantastic 
North American colleagues David Griffith, Richard Wallace Jr., Timothy 
Aksamit, Kevin Winthrop, Theodore Marras, Kenneth Olivier, Gwen Huitt 
and of course Michael Iseman and Charles Daley. Our annual get-togethers at 
the American Thoracic Society conference were a wonderful concoction of fun 
and science. It was an immense honor to contribute to the postgraduate course 
on NTM disease. Professor Charles Daley, dear Chuck, thank you so much for 
your willingness to participate in the Doctoral Thesis Committee. I already 
look forward to join your great team for a while next year.
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Joe Falkinham III, we have only met once (yet), but an hour of talking to you 
saves a year in the laboratory! Thanks for sharing your experience and the 
knowledge of the works of researchers that predate even my grandparents.
Graag wil ik de Nederlandse leden van de manuscriptcommissie, Prof. Dr. 
J.W.M. van der Meer en Prof. Dr. P.E. Verweij bedanken voor de beoordeling 
van dit proefschrift.
De directie van het RIVM/CIb wil ik bedanken voor de mogelijkheid die ik 
heb gekregen om in het instituut de laatste fase van mijn promotietraject in te 
vullen. Voorlopig blijf ik nog even, want er is nog meer te doen.
Matthijs Poll, jouw naam kan hier gemakkelijk vier keer in de lijst. Allereerst 
heel erg bedankt voor je geweldige werk aan de vormgeving van dit boek, 
maar natuurlijk ook voor vele jaren vriendschap en de gehele gezamenlijke 
geschiedenis in beeld en geluid, vanaf Brom 20 (Vet Oi, the movie!) tot aan 
DDT/Stennis.
Natuurlijk bedank ik mijn ouders, mijn twee zussen en zwagers, maar voor 
veel meer dan ondersteuning tijdens de totstandkoming van dit proefschrift. 
Jullie zijn allemaal fantastisch! Bedankt voor alle kansen die ik heb gekregen 
om mezelf te ontwikkelen en voor hoe jullie me gevormd hebben tot wie ik nu 
ben. Hopelijk heb ik vanaf nu wat meer tijd om over de dijk jullie kant op te 
komen fietsen.
Als kind heb ik het geluk gehad ook nog twee bijzondere “bij-moeders” te 
hebben; Alie en Jannie, ook bedankt voor alles!
Joe Cocker weet het mooier te zeggen, maar over “a little help from my friends” 
heb ik nooit te klagen gehad! De hele clan in Nijmegen (Caroline, Dagmar, 
Femke, Janneke, Joost, Koen, Maartje, Marjolein, Menno, Mieke, Sander, 
Steven, Sven en inmiddels ook Bas, Guusje en Jet) zeg ik: Bedankt voor de 
avonden (uit) eten, naar de kroeg, appeltjestabak of Cubaanse sigaren roken, 
spelletjes doen, Top Gear kijken en andere zinvolle tijdsbesteding!
Femke, na vele jaren van een bijzondere vriendschap vind ik het zo leuk dat 
je paranimf wilde zijn! Bedankt voor alle ondersteuning, want ik weet: rafiki 
akupendaye ni yule akukumbaye (ja toch?).
Joshan en Karima Azizi wil ik graag bedanken voor hun warme vriendschap, 
gastvrijheid en de bijzondere kennismaking met jullie geboorteland, 
Afghanistan. Tashakor!
Ook bedank ik graag mijn bandmaatjes van DDT (Jan Willem!) en Stennis; 
jullie hebben ervoor gezorgd dat eventuele stress en frustraties via het drumstel 
een “mooie” uitweg vonden. Spelen!
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Cafeïne was een belangrijke drijvende kracht achter dit proefschrift; graag 
bedank ik Coffyn (Nijmegen) en Maison Blanche Dael / Coffeelovers 
(Maastricht) voor het branden van fantastische koffie en de vele zaterdagen en 
zondagen die ik er heb mogen doorbrengen.
De uitvinder van de lithium-ion battery verdient een woord van dank; zonder 
diens werk was er geen laptop, geen mobiele telefoon en geen MP3 speler en 
daarmee ook geen proefschrift voor mij. De muziek van Ignite, Bane, Johnny 
Cash, Ali “Farka” Toure en Monster Magnet was onmisbaar tijdens het werken 
thuis en in de trein. De Nederlandse Spoorwegen en alle busmaatschappijen 
verdienen ook een bedankje; van Maastricht tot Delfzijl en van Hoorn tot 
Vlissingen, overal wisten jullie me voor het ziekenhuis af te zetten en veilig 
weer thuis te brengen.
Lieve Hilde, als ik iemand moet bedanken dan ben jij het. We zijn al meer dan 
elf mooie jaren samen, hebben prachtige reizen gemaakt en nog zoveel mooie 
plannen. Je hebt me altijd de ruimte gegeven om te kiezen voor wat ik het 
liefst wilde doen, al betekent het nu jarenlang uit elkaar wonen. Ons “tweede 
huis” in Maastricht is een heerlijke plek geworden (en een half museum voor 
oriëntaalse kunst!) waar een belangrijk deel van dit boekje geschreven is. Ik 
ben er enorm trots op dat jij al bijna neurologe bent én al een eind op weg voor 
jouw boek!
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